10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-07434

Aflac Incorporated

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Georgia			58-1167100
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
1932 Wynnton Road	Columbus,	Georgia	31999
(Address of principal executive offices)			(ZIP Code)

706.323.3431

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.10 par value per share	AFL	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  þ  Yes  ¨  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).            þ  Yes  ¨  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	þ	Accelerated filer	☐
Non-accelerated filer	¨	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐  Yes  þ  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 540,645,028 shares of the issuer's common stock were outstanding as of April 29, 2025.

Aflac Incorporated and Subsidiaries

Quarterly Report on Form 10-Q

For the Quarter Ended March 31, 2025

Table of Contents

PART I.		FINANCIAL INFORMATION:	Page
	Item 1.	Financial Statements (Unaudited)
		Consolidated Statements of Earnings    Three Months Ended March 31, 2025 and 2024	1
		Consolidated Statements of Comprehensive Income (Loss)     Three Months Ended March 31, 2025 and 2024	2
		Consolidated Balance Sheets    March 31, 2025, and December 31, 2024	3
		Consolidated Statements of Shareholders' Equity    Three Months Ended March 31, 2025 and 2024	4
		Consolidated Statements of Cash Flows    Three Months Ended March 31, 2025 and 2024	5
		Notes to the Consolidated Financial Statements	6
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	71
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	106
	Item 4.	Controls and Procedures	106
PART II.		OTHER INFORMATION:
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	107
	Item 5.	Other Information	107
	Item 6.	Exhibits	108
Glossary of Selected Terms			109

Items other than those listed above are omitted because they are not required or are not applicable.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Statements of Earnings

	Three Months Ended March 31,
(In millions, except for share and per-share amounts - Unaudited)	2025			2024
Revenues:
Net earned premiums, principally supplemental health insurance (1)		$	3,381		$	3,456
Net investment income		955			1,000
Net investment gains (losses)		(963)			951
Other income (loss)		25			29
Total revenues		3,398			5,436
Benefits and expenses:
Benefits and claims, excluding reserve remeasurement		1,986			2,066
Reserve remeasurement (gains) losses		(41)			(56)
Total benefits and claims, net		1,945			2,010
Acquisition and operating expenses:
Amortization of deferred policy acquisition costs		216			215
Insurance commissions		240			255
Insurance and other expenses		802			739
Interest expense		50			47
Total acquisition and operating expenses		1,308			1,256
Total benefits and expenses		3,253			3,266
Earnings before income taxes		145			2,170
Income taxes		116			291
Net earnings		$	29		$	1,879
Net earnings per share:
Basic		$	.05		$	3.27
Diluted		.05			3.25
Weighted-average outstanding common shares used in   computing earnings per share (In thousands):
Basic		544,707			574,886
Diluted		546,878			577,482
Cash dividends per share		$	.58		$	.50

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

See the accompanying Notes to the Consolidated Financial Statements.

1

Aflac Incorporated and Subsidiaries

Consolidated Statements of Comprehensive Income (Loss)

	Three Months Ended March 31,
(In millions - Unaudited)	2025			2024
Net earnings		$	29		$	1,879
Other comprehensive income (loss) before income taxes:
Unrealized foreign currency translation gains (losses) during    period		352			(501)
Unrealized gains (losses) on fixed maturity securities:
Unrealized holding gains (losses) on fixed maturity securities    during period		(1,541)			103
Reclassification adjustment for (gains) losses on    fixed maturity securities included in net earnings		(40)			(168)
Unrealized gains (losses) on derivatives during period		2			(5)
Effect of changes in discount rate assumptions during period		2,396			1,348
Pension liability adjustment during period		41			2
Total other comprehensive income (loss) before income taxes		1,210			779
Income tax expense (benefit) related to items of other comprehensive    income (loss)		91			361
Other comprehensive income (loss), net of income taxes		1,119			418
Total comprehensive income (loss)		$	1,148		$	2,297

See the accompanying Notes to the Consolidated Financial Statements.

2

Aflac Incorporated and Subsidiaries

Consolidated Balance Sheets

(In millions, except for share and per-share amounts)	March 31, 2025 (Unaudited)			December 31, 2024
Assets:
Investments and cash:
Fixed maturity securities available-for-sale, at fair value (no allowance for credit losses in   2025 and 2024, amortized cost $64,638 in 2025 and $61,455 in 2024)		$	63,547		$	61,841
Fixed maturity securities available-for-sale - consolidated variable interest entities, at fair value   (amortized cost $2,907 in 2025 and $2,634 in 2024)		3,597			3,428
Fixed maturity securities held-to-maturity, at amortized cost, net of allowance   for credit losses of $5 in 2025 and $5 in 2024 (fair value $17,135 in 2025 and $16,772 in 2024)		16,888			15,966
Equity securities, at fair value		764			796
Commercial mortgage and other loans, net of allowance for credit losses of $368 in 2025 and $355   in 2024 (includes $8,540 in 2025 and $8,693 in 2024 of consolidated variable interest entities)		10,656			10,869
Other investments   (includes $2,151 in 2025 and $2,176 in 2024 of consolidated variable interest entities)		6,763			5,958
Cash and cash equivalents		5,231			6,229
Total investments and cash		107,446			105,087
Receivables		894			779
Accrued investment income		682			710
Deferred policy acquisition costs		9,083			8,758
Property and equipment, at cost less accumulated depreciation		391			387
Other		1,762			1,845
Total assets		$	120,258		$	117,566
Liabilities and shareholders’ equity:
Liabilities:
Policy liabilities:
Future policy benefits		$	71,197		$	70,381
Unpaid policy claims		411			381
Unearned premiums		1,357			1,286
Other policyholders’ funds		5,863			5,460
Total policy liabilities		78,828			77,508
Income taxes		815			573
Payables for return of cash collateral on loaned securities		3,142			2,037
Notes payable and lease obligations		7,751			7,498
Other		3,384			3,852
Total liabilities		93,920			91,468
Commitments and contingent liabilities (Note 13)
Shareholders’ equity:
Common stock of $.10 par value. In thousands: authorized 1,900,000    shares in 2025 and 2024; issued 1,357,752 shares in 2025 and 1,356,763 shares in 2024		136			136
Additional paid-in capital		2,919			2,894
Retained earnings		52,308			52,277
Accumulated other comprehensive income (loss):
Unrealized foreign currency translation gains (losses)		(4,549)			(4,998)
Unrealized gains (losses) on fixed maturity securities		(1,233)			24
Unrealized gains (losses) on derivatives		(18)			(20)
Effect of changes in discount rate assumptions		3,899			2,006
Pension liability adjustment		42			10
Treasury stock, at average cost		(27,166)			(26,231)
Total shareholders’ equity		26,338			26,098
Total liabilities and shareholders’ equity		$	120,258		$	117,566

See the accompanying Notes to the Consolidated Financial Statements.

3

Aflac Incorporated and Subsidiaries

Consolidated Statements of Shareholders’ Equity

(In millions, except for per share amounts - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2024	$	136	$	2,894	$	52,277	$	(2,978)	$	(26,231)	$	26,098
Net earnings	0		0		29		0		0		29
Unrealized foreign currency translation    gains (losses) during period, net of    income taxes	0		0		0		449		0		449
Unrealized gains (losses) on fixed maturity    securities during period, net of income    taxes and reclassification adjustments	0		0		0		(1,257)		0		(1,257)
Unrealized gains (losses) on derivatives    during period, net of income taxes	0		0		0		2		0		2
Effect of changes in discount rate assumptions    during period, net of income taxes	0		0		0		1,893		0		1,893
Pension liability adjustment during period,    net of income taxes	0		0		0		32		0		32
Dividends to shareholders (1)   ($.00 per share)	0		0		2		0		0		2
Exercise of stock options	0		4		0		0		0		4
Share-based compensation	0		8		0		0		0		8
Purchases of treasury stock	0		0		0		0		(949)		(949)
Treasury stock reissued	0		13		0		0		14		27
Balance at March 31, 2025	$	136	$	2,919	$	52,308	$	(1,859)	$	(27,166)	$	26,338

(In millions, except for per share amounts - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2023	$	136	$	2,771	$	47,993	$	(5,520)	$	(23,395)	$	21,985
Net earnings	0		0		1,879		0		0		1,879
Unrealized foreign currency translation    gains (losses) during period, net of    income taxes	0		0		0		(597)		0		(597)
Unrealized gains (losses) on fixed maturity    securities during period, net of income    taxes and reclassification adjustments	0		0		0		(47)		0		(47)
Unrealized gains (losses) on derivatives    during period, net of income taxes	0		0		0		(4)		0		(4)
Effect of changes in discount rate assumptions    during period, net of income taxes	0		0		0		1,065		0		1,065
Pension liability adjustment during period,    net of income taxes	0		0		0		1		0		1
Dividends to shareholders (1)   ($.00 per share)	0		0		0		0		0		0
Exercise of stock options	0		4		0		0		0		4
Share-based compensation	0		18		0		0		0		18
Purchases of treasury stock	0		0		0		0		(793)		(793)
Treasury stock reissued	0		13		0		0		13		26
Balance at March 31, 2024	$	136	$	2,806	$	49,872	$	(5,102)	$	(24,175)	$	23,537

(1) Dividends to shareholders are recorded in the period in which they are declared.

See the accompanying Notes to the Consolidated Financial Statements.

4

Aflac Incorporated and Subsidiaries

Consolidated Statements of Cash Flows

	Three Months Ended March 31,
(In millions - Unaudited)	2025			2024
Cash flows from operating activities:
Net earnings		$	29		$	1,879
Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Change in receivables and advance premiums		(37)			32
Capitalization of deferred policy acquisition costs		(246)			(254)
Amortization of deferred policy acquisition costs		216			215
Increase in policy liabilities		(136)			(41)
Change in income tax liabilities		117			291
Net investment (gains) losses		963			(951)
Other, net		(317)			(322)
Net cash provided (used) by operating activities		589			849
Cash flows from investing activities:
Proceeds from investments sold or matured:
Available-for-sale fixed maturity securities		5,935			2,286
Equity securities		96			267
Commercial mortgage and other loans		500			379
Costs of investments acquired:
Available-for-sale fixed maturity securities		(6,624)			(2,127)
Equity securities		(101)			(73)
Commercial mortgage and other loans		(392)			(251)
Other investments, net		(697)			(2,119)
Settlement of derivatives, net		18			(256)
Cash received (pledged or returned) as collateral, net		984			1,973
Other, net		(78)			148
Net cash provided (used) by investing activities		(359)			227
Cash flows from financing activities:
Purchases of treasury stock		(900)			(750)
Proceeds from borrowings		0			823
Dividends paid to shareholders		(306)			(278)
Change in investment-type contracts, net		(58)			(50)
Treasury stock reissued		4			6
Other, net		(1)			(7)
Net cash provided (used) by financing activities		(1,261)			(256)
Effect of exchange rate changes on cash and cash equivalents		33			(28)
Net change in cash and cash equivalents		(998)			792
Cash and cash equivalents, beginning of period		6,229			4,306
Cash and cash equivalents, end of period		$	5,231		$	5,098
Supplemental disclosures of cash flow information:
Income taxes paid		$	(1)		$	0
Interest paid		40			34
Noncash interest		10			13
Noncash real estate acquired in satisfaction of debt		71			35
Noncash financing activities:
Lease obligations		10			5
Treasury stock issued for:
Associate stock bonus		5			4
Shareholder dividend reinvestment		11			10
Share-based compensation grants		7			6

See the accompanying Notes to the Consolidated Financial Statements.

5

Aflac Incorporated and Subsidiaries

Notes to the Consolidated Financial Statements

(Interim period data - Unaudited)

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in Japan and the United States (U.S.). The Company's insurance business is marketed and administered through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan and through American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS) in the U.S. The Company’s operations consist of two reportable business segments: Aflac Japan, which includes ALIJ, and Aflac U.S., which includes Aflac, Aflac New York, CAIC, TOIC, and ABS. Aflac New York is a wholly owned subsidiary of Aflac. Most of the Aflac U.S. policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ABS, and certain group life insurance products, Aflac U.S. markets and administers group products through CAIC, branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through TOIC. The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd.(Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits and income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in the consolidated financial statements. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, 2025 and December 31, 2024, and the consolidated statements of earnings, comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, 2025 and 2024. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

6

New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Accounting Standards Update (ASU) 2023-07 Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued amendments that add certain segment disclosures related to significant segment expenses and require that a public entity disclose the title and position of the Chief Operating Decision Maker (CODM) and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

The Company adopted this guidance for the annual period beginning January 1, 2024, and interim periods beginning January 1, 2025. The adoption of this guidance did not have an impact on the Company’s financial position or results of operations. See Note 2 for expanded disclosures required as a result of the amended guidance.

Accounting Pronouncements Pending Adoption

ASU 2024-03 Income Statement (Topic 220) - Disaggregation of Income Statement Expenses

In November 2024, the FASB issued amendments that require disaggregated disclosure, in the notes to the financial statements, of specified information about certain costs and expenses including (1) the amounts of employee compensation, depreciation, and intangible asset amortization; (2) certain expense, gain, or loss amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and (4) the total amount of selling expenses and, in annual reporting periods, the Company’s definition of selling expenses.

The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

ASU 2023-09 Income Taxes (Topic 740) - Improvements to Income Tax Disclosures

In December 2023, the FASB issued amendments that require enhanced income tax disclosures including (1) disclosure of specific categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures.

The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business.

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

7

2.    BUSINESS SEGMENT INFORMATION

The Company consists of two reportable insurance business segments: Aflac Japan and Aflac U.S., both of which sell supplemental health and life insurance. In addition, the Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re, and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other. The Company does not allocate corporate overhead expenses to business segments.

The Company’s reportable segments are regularly reviewed by the Company's CODM, Senior Executive Vice President and Chief Financial Officer, in deciding how to allocate resources and in assessing performance. The Company's CODM reviews and approves the annual budget and operating forecast, which allocates resources to segments and serves as a key benchmark for tracking performance and accountability of each segment's operating results. The Company’s CODM evaluates the performance of the segments using, in comparison to the annual budget, operating forecast and historical results, a financial performance measure called pretax adjusted earnings and believes this financial performance measure to be vitally important for understanding the underlying profitability drivers and trends of the Company’s insurance business.

•Pretax adjusted earnings are adjusted revenues less benefits and adjusted expenses. The adjustments to both revenues and expenses account for certain items that are outside management’s control because they tend to be driven by general economic conditions and events or are related to infrequent activities not directly associated with insurance operations. The Company excludes income taxes related to operations to arrive at pretax adjusted earnings.

◦Adjusted revenues are U.S. GAAP total revenues excluding net investment gains and losses, except for amortized hedge costs/income related to foreign currency exposure management strategies and net interest income/expense from derivatives associated with certain investment strategies, which are reclassified from net investment gains (losses) and included in adjusted earnings as a component of adjusted net investment income when analyzing operations. 

◦Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest from derivatives associated with notes payable but excluding any non-recurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company’s underlying business performance.

Aflac Japan's adjusted revenues as a percentage of the Company's total adjusted revenues were 53% and 56% in the three-month periods ended March 31, 2025 and 2024, respectively. The percentage of the Company's total assets attributable to Aflac Japan was 78% at March 31, 2025, compared with 77% at December 31, 2024.

8

Information regarding operations by reportable segment and Corporate and other is presented in the following tables.

	Three Months Ended March 31,
(In millions)	2025		2024
Revenues:
Aflac Japan:
Net earned premiums (1)	$	1,681	$	1,816
Adjusted net investment income	586		648
Other income	5		9
Total adjusted revenue Aflac Japan	2,272		2,473
Aflac U.S.:
Net earned premiums	1,502		1,475
Adjusted net investment income	202		206
Other income	17		18
Total adjusted revenue Aflac U.S.	1,721		1,699
Corporate and other (2)	326		247
Total adjusted revenues	4,319		4,419
Net investment gains (losses)	(963)		951
Reconciling items:
Amortized hedge costs	7		6
Amortized hedge income	(30)		(28)
Net interest (income) expense from derivatives   associated with certain investment strategies	65		88
Total revenues	$	3,398	$	5,436

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025 and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025 and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

9

	Three Months Ended March 31,
(In millions)	2025		2024
Adjusted revenues:
Aflac Japan (1)	$	2,272	$	2,473
Aflac U.S.	1,721		1,699
Corporate and other (2)	326		247
Total adjusted revenues	4,319		4,419
Benefits and adjusted expenses:
Aflac Japan:
Benefits and claims, excluding reserve remeasurement	1,130		1,243
Reserve remeasurement (gains) losses	(25)		(26)
Total benefits and claims, net	1,105		1,217
Adjusted expenses:
Amortization of deferred policy acquisition costs	79		83
Insurance commissions	105		114
Insurance and other expenses	261		249
Total benefits and adjusted expenses Aflac Japan	1,550		1,663
Aflac U.S.:
Benefits and claims, excluding reserve remeasurement	731		715
Reserve remeasurement (gains) losses	(15)		(29)
Total benefits and claims, net	716		686
Adjusted expenses:
Amortization of deferred policy acquisition costs	137		132
Insurance commissions	135		141
Insurance and other expenses	375		384
Total benefits and adjusted expenses Aflac U.S.	1,363		1,343
Corporate and other	283		250
Total adjusted expenses	$	3,196	$	3,256
Pretax earnings:
Aflac Japan (1)	$	722	$	810
Aflac U.S.	358		356
Corporate and other (2)	43		(3)
Pretax adjusted earnings	1,123		1,163
Other income (loss)	(53)		(2)
Net investment gains (losses)	(963)		951
Reconciling items:
Amortized hedge costs	7		6
Amortized hedge income	(30)		(28)
Net interest (income) expense from derivatives   associated with certain investment strategies	65		88
Impact of interest from derivatives associated   with notes payable	(4)		(8)
Total earnings before income taxes	$	145	$	2,170
Income taxes applicable to pretax adjusted earnings	$	217	$	202
Effect of foreign currency translation on after-tax   adjusted earnings	(8)		(44)

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025, and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025, and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

10

Internal Reinsurance: Aflac Re is a Bermuda domiciled insurer that reinsures certain policies issued by Aflac Japan and is reported as a part of Corporate and other. Under these internal reinsurance transactions, Aflac Japan's net earned premiums are reduced by the amount of premiums ceded to Aflac Re. Aflac Re recorded net earned premiums of $178 million and $136 million for the three-month periods ended March 31, 2025 and 2024, respectively, related to these reinsurance transactions with Aflac Japan. These internal reinsurance transactions have no financial statement impact on a consolidated basis, except for the effect of foreign currency accounting. For additional information on these internal reinsurance transactions, see the accompanying Note 8 and Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

Total Assets: The Company's total assets were as follows:

(In millions)	March 31, 2025			December 31, 2024
Assets:
Aflac Japan		$	93,430		$	90,210
Aflac U.S.		21,881			21,930
Corporate and other		4,947			5,426
Total assets		$	120,258		$	117,566

11

3.     INVESTMENTS

Investment Holdings

The amortized cost and allowance for credit losses for the Company's investments in fixed maturity securities and the fair values of these investments as well as the fair value of the Company's investments in equity securities are shown in the following tables.

	March 31, 2025
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	20,005	$	0	$	145	$	2,608	$	17,542
Municipalities	919		0		50		105		864
Mortgage- and asset-backed securities	342		0		2		29		315
Public utilities	2,771		0		155		155		2,771
Sovereign and supranational	349		0		9		10		348
Banks/financial institutions	5,553		0		225		448		5,330
Other corporate	5,655		0		475		413		5,717
Total yen-denominated	35,594		0		1,061		3,768		32,887
U.S. dollar-denominated:
U.S. government and agencies	275		0		2		2		275
Municipalities	1,190		0		69		68		1,191
Mortgage- and asset-backed securities	3,574		0		205		46		3,733
Public utilities	4,162		0		376		142		4,396
Sovereign and supranational	58		0		20		0		78
Banks/financial institutions	3,673		0		388		30		4,031
Other corporate	18,938		0		2,224		689		20,473
Total U.S. dollar-denominated	31,870		0		3,284		977		34,177
Other currencies:
Public utilities	55		0		0		1		54
Other corporate	26		0		0		0		26
Total other currencies	81		0		0		1		80
Total securities available-for-sale	$	67,545	$	0	$	4,345	$	4,746	$	67,144

12

	December 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	19,409	$	0	$	465	$	2,234	$	17,640
Municipalities	869		0		65		79		855
Mortgage- and asset-backed securities	327		0		4		23		308
Public utilities	2,746		0		202		108		2,840
Sovereign and supranational	330		0		16		8		338
Banks/financial institutions	5,376		0		267		342		5,301
Other corporate	5,329		0		568		305		5,592
Total yen-denominated	34,386		0		1,587		3,099		32,874
U.S. dollar-denominated:
U.S. government and agencies	208		0		1		3		206
Municipalities	1,167		0		65		53		1,179
Mortgage- and asset-backed securities	2,987		0		302		34		3,255
Public utilities	3,938		0		418		151		4,205
Sovereign and supranational	57		0		21		0		78
Banks/financial institutions	3,271		0		420		36		3,655
Other corporate	18,050		0		2,493		752		19,791
Total U.S. dollar-denominated	29,678		0		3,720		1,029		32,369
Other currencies:
Other corporate	25		0		1		0		26
Total other currencies	25		0		1		0		26
Total securities available-for-sale	$	64,089	$	0	$	5,308	$	4,128	$	65,269

	March 31, 2025
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	16,195	$	2	$	16,193	$	368	$	155	$	16,406
Municipalities	249		0		249		11		0		260
Public utilities	33		0		33		0		0		33
Sovereign and supranational	399		3		396		22		0		418
Other corporate	17		0		17		1		0		18
Total yen-denominated	16,893		5		16,888		402		155		17,135
Total securities held-to-maturity	$	16,893	$	5	$	16,888	$	402	$	155	$	17,135

13

	December 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	15,311	$	2	$	15,309	$	759	$	9	$	16,059
Municipalities	235		0		235		22		0		257
Public utilities	32		0		32		1		0		33
Sovereign and supranational	377		3		374		31		0		405
Other corporate	16		0		16		2		0		18
Total yen-denominated	15,971		5		15,966		815		9		16,772
Total securities held-to-maturity	$	15,971	$	5	$	15,966	$	815	$	9	$	16,772

	March 31, 2025			December 31, 2024
(In millions)	Fair Value			Fair Value
Equity securities, carried at fair value through net earnings:
Equity securities:
Yen-denominated		$	491		$	484
U.S. dollar-denominated		273			312
Total equity securities		$	764		$	796

The methods of determining the fair values of the Company's investments in fixed maturity securities and equity securities are described in Note 5.

During the first three months of 2025 and 2024, respectively, the Company did not reclassify any investments from the held-to-maturity category to the available-for-sale category.

Contractual and Economic Maturities

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, 2025, were as follows:

(In millions)	Amortized Cost (1)			Fair Value
Available-for-sale:
Due in one year or less		$	1,572		$	1,728
Due after one year through five years		8,158			8,943
Due after five years through 10 years		15,563			16,267
Due after 10 years		38,336			36,158
Mortgage- and asset-backed securities		3,916			4,048
Total fixed maturity securities available-for-sale		$	67,545		$	67,144
Held-to-maturity:
Due in one year or less		$	33		$	35
Due after one year through five years		2			2
Due after five years through 10 years		9,008			9,346
Due after 10 years		7,845			7,752
Total fixed maturity securities held-to-maturity		$	16,888		$	17,135

(1) Net of allowance for credit losses

14

Economic maturities are used for certain debt instruments with no stated maturity where the expected maturity date is based on the combination of features in the financial instrument such as the right to call or prepay obligations or changes in coupon rates.

Investment Concentrations

The Company's process for investing in credit-related investments begins with an independent approach to underwriting each issuer's fundamental credit quality. The Company evaluates independently those factors that it believes could influence an issuer's ability to make payments under the contractual terms of the Company's instruments. This includes a thorough analysis of a variety of items including the issuer's country of domicile (including political, legal, and financial considerations); the industry in which the issuer competes (with an analysis of industry structure, end-market dynamics, and regulation); company specific issues (such as management, assets, earnings, cash generation, and capital needs); and contractual provisions of the instrument (such as financial covenants and position in the capital structure). The Company further evaluates the investment considering broad business and portfolio management objectives, including asset/liability needs, portfolio diversification, and expected income.

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

	March 31, 2025			December 31, 2024
(In millions)	Credit Rating	Amortized Cost	Fair Value	Credit Rating	Amortized Cost	Fair Value
Japan National Government(1)	A+	$35,251	$33,082	A+	$33,822	$32,844

(1) Japan Government Bonds (JGBs) or JGB-backed securities

15

Net Investment Gains and Losses

Information regarding pretax net gains and losses from investments is as follows:

	Three Months Ended March 31,
(In millions)	2025		2024
Net investment gains (losses):
Sales and redemptions:
Fixed maturity securities available-for-sale:
Gross gains from sales	$	114	$	34
Gross losses from sales	(235)		(282)
Foreign currency gains (losses)	161		416
Other investments:
Gross gains (losses) from sales and redemptions	1		5
Total sales and redemptions	41		173
Equity securities	(61)		76
Credit losses:
Fixed maturity securities held-to-maturity	0		0
Commercial mortgage and other loans	(53)		(7)
Impairment losses	0		0
Loan commitments	(2)		1
Reinsurance recoverables and other	0		5
Total credit losses	(55)		(1)
Derivatives and other:
Derivative gains (losses)	(45)		(215)
Foreign currency gains (losses)	(843)		918
Total derivatives and other	(888)		703
Total net investment gains (losses)	$	(963)	$	951

The unrealized holding gains, net of losses, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2025 that relate to equity securities held at the March 31, 2025 reporting date were $55 million. The unrealized holding gains, net of losses, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2024 that relate to equity securities held at the March 31, 2024 reporting date were $71 million.

Unrealized Investment Gains and Losses

Effect on Shareholders’ Equity

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:

(In millions)	March 31, 2025			December 31, 2024
Unrealized gains (losses) on securities available-for-sale		$	(401)		$	1,180
Deferred income taxes		(832)			(1,156)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	(1,233)		$	24

16

Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, 2025 and December 31, 2024, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

	March 31, 2025
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and     agencies:
U.S. dollar-denominated		$	68		$	2		$	33		$	0		$	35		$	2
Japan government and     agencies:
Yen-denominated		11,951			2,608			6,090			179			5,861			2,429
Municipalities:
U.S. dollar-denominated		656			68			72			3			584			65
Yen-denominated		339			105			96			8			243			97
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		1,091			46			697			20			394			26
Yen-denominated		208			29			22			0			186			29
Public utilities:
U.S. dollar-denominated		1,689			142			816			17			873			125
Yen-denominated		1,037			155			258			23			779			132
Other currencies		53			1			53			1			0			0
Sovereign and supranational:
U.S. dollar-denominated		0			0			0			0			0			0
Yen-denominated		49			10			0			0			49			10
Banks/financial institutions:
U.S. dollar-denominated		749			30			544			7			205			23
Yen-denominated		3,576			448			472			14			3,104			434
Other corporate:
U.S. dollar-denominated		6,596			689			2,690			58			3,906			631
Yen-denominated		2,302			413			810			53			1,492			360
Total		$	30,364		$	4,746		$	12,653		$	383		$	17,711		$	4,363

17

	December 31, 2024
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and     agencies:
U.S. dollar-denominated		$	106		$	3		$	59		$	1		$	47		$	2
Japan government and     agencies:
Yen-denominated		8,136			2,234			2,070			57			6,066			2,177
Municipalities:
U.S. dollar-denominated		666			53			67			3			599			50
Yen-denominated		341			79			96			2			245			77
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		567			34			173			2			394			32
Yen-denominated		196			23			12			0			184			23
Public utilities:
U.S. dollar-denominated		1,570			151			699			19			871			132
Yen-denominated		1,020			108			368			11			652			97
Sovereign and supranational:
Yen-denominated		47			8			0			0			47			8
Banks/financial institutions:
U.S. dollar-denominated		625			36			376			7			249			29
Yen-denominated		3,197			342			471			22			2,726			320
Other corporate:
U.S. dollar-denominated		6,097			752			2,036			59			4,061			693
Yen-denominated		1,733			305			289			14			1,444			291
Total		$	24,301		$	4,128		$	6,716		$	197		$	17,585		$	3,931

Analysis of Securities in Unrealized Loss Positions

The unrealized losses on the Company's available-for-sale securities have been primarily related to general market factors such as changes in interest rates, foreign exchange rates, and/or the levels of credit spreads rather than specific concerns with the issuer's ability to pay interest and repay principal.

For available-for-sale securities in an unrealized loss position, the Company performs detailed analyses to identify whether the drivers of the decline in fair value are due to general market factors, such as the recent rise in interest rates, or due to credit-related factors. Identifying the drivers of the declines in fair value helps to align and allocate the Company‘s resources to the review and monitoring of securities with real credit-related concerns that could impact ultimate collection of principal and interest. For any significant declines in fair value determined to be non-interest rate or market-related, the Company performs a more focused review of the related issuers' specific credit profile.

For corporate issuers, the Company evaluates their assets and business profile, including industry dynamics and competitive positioning, financial statements and other available financial data. For non-corporate issuers, the Company analyzes all sources of credit support, including issuer-specific factors. The Company utilizes information available in the public domain and, for certain private placement issuers, from consultations with the issuers directly. The Company also considers ratings from Nationally Recognized Statistical Rating Organizations (NRSROs), as well as the specific characteristics of the security it owns including seniority in the issuer's capital structure, covenant protections, or other relevant features. From these reviews, the Company evaluates the issuers' continued ability to service the Company's investment through payment of interest and principal.

18

Assuming no credit-related factors develop, unrealized gains and losses on available-for-sale securities are expected to diminish as investments near maturity. Based on its credit analysis, the Company believes that the issuers of its available-for-sale investments in the sectors shown in the table above have the ability to service their obligations to the Company. Further, the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

However, if the Company identifies certain available-for-sale securities where the amortized cost basis exceeds the present value of the cash flows expected to be collected due to credit-related factors, an allowance for credit losses is recognized. Based on an evaluation of its securities currently in an unrealized loss position, the Company has determined that those securities should not have an allowance for credit losses as of March 31, 2025. Refer to the Allowance for Credit Losses section below for additional information.

As of March 31, 2025 and December 31, 2024, the Company had an immaterial amount of fixed maturity securities on nonaccrual status.

Commercial Mortgage and Other Loans

The Company classifies its transitional real estate loans (TREs), commercial mortgage loans (CMLs), middle market loans (MMLs), and other loans as held-for-investment and includes them in the commercial mortgage and other loans line on the consolidated balance sheets. The Company carries them on the balance sheet at amortized cost less an estimated allowance for credit losses.

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.

	March 31, 2025				December 31, 2024
(In millions)	Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:
Transitional real estate loans:
Office	$	1,238	11.2	%	$	1,361	12.1	%
Retail	350		3.2		349		3.1
Apartments/Multi-Family	2,158		19.6		2,201		19.6
Industrial	100		.9		117		1.1
Hospitality	526		4.8		556		5.0
Other	306		2.8		318		2.8
Total transitional real estate loans	4,678		42.5		4,902		43.7
Commercial mortgage loans:
Office	298		2.7		300		2.7
Retail	212		1.9		214		1.9
Apartments/Multi-Family	569		5.1		572		5.1
Industrial	433		3.9		436		3.9
Other	14		.1		15		.1
Total commercial mortgage loans	1,526		13.7		1,537		13.7
Middle market loans	4,451		40.4		4,423		39.4
Other loans	369		3.4		362		3.2
Total commercial mortgage and other loans	$	11,024	100.0	%	$	11,224	100.0	%
Allowance for credit losses	(368)				(355)
Total net commercial mortgage and other loans	$	10,656			$	10,869

CMLs and TREs are secured by properties entirely within the U.S. (with the largest concentrations in California (21%), Texas (14%) and Florida (10%)). MMLs are issued only to companies domiciled within the U.S. and Canada.

19

Transitional Real Estate Loans

TREs are relatively short-term floating rate commercial mortgage loans that are secured by a first lien on the property. These loans provide funding for properties undergoing a change in their physical characteristics and/or economic profile and do not typically require any principal repayment prior to the maturity date.

As of March 31, 2025, the Company had $245 million in outstanding commitments to fund TREs. These commitments are contingent on the final underwriting and due diligence to be performed.

Commercial Mortgage Loans

CMLs are typically fixed rate loans on commercial real estate with partial repayment of principal over the life of the loan with the remaining outstanding principal being repaid upon maturity. This loan portfolio is generally considered higher quality investment grade loans.

Middle Market Loans

MMLs are typically first lien senior secured cash flow loans to small to mid-size companies for working capital, refinancing, acquisition, and recapitalization. These loans are generally considered to be below investment grade.

As of March 31, 2025, the Company had commitments of approximately $664 million to fund future MMLs. These commitments are contingent upon the availability of MMLs that meet the Company's underwriting criteria.

Other Loans

Other loans are primarily infrastructure loans. Infrastructure loans are typically senior secured, financing operating portfolios of renewable and conventional energy generation assets characterized by predictable, often contractual cash flows for loan repayment. The infrastructure loan portfolio weighted average rating is investment grade.

As of March 31, 2025, the Company had commitments of approximately $1 million to fund future other loans. These commitments are contingent upon the availability of other loans that meet the Company's underwriting criteria.

Credit Quality Indicators

For TREs, the Company’s key credit quality indicators include performance of the loan and loan-to-value (LTV), which is calculated by dividing the current outstanding loan balance by the estimated property value, primarily using values at origination. Given that TREs involve properties undergoing a repositioning of their commercial profile, LTV provides the most insight into the credit risk of the loan. The Company monitors the performance of the loans periodically, but not less frequently than quarterly. The monitoring process also focuses on higher risk loans, which include those that are delinquent or for which foreclosure or deed in lieu of foreclosure is anticipated.

For CMLs, the Company’s key credit quality indicators include LTV and debt service coverage ratios (DSCR). DSCR is the most recently available net operating income of the underlying property compared to the required debt service of the loan.

For MMLs and held-to-maturity fixed maturity securities, the Company’s key credit quality indicator is credit ratings. The Company’s held-to-maturity portfolio is composed of investment grade securities that are senior unsecured instruments, while its MMLs generally have below-investment-grade ratings but are typically senior secured instruments. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

For other loans, the Company’s key credit quality indicator is credit ratings. The Company monitors these credit ratings periodically, but not less frequently than quarterly.

20

The following tables present as of March 31, 2025 the amortized cost basis of TREs, CMLs, MMLs, and other loans by year of origination and credit quality indicator.

Transitional Real Estate Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Total
Loan-to-Value Ratio:
0%-59.99%	$	0	$	0	$	0	$	371	$	390	$	47	$	808
60%-69.99%	0		0		77		431		442		396		1,346
70%-79.99%	14		0		14		823		625		64		1,540
80% or greater	0		0		0		335		353		296		984
Total	$	14	$	0	$	91	$	1,960	$	1,810	$	803	$	4,678
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	24	$	24

Commercial Mortgage Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:
0%-59.99%	$	0	$	0	$	32	$	0	$	265	$	1,009	$	1,306	2.72
60%-69.99%	0		0		0		0		25		47		72		2.11
70%-79.99%	0		0		0		0		0		55		55		1.69
80% or greater	0		13		0		0		0		80		93		0.57
Total	$	0	$	13	$	32	$	0	$	290	$	1,191	$	1,526	2.52
Weighted Average DSCR	0.00		1.13		2.62		0.00		3.16		2.38
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Middle Market Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Revolving Loans		Total
Credit Ratings:
BBB	$	0	$	30	$	29	$	0	$	78	$	108	$	12	$	257
BB	61		425		43		426		374		607		76		2,012
B	34		226		53		234		480		662		46		1,735
CCC	0		5		0		14		61		223		19		322
CC	0		0		0		13		0		16		5		34
C and lower	0		0		0		0		0		87		4		91
Total	$	95	$	686	$	125	$	687	$	993	$	1,703	$	162	$	4,451
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	11	$	3	$	0	$	14

Other Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Revolving Loans		Total
Credit Ratings:
A	$	0	$	0	$	0	$	79	$	0	$	0	$	0	$	79
AA	0		0		0		8		3		0		0		11
BBB	0		184		68		27		0		0		0		279
BB	0		0		0		0		0		0		0		0
Total	$	0	$	184	$	68	$	114	$	3	$	0	$	0	$	369
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0

21

Past Due and Nonaccrual Loans

The following tables present an aging of past due and nonaccrual loans at amortized cost, before allowance for credit losses, as of the periods presented.

	March 31, 2025
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	4,193	$	18	$	467	$	485	$	4,678	$	467
Commercial mortgage loans	1,526		0		0		0		1,526		0
Middle market loans	4,301		70		80		150		4,451		128
Other loans	369		0		0		0		369		0
Total	$	10,389	$	88	$	547	$	635	$	11,024	$	595

(1) As of March 31, 2025, there were no loans that were 90 days or more past due that continued to accrue interest.

	December 31, 2024
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	4,364	$	195	$	343	$	538	$	4,902	$	378
Commercial mortgage loans	1,537		0		0		0		1,537		0
Middle market loans	4,295		63		65		128		4,423		108
Other loans	362		0		0		0		362		0
Total	$	10,558	$	258	$	408	$	666	$	11,224	$	486

(1) As of December 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

For the three-month period ended March 31, 2025, the Company recognized $1 million of interest income for TREs, CMLs, MMLs, or other loans on nonaccrual status. For the three-month period ended March 31, 2024, the Company recognized no interest income for TREs, CMLs, MMLs, or other loans on nonaccrual status. Of these loans, TREs with an amortized cost of $146 million and $140 million had no credit loss allowance as of March 31, 2025 and December 31, 2024, respectively, because these loans are collateral dependent assets for which the estimated fair values of the collateral were in excess of amortized cost. As of March 31, 2025 and December 31, 2024, MMLs with an amortized cost of $20 million and $5 million, respectively, were on nonaccrual status without an allowance for credit losses.

Loan Modifications to Borrowers Experiencing Financial Difficulties

The Company granted certain loan modifications to borrowers experiencing financial difficulty during the first three months of 2025 and 2024. The types of modifications granted may include interest rate reductions, principal forgiveness, other-than-insignificant payment delays, term extensions or a combination of these types of modifications. The amount, timing, and extent of modifications granted are considered in determining any credit loss allowance recorded.

Loans that have both been modified and are paid or written off during the period, resulting in an amortized cost balance of zero at the end of the period, are not included in the disclosures below.

22

The following tables present the amortized cost basis of modified loans to borrowers experiencing financial difficulty and the financial effect of the modifications, disaggregated by loan classification and type of modification.

Three Months Ended March 31, 2025
(In millions)	Amortized Cost (1)		% of Total		Financial Effect
Middle Market Loans:
Principal forgiveness	$	1	0.0	%	Reduction in the amortized cost basis of $3 million
Term extension	33		1.0		Term extension of six months on average
Other-than-insignificant   payment delays	47		1.0		Delay in principal and interest payments of 23 months on average

(1) Net of allowance for credit losses

Three Months Ended March 31, 2024
(In millions)	Amortized Cost (1)		% of Total		Financial Effect
Transitional Real Estate Loans:
Other-than-insignificant payment   delays and interest rate   reduction	$	210	3.0	%	Delay in payments of 51 months on average and reduction in the weighted-average contractual interest rate from 8.3% to 6.9%

(1) Net of allowance for credit losses

The following table presents an aging of loans that received modifications in the 12 months preceding the period presented, at amortized cost.

	March 31, 2025
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More Past Due		Nonaccrual Status
Transitional real estate loans	$	347	$	0	$	0	$	0
Middle market loans	96		0		0		20
Total	$	443	$	0	$	0	$	20

The Company closely monitors the performance of the loans that are modified to borrowers experiencing financial difficulty to understand the effectiveness of its modification efforts. Loans that were granted a modification in the past 12 months, as of March 31, 2025 and 2024, and subsequently defaulted in the three-month periods ended March 31, 2025 and 2024, were immaterial.

As of March 31, 2025, the Company had $5 million of outstanding commitments to lend additional funds to borrowers experiencing financial difficulty that were granted a loan modification, compared with $14 million as of December 31, 2024.

23

Allowance for Credit Losses

The Company calculates its allowance for credit losses for held-to-maturity securities, loan receivables and loan commitments by grouping assets with similar risk characteristics when there is not a specific expectation of a loss for an individual asset. For held-to-maturity securities, MMLs, and MML commitments, the Company groups assets by credit ratings, industry, and country.

The Company groups CMLs and TREs and respective loan commitments by property type, property location and the property’s LTV and DSCR. On a quarterly basis, CMLs and TREs within a portfolio segment that share similar risk characteristics are pooled for calculation of credit loss allowance. On an ongoing basis, TREs, CMLs and other loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is probable), are evaluated individually for credit loss. For example, the credit loss allowance for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of the collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the credit loss allowance as a component of net investment gains (losses) in the consolidated statements of earnings.

The credit allowance for held-to-maturity securities and loan receivables is estimated using a probability-of-default (PD) / loss-given-default (LGD) method, discounted for the time value of money. For held-to-maturity securities, available-for-sale securities and loan receivables, the Company includes the change in present value due to the passage of time in the change in the allowance for credit losses. The Company’s methodology for estimating credit losses utilizes the contractual maturity date of the financial asset, adjusted when necessary to reflect the expected timing of repayment (such as prepayment options, renewal options, call options, or extension options). The Company applies reasonable and supportable forecasts of macroeconomic variables that impact the determination of PD / LGD over a two-year period for held-to-maturity securities and MMLs. The Company reverts to historical loss information over one year, following the two-year forecast period. For the CML and TRE portfolio, the Company applies reasonable and supportable forecasts of macroeconomic variables as well as national and local real-estate market factors to estimate future credit losses where the market factors revert back to historical levels over time with the period being dependent on current market conditions, projected market conditions and difference in the current and historical market levels for each factor. The Company continuously monitors the estimation methodology, due to changes in portfolio composition, changes in underwriting practices and significant events or conditions and makes adjustments as necessary.

The Company’s held-to-maturity portfolio includes Japan Government and Agency securities of $16.1 billion amortized cost as of March 31, 2025 that meet the requirements for zero-credit-loss expectation and therefore these asset classes have been excluded from the current expected credit loss measurement.

An investment in an available-for-sale security may be impaired if the fair value falls below amortized cost. The Company regularly reviews its available-for-sale portfolio for declines in fair value. The Company's available-for-sale impairment model focuses on the ultimate collection of the cash flows from its investments and whether the Company has the intent to sell or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. The determination of the amount of impairments under this model is based upon the Company's periodic evaluation and assessment of known and inherent risks associated with the respective securities. Such evaluations and assessments are revised as conditions change and new information becomes available.

When determining the Company's intention to sell a security prior to recovery of its amortized cost basis, the Company evaluates facts and circumstances such as, but not limited to, future cash flow needs, decisions to reposition its security portfolio, and risk profile of individual investment holdings. The Company performs ongoing analyses of its liquidity needs, which includes cash flow testing of its policy liabilities, debt maturities, projected dividend payments, and other cash flow and liquidity needs.

The Company’s methodology for estimating credit losses for available-for-sale securities utilizes the discounted cash flow model, based on past events, current market conditions and future economic conditions, as well as industry analysis and credit ratings of the securities. In addition, the Company evaluates the specific issuer’s probability of default and expected recovery of its position in the event of default based on the underlying financial condition and assets of the borrower as well as seniority and/or security of other debt holders in the issuer when developing management’s best estimate of expected cash flows.

24

The following table presents the roll forward of the allowance for credit losses by portfolio segment for loans and by accounting classification for securities.

(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Other Loans and Loan Commitments		Held-to- Maturity Securities		Available- for-Sale Securities		Total
Three Months Ended March 31, 2025:
Balance at December 31, 2024	$	(199)	$	(14)	$	(140)	$	(17)	$	(5)	$	0	$	(375)
(Addition to) release of allowance    for credit losses	(28)		(1)		(24)		(2)		0		0		(55)
Writeoffs, net of recoveries	24		0		14		0		0		0		38
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2025	$	(203)	$	(15)	$	(150)	$	(19)	$	(5)	$	0	$	(392)
Three Months Ended March 31, 2024:
Balance at December 31, 2023	$	(112)	$	(16)	$	(146)	$	(16)	$	(5)	$	0	$	(295)
(Addition to) release of allowance    for credit losses	(2)		(3)		(3)		1		0		0		(7)
Writeoffs, net of recoveries	0		0		50		0		0		0		50
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2024	$	(114)	$	(19)	$	(99)	$	(15)	$	(5)	$	0	$	(252)

As of March 31, 2025, the Company identified TREs with an amortized cost of $311 million in anticipation of potential foreclosure or deed in lieu of foreclosure transactions. As of March 31, 2025, the Company established a credit allowance of $25 million related to these loans.

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.

(In millions)	March 31, 2025			December 31, 2024
Other investments:
Policy loans		$	211		$	203
Short-term investments (1)		2,259			1,599
Limited partnerships (2)		3,482			3,435
Real estate owned		774			682
Other		37			39
Total other investments		$	6,763		$	5,958

(1) Includes securities lending collateral

(2) Includes tax credit investments and asset classes such as private equity and real estate funds

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheets. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statements of earnings.

Real estate owned (REO) consists of office buildings or other commercial properties obtained through foreclosure or deed in lieu of foreclosure of certain of the Company’s TREs. As of March 31, 2025 and December 31, 2024, all REO was classified as held-and-used for the production of income, which is carried at cost less accumulated depreciation. Depreciation expense was $6 million and $1 million for the three-month periods ended March 31, 2025 and 2024, respectively. Additionally, as of March 31, 2025 and December 31, 2024, accumulated depreciation was $20 million and $14 million, respectively.

The Company had $2.6 billion and $2.8 billion in outstanding commitments to fund investments in limited partnerships, which includes $2.0 billion and $2.1 billion of unfunded commitments related to VIEs that are non-consolidated as of March 31, 2025 and December 31, 2024, respectively.

25

Variable Interest Entities (VIEs)

In the normal course of its activities, the Company invests in legal entities that are VIEs. The Company's variable interests in VIEs are limited to the debt and equity instruments issued by them. With the exception of commitments to limited partnerships and to certain loan investments made in the normal course of business, the Company has not provided any direct or contingent obligations to fund the limited activities of these VIEs, or support related to the limited activities of these VIEs and does not have any intention to do so in the future, nor has it provided any direct or indirect financial guarantees.

The Company's risk of loss related to its interests in any of its VIEs is limited to the carrying value of the related investments, and in certain cases, to any unfunded commitments held in the VIE.

For those VIEs other than certain unit trust structures, the Company's involvement is passive in nature.

VIEs - Consolidated

If the Company determines that it is the VIE’s primary beneficiary, it consolidates the VIE. Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company except to the extent of the unfunded commitments referenced above, as the Company’s obligation to each VIE is limited to the amount of its committed investment.

The following table presents the carrying value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities

(In millions)	March 31, 2025			December 31, 2024
Assets:
Fixed maturity securities, available-for-sale		$	3,597		$	3,428
Commercial mortgage and other loans		8,540			8,693
Other investments (1)		2,151			2,176
Other assets (2)		49			53
Total assets of consolidated VIEs		$	14,337		$	14,350
Liabilities:
Other liabilities (2)		$	642		$	604
Total liabilities of consolidated VIEs		$	642		$	604

(1) Consists entirely of alternative investments in limited partnerships, which represent VIEs where the Company is not the primary beneficiary and, therefore, are not consolidated

(2) Consists entirely of derivatives

The Company is the sole investor in the consolidated VIEs listed in the table above. The Company invests in fixed maturity securities issued by VIEs that in turn hold U.S. dollar-denominated fixed maturity securities coupled with foreign currency swap agreements. The weighted-average lives of the Company's investments in these VIEs are very similar to the underlying collateral held by these VIEs. The activities of these VIEs are limited to holding invested assets and foreign currency swaps and utilizing the cash flows from these securities to service the VIEs' debt. Neither the Company nor any of its creditors are able to obtain the underlying collateral of these VIEs unless there is an event of default or other specified event. The Company is not a direct counterparty to the foreign currency swap contracts and has no control over them. The Company's loss exposure to these VIEs is limited to its original investment. These consolidated VIEs do not rely on outside or ongoing sources of funding to support their activities beyond the underlying collateral and foreign currency swap contracts, if applicable. The underlying collateral assets and funding of these consolidated VIEs are generally static in nature.

26

Investments in Unit Trust Structures

The Company also utilizes unit trust structures in its Aflac Japan segment to invest in various asset classes, which include CMLs, MMLs, TREs, other loans and limited partnerships. As the sole investor of these VIEs, the Company is required to consolidate these trusts under U.S. GAAP. The limited partnership investments are comprised of private equity and real estate funds. The Company's loss exposure to these VIEs is limited to its original investments, together with any unfunded portion of the Company's commitments made in the normal course of business to fund certain loan investments and limited partnership investments, as described in the Commercial Mortgage and Other Loans and Other Investments sections of this note. Excluding these commitments, the Company does not provide financial or other support to consolidated VIEs.

VIEs - Not Consolidated

The table below reflects the carrying value and balance sheet caption in which the Company's investments in VIEs that are not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated

(In millions)	March 31, 2025			December 31, 2024
Assets:
Fixed maturity securities, available-for-sale		$	6,624		$	6,243
Other investments (1)		1,194			1,124
Total investments in VIEs not consolidated		$	7,818		$	7,367

(1) Consists entirely of alternative investments in limited partnerships

Certain investments in VIEs that the Company is not required to consolidate are investments that are in the form of debt obligations issued by the VIEs. These fixed maturity securities include structured securities, primarily asset-backed securities. The Company's involvement in the related VIEs is limited to that of a passive investor in asset-backed securities issued by the VIEs. The Company also invests in fixed maturity debt securities issued by VIEs that are the primary financing vehicles used by their corporate sponsors to raise financing in the capital markets. The variable interests created by these VIEs are principally or solely a result of the debt instruments issued by them. The Company does not have the power to direct the activities that most significantly impact the entity's economic performance, nor does it have the obligation to absorb losses of the VIE entity or the right to receive benefits from the entity that could be significant to the entity. As such, the Company is not the primary beneficiary of these VIEs and therefore is not required to consolidate them.

The Company also holds equity investments in limited partnerships that have been determined to be VIEs. These partnerships primarily invest in private equity and real estate funds. The Company’s maximum exposure to loss on these investments is limited to the amount of its investment and any unfunded commitments. As described in the Other Investments section of this note, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to unconsolidated VIEs. The Company is not the primary beneficiary of these VIEs and is therefore not required to consolidate them. The Company classifies these investments as other investments in the consolidated balance sheets.

Securities Lending and Pledged Securities

The Company lends fixed maturity securities and, from time to time, public equity securities to financial institutions in short-term securities lending transactions. These short-term securities lending arrangements increase investment income with minimal risk. The Company receives cash or other securities as collateral for such loans. The Company's securities lending policy requires that the fair value of the securities received as collateral be 102% or more of the fair value of the loaned securities and that unrestricted cash received as collateral be 100% or more of the fair value of the loaned securities. The securities loaned continue to be carried as investment assets on the Company's balance sheet during the terms of the loans and are not reported as sales. For loans involving unrestricted cash or securities as collateral, the collateral is reported as an asset with a corresponding liability for the return of the collateral. For loans where the Company receives as collateral securities that the Company is not permitted to sell or repledge, the collateral is not reflected in the consolidated financial statements.

27

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:

Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements
	March 31, 2025						December 31, 2024
(In millions)	Overnight and Continuous(1)		Up to 30 days		Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending   transactions:
Fixed maturity securities:
Japan government and agencies	$	0	$	2,303	$	2,303	$	0	$	1,027	$	1,027
Public utilities	39		0		39		34		0		34
Banks/financial institutions	131		0		131		193		0		193
Other corporate	669		0		669		783		0		783
Total borrowings	$	839	$	2,303	$	3,142	$	1,010	$	1,027	$	2,037
Gross amount of recognized liabilities for securities    lending transactions					$	3,142					$	2,037

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

In connection with securities lending, in addition to cash collateral received, the Company received from counterparties securities collateral of $1.3 billion and $3.0 billion at March 31, 2025 and December 31, 2024, respectively, which may not be sold or re-pledged, unless the counterparty is in default. Such securities collateral is not reflected on the consolidated financial statements.

The Company did not have any repurchase agreements or repurchase-to-maturity transactions outstanding as of March 31, 2025, and December 31, 2024, respectively.

Certain fixed maturity securities can be pledged as collateral as part of derivative transactions, or pledged to support state deposit requirements on certain investment programs. For additional information regarding pledged securities related to derivative transactions, see Note 4.

4.    DERIVATIVE INSTRUMENTS

The Company's freestanding derivative financial instruments include:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening yen;

•cross-currency swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated debentures;

•foreign currency swaps that are associated with VIE bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Some of the Company's derivatives are designated as cash flow hedges, fair value hedges or net investment hedges; however, other derivatives do not qualify for hedge accounting or the Company elects not to designate them as accounting hedges.

28

Derivative Types

Foreign currency forwards and options are executed for the Aflac Japan segment in order to hedge the currency risk on the carrying value of certain U.S. dollar-denominated investments. The average maturity of these forwards and options can change depending on factors such as market conditions and types of investments being held. In situations where the maturity of the forwards and options is shorter than the underlying investment being hedged, the Company may enter into new forwards and options near maturity of the existing derivative in order to continue hedging the underlying investment. In forward transactions, Aflac Japan agrees with another party to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. The Company also uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also executes foreign currency option transactions in a collar strategy, where Aflac Japan agrees with another party to simultaneously purchase put options and sell call options. In the purchased put transactions, Aflac Japan obtains the option to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. In the sold call transactions, Aflac Japan agrees to sell a fixed amount of yen and buy a corresponding amount of U.S. dollars at a specified future date. The combination of purchasing the put option and selling the call option results in no net premium being paid (i.e. a costless or zero-cost collar).

From time to time, the Company may also enter into foreign currency forwards and options to hedge the currency risk associated with the net investment in Aflac Japan. In these forward transactions, the Company agrees with another party to buy a fixed amount of U.S. dollars and sell a corresponding amount of yen at a specified price at a specified future date. In the option transactions, the Company may use a combination of foreign currency options to protect expected future cash flows by simultaneously purchasing yen put options (options that protect against a weakening yen) and selling yen call options (options that limit participation in a strengthening yen). The combination of these two actions create a zero-cost collar. Additionally, the Company enters into purchased options to hedge cash flows from the net investment in Aflac Japan.

The Company enters into foreign currency swaps pursuant to which it exchanges an initial principal amount in one currency for an initial principal amount of another currency, with an agreement to re-exchange the principal amounts at a future date. There may also be periodic exchanges of payments at specified intervals based on the agreed upon rates and notional amounts. Foreign currency swaps are used primarily in the consolidated VIEs in the Company's Aflac Japan portfolio to convert foreign-denominated cash flows to yen, the functional currency of Aflac Japan, in order to minimize cash flow fluctuations. The Company also uses foreign currency swaps to economically convert certain of its U.S. dollar-denominated senior note and subordinated debenture principal and interest obligations into yen-denominated obligations.

In order to reduce investment income volatility from its variable-rate investments, the Company enters into receive–fixed, pay–floating interest rate swaps. These derivatives are cleared and settled through a central clearinghouse.

Swaptions are used to mitigate the adverse impact resulting from significant changes in the fair value of U.S. dollar-denominated available-for-sale securities due to fluctuation in interest rates. In a payer swaption, the Company pays a premium to obtain the right, but not the obligation, to enter into a swap contract where it will pay a fixed rate and receive a floating rate. Interest rate swaption collars are combinations of two swaption positions. In order to maximize the efficiency of the collars while minimizing cost, a collar strategy is used whereby the Company purchases a long payer swaption (the Company purchases an option that allows it to enter into a swap where the Company will pay the fixed rate and receive the floating rate of the swap) and sells a short receiver swaption (the Company sells an option that provides the counterparty with the right to enter into a swap where the Company will receive the fixed rate and pay the floating rate of the swap). The combination of purchasing the long payer swaption and selling the short receiver swaption results in no net premium being paid (i.e. a costless or zero-cost collar).

Bond purchase commitments result from repackaged bond structures that are consolidated VIEs whereby there is a delay in the trade date and settlement date of the bond within the structure to ensure completion of all necessary legal agreements to support the consolidated VIE that issues the repackaged bond. Since the Company has a commitment to purchase the underlying bond at a specified price, the agreement meets the definition of a derivative where the value is derived based on the current market value of the bond compared to the fixed purchase price to be paid on the settlement date.

29

Derivative Balance Sheet Classification

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in other assets, while derivative liabilities are included in other liabilities within the Company’s consolidated balance sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.

		March 31, 2025									December 31, 2024
(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative   Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:
Foreign currency swaps - VIE		$	18		$	0		$	5		$	18		$	0		$	6
Total cash flow hedges		18			0			5			18			0			6
Net investment hedge:
Foreign currency forwards		2,674			91			38			1,809			185			0
Total net investment hedge		2,674			91			38			1,809			185			0
Non-qualifying strategies:
Foreign currency swaps		0			0			0			450			2			0
Foreign currency swaps - VIE		3,068			49			637			3,042			53			598
Foreign currency forwards		173			1			1			0			0			0
Foreign currency options		24,195			2			0			24,195			0			0
Interest rate swaps		29,280			5			304			17,230			0			329
Total non-qualifying strategies		56,716			57			942			44,917			55			927
Total derivatives		$	59,408		$	148		$	985		$	46,744		$	240		$	933

Cash Flow Hedges

From time to time, for certain variable-rate available-for-sale securities held by Aflac Japan via consolidated VIEs, foreign currency swaps are used to swap the variable rate interest to fixed rate interest as well as interest cash flows between Japanese yen and U.S. dollar. The Company has designated foreign currency swaps as a hedge of the variability in cash flows of a forecasted transaction or of amounts to be received or paid related to a recognized asset (“cash flow” hedge). The remaining maximum length of time for which these cash flows are hedged is approximately two years. The derivatives in the Company's consolidated VIEs that are not designated as accounting hedges are discussed in the Non-qualifying Strategies section of this note.

Fair Value Hedges

The Company designates and accounts for certain foreign currency forwards, options, and interest rate swaptions as fair value hedges when they meet the requirements for hedge accounting. The Company recognizes gains and losses on these derivatives as well as the offsetting gain or loss on the related hedged items in current earnings.

Foreign currency forwards and options hedge the foreign currency exposure of certain U.S. dollar-denominated available-for-sale fixed-maturity investments held in Aflac Japan. The change in the fair value of the foreign currency forwards related to the changes in the difference between the spot rate and the forward price is excluded from the assessment of hedge effectiveness. The change in fair value of the foreign currency option related to the time value of the option is recognized in current earnings and is excluded from the assessment of hedge effectiveness.

Interest rate swaptions hedge the interest rate exposure of certain U.S. dollar-denominated available-for-sale securities held in Aflac Japan. For these hedging relationships, the Company excludes time value from the assessment of hedge effectiveness and recognizes changes in the intrinsic value of the swaptions in current earnings within net investment income. The change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into earnings (net investment income) over its legal term.

30

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount. The Company had no fair value hedges of interest rate risk as of March 31, 2025 and December 31, 2024; therefore, the amounts presented in the table below are related to previous fair value hedges of interest rate risk that were discontinued.

(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
		March 31, 2025		December 31, 2024		March 31, 2025		December 31, 2024
Fixed maturity securities		$	1,305	$	1,294	$	128	$	137

(1) The balance includes hedging adjustment on discontinued hedging relationships of $128 in 2025 and $137 in 2024.

Net Investment Hedge

The Company's investment in Aflac Japan is affected by changes in the yen/dollar exchange rate. To mitigate this exposure, the Parent Company's yen-denominated liabilities (see Note 9) have been designated as non-derivative hedges and certain foreign currency forwards and options have been designated as derivative hedges of the foreign currency exposure of the Company's net investment in Aflac Japan.

The Company's net investment hedge was effective during the three-month periods ended March 31, 2025 and 2024, respectively.

Non-qualifying Strategies

For the Company's derivative instruments in consolidated VIEs that do not qualify for hedge accounting treatment, all changes in their fair value are reported in current period earnings in net investment gains (losses). The amount of gain or loss recognized in earnings for the Company's VIEs is attributable to the derivatives in those investment structures. While the change in value of the swaps is recorded in current period earnings, the change in value of the available-for-sale fixed maturity securities associated with these swaps is recorded in other comprehensive income.

The Parent Company had cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert interest and principal on the notes from U.S. dollar to Japanese yen. These swaps matured in March 2025. Changes in the values of these swaps were recorded in earnings in the period where they occurred.

The Company uses foreign currency forwards and options to economically mitigate the currency risk of some of its U.S. dollar-denominated loan receivables and U.S. government fixed maturity securities held in the Aflac Japan segment. These arrangements are not designated as accounting hedges, as the foreign currency remeasurement of the loan receivables impacts current period earnings, and substantially offsets gains and losses from foreign currency forwards within net investment gains (losses). The Company also has certain foreign currency forwards on U.S. dollar-denominated available-for-sale securities where hedge accounting is not being applied.

The Company uses interest rate swaps to economically convert the variable rate investment income to a fixed rate on certain variable-rate investments.

31

Impact of Derivatives and Hedging Instruments

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

	Three Months Ended March 31,
	2025										2024
(In millions)	Net Investment Income			Net Investment Gains (Losses)				Other Comprehensive  Income (Loss)			Net Investment Income			Net Investment Gains (Losses)				Other Comprehensive  Income (Loss)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	2		$	0		$	(1)			$	0
Total cash flow hedges		0			(1)		(1)		2			0			(1)		(1)		0
Net investment hedge:
Non-derivative hedging           instruments					0				(240)						0				236
Foreign currency forwards					36				(144)						44				145
Total net investment hedge					36				(384)						44				381
Non-qualifying strategies:
Foreign currency swaps					0										1
Foreign currency swaps - VIE					(57)										(88)
Foreign currency forwards					0										17
Foreign currency options					(5)										(41)
Interest rate swaps					(18)										(147)
Total non-qualifying strategies					(80)										(258)
Total		$	0		$	(45)			$	(382)		$	0		$	(215)			$	381

(1) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2025, and $1 of losses during the three-month period ended March 31, 2024.

Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedged item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items. Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statements of comprehensive income (loss).

As of March 31, 2025, $3 million of deferred losses on derivative instruments recorded in accumulated other comprehensive income are expected to be reclassified into earnings during the next twelve months.

Credit Risk Assumed through Derivatives

For the foreign currency swaps associated with the Company's VIE investments for which it is the primary beneficiary, the Company bears the risk of loss due to counterparty default even though it is not a direct counterparty to those contracts.

The Company is a direct counterparty to the foreign currency swaps that it has entered into in connection with certain of its senior notes and subordinated debentures; foreign currency forwards; and foreign currency options, and therefore the Company is exposed to credit risk in the event of nonperformance by the counterparties in those contracts. The risk of counterparty default for the Company's foreign currency swaps, certain foreign currency forwards, and foreign currency options is mitigated by collateral posting requirements that counterparties to those transactions must meet.

As of March 31, 2025, all of the Company's derivative agreement counterparties were investment grade.

32

The Company engages in over-the-counter (OTC) bilateral derivative transactions directly with unaffiliated third parties under International Swaps and Derivatives Association, Inc. (ISDA) agreements and other documentation. Most of the ISDA agreements also include Credit Support Annexes (CSAs) provisions, which generally provide for two-way collateral postings at the first dollar of exposure. The Company mitigates the risk that counterparties to transactions might be unable to fulfill their contractual obligations by monitoring counterparty credit exposure and collateral value while generally requiring that collateral be posted at the outset of the transaction. In addition, a significant portion of the derivative transactions have provisions that give the counterparty the right to terminate the transaction upon a downgrade of the Company's financial strength rating. The actual amount of payments that the Company could be required to make depends on market conditions, the fair value of outstanding affected transactions, and other factors prevailing at and after the time of the downgrade.

The Company also engages in OTC cleared derivative transactions through regulated central clearing counterparties. These positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to these derivatives.

Collateral posted by the Company to third parties for derivative transactions can generally be repledged or resold by the counterparties. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position by counterparty was approximately $883 million and $804 million as of March 31, 2025 and December 31, 2024, respectively. If the credit-risk-related contingent features underlying these agreements had been triggered on March 31, 2025, the Company estimates that it would be required to post a maximum of $584 million of additional collateral to these derivative counterparties. The Company is generally allowed to sell or repledge collateral obtained from its derivative counterparties, although it does not typically exercise such rights. See the Offsetting tables below for collateral posted or received as of the reported balance sheet dates.

Offsetting of Financial Instruments and Derivatives

Most of the Company's derivative instruments are subject to enforceable master netting arrangements that provide for the net settlement of all derivative contracts between the Parent Company or its subsidiaries and the respective counterparty in the event of default or upon the occurrence of certain termination events. Collateral support agreements with the master netting arrangements generally provide that the Company will receive or pledge financial collateral at the first dollar of exposure.

The Company has securities lending agreements with unaffiliated financial institutions that post collateral to the Company in return for the use of its fixed maturity and public equity securities (see Note 3). When the Company has entered into securities lending agreements with the same counterparty, the agreements generally provide for net settlement in the event of default by the counterparty. This right of set-off allows the Company to keep and apply collateral received if the counterparty failed to return the securities borrowed from the Company as contractually agreed.

The tables below summarize the Company's derivatives and securities lending transactions, and as reflected in the tables, in accordance with U.S. GAAP, the Company's policy is to not offset these financial instruments in the consolidated balance sheets.

33

Offsetting of Financial Assets and Derivative Assets

March 31, 2025
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	94		$	0		$	94		$	(36)	$	(12)		$	(46)		$	0
OTC - cleared		5			0			5			(5)		0			0			0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		99			0			99			(41)		(12)			(46)			0
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		49						49											49
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		49						49											49
Total derivative       assets		148			0			148			(41)		(12)			(46)			49
Securities lending    and similar    arrangements		3,128			0			3,128			0		0			(3,128)			0
Total		$	3,276		$	0		$	3,276		$	(41)	$	(12)		$	(3,174)		$	49

34

December 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	187		$	0		$	187		$	0	$	(45)		$	(135)		$	7
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		187			0			187			0		(45)			(135)			7
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		53						53											53
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		53						53											53
Total derivative       assets		240			0			240			0		(45)			(135)			60
Securities lending    and similar    arrangements		2,001			0			2,001			0		0			(2,001)			0
Total		$	2,241		$	0		$	2,241		$	0	$	(45)		$	(2,136)		$	60

35

Offsetting of Financial Liabilities and Derivative Liabilities

March 31, 2025
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	39		$	0		$	39		$	(36)	$	0		$	0		$	3
OTC - cleared		304			0			304			(5)		(17)			(282)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		343			0			343			(41)		(17)			(282)			3
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		642						642											642
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		642						642											642
Total derivative       liabilities		985			0			985			(41)		(17)			(282)			645
Securities lending    and similar    arrangements		3,142			0			3,142			(3,128)		0			0			14
Total		$	4,127		$	0		$	4,127		$	(3,169)	$	(17)		$	(282)		$	659

36

December 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - cleared		$	329		$	0		$	329		$	0	$	0		$	(329)		$	0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		329			0			329			0		0			(329)			0
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		604						604											604
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		604						604											604
Total derivative       liabilities		933			0			933			0		0			(329)			604
Securities lending    and similar    arrangements		2,037			0			2,037			(2,001)		0			0			36
Total		$	2,970		$	0		$	2,970		$	(2,001)	$	0		$	(329)		$	640

For additional information on the Company's financial instruments, see the accompanying Notes 3 and 5 and Notes 1, 3 and 5 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

37

5.    FAIR VALUE MEASUREMENTS

Fair Value Hierarchy

U.S. GAAP specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. These two types of inputs create three valuation hierarchy levels, as follows:

•Level 1 valuations reflect quoted market prices for identical assets or liabilities in active markets.

•Level 2 valuations reflect quoted market prices for similar assets or liabilities in an active market, quoted market prices for identical or similar assets or liabilities in non-active markets or model-derived valuations in which all significant valuation inputs are observable in active markets.

•Level 3 valuations reflect valuations in which one or more of the significant inputs are not observable in an active market.

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	16,972		$	845		$	0		$	17,817
Municipalities		0			2,055			0			2,055
Mortgage- and asset-backed securities		0			2,445			1,603			4,048
Public utilities		0			6,465			756			7,221
Sovereign and supranational		0			402			24			426
Banks/financial institutions		0			9,351			10			9,361
Other corporate		0			26,079			137			26,216
Total fixed maturity securities		16,972			47,642			2,530			67,144
Equity securities		604			0			160			764
Other investments		2,259			0			0			2,259
Cash and cash equivalents		5,231			0			0			5,231
Other assets:
Foreign currency swaps		0			49			0			49
Foreign currency forwards		0			92			0			92
Foreign currency options		0			2			0			2
Interest rate swaps		0			5			0			5
Total other assets		0			148			0			148
Total assets		$	25,066		$	47,790		$	2,690		$	75,546
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	642		$	0		$	642
Foreign currency forwards		0			39			0			39
Interest rate swaps		0			304			0			304
Total liabilities		$	0		$	985		$	0		$	985

38

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	17,088		$	758		$	0		$	17,846
Municipalities		0			2,034			0			2,034
Mortgage- and asset-backed securities		0			2,407			1,156			3,563
Public utilities		0			6,398			647			7,045
Sovereign and supranational		0			393			23			416
Banks/financial institutions		0			8,946			10			8,956
Other corporate		0			25,178			231			25,409
Total fixed maturity securities		17,088			46,114			2,067			65,269
Equity securities		639			0			157			796
Other investments		1,599			0			0			1,599
Cash and cash equivalents		6,229			0			0			6,229
Other assets:
Foreign currency swaps		0			55			0			55
Foreign currency forwards		0			185			0			185
Total other assets		0			240			0			240
Total assets		$	25,555		$	46,354		$	2,224		$	74,133
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	604		$	0		$	604
Interest rate swaps		0			329			0			329
Total liabilities		$	0		$	933		$	0		$	933

39

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.

	March 31, 2025
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,     carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	16,193		$	16,262		$	144		$	0		$	16,406
Municipalities		249			0			260			0			260
Public utilities		33			0			33			0			33
Sovereign and    supranational		396			0			418			0			418
Other corporate		17			0			18			0			18
Commercial mortgage and     other loans		10,656			0			0			10,451			10,451
Other investments (1)		37			0			37			0			37
Total assets		$	27,581		$	16,262		$	910		$	10,451		$	27,623
Liabilities:
Other policyholders’ funds		$	5,863		$	0		$	0		$	5,789		$	5,789
Notes payable    (excluding leases)		7,653			0			6,533			714			7,247
Total liabilities		$	13,516		$	0		$	6,533		$	6,503		$	13,036

(1) Excludes policy loans of $211, equity method investments of $3,482, and REO of $774, at carrying value

40

	December 31, 2024
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,    carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	15,309		$	15,916		$	143		$	0		$	16,059
Municipalities		235			0			257			0			257
Public utilities		32			0			33			0			33
Sovereign and    supranational		374			0			405			0			405
Other corporate		16			0			18			0			18
Commercial mortgage and     other loans		10,869			0			0			10,653			10,653
Other investments (1)		39			0			39			0			39
Total assets		$	26,874		$	15,916		$	895		$	10,653		$	27,464
Liabilities:
Other policyholders’ funds		$	5,460		$	0		$	0		$	5,389		$	5,389
Notes payable    (excluding leases)		7,402			0			6,352			675			7,027
Total liabilities		$	12,862		$	0		$	6,352		$	6,064		$	12,416

(1) Excludes policy loans of $203, equity method investments of $3,435, and REO of $682, at carrying value

Fair Value of Financial Instruments

Fixed maturity and equity securities

The fair values of the Company's public fixed maturity securities are generally based on prices provided by third-party pricing vendors. The Company utilizes internally generated valuations or broker quotes for privately issued fixed maturity securities or fixed maturity securities where there is no price available from a third-party pricing vendor.

The fair values of the Company's public equity securities are generally based on price quotes, including quoted market prices readily available from independent public exchange markets or established security dealer associations. The Company determines the fair values of privately issued equity securities using the following approaches or techniques:

•price quotes and valuations from third-party pricing vendors,

•in-house valuations, and

•non-binding price quotes the Company obtains from outside brokers.

The pricing data and market quotes the Company obtains from outside sources, including third-party pricing services, are reviewed internally for reasonableness. If a fair value appears unreasonable, the Company will re-examine the inputs and assess the reasonableness of the pricing data with the provider. Additionally, the Company may compare the inputs to relevant market indices and other performance measurements. Based on management's analysis, the valuation is confirmed or may be revised if there is evidence of a more appropriate estimate of fair value based on available market data. The Company has performed verification of the inputs and calculations in any valuation models, including independent validations and back testing, to confirm that the valuations represent reasonable estimates of fair value. For the periods presented, the Company has not adjusted the quotes or prices it obtains from the pricing services and brokers it uses.

For internally generated valuations, the Company utilizes valuation models developed by a third-party pricing vendor. The models and associated processes and controls are executed by Company personnel.

41

These models are discounted cash flow (DCF) valuation models but also use information from related markets, specifically public bond markets and the credit default swap (CDS) market, to estimate expected cash flows. The models take into consideration any unique characteristics of the securities and make various adjustments to arrive at an appropriate issuer-specific loss adjusted credit curve using the most appropriate comparable security(ies) of the issuer and issuer-specific CDS spreads. This credit curve is then used with the relevant recovery rates to estimate expected cash flows and modeling of additional features, including illiquidity adjustments, if necessary, to price the security by discounting those loss adjusted cash flows. In cases where a credit curve cannot be developed from market information for the specific issuer, the valuation methodology takes into consideration other market observable inputs, including:

•the most appropriate comparable security(ies) of a guarantor and/or parent

•CDS spreads of a guarantor and/or parent

•bonds of comparable issuers with similar characteristics such as rating, geography, or sector

•CDS spreads of an appropriate index or of comparable issuers with similar characteristics such as rating, geography, or sector

•bond indices that are comparative in rating, industry, maturity, and region.

42

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	16,972		$	524		$	0		$	17,496
Internal		0			321			0			321
Total government and agencies		16,972			845			0			17,817
Municipalities:
Third-party pricing vendor		0			1,812			0			1,812
Internal		0			243			0			243
Total municipalities		0			2,055			0			2,055
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,258			0			2,258
Internal		0			187			37			224
Broker/other		0			0			1,566			1,566
Total mortgage- and asset-backed securities		0			2,445			1,603			4,048
Public utilities:
Third-party pricing vendor		0			3,644			0			3,644
Internal		0			2,821			0			2,821
Broker/other		0			0			756			756
Total public utilities		0			6,465			756			7,221
Sovereign and supranational:
Third-party pricing vendor		0			78			0			78
Internal		0			324			0			324
Broker/other		0			0			24			24
Total sovereign and supranational		0			402			24			426
Banks/financial institutions:
Third-party pricing vendor		0			5,416			0			5,416
Internal		0			3,935			6			3,941
Broker/other		0			0			4			4
Total banks/financial institutions		0			9,351			10			9,361
Other corporate:
Third-party pricing vendor		0			20,762			0			20,762
Internal		0			5,317			21			5,338
Broker/other		0			0			116			116
Total other corporate		0			26,079			137			26,216
Total securities available-for-sale		$	16,972		$	47,642		$	2,530		$	67,144
Equity securities, carried at fair value:
Third-party pricing vendor		$	604		$	0		$	0		$	604
Internal		0			0			26			26
Broker/other		0			0			134			134
Total equity securities		$	604		$	0		$	160		$	764

43

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	16,262		$	144		$	0		$	16,406
Total government and agencies		16,262			144			0			16,406
Municipalities:
Third-party pricing vendor		0			260			0			260
Total municipalities		0			260			0			260
Public utilities:
Third-party pricing vendor		0			33			0			33
Total public utilities		0			33			0			33
Sovereign and supranational:
Third-party pricing vendor		0			205			0			205
Internal		0			213			0			213
Total sovereign and supranational		0			418			0			418
Other corporate:
Third-party pricing vendor		0			18			0			18
Total other corporate		0			18			0			18
Total securities held-to-maturity		$	16,262		$	873		$	0		$	17,135

44

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	17,088		$	446		$	0		$	17,534
Internal		0			312			0			312
Total government and agencies		17,088			758			0			17,846
Municipalities:
Third-party pricing vendor		0			1,791			0			1,791
Internal		0			243			0			243
Total municipalities		0			2,034			0			2,034
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,352			0			2,352
Internal		0			55			37			92
Broker/other		0			0			1,119			1,119
Total mortgage- and asset-backed securities		0			2,407			1,156			3,563
Public utilities:
Third-party pricing vendor		0			3,628			0			3,628
Internal		0			2,770			0			2,770
Broker/other		0			0			647			647
Total public utilities		0			6,398			647			7,045
Sovereign and supranational:
Third-party pricing vendor		0			78			0			78
Internal		0			315			0			315
Broker/other		0			0			23			23
Total sovereign and supranational		0			393			23			416
Banks/financial institutions:
Third-party pricing vendor		0			4,975			0			4,975
Internal		0			3,971			5			3,976
Broker/other		0			0			5			5
Total banks/financial institutions		0			8,946			10			8,956
Other corporate:
Third-party pricing vendor		0			20,051			0			20,051
Internal		0			5,127			116			5,243
Broker/other		0			0			115			115
Total other corporate		0			25,178			231			25,409
Total securities available-for-sale		$	17,088		$	46,114		$	2,067		$	65,269
Equity securities, carried at fair value:
Third-party pricing vendor		$	639		$	0		$	0		$	639
Internal		0			0			26			26
Broker/other		0			0			131			131
Total equity securities		$	639		$	0		$	157		$	796

45

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	15,916		$	143		$	0		$	16,059
Total government and agencies		15,916			143			0			16,059
Municipalities:
Third-party pricing vendor		0			257			0			257
Total municipalities		0			257			0			257
Public utilities:
Third-party pricing vendor		0			33			0			33
Total public utilities		0			33			0			33
Sovereign and supranational:
Third-party pricing vendor		0			198			0			198
Internal		0			207			0			207
Total sovereign and supranational		0			405			0			405
Other corporate:
Third-party pricing vendor		0			18			0			18
Total other corporate		0			18			0			18
Total securities held-to-maturity		$	15,916		$	856		$	0		$	16,772

The following is a discussion of the determination of fair value of the Company's remaining financial instruments.

Derivatives

The Company uses derivative instruments to manage the risk associated with certain assets. However, the derivative instrument may not be classified in the same fair value hierarchy level as the associated asset. The significant inputs to pricing derivatives are generally observable in the market or can be derived by observable market data. When these inputs are observable, the derivatives are classified as Level 2.

The Company uses present value techniques to value non-option based derivatives. It also uses option pricing models to value option based derivatives. Key inputs are as follows:

Instrument Type	Level 2
Interest rate derivatives	Swap yield curves Basis curves Interest rate volatility (1)
Foreign currency exchange rate derivatives - Non-VIEs (forwards, swaps and options)	Foreign currency forward rates Swap yield curves Basis curves Foreign currency spot rates Foreign cross-currency basis curves Foreign currency volatility (1)
Foreign currency exchange rate derivatives - VIEs (swaps)	Foreign currency spot rates Swap yield curves Credit default swap curves Basis curves Recovery rates Foreign currency forward rates Foreign cross-currency basis curves

(1) Option-based only

46

The fair values of the foreign currency forwards and options are based on observable market inputs, therefore they are classified as Level 2.

The Parent Company had cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S. dollar to Japanese yen. These swaps matured in March 2025. Their fair values were based on observable market inputs, therefore they were classified as Level 2.

To determine the fair value of its interest rate derivatives, the Company uses inputs that are generally observable in the market or can be derived from observable market data. Interest rate swaps are cleared trades. In a cleared swap contract, the clearinghouse provides benefits to the counterparties similar to contracts listed for investment traded on an exchange since it maintains a daily margin to mitigate counterparties' credit risk. These derivatives are priced using observable inputs, accordingly, they are classified as Level 2.

For derivatives associated with VIEs where the Company is the primary beneficiary, the Company is not the direct counterparty to the swap contracts. Nevertheless, the Company has full transparency into the contracts to properly value the swaps for reporting purposes. For these derivatives, the Company utilizes valuation models developed by independent valuation analytics providers. The models are market standard DCF models and all associated processes and controls are executed by Company personnel. These models take into consideration any unique characteristics of the derivatives in determining the appropriate valuation methodology to estimate expected cash flows. The fair values of these swaps are based on observable market inputs and are classified as Level 2 within the fair value hierarchy.

For forward bond purchase commitments with VIEs, the fair value of the derivative is based on the difference in the fixed purchase price and the current market value of the related bond prior to the settlement date. Since the bond is typically a public bond with readily available pricing, the derivatives associated with the forward purchase commitment are classified as Level 2 within the fair value hierarchy.

Commercial mortgage and other loans

Commercial mortgage and other loans include TREs, CMLs, MMLs and other loans. The Company's loan receivables do not have readily determinable market prices and generally lack market liquidity. Fair values for loan receivables are determined based on the present value of expected future cash flows discounted at the applicable U.S. Treasury or floating-rate benchmark yield plus an appropriate spread that considers other risk factors, such as credit and liquidity risk. The spreads are a significant component of the pricing inputs and are generally considered unobservable. Therefore, these investments are classified as Level 3 within the fair value hierarchy.

Other investments

Other investments includes short-term investments that are measured at fair value where amortized cost approximates fair value.

Other policyholders' funds

The largest component of the other policyholders' funds liability is the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums. For this product, the Company estimates the fair value to be equal to the cash surrender value. This is analogous to the value paid to policyholders on the valuation date if they were to surrender their policy. The Company periodically checks the cash value against discounted cash flow projections for reasonableness. The Company considers its inputs for this valuation to be unobservable and have accordingly classified this valuation as Level 3.

Notes payable

The fair values of the Company's publicly issued notes payable are determined by utilizing available sources of observable inputs from third-party pricing vendors and are classified as Level 2. The Company's private placement notes payable are valued using the same internal models that the Company uses for its yen-denominated and U.S. dollar-denominated private placement investment portfolio. The fair values for these private placements are deemed Level 2 valuations, as they are model-derived valuations that are generated internally with all significant valuation inputs being observed in active markets. The fair values of the Company's yen-denominated loans approximate their carrying values and are classified as Level 3.

47

Transfers between Hierarchy Levels and Level 3 Rollforward

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

The following tables present the changes in fair value of the Company's investments carried at fair value classified as Level 3.

Three Months Ended March 31, 2025
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	1,156	$	647	$	23	$	10	$	231	$	157	$	2,224
Net investment gains (losses) included   in earnings	0		0		0		0		0		1		1
Unrealized gains (losses) included in   other comprehensive income (loss)	10		6		1		0		2		0		19
Purchases, issuances, sales and   settlements:
Purchases	434		110		0		0		0		3		547
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		(1)		(1)
Settlements	(12)		(7)		0		0		(1)		0		(20)
Transfers into Level 3	15		0		0		0		0		0		15
Transfers out of Level 3	0		0		0		0		(95)		0		(95)
Balance, end of period	$	1,603	$	756	$	24	$	10	$	137	$	160	$	2,690
Changes in unrealized gains (losses)   relating to Level 3 assets and liabilities   still held at the end of the period   included in earnings	$	0	$	0	$	0	$	0	$	0	$	1	$	1

Three Months Ended March 31, 2024
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	772	$	253	$	30	$	78	$	648	$	248	$	2,029
Net investment gains (losses) included   in earnings	1		0		0		0		0		(5)		(4)
Unrealized gains (losses) included in   other comprehensive income (loss)	(4)		(10)		(2)		(4)		1		0		(19)
Purchases, issuances, sales and   settlements:
Purchases	118		60		0		5		37		0		220
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(28)		(22)		0		(5)		(3)		(84)		(142)
Transfers into Level 3	0		226		0		0		0		0		226
Transfers out of Level 3	0		0		0		0		(233)		0		(233)
Balance, end of period	$	859	$	507	$	28	$	74	$	450	$	159	$	2,077
Changes in unrealized gains (losses)   relating to Level 3 assets and liabilities   still held at the end of the period   included in earnings	$	1	$	0	$	0	$	0	$	0	$	(3)	$	(2)

48

Fair Value Sensitivity

Level 3 Significant Unobservable Input Sensitivity

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

March 31, 2025
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	1,603	Consensus pricing	Offered quotes	86.24	-	106.46	(a)	99.62
Public utilities		756		Discounted cash flow	Credit spreads	100 bps	-	407 bps	(c)	164 bps
Sovereign and supranational		24		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		10		Adjusted cost	Private financials	N/A			(d)	N/A
Other corporate		137		Discounted cash flow	Credit spreads	100 bps	-	294 bps	(c)	198 bps
Equity securities		160		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,690

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

(b) Category represents a single security; range not applicable

(c) Actual or equivalent credit spreads in basis points

(d) Prices do not utilize credit spreads; therefore, range is not applicable

December 31, 2024
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	1,156	Consensus pricing	Offered quotes	84.08	-	104.60	(a)	99.07
Public utilities		647		Discounted cash flow	Credit spreads	100 bps	-	375 bps	(c)	162 bps
Sovereign and supranational		23		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		10		Adjusted cost	Private financials	N/A			(d)	N/A
Other corporate		231		Discounted cash flow	Credit spreads	91 bps	-	294 bps	(c)	173 bps
Equity securities		157		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,224

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

(b) Category represents a single security; range not applicable

(c) Actual or equivalent credit spreads in basis points

(d) Prices do not utilize credit spreads; therefore, range is not applicable

49

The following is a discussion of the significant unobservable inputs or valuation techniques used in determining the fair value of securities classified as Level 3.

Credit Spreads

The Company holds certain assets that are of a unique, specialized, and/or securitized nature that do not trade on a regular basis in an active market, which makes their fair values difficult to estimate. Most of these assets are managed by external asset managers and the Company utilizes these managers for their expertise when evaluating various inputs used to determine the fair values for these assets, including identifying the appropriate credit or risk spread over risk-free interest rates that incorporates the unique nature or structure of the asset in the valuations. For those assets of a similar nature but not managed by external asset managers, the Company internally estimates the spreads and risk adjustments over risk-free interest rates that reflect the unique nature or structure of the asset as well as the current pricing environment and market conditions for comparable or related investments. Credit or risk spreads are an important input needed to complete the discounted cash flow analyses used to estimate an investment’s fair value. Credit or risk spreads underlying these fair values are a significant, unobservable input whose derivation is based on the Company’s evaluation of a combination of the external manager’s expertise and knowledge, the current pricing environment, and market conditions for the specific asset.

Offered Quotes

In circumstances where the Company's valuation model price is overridden because it implies a value that is not consistent with current market conditions, the Company will solicit bids from a limited number of brokers. The Company also receives unadjusted prices from brokers for certain of its mortgage and asset-backed securities. These quotes are non-binding but are reflective of valuation best estimates at that particular point in time. Offered quotes are an unobservable input in the determination of fair value of mortgage- and asset-backed securities, certain banks/financial institutions, certain other corporate, and equity securities investments.

Private Financials

The Company invests in the debt and equity securities of private companies operating in the cancer, healthtech, insurtech, finance, internet of things, big data and analytics sectors. Due to their private and often small, startup nature, these companies rely on capital provided by institutional and private equity investors for their ongoing operations. They do not have public securities that trade on a regular basis in an active market, which makes their fair values difficult to estimate. The Company values these investments on a cost basis with appropriate adjustments made based on monitoring private financial information provided by these companies. Adjustments to valuations are generally made as new funding tranches are executed or if the financial information provided significantly changes indicating the need for impairment. This private financial information is unobservable and is a significant determinant in the fair value of these corporate venture investments.

For additional information on the Company's investments and financial instruments, see the accompanying Notes 3 and 4 and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

6.     DEFERRED POLICY ACQUISITION COSTS

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.

50

	March 31, 2025
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2024	$	2,776	$	1,833	$	441	$	52	$	915	$	636	$	1,348	$	452	$	86	$	219	$	0	$	8,758
Capitalization	61		27		9		1		33		31		38		21		3		22		0		246
Amortization expense	(46)		(25)		(8)		0		(36)		(31)		(39)		(19)		(3)		(9)		0		(216)
Foreign currency translation and   other	160		107		27		1		0		0		0		0		0		0		0		295
Balance at March 31, 2025	$	2,951	$	1,942	$	469	$	54	$	912	$	636	$	1,347	$	454	$	86	$	232	$	0	$	9,083

	December 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132
Capitalization	300		103		36		4		141		129		165		89		12		77		0		1,056
Amortization expense	(184)		(100)		(34)		(3)		(143)		(118)		(153)		(73)		(12)		(30)		(1)		(851)
Foreign currency translation and   other	(311)		(211)		(52)		(5)		0		0		0		0		0		0		0		(579)
Balance at December 31, 2024	$	2,776	$	1,833	$	441	$	52	$	915	$	636	$	1,348	$	452	$	86	$	219	$	0	$	8,758

The Company uses the following constant level bases to amortize deferred policy acquisition costs:

Policy Type	Constant-level Basis
Life Products (U.S.)	Face Amount
Health Products (U.S.)	Number of Policies in Force
Health & Life Products (Japan)	Units in Force

Face amount is the stated dollar amount that the policy’s beneficiaries receive upon the death of the insured. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount and insurance in force, respectively. Future DAC amortization is impacted by persistency.

There were no changes to the inputs, judgments, assumptions or methods used to determine amortization amounts during the three-month periods ended March 31, 2025 and 2024. For additional information on deferred policy acquisition costs, see Notes 1 and 6 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

51

7.    POLICY LIABILITIES

Future Policy Benefits

The liability for future policy benefits is determined as the present value of expected future policy benefits to be paid to or on the behalf of policyholders and certain related expenses less the present value of expected future net premiums receivable under the Company's insurance contracts. Future net premiums receivable are future gross premiums receivable under the contract multiplied by the net premium ratio (NPR).

The following tables present the changes in the present value of expected future net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type. The present value of expected future net premiums and the present value of expected future policy benefits are presented gross of internal and external ceded reinsurance.

52

	March 31, 2025
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2024	$	14,184	$	11,817	$	5,156	$	846	$	2,497	$	1,635	$	3,901	$	1,122	$	196	$	909	$	826
Beginning balance at original discount rate	14,008		11,845		5,084		864		2,687		1,726		4,340		1,221		209		976		824
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(6)		(45)		(10)		(2)		(14)		(18)		(9)		(1)		(4)		(9)		3
Adjusted beginning of period balance	14,002		11,800		5,074		862		2,673		1,708		4,331		1,220		205		967		827
Issuances	211		72		120		3		108		118		214		88		17		70		229
Interest accrual	91		72		27		4		27		17		44		12		2		10		11
Net premiums collected (1)	(350)		(268)		(201)		(24)		(119)		(99)		(142)		(61)		(10)		(41)		(22)
Foreign currency translation	812		685		292		50		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		(10)
Ending balance at original discount rate	14,766		12,361		5,312		895		2,689		1,744		4,447		1,259		214		1,006		1,035
Effect of changes in discount rate assumptions	(270)		(415)		(29)		(42)		(160)		(72)		(389)		(86)		(11)		(53)		55
Balance at March 31, 2025	$	14,496	$	11,946	$	5,283	$	853	$	2,529	$	1,672	$	4,058	$	1,173	$	203	$	953	$	1,090
Present value of expected future policy benefits:
Balance at December 31, 2024	$	40,781	$	20,606	$	24,265	$	4,225	$	3,127	$	2,330	$	10,701	$	1,897	$	441	$	1,847	$	1,288
Beginning balance at original discount rate	37,856		21,957		26,330		4,765		3,386		2,466		12,013		2,073		477		2,126		1,293
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(20)		(55)		(7)		(7)		(13)		(24)		(13)		(3)		(4)		(14)		4
Adjusted beginning of period balance	37,836		21,902		26,323		4,758		3,373		2,442		12,000		2,070		473		2,112		1,297
Issuances	215		75		122		4		113		125		226		92		15		77		232
Interest accrual	324		138		141		22		34		24		129		21		5		21		17
Benefit payments	(666)		(246)		(604)		(57)		(144)		(120)		(249)		(84)		(15)		(27)		(41)
Foreign currency translation	2,191		1,270		1,518		276		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		0
Ending balance at original discount rate	39,900		23,139		27,500		5,003		3,376		2,471		12,106		2,099		478		2,183		1,505
Effect of changes in discount rate assumptions	1,538		(2,291)		(3,022)		(736)		(221)		(109)		(1,184)		(154)		(30)		(255)		52
Balance at March 31, 2025	41,438		20,848		24,478		4,267		3,155		2,362		10,922		1,945		448		1,928		1,557
Net liability for future policy benefits	26,942		8,902		19,195		3,414		626		690		6,864		772		245		975		467
Less: reinsurance recoverable	5,156		1,259		0		0		0		0		0		0		0		20		2
Net liability for future policy benefits after   reinsurance recoverable	$	21,786	$	7,643	$	19,195	$	3,414	$	626	$	690	$	6,864	$	772	$	245	$	955	$	465

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

53

	December 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Beginning balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in cash flow assumptions	(625)		(154)		(190)		(19)		65		(47)		(106)		(21)		(17)		(5)		(8)
Effect of actual variances from expected    experience	(71)		(164)		(97)		(14)		66		12		(100)		21		(12)		(29)		13
Adjusted beginning of period balance	15,756		13,722		5,971		1,036		2,761		1,703		4,210		1,193		188		875		277
Issuances	983		361		478		16		307		364		543		231		52		226		592
Interest accrual	378		302		110		17		106		66		173		46		9		37		25
Net premiums collected (1)	(1,453)		(1,135)		(862)		(101)		(479)		(401)		(578)		(244)		(39)		(157)		(53)
Foreign currency translation	(1,655)		(1,405)		(613)		(104)		0		0		0		0		0		0		0
Other	(1)		0		0		0		(8)		(6)		(8)		(5)		(1)		(5)		(17)
Ending balance at original discount rate	14,008		11,845		5,084		864		2,687		1,726		4,340		1,221		209		976		824
Effect of changes in discount rate assumptions	176		(28)		72		(18)		(190)		(91)		(439)		(99)		(13)		(67)		2
Balance at December 31, 2024	$	14,184	$	11,817	$	5,156	$	846	$	2,497	$	1,635	$	3,901	$	1,122	$	196	$	909	$	826
Present value of expected future policy benefits:
Balance at December 31, 2023	$	50,161	$	25,257	$	29,731	$	5,178	$	3,109	$	2,422	$	11,290	$	1,943	$	478	$	1,764	$	798
Beginning balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in cash flow assumptions	(815)		(228)		(302)		(7)		109		(73)		(112)		(31)		(28)		(3)		(12)
Effect of actual variances from expected    experience	(117)		(193)		(110)		(24)		91		(16)		(144)		21		(16)		(43)		(7)
Adjusted beginning of period balance	42,694		24,602		29,844		5,413		3,502		2,452		11,864		2,066		462		1,925		750
Issuances	1,004		373		488		22		311		381		559		237		55		231		597
Interest accrual	1,356		570		582		93		133		98		515		84		20		78		50
Benefit payments	(2,773)		(1,033)		(1,510)		(208)		(560)		(465)		(925)		(314)		(60)		(108)		(104)
Foreign currency translation	(4,425)		(2,555)		(3,074)		(555)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		0
Ending balance at original discount rate	37,856		21,957		26,330		4,765		3,386		2,466		12,013		2,073		477		2,126		1,293
Effect of changes in discount rate assumptions	2,925		(1,351)		(2,065)		(540)		(259)		(136)		(1,312)		(176)		(36)		(279)		(5)
Balance at December 31, 2024	40,781		20,606		24,265		4,225		3,127		2,330		10,701		1,897		441		1,847		1,288
Net liability for future policy benefits	26,597		8,789		19,109		3,379		630		695		6,800		775		245		938		462
Less: reinsurance recoverable	5,085		1,245		0		0		0		0		0		0		0		18		0
Net liability for future policy benefits after    reinsurance recoverable	$	21,512	$	7,544	$	19,109	$	3,379	$	630	$	695	$	6,800	$	775	$	245	$	920	$	462

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

54

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.

	March 31, 2025
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/ Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	4.0 %	4.3 %	4.6 %	4.5 %	4.3 %	3.9 %	5.5 %
Weighted-average interest, current discount rate (1)	2.7 %	3.2 %	2.6 %	3.0 %	5.3 %	5.2 %	5.5 %	5.4 %	5.3 %	5.4 %	5.5 %
Weighted-average liability duration (years)	12.6	23.2	16.2	16.5	7.7	5.6	11.0	9.0	7.6	13.5	8.8

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

	December 31, 2024
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/ Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	4.0 %	4.3 %	4.6 %	4.5 %	4.3 %	3.8 %	5.4 %
Weighted-average interest, current discount rate (1)	2.2 %	2.8 %	2.1 %	2.5 %	5.3 %	5.2 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	12.6	23.5	16.1	16.7	7.7	5.6	11.1	9.0	7.6	13.5	9.1

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

55

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the consolidated balance sheets. The deferred profit liability for limited-payment contracts and the deferred reinsurance gain liability are presented together with the liability for future policy benefits in the consolidated balance sheets and have been included as reconciling items in the table below.

(In millions)	March 31, 2025			December 31, 2024
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	26,942		$	26,597
Medical and other health		8,902			8,789
Life insurance		19,195			19,109
Other		3,414			3,379
Aflac U.S.
Accident		626			630
Disability		690			695
Critical care		6,864			6,800
Hospital indemnity		772			775
Dental/vision		245			245
Life insurance		975			938
Other		467			462
Corporate and other		5,116			5,072
Deferred profit liability		1,990			1,844
Deferred reinsurance gain liability		860			806
Intercompany eliminations (1)		(5,861)			(5,760)
Total		$	71,197		$	70,381

(1) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

Discount rates are determined using upper-medium grade (low credit risk) fixed-income instrument yields that reflect the duration characteristics of the liability. Locked-in discount rates are determined separately for each issue-year cohort as a single discount rate, calculated as the weighted-average of monthly upper-medium grade (low credit risk) fixed-income instrument forward curves in the calendar year, where the weights are the annualized premiums issued for each month of the cohort. The single discount rate for each issue-year cohort is determined by solving for a rate that produces an equivalent NPR to the forward curve and will remain unchanged after the calendar year of issue.

Discount rates are updated each reporting period and require estimation techniques (e.g., interpolation, extrapolation) for determination of points on the curve for which there is limited or no observable market data. The Company constructs a current discount rate curve separately for discounting cash flows used to calculate each of the Japan and U.S. liabilities for future policy benefits, reflective of the characteristics of the corresponding insurance liabilities, such as currency and tenor.

In the Aflac Japan segment, all long-duration insurance policies are denominated in yen. A significant portion of policies are characterized by tenors exceeding the availability of liquid market data in Japan for single-A rated (as a proxy for upper-medium grade) corporate yen-denominated debt. The discount rate curve is designed to prioritize the observable inputs where available, while past the last liquid point, the data is derived based on estimation techniques consistent with the fair value guidance in ASC 820. The Aflac Japan segment curve utilizes liquid market indices tracking publicly traded yen-denominated single-A corporate debt for the initial 10-year tenor. For the bonds within these market indices where only local ratings are available, the Company prioritizes the bonds with local ratings that are equivalent to a single-A rating based on international rating standards.

For the discount rates applicable to tenors for which the Japan single-A debt market is not liquid but there is sufficient observable market data and/or the observable market data is available for similar instruments (between 10 and 30 years), the Company estimates tenor-specific single-A credit spreads and applies them to risk-free government rates. Lastly, for the tenors where there is limited or no observable single-A or similar market data or risk-free government rates (beyond 30

56

years), the discount curve is derived by extrapolation of risk free rates beyond their last liquid point following the Smith-Wilson method and grading of the estimated forward credit spread anchored by the ultimate forward rate. The ultimate forward rate is based on the economic value-based solvency regime, which is consistent with the International Association of Insurance Supervisors (IAIS) Insurance Capital Standards (ICS) (effective for Aflac Japan's 2025 fiscal year-end), and is adjusted for credit and inflation components.

For the Aflac U.S. segment where all long-duration insurance policies are denominated in U.S. dollars and substantially all have cash flow duration within 30 years, for which the U.S. upper-medium grade fixed-income market is liquid and observable, the Company uses data from a liquid fixed-income market index tracking single-A U.S. corporate debt. For the insignificant portion of the policies with cash flow tenors exceeding 30 years, the discount curve beyond that tenor is extrapolated following the Smith-Wilson method from year 30 to the same ultimate forward rate calculated for the Japan discount curve at year 60 and held constant thereafter. The use of the same ultimate rate for U.S. and Japan segments is based on the assumption of long-term global economic convergence.

There were no changes to the methods used to determine the discount rates during the three-month periods ended March 31, 2025 and 2024.

Mortality rate assumptions are based on industry tables and adjusted for the Company's actual or expected experience where credible or appropriate. These assumptions typically vary by age, gender, and other demographic characteristics such as smoking status.

Morbidity assumptions are based on the Company's internal data and consider emerging experience. These assumptions are reflective of the coverage and benefits provided and generally vary by age, gender, duration, and any other material policyholder characteristics. In cases where a calendar-year trend is significant, future cash flow projections may include a trend adjustment.

In Japan, separate lapse assumptions are set based on actual or expected experience. These lapse and total termination rate assumptions vary by line of business and with policyholder characteristics such as duration. In the U.S., the majority of the future cash flows are modeled using total termination rates (which include both lapse and mortality) and are adjusted for actual experience. Policy provisions, such as reaching premium paid-up status, are taken into account when setting assumptions.

For the three-month periods ended March 31, 2025 and 2024 the variance of actual experience from expected experience was primarily due to favorable variances in morbidity assumptions as compared to actual experience. There were no changes to the inputs, judgments, assumptions or methods used in measuring the liability for future policy benefits during the three-month periods ended March 31, 2025 and 2024.

The Company performs an annual review of its assumptions during the third quarter. In 2024, the Company's annual assumption review process resulted in favorable changes largely due to reflecting more favorable Japan morbidity experience.

57

The following table summarizes the amount of net earned premiums recognized in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2025		2024
Net earned premiums:
Aflac Japan
Cancer	$	839	$	878
Medical and other health	529		605
Life insurance	316		339
Other	32		34
Aflac U.S.
Accident	311		325
Disability	352		333
Critical care	441		444
Hospital indemnity	184		185
Dental/vision	49		59
Life insurance	169		138
Other	49		20
Corporate and other	198		165
Reinsurance ceded	(88)		(69)
Total	$	3,381	$	3,456

The following table summarizes the amount of interest expense related to insurance contracts recognized in benefits and claims, excluding reserve remeasurement in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2025		2024
Interest expense:
Aflac Japan
Cancer	$	233	$	246
Medical and other health	66		65
Life insurance	114		118
Other	18		19
Aflac U.S.
Accident	7		6
Disability	7		8
Critical care	85		85
Hospital indemnity	9		9
Dental/vision	3		3
Life insurance	11		10
Other	6		7
Total	$	559	$	576

58

The following tables summarize the amount of undiscounted expected future gross premiums and expected future policy benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future policy benefits and expenses by reporting segment and disaggregated by product type. These tables are presented gross of internal and external ceded reinsurance. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business of the Company.

	March 31, 2025						December 31, 2024
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums   and expected future policy benefits and   expenses:
Aflac Japan
Cancer		$	54,446		$	59,903		$	51,712		$	56,881
Medical and other health		34,739			36,751			33,250			34,864
Life insurance		11,492			39,412			10,915			37,520
Other		1,538			6,790			1,477			6,479
Aflac U.S.
Accident		8,843			4,673			8,862			4,687
Disability		5,748			3,110			5,727			3,094
Critical care		19,780			20,463			19,624			20,340
Hospital indemnity		4,937			3,052			4,859			3,017
Dental/vision		1,117			684			1,118			679
Life insurance		3,091			3,686			2,966			3,559
Other		2,764			2,691			2,143			2,273
Total		$	148,495		$	181,215		$	142,653		$	173,393

	March 31, 2025						December 31, 2024
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums   and expected future policy benefits and   expenses:
Aflac Japan
Cancer		$	40,989		$	41,438		$	40,170		$	40,781
Medical and other health		25,461			20,848			25,171			20,606
Life insurance		9,630			24,478			9,367			24,265
Other		1,219			4,267			1,204			4,225
Aflac U.S.
Accident		6,116			3,155			6,057			3,127
Disability		4,456			2,362			4,404			2,330
Critical care		12,152			10,922			11,900			10,701
Hospital indemnity		3,412			1,945			3,312			1,897
Dental/vision		768			448			761			441
Life insurance		2,160			1,928			2,050			1,847
Other		1,668			1,557			1,290			1,288
Total		$	108,031		$	113,348		$	105,686		$	111,508

Loss expense as a result of NPR capping for the three-month periods ended March 31, 2025 and 2024 was immaterial.

59

Other Policyholders' Funds

As of March 31, 2025 and December 31, 2024, the largest component of the other policyholders' funds liability was the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums.

The following table presents the changes in other policyholders’ funds.

(In millions)	March 31, 2025		December 31, 2024
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	5,221	$	5,939
Premiums received	29		104
Transfers from WAYS conversions	74		249
Surrenders and withdrawals	(18)		(58)
Benefit payments	(128)		(446)
Interest credited	12		49
Foreign currency translation and other	304		(616)
Fixed annuities account balance, end of period	5,494		5,221
Other deposit type reserves	369		239
Total	$	5,863	$	5,460

(1) Aflac Japan fixed annuities

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

	March 31, 2025			December 31, 2024
(In millions)	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value
Fixed annuities (1)	0.5% - 2.2%	$5,494	$5,420	0.5% - 2.2%	$5,221	$5,150

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2025 and December 31, 2024.

Aflac Japan’s fixed annuities have guaranteed fixed crediting rates which results in the policyholders' funds balances being sufficient to cover all guaranteed benefit amounts. The reserves are adequate to fully fund future benefits at any given time.

For additional information on policy liabilities, see Notes 1 and 7 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

8.    REINSURANCE

The Company periodically enters into fixed quota-share coinsurance agreements in the normal course of business, primarily to provide additional capacity for future growth, optimize capital, limit losses, and minimize exposure to significant risks. For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. These reinsurance transactions are indemnity reinsurance agreements that do not relieve the Company from its obligations to policyholders. In the event that the reinsurer is unable to meet their obligations, the Company remains liable for the reinsured claims.

60

The following table reconciles direct earned premiums, direct benefits and claims, excluding reserve remeasurement gains and losses, and reserve remeasurement gains and losses to net amounts after the effect of reinsurance.

	Three Months Ended March 31,
(In millions)	2025			2024
Earned premiums:
Direct		$	3,433		$	3,482
Ceded		(88)			(69)
Assumed		36			43
Net earned premiums		$	3,381		$	3,456
Benefits and claims, excluding reserve remeasurement:
Direct		$	2,031		$	2,082
Ceded		(56)			(33)
Assumed		11			17
Benefits and claims, excluding reserve remeasurement		1,986			2,066
Reserve remeasurement (gains) losses:
Direct		(41)			(57)
Ceded		0			1
Reserve remeasurement (gains) losses		(41)			(56)
Total benefits and claims, net		$	1,945		$	2,010

The Company has recorded a deferred reinsurance gain liability related to reinsurance transactions which represents ceded reserves in excess of consideration paid, or consideration received in excess of assumed reserves. The remaining consolidated deferred reinsurance gain liability of $152 million and $146 million as of March 31, 2025 and December 31, 2024, respectively, is included in future policy benefits in the consolidated balance sheets and is being amortized into income over the expected lives of the policies.

The Company has also recorded a reinsurance recoverable for reinsurance transactions. The reinsurance recoverable, which is included in other assets in the consolidated balance sheets, is reported net of allowance for credit losses and had a remaining balance of $166 million and $163 million as of March 31, 2025 and December 31, 2024, respectively. As of both March 31, 2025 and December 31, 2024, the allowance for credit losses related to the Company's reinsurance recoverable balance was $4 million. The credit allowance for the reinsurance recoverable balance is estimated using a PD / LGD method and the key credit quality indicator is the credit rating of the Company’s reinsurance counterparty. The Company uses external credit ratings focused on the reinsurer’s financial strength and credit worthiness. As of March 31, 2025, the Company's reinsurance counterparties were rated A+. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

Aflac Re is a Bermuda domiciled insurer that reinsures certain policies issued by ALIJ. The inter-segment amounts associated with these internal reinsurance transactions are eliminated in consolidation.

For additional information on reinsurance, see Notes 1 and 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

61

9.    NOTES PAYABLE AND LEASE OBLIGATIONS

A summary of notes payable and lease obligations follows:

(In millions)	March 31, 2025			December 31, 2024
1.125% senior sustainability notes due March 2026		$	399		$	399
2.875% senior notes due October 2026		299			299
3.60% senior notes due April 2030		994			994
6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040		255			255
4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049		542			542
Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)		83			79
.932% senior notes due January 2027 (principal amount ¥60.0 billion)		400			378
1.048% senior notes due March 2029 (principal amount ¥13.0 billion)		86			81
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		223			211
.500% senior notes due December 2029 (principal amount ¥12.6 billion)		84			79
.550% senior notes due March 2030 (principal amount ¥13.3 billion)		89			84
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		195			184
1.412% senior notes due March 2031 (principal amount ¥27.9 billion)		186			176
.633% senior notes due April 2031 (principal amount ¥30.0 billion)		200			189
.843% senior notes due December 2031 (principal amount ¥9.3 billion)		62			58
.750% senior notes due March 2032 (principal amount ¥20.7 billion)		137			130
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		141			133
.844% senior notes due April 2033 (principal amount ¥12.0 billion)		80			76
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		101			95
1.682% senior notes due March 2034 (principal amount ¥7.7 billion)		51			48
1.600% senior notes due March 2034 (principal amount ¥18.3 billion)		122			115
.934% senior notes due December 2034 (principal amount ¥9.8 billion)		65			62
.830% senior notes due March 2035 (principal amount ¥10.6 billion)		70			66
1.740% senior notes due March 2036 (principal amount ¥15.0 billion)		99			94
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		66			63
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		43			41
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		59			56
1.920% senior notes due March 2039 (principal amount ¥16.5 billion)		109			103
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		42			39
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		66			63
2.160% senior notes due March 2044 (principal amount ¥5.7 billion)		37			35
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		397			375
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		133			125
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		80			75
1.958% subordinated bonds due December 2053 (principal amount ¥30.0 billion)		200			188
2.400% senior notes due March 2054 (principal amount ¥19.5 billion)		129			122
Yen-denominated loans:
Variable interest rate loan due August 2027 (1.07% in 2025 and .84% in 2024,   principal amount ¥11.7 billion)		78			74
Variable interest rate loan due August 2029 (1.17% in 2025 and .94% in 2024,   principal amount ¥25.3 billion)		169			160
Variable interest rate loan due August 2032 (1.32% in 2025 and 1.09% in 2024,   principal amount ¥70.0 billion)		467			441
Finance lease obligations payable through 2030		4			5
Operating lease obligations payable through 2049		94			91
Total notes payable and lease obligations		$	7,751		$	7,498

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

62

Interest expense related to the Company's notes payable, which is included in interest expense in the consolidated statements of earnings, was $49 million and $46 million for the three-month periods March 31, 2025 and 2024, respectively.

A summary of the Company's lines of credit as of March 31, 2025 follows:

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
Aflac Incorporated and Aflac	uncommitted bilateral	364 days	December 5, 2025	$100 million	$0 million	The rate quoted by the bank and agreed upon at the time of borrowing	Up to 3 months	None	General corporate purposes
Aflac Incorporated	unsecured revolving	5 years	May 9, 2027, or the date commitments are terminated pursuant to an event of default	¥100.0 billion	¥0.0 billion	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period	No later than May 10, 2027	.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	unsecured revolving	5 years	November 15, 2027, or the date commitments are terminated pursuant to an event of default	$1.0 billion	$0.0 billion	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar-denominated borrowings or TIBOR for Japanese yen-denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin	No later than November 15, 2027	.08% to .20%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	uncommitted bilateral	None specified	None specified	$50 million	$0 million	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%	Up to 3 months	None	General corporate purposes
Aflac(1)	uncommitted revolving	364 days	December 1, 2025	$250 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac Incorporated(1) (Tranche 1)	uncommitted revolving	364 days	November 25, 2025	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2025	None	General corporate purposes
Aflac Incorporated(1) (Tranche 2)	uncommitted revolving	364 days	November 25, 2025	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2025	None	General corporate purposes
Aflac New York(1)	uncommitted revolving	364 days	December 1, 2025	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
CAIC(1)	uncommitted revolving	364 days	December 1, 2025	$15 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes

(1) Intercompany credit agreement

(continued)

63

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
TOIC(1)	uncommitted revolving	364 days	December 1, 2025	$0.3 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac GI Holdings LLC(1)	uncommitted revolving	364 days	December 1, 2025	$30 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac Incorporated(1)	uncommitted revolving	364 days	December 1, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Re(1)	uncommitted revolving	364 days	December 1, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Asset Management LLC(1)	uncommitted revolving	364 days	December 1, 2025	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Global Ventures LLC(1)	uncommitted revolving	364 days	December 1, 2025	$2 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes

(1) Intercompany credit agreement

The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, 2025. No events of default or defaults occurred during the three-month period ended March 31, 2025.

For additional information, see Notes 4 and 9 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

64

10.    SHAREHOLDERS’ EQUITY

Share Data: The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.

(In thousands of shares)	2025	2024
Common stock - issued:
Balance, beginning of period	1,356,763	1,355,398
Exercise of stock options and issuance of restricted shares	989	1,082
Balance, end of period	1,357,752	1,356,480
Treasury stock:
Balance, beginning of period	806,799	776,919
Purchases of treasury stock:
Share repurchase program	8,497	9,276
Other	398	457
Dispositions of treasury stock:
Shares issued to AFL Stock Plan	(173)	(212)
Exercise of stock options	(41)	(55)
Other	(221)	(183)
Balance, end of period	815,259	786,202
Shares outstanding, end of period	542,493	570,278

Share Repurchase Program: During the first three months of 2025, the Company repurchased 8.5 million shares of its common stock for $900 million as part of its share repurchase program. During the first three months of 2024, the Company repurchased 9.3 million shares of its common stock for $750 million as part of its share repurchase program. As of March 31, 2025, a remaining balance of 38.8 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

EPS: Outstanding share-based awards are excluded from the calculation of weighted-average shares used in the computation of basic earnings per share (EPS), but are included in the calculation of weighted-average shares used in the computation of diluted EPS. Anti-dilutive share-based awards are excluded from the computation of diluted EPS.

The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.

	Three Months Ended March 31,
(In thousands)	2025		2024
Anti-dilutive share-based awards		0		69

65

Reclassifications from Accumulated Other Comprehensive Income

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income

Three Months Ended March 31, 2025
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2024		$	(4,998)		$	24		$	(20)		$	2,006		$	10		$	(2,978)
Other comprehensive    income (loss) before    reclassification		449			(1,225)			1			1,893			33			1,151
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(32)			1			0			(1)			(32)
Net current-period other    comprehensive    income (loss)		449			(1,257)			2			1,893			32			1,119
Balance at March 31, 2025		$	(4,549)		$	(1,233)		$	(18)		$	3,899		$	42		$	(1,859)

All amounts in the table above are net of tax.

Three Months Ended March 31, 2024
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2023		$	(4,069)		$	1,139		$	(22)		$	(2,560)		$	(8)		$	(5,520)
Other comprehensive    income (loss) before    reclassification		(597)			86			(5)			1,065			1			550
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(133)			1			0			0			(132)
Net current-period other    comprehensive    income (loss)		(597)			(47)			(4)			1,065			1			418
Balance at March 31, 2024		$	(4,666)		$	1,092		$	(26)		$	(1,495)		$	(7)		$	(5,102)

All amounts in the table above are net of tax.

66

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

(In millions)	Three Months Ended March 31, 2025
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	40	Net investment gains (losses)
		(8)		Tax (expense) or benefit(1)
		$	32	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Amortization of defined benefit pension items:
Actuarial gains (losses)		$	1	Acquisition and operating expenses(2)
Prior service (cost) credit		0		Acquisition and operating expenses(2)
		0		Tax (expense) or benefit(1)
		$	1	Net of tax
Total reclassifications for the period		$	32	Net of tax

(1) Based on 21% tax rate

(2) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost (see Note 12 for additional details).

(In millions)	Three Months Ended March 31, 2024
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	168	Net investment gains (losses)
		(35)		Tax (expense) or benefit(1)
		$	133	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	132	Net of tax

(1) Based on 21% tax rate

11.    SHARE-BASED COMPENSATION

As of March 31, 2025, the Company has outstanding share-based awards under the Aflac Incorporated Long-Term Incentive Plan (As Amended and Restated February 14, 2017), as further amended on August 9, 2022 (the Plan). Share-based awards are designed to reward employees for their long-term contributions to the Company and provide incentives for them to remain with the Company. The number and frequency of share-based awards are based on competitive practices, operating results of the Company, government regulations, and other factors.

The Plan allows for a maximum number of shares issuable over its term of 75 million shares including 38 million shares that may be awarded in respect of awards other than options or stock appreciation rights. If any awards granted under the Plan are forfeited or are terminated before being exercised or settled for any reason other than tax forfeiture, then the shares underlying the awards will again be available under the Plan.

67

The Plan allows awards to Company employees for incentive stock options (ISOs), non-qualifying stock options (NQSOs), stock appreciation rights, restricted stock and restricted stock units. Non-employee directors are eligible for grants of NQSOs, restricted stock, and stock appreciation rights. As of March 31, 2025, approximately 32.6 million shares were available for future grants under this plan.

The ISOs, NQSOs and stock appreciation rights granted under the amended Plan have an exercise price of at least the fair market value of the underlying stock on the grant date and have an expiration date no later than 10 years from the grant date. The share-based awards vest upon time-based conditions or time and performance-based conditions. Time-based vesting generally occurs after three years. Performance-based vesting conditions generally include the attainment of goals related to the Company's financial performance. As of March 31, 2025, the only performance-based awards issued and outstanding were restricted stock awards and units. The Compensation Committee of the Board of Directors has the discretion to determine vesting schedules.

Share-based awards granted to U.S.-based grantees are settled with authorized but unissued Company stock, while those issued to Japan-based grantees are settled with treasury shares.

The following table provides information on stock options outstanding and exercisable at March 31, 2025.

	Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding		459		1.7		$	35		$	34.90
Exercisable		459		1.7		35			34.90

The Company received cash from the exercise of stock options in the amount of $5 million during the first three months of both 2025 and 2024. The tax benefit realized as a result of stock option exercises and restricted stock releases was $29 million in the first three months of 2025, compared with $24 million in the first three months of 2024.

As of March 31, 2025, total compensation cost not yet recognized in the Company's consolidated financial statements related to restricted stock awards and units was $50 million, of which $25 million (1.2 million shares) was related to restricted stock awards and units with a performance-based vesting condition. The Company expects to recognize these amounts over a weighted-average period of approximately 2.0 years. There are no other contractual terms covering restricted stock awards once vested.

The following table summarizes restricted stock activity during the three-month period ended March 31, 2025.

(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2024	2,099		$	73.65
Granted in 2025	1,059		104.43
Canceled in 2025	(14)		76.04
Vested in 2025	(1,238)		68.36
Restricted stock at March 31, 2025	1,906		$	85.21

In February 2025, the Company granted 284 thousand performance-based stock awards and units, which are contingent on the achievement of the Company's financial performance metrics and its market-based conditions. On the date of grant, the Company estimated the fair value of restricted stock awards and units with market-based conditions using a Monte Carlo simulation model. The model discounts the value of the stock at the assumed vesting date based on the risk-free interest rate. Based on estimates of actual performance versus the vesting thresholds, the calculated fair value percentage payout estimate will be updated each quarter.

The Company uses third-party analyses to assist in developing the assumptions used in, as well as calibrating, a Monte Carlo simulation model. The Company is responsible for determining the assumptions used in estimating the fair value of its share-based payment awards.

For additional information on the Company's long-term share-based compensation plans and the types of share-based awards, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2024 Annual Report.

68

12.    BENEFIT PLANS

The Company has funded defined benefit plans in Japan and the U.S.; however, future benefits under the U.S. plan were frozen effective January 1, 2024. In January 2025, the Company purchased a nonparticipating single premium group annuity contract from an external insurer to settle its obligations under the U.S. defined pension plan and paid to the insurer the related annuity premium. As a result, the Company recognized a settlement charge of $55 million in the first quarter of 2025. Effective April 1, 2025, the external insurer began making annuity payments to plan participants.

The Company also maintains non-qualified, unfunded supplemental retirement plans that provide defined pension benefits in excess of limits imposed by federal tax law for certain Japanese, U.S. and former employees. However, future benefits under the Company's Supplemental Executive Retirement Plan and Retirement Plan for Senior Officers were frozen effective January 1, 2024, provided that actively employed participants may continue to accrue service toward eligibility for early retirement benefits or delayed early retirement benefits.

The Company provides certain health care benefits for eligible U.S. retired employees, their beneficiaries and covered dependents (other postretirement benefits). The health care plan is contributory and unfunded. For certain employees and former employees, additional coverage is provided for all medical expenses for life.

Pension and other postretirement benefit expenses are included in acquisition and operating expenses in the consolidated statements of earnings, which includes other components of net periodic pension cost and postretirement costs (other than service costs) of $57 million and $2 million for the three-month periods ended March 31, 2025 and 2024, respectively. Total net periodic benefit cost includes the following components:

	Three Months Ended March 31,
	Pension Benefits												Other
	Japan						U.S.						Postretirement Benefits
(In millions)	2025			2024			2025			2024			2025			2024
Components of net periodic   benefit cost:
Service cost		$	3		$	4		$	0		$	0		$	0		$	0
Interest cost		2			2			8			9			0			0
Expected return on plan assets		(2)			(2)			(5)			(7)			0			0
Amortization of net actuarial   (gain) loss		0			0			(1)			0			0			0
Settlement (gain) loss		0			0			55			0			0			0
Net periodic benefit cost (credit)		$	3		$	4		$	57		$	2		$	0		$	0

During the three months ended March 31, 2025, Aflac Japan contributed approximately $6 million (using the weighted-average yen/dollar exchange rate for the three-month period ended March 31, 2025) to the Japanese funded defined benefit plan, and Aflac U.S. did not make a contribution to the U.S. funded defined benefit plan.

For additional information regarding the Company's Japanese and U.S. benefit plans, see Note 14 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

69

13.    COMMITMENTS AND CONTINGENT LIABILITIES

In February 2025, the Company renewed an outsourcing agreement with an information technology and data services company to provide application maintenance and development services for Aflac Japan. The agreement has a remaining term of three years with an aggregate remaining cost of ¥10.3 billion ($69 million using the March 31, 2025 exchange rate).

The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business. Members of the Company's senior legal and financial management teams review litigation and regulatory inquiries on a quarterly and annual basis. The final results of any litigation or regulatory inquiries cannot be predicted with certainty. Although some of this litigation is pending in states where large punitive damages, bearing little relation to the actual damages sustained by plaintiffs, have been awarded in recent years, the Company believes the outcome of pending litigation will not have a material adverse effect on its financial position, results of operations, or cash flows.

See Note 3 for details on certain investment commitments.

Guaranty Fund Assessments

The U.S. insurance industry has a policyholder protection system that is monitored and regulated by state insurance departments. These life and health insurance guaranty associations are state entities (in all 50 states as well as Puerto Rico and the District of Columbia) created to protect policyholders of an insolvent insurance company. All insurance companies (with limited exceptions) licensed to sell life or health insurance in a state must be members of that state’s guaranty association. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business.

Guaranty fund assessments for the three-month periods ended March 31, 2025 and 2024 were immaterial.

70

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

FORWARD-LOOKING INFORMATION

The Private Securities Litigation Reform Act of 1995 provides a safe harbor to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. Aflac Incorporated (the Parent Company) and its subsidiaries (collectively with the Parent Company, the Company) desire to take advantage of these provisions. This report contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by Company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as the ones listed below or similar words, as well as specific projections of future results, generally qualify as forward-looking. The Company undertakes no obligation to update such forward-looking statements.

• expect	• anticipate	• believe	• goal	• objective
• may	• should	• estimate	• intends	• projects
• will	• assumes	• potential	• target	• outlook

The Company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements:

•difficult conditions in global capital markets and the economy, including inflation

•defaults and credit downgrades of investments

•global fluctuations in interest rates and exposure to significant interest rate risk

•concentration of business in Japan

•limited availability of acceptable yen-denominated investments

•foreign currency fluctuations in the yen/dollar exchange rate

•differing interpretations applied to investment valuations

•significant valuation judgments in determination of expected credit losses recorded on the Company's investments

•decreases in the Company's financial strength or debt ratings

•decline in creditworthiness of other financial institutions

•the Company's ability to attract and retain qualified sales associates, brokers, employees, and distribution partners

•deviations in actual experience from pricing and reserving assumptions

•ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives

•interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality, integrity or privacy of sensitive data residing on such systems

•subsidiaries' ability to pay dividends to the Parent Company

•inherent limitations to risk management policies and procedures

•operational risks of third-party vendors

•tax rates applicable to the Company may change

•failure to comply with restrictions on policyholder privacy and information security

•extensive regulation and changes in law or regulation by governmental authorities

•competitive environment and ability to anticipate and respond to market trends

•catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics, tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, major public health issues, terrorism or other acts of violence, and damage incidental to such events

•ability to protect the Aflac brand and the Company's reputation

•ability to effectively manage key executive succession

•changes in accounting standards

•level and outcome of litigation or regulatory inquiries

•allegations or determinations of worker misclassification in the United States

71

MD&A OVERVIEW

MD&A is intended to inform the reader about matters affecting the financial condition and results of operations of Aflac Incorporated and its subsidiaries for the three-month periods ended March 31, 2025 and 2024, respectively. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, the following discussion should be read in conjunction with the consolidated financial statements and notes that are included in the Company's annual report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report). In this MD&A, amounts may not foot due to rounding.

This MD&A is divided into the following sections:

	Page
Executive Summary	73
Results of Operations	74
Investments	91
Hedging Activities	96
Deferred Policy Acquisition Costs	99
Policy Liabilities	99
Benefit Plans	100
Policyholder Protection	100
Liquidity and Capital Resources	100
Critical Accounting Estimates	105

72

EXECUTIVE SUMMARY

Company Overview

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) provide financial protection to millions of policyholders and customers in Japan and the United States (U.S.). The Company’s principal business is supplemental health and life insurance products with the goal to provide customers the best value in supplemental insurance products in Japan and the U.S. The Company's insurance business consists of two reporting segments: Aflac Japan and Aflac U.S. The Parent Company’s primary insurance subsidiaries are Aflac Life Insurance Japan Ltd. in Japan (Aflac Japan) and American Family Life Assurance Company of Columbus (Aflac); Continental American Insurance Company (CAIC), branded as Aflac Group Insurance (AGI); American Family Life Assurance Company of New York (Aflac New York); Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS), which provides a platform for Aflac Dental and Vision in the U.S. (collectively, Aflac U.S.). The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd. (Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Performance Highlights

Total revenues were $3.4 billion in the first quarter of 2025, compared with $5.4 billion in the first quarter of 2024, primarily due to net investment losses of $963 million in the first quarter of 2025 compared with net investment gains of $951 million in the first quarter of 2024. Net earnings were $29 million, or $.05 per diluted share, in the first quarter of 2025, compared with $1.9 billion, or $3.25 per diluted share, in the first quarter of 2024.

Net earnings in the first quarter of 2025 included net investment losses of $963 million, compared with net investment gains of $951 million in the first quarter of 2024. Net investment losses in the first quarter of 2025 included $888 million of net losses from certain derivative and foreign currency gains or losses; $61 million of net losses on equity securities; an increase in credit loss allowances of $55 million; and $41 million of net gains from sales and redemptions.

The average yen/dollar exchange rate(1) for the three-month period ended March 31, 2025 was 152.40, or 2.4% weaker than the average yen/dollar exchange rate(1) of 148.67 for the same period in 2024.

Adjusted earnings(2) in the first quarter of 2025 were $906 million, or $1.66 per diluted share, compared with $961 million, or $1.66 per diluted share, in the first quarter of 2024. The weaker yen/dollar exchange rate negatively impacted adjusted earnings per diluted share by $.01.

In the first three months of 2025, Aflac Incorporated repurchased $900 million, or 8.5 million of its common shares. At March 31, 2025, the Company had 38.8 million remaining shares authorized for repurchase.

Shareholders’ equity was $26.3 billion, or $48.55 per share, at March 31, 2025, compared with $26.1 billion, or $47.45 per share, at December 31, 2024. Shareholders’ equity at March 31, 2025 included a cumulative increase of $3.9 billion from the effect of changes in discount rate assumptions on insurance reserves, compared with a corresponding cumulative increase of $2.0 billion at December 31, 2024, and a net unrealized loss on investment securities and derivatives of $1.3 billion, compared with a net unrealized gain of $4 million at December 31, 2024. Shareholders’ equity at March 31, 2025 also included an unrealized foreign currency translation loss of $4.5 billion, compared with an unrealized foreign currency translation loss of $5.0 billion at December 31, 2024. The annualized return on average shareholders’ equity in the first quarter of 2025 was .4%.

Shareholders’ equity excluding accumulated other comprehensive income (AOCI)(2) (adjusted book value) was $28.2 billion, or $51.98 per share, at March 31, 2025, compared with $29.1 billion, or $52.87 per share, at December 31, 2024. Adjusted book value excluding foreign currency remeasurement(2) was $23.1 billion, or $42.61 per share, at March 31, 2025, compared with $23.4 billion, or $42.46 per share, at December 31, 2024. The annualized adjusted return on equity (ROE) excluding foreign currency remeasurement(2) in the first quarter of 2025 was 15.6%.

(1) Yen/U.S. dollar exchange rates are based on the published MUFG Bank, Ltd. telegraphic transfer middle rate (TTM).

(2) See the Results of Operations section of this MD&A for a definition of this non-U.S. GAAP financial measure.

73

RESULTS OF OPERATIONS

The Company earns its revenues principally from insurance premiums and investments. The Company’s operating expenses primarily consist of insurance benefits provided and reserves established for anticipated future insurance benefits, general business expenses, commissions and other costs of selling and servicing its products. Profitability for the Company depends principally on its ability to price its insurance products at a level that enables the Company to earn a margin over the costs associated with providing benefits and administering those products. Profitability also depends on, among other items, actuarial and policyholder behavior experience on insurance products, and the Company's ability to attract and retain customer assets, generate and maintain favorable investment results, effectively deploy capital and utilize tax capacity, and manage expenses.

This document includes references to the Company’s financial performance measures which are not calculated in accordance with United States generally accepted accounting principles (U.S. GAAP) (non-U.S. GAAP). The financial measures exclude items that the Company believes may obscure the underlying fundamentals and trends in insurance operations because they tend to be driven by general economic conditions and events or related to infrequent activities not directly associated with insurance operations.

Due to the size of Aflac Japan, where the functional currency is the Japanese yen, fluctuations in the yen/dollar exchange rate can have a significant effect on reported results. In periods when the yen weakens, translating yen into dollars results in fewer dollars being reported. When the yen strengthens, translating yen into dollars results in more dollars being reported. Consequently, yen weakening has the effect of suppressing current period results in relation to the comparable prior period, while yen strengthening has the effect of magnifying current period results in relation to the comparable prior period. A significant portion of the Company’s business is conducted in yen and never converted into dollars but translated into dollars for U.S. GAAP reporting purposes, which results in foreign currency impact to earnings, cash flows and book value on a U.S. GAAP basis. Management evaluates the Company's financial performance both including and excluding the impact of foreign currency translation to monitor, respectively, cumulative currency impacts and the currency-neutral operating performance over time. The average yen/dollar exchange rate is based on the published MUFG Bank, Ltd. telegraphic transfer middle rate (TTM).

The Company defines the non-U.S. GAAP financial measures included in this document as follows:

•Adjusted earnings are adjusted revenues less benefits and adjusted expenses. Adjusted earnings per share (basic or diluted) are the adjusted earnings for the period divided by the weighted average outstanding shares (basic or diluted) for the period presented. The adjustments to both revenues and expenses account for certain items that are outside of management’s control because they tend to be driven by general economic conditions and events or are related to infrequent activities not directly associated with insurance operations. Adjusted revenues are U.S. GAAP total revenues excluding adjusted net investment gains and losses. Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest from derivatives associated with notes payable but excluding any non-recurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company's underlying business performance. Management uses adjusted earnings and adjusted earnings per diluted share to evaluate the financial performance of the Company’s insurance operations on a consolidated basis and believes that a presentation of these financial measures is vitally important to an understanding of the underlying profitability drivers and trends of the Company’s insurance business. The most comparable U.S. GAAP financial measures for adjusted earnings and adjusted earnings per share (basic or diluted) are net earnings and net earnings per share, respectively.

•Adjusted net investment gains and losses are net investment gains and losses adjusted for i) amortized hedge cost/income related to foreign currency exposure management strategies and certain derivative activity, ii) net interest income/expense from foreign currency and interest rate derivatives associated with certain investment strategies, which are both reclassified to net investment income, and iii) the impact of interest from derivatives associated with notes payable, which is reclassified to interest expense as a component of total adjusted expenses. The Company considers adjusted net investment gains and losses important as it represents the remainder amount that is considered outside management’s control, while excluding the components that are within management’s control and are accordingly reclassified to net investment income and interest expense. The most comparable U.S. GAAP financial measure for adjusted net investment gains and losses is net investment gains and losses.

•Amortized hedge costs/income represent costs/income incurred or recognized as a result of using foreign currency derivatives to hedge certain foreign exchange risks in the Company's Japan segment or in Corporate

74

and other. These amortized hedge costs/income are estimated at the inception of the derivatives based on the specific terms of each contract and are recognized on a straight-line basis over the contractual term of the derivative. The Company believes that amortized hedge costs/income measure the periodic currency risk management costs/income related to hedging certain foreign currency exchange risks and are an important component of net investment income. There is no comparable U.S. GAAP financial measure for amortized hedge costs/income.

•Adjusted earnings excluding current period foreign currency impact are computed using the average foreign currency exchange rate for the comparable prior-year period, which eliminates fluctuations driven solely by foreign currency exchange rate changes. Adjusted earnings per diluted share excluding current period foreign currency impact is adjusted earnings excluding current period foreign currency impact divided by the weighted average outstanding diluted shares for the period presented. The Company considers adjusted earnings excluding current period foreign currency impact and adjusted earnings per diluted share excluding current period foreign currency impact important because a significant portion of the Company's business is conducted in Japan and foreign exchange rates are outside management’s control; therefore, the Company believes it is important to understand the impact of translating foreign currency (primarily Japanese yen) into U.S. dollars. The most comparable U.S. GAAP financial measures for adjusted earnings excluding current period foreign currency impact and adjusted earnings per diluted share excluding current period foreign currency impact are net earnings and net earnings per share, respectively.

•Adjusted book value is the U.S. GAAP book value (representing total shareholders’ equity), less accumulated other comprehensive income as recorded on the U.S. GAAP balance sheet. Adjusted book value per common share is adjusted book value at the period end divided by the ending outstanding common shares for the period presented. The Company considers adjusted book value and adjusted book value per common share important as they exclude accumulated other comprehensive income, which fluctuates due to market movements that are outside management’s control. The most comparable U.S. GAAP financial measures for adjusted book value and adjusted book value per common share are total book value and total book value per common share, respectively.

•Adjusted book value excluding foreign currency remeasurement is the U.S. GAAP book value (representing total shareholders’ equity), less accumulated other comprehensive income as recorded on the U.S. GAAP balance sheet and excluding the cumulative [beginning January 1, 2021] foreign currency gains/losses associated with i) foreign currency remeasurement and ii) sales and redemptions of invested assets. Adjusted book value excluding foreign currency remeasurement per common share is adjusted book value excluding foreign currency remeasurement at the period end divided by the ending outstanding common shares for the period presented. The Company considers adjusted book value excluding foreign currency remeasurement and adjusted book value excluding foreign currency remeasurement per common share important as they exclude both accumulated other comprehensive income and the cumulative foreign currency remeasurement gains/losses, which fluctuate due to market movements that are outside management's control. The most comparable U.S. GAAP financial measures for adjusted book value excluding foreign currency remeasurement and adjusted book value excluding foreign currency remeasurement per common share are total book value and total book value per common share, respectively.

•Adjusted return on equity is annualized adjusted earnings divided by average shareholders’ equity, excluding AOCI. Management uses adjusted return on equity to evaluate the financial performance of the Company’s insurance operations on a consolidated basis and believes that a presentation of this financial measure is vitally important to an understanding of the underlying profitability drivers and trends of the Company’s insurance business. The Company considers adjusted return on equity important as it excludes components of AOCI, which fluctuate due to market movements that are outside management's control. The most comparable U.S. GAAP financial measure for adjusted return on equity is return on average equity as determined using annualized net earnings and average total shareholders’ equity.

•Adjusted return on equity excluding foreign currency remeasurement is annualized adjusted earnings divided by average shareholders’ equity, excluding both AOCI and the cumulative [beginning January 1, 2021] foreign currency gains/losses associated with i) foreign currency remeasurement and ii) sales and redemptions of invested assets. The Company considers adjusted return on equity excluding foreign currency remeasurement important because it excludes both AOCI and the cumulative foreign currency remeasurement gains/losses, which fluctuate due to market movements that are outside management's control. The most comparable U.S. GAAP financial measure for adjusted return on equity excluding foreign currency remeasurement is ROE as determined using annualized net earnings and average total shareholders’ equity.

75

•U.S. dollar-denominated investment income excluding foreign currency impact represents amounts excluding foreign currency impact on U.S. dollar-denominated investment income using the average foreign currency exchange rate for the comparable prior year period. The Company considers U.S. dollar-denominated investment income excluding foreign currency impact important as it eliminates the impact of foreign currency changes on the Aflac Japan segment results, which are outside management’s control. The most comparable U.S. GAAP financial measure for U.S. dollar-denominated investment income excluding foreign currency impact is the corresponding net investment income amount from the U.S. dollar denominated investments translated to yen.

The following table is a reconciliation of items impacting adjusted earnings and adjusted earnings per diluted share to the most directly comparable U.S. GAAP financial measures of net earnings and net earnings per diluted share, respectively.

Reconciliation of Net Earnings to Adjusted Earnings

	In Millions				Per Diluted Share
	Three Months Ended March 31,
	2025		2024		2025		2024
Net earnings	$	29	$	1,879	$	.05	$	3.25
Items impacting net earnings:
Adjusted net investment (gains) losses (1)	924		(1,009)		1.69		(1.75)
Other and non-recurring (income) loss	53		2		.10		.00
Income tax (benefit) expense on items excluded from adjusted earnings	(100)		89		(.18)		.15
Adjusted earnings	906		961		1.66		1.66
Current period foreign currency impact (2)	8		N/A		.01		N/A
Adjusted earnings excluding current period foreign currency impact	$	914	$	961	$	1.67	$	1.66

(1) See reconciliation of net investment (gains) losses to adjusted net investment (gains) losses below.

(2) Prior period foreign currency impact reflected as “N/A” to isolate change for current period only.

Reconciling Items

Net Investment Gains and Losses

The following table is a reconciliation of items impacting adjusted net investment (gains) losses to the most directly comparable U.S. GAAP financial measure of net investment (gains) losses.

Reconciliation of Net Investment (Gains) Losses to Adjusted Net Investment (Gains) Losses

	Three Months Ended March 31,
(In millions)	2025		2024
Net investment (gains) losses	$	963	$	(951)
Items impacting net investment (gains) losses:
Amortized hedge costs	(7)		(6)
Amortized hedge income	30		28
Net interest income (expense) from derivatives associated   with certain investment strategies	(65)		(88)
Impact of interest from derivatives associated with notes payable	4		8
Adjusted net investment (gains) losses	$	924	$	(1,009)

The Company's investment strategy is to invest primarily in fixed maturity securities to provide a reliable stream of investment income, which is one of the drivers of the Company’s profitability. This investment strategy incorporates asset-liability matching (ALM) to align the expected cash flows of the portfolio to the needs of the Company's liability structure. The Company does not purchase securities with the intent of generating investment gains or losses. However, investment gains and losses may be realized as a result of changes in the financial markets and the creditworthiness of specific issuers, tax planning strategies, and/or general portfolio management and rebalancing. The realization of investment gains and losses is independent of the underwriting and administration of the Company's insurance products.

76

Net investment gains and losses excluded from adjusted earnings include the following:

•Securities Transactions

•Credit Losses

•Changes in the Fair Value of Equity Securities

•Certain Derivative and Foreign Currency Activities.

Securities Transactions, Credit Losses and Changes in the Fair Value of Equity Securities

Securities transactions include gains and losses from sales and redemptions of investments where the amount received is different from the amortized cost of the investment. Credit losses include losses for held-to-maturity fixed maturity securities, available-for-sale fixed maturity securities, loan receivables, loan commitments and reinsurance recoverables. Changes in the fair value of equity securities are the result of gains or losses driven by fluctuations in market prices.

Certain Derivative and Foreign Currency Activities

The Company's derivative activities include:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening yen;

•cross-currency swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated debentures;

•foreign currency swaps that are associated with variable interest entity (VIE) bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Gains and losses are recognized as a result of valuing these derivatives, net of the effects of hedge accounting.

The Company also excludes from adjusted earnings the accounting impacts of foreign currency remeasurement associated with changes in the foreign currency exchange rate.

For additional information regarding net investment gains and losses, including details of reported amounts for the periods presented, see Notes 3 and 4 of the Notes to the Consolidated Financial Statements.

Other and Non-recurring Items

The U.S. insurance industry has a policyholder protection system that provides funds for the policyholders of insolvent insurers. The system can result in periodic charges to the Company as a result of insolvencies/bankruptcies that occur with other companies in the life insurance industry. Some states permit member insurers to recover assessments paid through full or partial premium tax offsets. These charges neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, but result from external situations not controlled by the Company. The Company excludes any charges associated with U.S. guaranty fund assessments and the corresponding tax benefit or expense from adjusted earnings.

In Japan, the government also requires the insurance industry to contribute to a policyholder protection corporation that provides funds for the policyholders of insolvent insurers; however, these costs are calculated and administered differently than in the U.S. In Japan, these costs are not directly related to specific insolvencies or bankruptcies, but are rather a regular operational cost for an insurance company. Based on this structure, the Company does not remove the Japan policyholder protection expenses from adjusted earnings.

77

The Company considers the costs associated with the early redemption of its debt to be unrelated to the underlying fundamentals and trends in its insurance operations. Additionally, these costs are driven by changes in interest rates subsequent to the issuance of the debt, and the Company considers these interest rate changes to represent economic conditions not directly associated with its insurance operations.

In 2025, as part of the U.S. defined benefit plan freeze, the Company purchased a nonparticipating single premium group annuity contract from an external insurer to settle its obligations under the plan and paid to the insurer the related annuity premium. As a result, the Company recognized a settlement charge of $55 million in the first quarter of 2025. The settlement charge was both unusual and non-recurring; therefore, the Company excluded the settlement charge from adjusted earnings.

Foreign Currency Translation

Aflac Japan’s premiums and a significant portion of its investment income are received in yen, and its claims and most expenses are paid in yen. Aflac Japan purchases yen-denominated assets and U.S. dollar-denominated assets, which may be hedged to yen, to support yen-denominated policy liabilities. Yen-denominated income statement accounts are translated to U.S. dollars using the weighted average Japanese yen/U.S. dollar foreign exchange rate for the reporting period, except realized gains and losses on securities transactions which are translated at the exchange rate on the trade date of each transaction. Yen-denominated balance sheet accounts are translated to U.S. dollars using the spot Japanese yen/U.S. dollar foreign exchange rate at the end of the reporting period.

In recent periods, the Japanese yen has weakened against the U.S. dollar; however, the yen strengthened against the U.S. dollar during the first quarter of 2025. Although the Company is unable to predict the timing or extent of future movements of the Japanese yen/U.S. dollar foreign exchange rate, the Company maintains hedging strategies (see the Hedging Activities section of this MD&A) that are intended to mitigate the impacts of yen fluctuation on the Company’s financial position and results of operations. See the risk factor entitled “The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate” in Item 1A. Risk Factors of the 2024 Annual Report for more information.

Income Taxes

The Company's combined U.S. and Japanese effective income tax rate on pretax earnings was 80.3% for the three-month period ended March 31, 2025, compared with 13.4% for the same period in 2024. The combined effective tax rate differs from the U.S. statutory rate primarily due to the exclusion of foreign currency translation gains and losses on certain Aflac Japan U.S. dollar-denominated investments held in the Delaware Statutory Trust and the impact of historic and solar tax credits.

For additional information, see Note 10 of the Notes to the Consolidated Financial Statements and the Critical Accounting Estimates - Income Taxes section of Item 7. MD&A in the 2024 Annual Report. The effective tax rate continues to be subject to future tax law changes both in the U.S. and in foreign jurisdictions. See the risk factor entitled "Tax rates applicable to the Company may change" in Item 1A. Risk Factors of the 2024 Annual Report for more information.

78

Reconciliation of Book Value to Adjusted Book Value

(Excluding Foreign Currency Remeasurement)

The following table is a reconciliation of items impacting adjusted book value and adjusted book value per diluted share excluding foreign currency remeasurement to the most directly comparable U.S. GAAP financial measures of book value and book value per diluted share, respectively.

(In millions, except for share and per-share amounts)	March 31, 2025			December 31, 2024
U.S. GAAP book value		$	26,338		$	26,098
Items impacting U.S. GAAP book value:
Unrealized foreign currency translation gains (losses)		(4,549)			(4,998)
Unrealized gains (losses) on securities and derivatives		(1,251)			4
Effect of changes in discount rate assumptions		3,899			2,006
Pension liability adjustment		42			10
Total accumulated other comprehensive income		(1,859)			(2,978)
Adjusted book value		28,197			29,076
Foreign currency remeasurement gains (losses)		5,083			5,725
Adjusted book value excluding foreign currency remeasurement		23,114			23,351
Number of shares outstanding at end of period		542,493			549,964
U.S. GAAP book value per common share		$	48.55		$	47.45
Items impacting U.S. GAAP book value per common share:
Unrealized foreign currency translation gains (losses) per common share		(8.39)			(9.09)
Unrealized gains (losses) on securities and derivatives per common share		(2.31)			.01
Effect of changes in discount rate assumptions per common share		7.19			3.65
Pension liability adjustment per common share		.08			.02
Total accumulated other comprehensive income per common share		(3.43)			(5.41)
Adjusted book value per common share		51.98			52.87
Foreign currency remeasurement gains (losses) per common share		9.37			10.41
Adjusted book value excluding foreign currency remeasurement per   common share		42.61			42.46

79

Reconciliation of Return on Equity to Adjusted Return on Equity

(Excluding Foreign Currency Remeasurement)

The following table is a reconciliation of items impacting adjusted return on equity excluding foreign currency remeasurement to the most directly comparable U.S. GAAP financial measure of return on equity.

	Three Months Ended March 31,
	2025		2024
U.S. GAAP return on equity - net earnings (1)	.4	%	33.0	%
Impact of excluding unrealized foreign currency translation gains (losses)	.0		(5.1)
Impact of excluding unrealized gains (losses) on securities and derivatives	.0		1.3
Impact of excluding effect of changes in discount rate assumptions	.0		(2.4)
Impact of excluding pension liability adjustment	.0		.0
Impact of excluding accumulated other comprehensive income	.0		(6.2)
U.S. GAAP return on equity less accumulated other comprehensive income	.4		26.8
Differences between adjusted earnings and net earnings (2)	12.2		(13.1)
Adjusted return on equity - reported	12.7		13.7
Impact of excluding gains (losses) associated with foreign currency remeasurement (3)	2.9		2.5
Adjusted return on equity excluding foreign currency remeasurement	15.6		16.2

(1) U.S. GAAP return on equity is calculated by dividing net earnings (annualized) by average shareholders' equity.

(2) See separate reconciliation of net earnings to adjusted earnings above.

(3) Impact of gains/losses associated with foreign currency remeasurement is calculated by excluding the cumulative [beginning January 1, 2021] foreign currency gains/losses associated with i) foreign currency remeasurement and ii) sales and redemptions of invested assets. The impact is the difference of adjusted return on equity - reported compared with adjusted return on equity, excluding from shareholders' equity, gains/losses associated with foreign currency remeasurement.

RESULTS OF OPERATIONS BY SEGMENT

U.S. GAAP financial reporting requires that a company report financial and descriptive information about operating segments in its annual and interim period financial statements. Furthermore, the Company is required to report a measure of segment profit or loss, certain revenue and expense items, and segment assets. The Company's insurance business consists of two segments: Aflac Japan and Aflac U.S. Aflac Japan is the principal contributor to consolidated earnings. In addition, the Parent Company, other business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re, and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other. See Item 1. Business in the 2024 Annual Report for a summary of each segment's products and distribution channels.

Consistent with U.S. GAAP guidance for segment reporting, pretax adjusted earnings is the Company's U.S. GAAP measure of segment performance. The Company believes that a presentation of this measure is vitally important to an understanding of the underlying profitability drivers and trends of its business. Additional performance measures used to evaluate the financial condition and performance of the Company's segments are listed below.

•Operating Ratios

•New Annualized Premium Sales

•New Money Yield

•Return on Average Invested Assets

•Average Weekly Producer

•Premium Persistency

For additional information on the Company’s performance measures included in this MD&A, see the Glossary of Selected Terms found directly following Part II. Other Information. See Note 2 of the Notes to the Consolidated Financial Statements for the reconciliation of segment results to the Company's consolidated U.S. GAAP results and additional information.

80

AFLAC JAPAN SEGMENT

Aflac Japan Pretax Adjusted Earnings

Changes in Aflac Japan’s pretax adjusted earnings and profit margins are primarily affected by morbidity, mortality, expenses, persistency and investment yields. The following table presents a summary of operating results for Aflac Japan.

Aflac Japan Summary of Operating Results

	In Dollars						In Yen
	Three Months Ended March 31,						Three Months Ended March 31,
(In millions of dollars and billions of yen)	2025			2024			2025			2024
Net earned premiums (1)	$	1,681		$	1,816		¥	256		¥	270
Net investment income: (2)
Yen-denominated investment income	224			231			34			34
U.S. dollar-denominated investment income	369			424			56			63
Net investment income	593			655			90			97
Amortized hedge costs	7			6			1			1
Adjusted net investment income	586			648			89			97
Other income (loss)	5			9			1			1
Total adjusted revenues	2,272			2,473			346			368
Benefits and claims:
Benefits and claims, excluding reserve remeasurement	1,130			1,243			172			185
Reserve remeasurement (gains) losses	(25)			(26)			(4)			(4)
Total benefits and claims, net	1,105			1,217			169			181
Adjusted expenses:
Amortization of deferred policy acquisition costs	79			83			12			12
Insurance commissions	105			114			16			17
Insurance and other expenses	261			249			40			37
Total adjusted expenses	445			445			68			66
Total benefits and adjusted expenses	1,550			1,663			236			247
Pretax adjusted earnings	$	722		$	810		¥	110		¥	121
Weighted-average yen/dollar exchange rate	152.40			148.67			—			—
Percentage change over previous period:
Net earned premiums	(7.4)		%	(16.3)		%	(5.0)		%	(6.0)		%
Adjusted net investment income	(9.6)			6.1			(7.6)			19.3
Total adjusted revenues	(8.1)			(11.4)			(5.7)			(.4)
Total benefits and claims, net	(9.2)			(16.2)			(6.8)			(5.9)
Total adjusted expenses	.0			(18.9)			2.5			(8.9)
Pretax adjusted earnings	(10.9)			2.8			(8.7)			15.6

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) Net interest income/expense from derivatives associated with certain investment strategies of $(58) and $(79) for the three-month periods ended March 31, 2025 and 2024, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income.

For the three-month period ended March 31, 2025, operating results in yen terms compared to the same period in the previous year were as follows:

•Net earned premiums decreased primarily due to approximately ¥7 billion related to the internal cancer reinsurance transaction with Aflac Re established in the fourth quarter of 2024 and approximately ¥4 billion from limited-pay products reaching premium paid-up status.

•Adjusted net investment income decreased primarily due to lower floating rate income and fixed-rate yen-denominated income.

81

•Total adjusted revenues decreased primarily due to the decreases in net earned premiums and adjusted net investment income.

•Total benefits and claims decreased primarily due to the internal reinsurance transaction with Aflac Re established in the fourth quarter of 2024 and the impact of assumption updates performed in the third quarter of 2024.

•Total adjusted expenses increased primarily due to an increase in technology expenses, partially offset by the impact of the internal reinsurance transaction with Aflac Re established in the fourth quarter of 2024.

•Pretax adjusted earnings decreased primarily due to the decrease in total adjusted revenue, partially offset by the decrease in total benefits and claims.

Annualized premiums in force decreased 2.7% to ¥1.20 trillion as of March 31, 2025, compared with ¥1.23 trillion as of March 31, 2024. The decrease in annualized premiums in force in yen was driven primarily by limited-pay products reaching premium paid-up status. Annualized premiums in force, translated into dollars at respective period-end exchange rates, were $8.0 billion at March 31, 2025, compared with $8.1 billion at March 31, 2024. As of March 31, 2025, Aflac Japan exceeded 22 million individual policies in force in Japan, with approximately 14 million cancer policies in force in Japan.

Aflac Japan's investment portfolios include U.S. dollar-denominated securities and reverse dual-currency securities (yen-denominated debt securities with dollar coupon payments). In years when the yen strengthens in relation to the dollar, translating Aflac Japan's U.S. dollar-denominated investment income into yen lowers growth rates for net investment income, total adjusted revenues, and pretax adjusted earnings in yen terms. In years when the yen weakens, translating U.S. dollar-denominated investment income into yen magnifies growth rates for net investment income, total adjusted revenues, and pretax adjusted earnings in yen terms.

The following table illustrates the effect of translating Aflac Japan’s U.S. dollar-denominated investment income and related items into yen by comparing certain segment results with those that would have been reported had foreign currency exchange rates remained unchanged from the comparable period in the prior year. Amounts excluding foreign currency impact on U.S. dollar-denominated investment income were determined using the average foreign currency exchange rate for the comparable prior year period. See non-U.S. GAAP financial measures defined above.

Aflac Japan Percentage Changes Over Previous Period

(Yen Operating Results)

For the Periods Ended March 31,

	Including Foreign Currency Changes				Excluding Foreign Currency Changes
	Three Months				Three Months
	2025		2024		2025		2024
Adjusted net investment income	(7.6)	%	19.3	%	(9.0)	%	10.7	%
Total adjusted revenues	(5.7)		(.4)		(6.1)		(2.3)
Pretax adjusted earnings	(8.7)		15.6		(9.8)		9.3

82

The following table presents a summary of operating ratios in yen terms for Aflac Japan followed by a discussion of the significant drivers of changes in operating ratios in yen compared to the same period in the previous year.

	Three Months Ended March 31,
Ratios to total adjusted revenues:	2025		2024
Total benefits and claims, net	48.7	%	49.2	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	3.5		3.3
Insurance commissions	4.6		4.6
Insurance and other expenses	11.5		10.0
Total adjusted expenses	19.6		18.0
Pretax adjusted earnings	31.8		32.8
Ratios to total premiums:
Total benefits and claims, net	65.8	%	67.0	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	4.7		4.6

•For the three-month period ended March 31, 2025, the total benefits and claims to total premiums ratio decreased primarily due to a decrease in total benefits and claims related to reinsurance activity and the impact of assumption updates performed in the third quarter of 2024, partially offset by the decline in net earned premiums resulting from reinsurance activity and limited-pay products reaching premium paid-up status.

•For the three-month period ended March 31, 2025, the total adjusted expense ratio increased primarily due to an increase in technology expenses.

•In total, the pretax adjusted profit margin decreased in the three-month period ended March 31, 2025 primarily due to the decrease in total adjusted revenues, partially offset by the decrease in total benefits and claims.

The following table presents Aflac Japan's premium persistency on a 12-month rolling basis as of March 31.

	2025		2024
Premium persistency	93.8	%	93.4	%

Aflac Japan Sales

The following table presents Aflac Japan’s new annualized premium sales for the periods ended March 31.

	In Dollars						In Yen
	Three Months						Three Months
(In millions of dollars and billions of yen)	2025			2024			2025			2024
New annualized premium sales	$	93		$	84		¥	14.1		¥	12.5
Increase (decrease) over prior period	10.1		%	(15.5)		%	12.6		%	(5.1)		%

The increase in new annualized premium sales on a yen basis in the first quarter of 2025 was driven primarily by strong sales of Tsumitasu as well as initial sales of a new cancer insurance product, Miraito, that was launched in certain sales channels in mid-March 2025 and available in all sales channels starting in the second quarter of 2025.

83

The following table details the contributions to Aflac Japan's new annualized premium sales by major insurance product for the periods ended March 31.

	Three Months
	2025		2024
Cancer	59.7	%	63.2	%
Medical and other health	15.3		21.4
Life insurance:
Traditional life (1)	22.3		8.1
WAYS	1.8		5.3
Child endowment	.1		.3
Other	.8		1.7
Total	100.0	%	100.0	%

(1) Includes term life, whole life and Tsumitasu

The foundation of Aflac Japan's product portfolio has been, and continues to be, third sector products, which include cancer, medical and other products. With continued cost pressure on Japan’s health care system, the Company expects the need for third sector products will continue to rise in the future and that the medical and cancer insurance products Aflac Japan provides will continue to be an important part of its product portfolio. Additionally, the Company believes that sales of first sector products, including Tsumitasu, WAYS and Child Endowment, position Aflac Japan for potential future long-term sales opportunities by marketing these products to a younger demographic as well as potential cross-selling opportunities of Aflac Japan's third sector products.

Aflac Japan continues to promote digital and web-based sales to groups and use of its system that enables smart device-based insurance application by allowing the customer and an Aflac Japan operator to see the same screen through their smart devices. Further, Aflac Japan continues to utilize its virtual sales tool that enables online consultations and policy applications to be completed entirely online.

The following table details the contributions to Aflac Japan's new annualized premium sales by agency type for the three-month periods ended March 31.

	2025		2024
Independent corporate and individual	52.8	%	48.9	%
Affiliated corporate (1)	43.8		48.0
Bank	3.4		3.1
Total	100.0	%	100.0	%

(1) Includes Japan Post Group, Dai-ichi Life and Daido Life

During the three-month period ended March 31, 2025, Aflac Japan recruited 18 new sales agencies. At March 31, 2025, Aflac Japan was represented by approximately 6,500 sales agencies, with approximately 113,000 licensed sales associates employed by those agencies. The number of sales agencies has declined in recent years due to Aflac Japan's focus on supporting agencies with strong management frameworks, high productivity and more producing agents.

At March 31, 2025, Aflac Japan had agreements to sell its products at 358 banks, approximately 90% of the total number of banks in Japan.

Aflac Japan Investments

The level of investment income in yen is affected by available cash flow from operations, the timing of investing the cash flow, yields on new investments, the effect of yen/dollar exchange rates on U.S. dollar-denominated investment income, and other factors.

As part of the Company's portfolio management and asset allocation process, Aflac Japan invests in yen and U.S. dollar-denominated investments. Yen-denominated investments primarily consist of Japan Government Bonds (JGBs), public and private fixed maturity securities and public equity securities. Aflac Japan's U.S. dollar-denominated investments include fixed maturity investments, loan receivables, and growth assets, including alternative investments in limited partnerships or similar investment vehicles. Aflac Japan invests in both publicly traded and privately originated U.S. dollar-

84

denominated investment-grade and below-investment-grade fixed maturity securities and loan receivables, and has entered into foreign currency derivatives to hedge the currency risk on the fair value of a portion of the U.S. dollar investments.

The following table details the investment purchases for Aflac Japan.

	Three Months Ended March 31,
(In millions)	2025		2024
Yen-denominated:
Fixed maturity securities:
Japan government and agencies	$	4,125	$	0
Private placements	0		67
Other fixed maturity securities	21		66
Equity securities	157		87
Commercial mortgage and other loans:
Other investments	10		7
Total yen-denominated	$	4,313	$	227
U.S. dollar-denominated:
Fixed maturity securities:
Other fixed maturity securities	$	1,662	$	1,548
Infrastructure debt	41		60
Collateralized loan obligations	0		27
Commercial mortgage and other loans:
Transitional real estate loans	11		22
Middle market loans	268		142
Other loans	33		0
Other investments	81		62
Total U.S. dollar-denominated	$	2,096	$	1,861
Other currencies:
Fixed maturity securities:
Infrastructure debt	$	52	$	0
Commercial mortgage and other loans:
Other loans	26		0
Other investments	1		0
Total other currencies	$	79	$	0
Total Aflac Japan purchases	$	6,488	$	2,088

See the Investments section of this MD&A for further discussion of these investment programs, and see Notes 3 and 4 of the Notes to the Consolidated Financial Statements and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report for more information regarding loans and loan receivables.

85

The following table presents the results of Aflac Japan’s investment yields for the periods ended March 31.

	Three Months
	2025			2024
Total purchases for the period (in millions) (1)	$	6,396		$	2,019
New money yield (1),(2)	3.30		%	5.57		%
Return on average invested assets (3)	3.00			3.14
Portfolio book yield, including U.S. dollar-denominated investments, end of period (1),(2)	3.22		%	3.24		%

(1) Includes fixed maturity securities, commercial mortgage and other loans, equity securities, and excludes alternative investments in limited partnerships

(2) Reported on a gross yield basis; excludes investment expenses, external management fees and amortized hedge costs

(3) Net of investment expenses and amortized hedge costs, year-to-date number reflected on a quarterly average basis

The decrease in the Aflac Japan new money yield in the three-month period ended March 31, 2025 was primarily due to lower allocations to higher yielding asset classes. See Notes 3, 4 and 5 of the Notes to the Consolidated Financial Statements and the Investments and Hedging Activities sections of this MD&A for additional information on the Company's investments and hedging strategies.

AFLAC U.S. SEGMENT

Aflac U.S. Pretax Adjusted Earnings

Changes in Aflac U.S. pretax adjusted earnings and profit margins are primarily affected by morbidity, mortality, expenses, persistency and investment yields. The following table presents a summary of operating results for Aflac U.S.

Aflac U.S. Summary of Operating Results

	Three Months Ended March 31,
(In millions)	2025			2024
Net earned premiums	$	1,502		$	1,475
Adjusted net investment income (1)	202			206
Other income	17			18
Total adjusted revenues	1,721			1,699
Benefits and claims:
Benefits and claims, excluding reserve remeasurement	731			715
Reserve remeasurement (gains) losses	(15)			(29)
Total benefits and claims, net	716			686
Adjusted expenses:
Amortization of deferred policy acquisition costs	137			132
Insurance commissions	135			141
Insurance and other expenses	375			384
Total adjusted expenses	647			658
Total benefits and adjusted expenses	1,363			1,343
Pretax adjusted earnings	$	358		$	356
Percentage change over previous period:
Net earned premiums	1.8		%	3.3		%
Adjusted net investment income	(1.9)			4.6
Total adjusted revenues	1.3			2.3
Total benefits and claims, net	4.4			5.4
Total adjusted expenses	(1.7)			.2
Pretax adjusted earnings	.6			1.1

(1) Net interest income/expense from derivatives associated with certain investment strategies of $(6) and $(9) for the three-month periods ended March 31, 2025 and 2024, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income.

86

For the three-month period ended March 31, 2025, operating results compared to the same period in the previous year were as follows:

•Net earned premiums increased primarily due to higher net earned premiums from growth initiatives including group life and disability and consumer markets businesses.

•Adjusted net investment income decreased primarily due to lower floating rate income.

•Total adjusted revenues increased primarily due to the increase in net earned premiums.

•Total benefits and claims increased primarily due to higher incurred claims and lower reserve remeasurement gains reflecting actual experience.

•Total adjusted expenses decreased primarily due to improved expense efficiency.

•Pretax adjusted earnings increased slightly primarily due to the increase in total adjusted revenues and the decrease in total adjusted expenses, mostly offset by the increase in total benefits and claims.

Annualized premiums in force increased 4.7% to $6.5 billion at March 31, 2025, compared with $6.2 billion at March 31, 2024.

The following table presents a summary of operating ratios for Aflac U.S followed by a discussion of the significant drivers of changes in operating ratios compared to the same period in the previous year.

	Three Months Ended March 31,
Ratios to total adjusted revenues:	2025		2024
Total benefits and claims	41.6	%	40.4	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	8.0		7.8
Insurance commissions	7.8		8.3
Insurance and other expenses	21.8		22.6
Total adjusted expenses	37.6		38.7
Pretax adjusted earnings	20.8		21.0
Ratios to total premiums:
Total benefits and claims	47.7	%	46.5	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	9.1		8.9

•For the three-month period ended March 31, 2025, the total benefits and claims ratio to total premiums ratio increased primarily due to higher incurred claims and lower reserve remeasurement gains reflecting actual experience.

•The total adjusted expense ratio decreased in the three-month period ended March 31, 2025 primarily due to expense efficiency efforts.

•In total, the pretax adjusted profit margin decreased slightly in the three-month period ended March 31, 2025, primarily due to the increase in the benefit ratio.

The following table presents premium persistency for Aflac U.S. on a 12-month rolling basis as of March 31.

	2025		2024
Premium persistency	79.3	%	78.7	%

87

Aflac U.S. Sales

The following table presents Aflac's U.S. new annualized premium sales for the periods ended March 31.

	Three Months
(In millions)	2025			2024
New annualized premium sales	$	309		$	298
Increase (decrease) over prior period	3.5		%	(5.2)		%

The increase in new annualized premium sales for Aflac U.S. in the first quarter of 2025 was primarily driven by sales of group products.

The following table details the contributions to Aflac's U.S. new annualized premium sales by major insurance product category for the periods ended March 31.

	Three Months
	2025		2024
Accident	21.1	%	22.5	%
Disability	22.8		23.0
Critical care(1)	21.8		22.1
Hospital indemnity	15.0		15.1
Dental/vision	6.8		6.5
Life	12.5		10.8
Total	100.0	%	100.0	%

(1) Includes cancer, critical illness, and hospital intensive care products

In the first quarter of 2025, the Aflac U.S. sales force included an average of approximately 5,100 U.S. agents, including brokers, who were actively producing business on a weekly basis. The Company believes that this average weekly producer equivalent metric allows sales management to monitor progress and needs, as well as serve as a leading indicator of future production capacity.

Aflac U.S. Investments

The level of investment income is affected by available cash flow from operations, the timing of investing the cash flow, yields on new investments, and other factors.

As part of the Company's portfolio management and asset allocation process, Aflac U.S. invests in fixed maturity investments, loan receivables, and growth assets, including public equity securities and alternative investments in limited partnerships. Aflac U.S. invests in both publicly traded and privately originated investment-grade and below-investment-grade fixed maturity securities and loan receivables.

88

The following table details the investment purchases for Aflac U.S.

	Three Months Ended March 31,
(In millions)	2025		2024
Fixed maturity securities:
Other fixed maturity securities	$	433	$	401
Infrastructure debt	2		24
Collateralized loan obligations	0		3
Equity securities	6		12
Commercial mortgage and other loans:
Transitional real estate loans	2		7
Middle market loans	40		72
Other loans	10		0
Other investments	14		7
Total Aflac U.S. Purchases	$	507	$	526

See Note 3 of the Notes to the Consolidated Financial Statements and Notes 1 and 3 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report for more information regarding loans and loans receivables.

The following table presents the results of Aflac's U.S. investment yields for the periods ended March 31.

	Three Months
	2025			2024
Total purchases for period (in millions) (1)	$	493		$	519
New money yield (1),(2)	6.61		%	6.66		%
Return on average invested assets (3)	4.80			4.87
Portfolio book yield, end of period (1),(2)	5.56		%	5.57		%

(1) Includes fixed maturity securities, commercial mortgage and other loans, equity securities, and excludes alternative investments in limited partnerships

(2) Reported on a gross yield basis; excludes investment expenses and external management fees

(3) Net of investment expenses, year-to-date number reflected on a quarterly average basis

The decrease in the Aflac U.S. new money yield in the three-month period ended March 31, 2025 was primarily due to lower allocations to higher yielding asset classes. See Notes 3 and 5 of the Notes to the Consolidated Financial Statements and the Investments section of this MD&A for additional information on the Company's investments.

89

CORPORATE AND OTHER

Changes in the pretax adjusted earnings of Corporate and other are primarily affected by internal reinsurance activity and net investment income. The following table presents a summary of operating results for Corporate and other.

Corporate and Other Summary of Operating Results

	Three Months Ended March 31,
(In millions)	2025			2024
Net earned premiums	$	198		$	165
Net investment income (loss) (1)	96			51
Amortized hedge income	30			28
Adjusted net investment income	126			79
Other income	2			3
Total adjusted revenues	326			247
Benefits and claims:
Benefits and claims, excluding reserve remeasurement	125			$	108
Reserve remeasurement (gains) losses	(1)			(1)
Total benefits and claims, net	124			107
Adjusted expenses:
Interest expense	45			36
Other adjusted expenses	114			107
Total adjusted expenses	159			143
Total benefits and adjusted expenses	283			250
Pretax adjusted earnings	$	43		$	(3)
Percentage change over previous period:
Net earned premiums	20.0		%	81.3		%
Adjusted net investment income	59.5			119.4
Total adjusted revenues	32.0			91.5
Total benefits and claims, net	15.9			132.6
Total adjusted expenses	11.2			58.9
Pretax adjusted earnings	1,533.3			57.1

(1) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025 and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025 and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 of the Notes to the Consolidated Financial Statements for additional information on these investments.

For the three-month period ended March 31, 2025, operating results compared to the same period in the previous year were as follows:

•Net earned premiums and total benefits and claims increased primarily due to higher reinsurance activity resulting from the agreement established in the fourth quarter of 2024.

•Adjusted net investment income increased primarily due to $24 million from a lower volume of federal historic rehabilitation and solar tax credit investments, with offsetting tax benefits recognized as a corresponding lower income tax expense, and higher Aflac Re consolidated investment income of $12 million from a higher volume of assets as part of the reinsurance agreement established in the fourth quarter of 2024.

•Total adjusted revenues increased primarily due to higher adjusted net investment income and net earned premiums.

•Total adjusted expenses increased primarily due to reinsurance activity and higher interest expense.

•Pretax adjusted earnings increased primarily due to higher total adjusted revenues partially offset by higher total benefits and adjusted expenses.

90

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheets. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statements of earnings.

INVESTMENTS

The Company’s investment strategy utilizes disciplined asset and liability management while seeking long-term risk-adjusted investment returns and the delivery of stable income within regulatory and capital objectives, and preserving shareholder value. In attempting to optimally balance these objectives, the Company seeks to maintain on behalf of Aflac Japan a diversified portfolio of yen-denominated investment assets, a U.S. dollar-denominated investment portfolio hedged back to yen and a portfolio of unhedged U.S. dollar-denominated assets. As part of the Company's portfolio management and asset allocation process, Aflac U.S. invests in fixed maturity investments and growth assets, including public equity securities and alternative investments in limited partnerships. Aflac U.S. invests in both publicly traded and privately originated investment-grade and below-investment-grade fixed maturity securities and loans.

For additional information concerning the Company's investments, see Notes 3, 4, and 5 of the Notes to the Consolidated Financial Statements.

The following tables detail investments by segment.

Investment Securities by Segment

	March 31, 2025
(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total
Available-for-sale, fixed maturity securities,    at fair value	$	47,308	$	12,543	$	7,293	$	67,144
Held-to-maturity, fixed maturity securities,    at amortized cost (1)	16,888		0		0		16,888
Equity securities	464		2		298		764
Commercial mortgage and other loans: (1)
Transitional real estate loans	3,441		848		186		4,475
Commercial mortgage loans	906		605		0		1,511
Middle market loans	3,896		405		0		4,301
Other loans	294		60		15		369
Other investments:
Policy loans	176		35		0		211
Short-term investments (2)	1,277		247		735		2,259
Limited partnerships	2,898		319		265		3,482
Real estate owned	676		98		0		774
Other	0		37		0		37
Investment in affiliate (3)	0		804		(804)		0
Total investments	78,224		16,003		7,988		102,215
Cash and cash equivalents	1,738		703		2,790		5,231
Total investments and cash	$	79,962	$	16,706	$	10,778	$	107,446

(1) Net of allowance for credit losses

(2) Includes securities lending collateral

(3) For consolidated reporting, Aflac U.S.'s investment in Aflac Re is eliminated in Corporate and other

91

	December 31, 2024
(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total
Available-for-sale, fixed maturity securities,    at fair value	$	45,970	$	12,296	$	7,003	$	65,269
Held-to-maturity, fixed maturity securities,    at amortized cost (1)	15,966		0		0		15,966
Equity securities	458		2		336		796
Commercial mortgage and other loans: (1)
Transitional real estate loans	3,648		866		189		4,703
Commercial mortgage loans	915		608		0		1,523
Middle market loans	3,847		436		0		4,283
Other loans	284		61		15		360
Other investments:
Policy loans	168		35		0		203
Short-term investments (2)	484		366		749		1,599
Limited partnerships	2,861		306		268		3,435
Real estate owned	570		112		0		682
Other	0		39		0		39
Investment in affiliate (3)	0		638		(638)		0
Total investments	75,171		15,765		7,922		98,858
Cash and cash equivalents	2,062		1,010		3,157		6,229
Total investments and cash	$	77,233	$	16,775	$	11,079	$	105,087

(1) Net of allowance for credit losses

(2) Includes securities lending collateral

(3) For consolidated reporting, Aflac U.S.'s investment in Aflac Re is eliminated in Corporate and other

The Company has invested in a variety of commercial mortgage loans (CMLs) and other loans including transitional real estate loans (TREs). The Company's TRE and CML investments are collateralized by commercial real estate, including some office properties. The Company considers these investments to be well diversified by geography and among property types. Further, the Company believes that the portfolio is generally well positioned with exposures concentrated in high quality underlying properties with institutional investors who are experienced in managing their assets during periods of market volatility.

While generally resilient, the Company's investments in TREs and CMLs have been affected by conditions in the commercial real estate market, with a greater impact on mortgages secured by office properties. The Company invested in certain TREs and CMLs that are currently in default of interest or maturity payments. The Company works with the affected borrowers to resolve specific situations through loan continuance with potential modifications, through loan sales, or through the process of foreclosure or deed in lieu of foreclosure. Since the third quarter of 2023, the Company has taken possession, through foreclosure or deed in lieu of foreclosure, of certain commercial real estate properties, which secured defaulted loans. Properties acquired by the Company through foreclosure and deed in lieu of foreclosure are reported as real estate owned (REO) in other investments in the Company's consolidated balance sheets.

In the three-month period ended March 31, 2025, the Company completed foreclosure or deed in lieu of foreclosure on TREs collateralized with commercial real estate properties with an amortized cost of $87 million. As a result of the amortized cost of the TREs exceeding the estimated fair value of the collateral upon consummating the foreclosures or deed in lieu of foreclosure transactions, the Company recognized a net loss of $16 million in net investment gains (losses) for the three-month period ended March 31, 2025. In the three-month period ended March 31, 2024, the Company completed foreclosure or deed in lieu of foreclosure on TREs collateralized with commercial real estate properties with an amortized cost of $31 million. As a result of the estimated fair value of the collateral exceeding the amortized cost of the TREs upon consummating the foreclosures or deed in lieu of foreclosure transactions, the Company recognized a net gain of $4 million in net investment gains (losses) for the three-month period ended March 31, 2024.

92

The Company utilizes third-party asset managers to source, underwrite and manage each loan, as well as any resulting REO. The Company closely monitors the activities of these managers. In the event that a loan workout is necessary, the Company believes these external managers have the experience and resources to manage the process to maximize recovery.

The Company also monitors its commercial mortgage and other loan investments internally on an ongoing basis, including a review of loans' credit quality indicators and payment status as current, past due, restructured or under foreclosure. See Note 3 of the Notes to the Consolidated Financial Statements for further information concerning credit quality indicators, information on loans that are on nonaccrual status, and REO obtained through foreclosure or deed in lieu of foreclosure. See also Item 1A. Risk Factors of the 2024 Annual Report for a discussion of risk factors associated with the Company's investments.

The ratings of the Company's securities referenced in the table below are based on the ratings designations provided by major rating organizations such as Moody's, Standard & Poor's and Fitch or, if not rated, are determined based on the Company's internal analysis of such securities. When the ratings issued by the rating agencies differ, the Company utilizes the second lowest rating when three or more rating agency ratings are available or the lowest rating when only two rating agency ratings are available.

The distributions of fixed maturity securities the Company owns, by credit rating, were as follows:

Composition of Fixed Maturity Securities by Credit Rating

		March 31, 2025						December 31, 2024
	Amortized Cost			Fair       Value			Amortized Cost			Fair       Value
AAA		1.3	%		1.4	%		1.5	%		1.5	%
AA		6.0			6.3			6.0			6.3
A		68.2			66.4			68.0			66.1
BBB		22.9			24.2			22.9			24.4
BB or lower		1.6			1.7			1.6			1.7
Total		100.0	%		100.0	%		100.0	%		100.0	%

As of March 31, 2025, the Company's direct and indirect exposure to securities in its investment portfolio that were guaranteed by third parties was immaterial both individually and in the aggregate.

The following table presents the 10 largest unrealized loss positions in the Company's portfolio as of March 31, 2025.

(In millions)	Credit Rating		Amortized Cost			Fair Value			Unrealized Loss
Japan National Government		A+		$	35,251		$	33,082		$	(2,169)
Urban Renaissance Agency		A+		163			113			(50)
KLM Royal Dutch Airlines		B+		133			96			(37)
JP Morgan Chase and Co.		A+		189			152			(37)
Prologis LP		A		151			121			(30)
Tokyo Gas Co Ltd		A+		100			74			(26)
Banco de Chile		A		134			108			(26)
Mitsubishi Estate Co Ltd.		A		133			108			(25)
SNCF Reseau		AA-		72			48			(24)
West Japan Railway Company		A+		79			55			(24)

Generally, declines in fair values can be a result of changes in interest rates, yen/dollar exchange rate, and changes in net spreads driven by a broad market move or a change in the issuer's underlying credit quality. The Company believes these issuers have the ability to continue making timely payments of principal and interest. See the Unrealized Investment Gains and Losses section in Note 3 of the Notes to the Consolidated Financial Statements for further discussions of unrealized losses related to the Company's investments.

93

Below-Investment-Grade Securities

The Company's portfolio of below-investment-grade securities includes debt securities purchased while the issuer was rated investment grade plus other loans and bonds invested in as part of an allocation to that segment of the market. The following is the Company's below-investment-grade exposure.

Below-Investment-Grade Investments

	March 31, 2025
(In millions)	Par Value		Amortized Cost (1)		Fair Value		Unrealized Gain (Loss)
Investcorp Capital Limited	$	231	$	230	$	209	$	(21)
Hella KG Hueck and Co.	147		147		139		(8)
Thames Water Utility	135		134		118		(16)
Telecom Italia SpA	134		134		175		41
KLM Royal Dutch Airlines	134		133		96		(37)
IKB Deutsche Industriebank AG	87		47		78		31
Generalitat de Catalunya	54		23		50		27
Hawaiian Electric Industries Inc	35		35		29		(6)
CPI Property Group SA	20		20		19		(1)
Other Issuers	24		26		23		(3)
Subtotal (2)	1,001		929		936		7
High yield corporate bonds	542		438		510		72
Middle market loans	4,223		4,045		3,982		(63)
Grand Total	$	5,766	$	5,412	$	5,428	$	16

(1) Net of allowance for credit losses

(2) Securities initially purchased as investment grade, but have subsequently been downgraded to below investment grade

The Company maintains an allocation to higher yielding corporate bonds within the Aflac Japan and Aflac U.S. portfolios. Most of these securities were rated below-investment-grade at the time of purchase, but the Company also purchased several that were rated investment grade which, because of market pricing, offer yields commensurate with below-investment-grade risk profiles. The objective of this allocation was to enhance the Company's yield on invested assets and further diversify credit risk. All investments in this program must have a minimum rating at purchase of low BB using the Company's above described rating methodology and are managed by the Company's internal credit portfolio management team.

The Company invests in middle market loans primarily to U.S. corporate borrowers, most of which have below-investment-grade ratings. The objectives of this program include enhancing the yield on invested assets, achieving further diversification of credit risk, and mitigating the risk of rising interest rates and hedge costs through the acquisition of floating rate assets.

94

Fixed Maturity Securities by Sector

The Company maintains diversification in investments by sector to avoid concentrations to any one sector, thus managing exposure risk. The following table shows the distribution of fixed maturities by sector classification.

	March 31, 2025
(In millions)	Amortized Cost (1)		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		% of Total
Government and agencies	$	36,473	$	515	$	(2,765)	$	34,223	43.2	%
Municipalities	2,358		130		(173)		2,315		2.8
Mortgage- and asset-backed securities	3,916		207		(75)		4,048		4.6
Public utilities	7,021		531		(297)		7,254		8.3
Electric	5,492		430		(182)		5,742		6.5
Natural Gas	882		63		(70)		873		1.0
Other	647		38		(45)		639		.8
Sovereign and supranational	803		51		(10)		844		1.0
Banks/financial institutions	9,226		613		(478)		9,361		10.9
Banking	5,322		372		(251)		5,442		6.3
Insurance	1,925		159		(71)		2,014		2.3
Other	1,979		82		(156)		1,905		2.3
Other corporate	24,636		2,700		(1,103)		26,234		29.2
Basic Industry	2,073		296		(101)		2,267		2.5
Capital Goods	2,623		244		(125)		2,743		3.1
Communications	2,610		426		(64)		2,972		3.1
Consumer Cyclical	1,962		182		(50)		2,094		2.3
Consumer Non-Cyclical	5,776		642		(257)		6,160		6.8
Energy	2,277		348		(33)		2,592		2.7
Other	1,126		69		(99)		1,097		1.3
Technology	3,258		204		(170)		3,293		3.9
Transportation	2,931		289		(204)		3,016		3.5
Total fixed maturity securities	$	84,433	$	4,747	$	(4,901)	$	84,279	100.0	%

(1) Net of allowance for credit losses

Securities by Type of Issuance

The Company has investments in both publicly and privately issued securities. The Company's ability to sell either type of security is a function of overall market liquidity which is impacted by, among other things, the amount of outstanding securities of a particular issuer or issuance, trading history of the issue or issuer, overall market conditions, and idiosyncratic events affecting the specific issue or issuer.

95

The following table details investment securities by type of issuance.

Investment Securities by Type of Issuance 

		March 31, 2025						December 31, 2024
(In millions)	Amortized Cost (1)			Fair    Value			Amortized Cost (1)			Fair   Value
Publicly issued securities:
Fixed maturity securities		$	68,471		$	67,979		$	65,291		$	66,476
Equity securities		603			603			638			638
Total publicly issued		69,074			68,582			65,929			67,114
Privately issued securities: (2)
Fixed maturity securities (3)		15,962			16,300			14,764			15,565
Equity securities		161			161			158			158
Total privately issued		16,123			16,461			14,922			15,723
Total investment securities		$	85,197		$	85,043		$	80,851		$	82,837

(1) Net of allowance for credit losses

(2) Primarily consists of securities owned by Aflac Japan

(3) Excludes Rule 144A securities

The following table details the Company's reverse dual-currency securities.

Reverse Dual-Currency Securities(1)

(Amortized cost, in millions)	March 31, 2025				December 31, 2024
Privately issued reverse dual-currency securities		$	3,567			$	3,368
Publicly issued collateral structured as reverse dual-currency securities		937				945
Total reverse dual-currency securities		$	4,504			$	4,313
Reverse dual-currency securities as a percentage of total investment    securities		5.3		%		5.3		%

(1) Principal payments in yen and interest payments in dollars

Aflac Japan has a portfolio of privately issued securities to better match liability characteristics and secure higher yields than those available on Japanese government or other public corporate bonds. Aflac Japan’s investments in yen-denominated privately issued securities consist primarily of non-Japanese issuers, are rated investment grade at purchase and have longer maturities, thereby allowing the Company to improve asset/liability matching and overall investment returns. These securities are generally either privately negotiated arrangements or issued under medium-term note programs and have standard documentation commensurate with credit ratings of the issuer, except when internal credit analysis indicates that additional protective and/or event-risk covenants were required. Many of these investments have protective covenants appropriate to the specific investment. These may include a prohibition of certain activities by the borrower, maintenance of certain financial measures, and specific conditions impacting the payment of the Company's notes.

HEDGING ACTIVITIES

The Company uses derivative contracts to hedge foreign currency exchange rate risk and interest rate risk. The Company uses various strategies, including derivatives, to manage these risks. See Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the 2024 Annual Report for more information about market risk and the Company’s use of derivatives.

Derivatives are designed to reduce risk on an economic basis while minimizing the impact on financial results. The Company’s derivatives programs vary depending on the type of risk being hedged. See Note 4 of the Notes to the Consolidated Financial Statements for:

•A description of the Company's derivatives, hedging strategies and underlying risk exposure.

•Information about the notional amount and fair market value of the Company's derivatives.

•Impact on earnings and other comprehensive income (loss) from various qualifying and non-qualifying hedging relationships.

96

Foreign Currency Exchange Rate Risk Hedge Program

The Company has deployed the following hedging strategies to mitigate exposure to foreign currency exchange rate risk:

•Aflac Japan hedges U.S. dollar-denominated investments back to yen (see Aflac Japan’s U.S. Dollar-Denominated Hedge Program below).

•Aflac Japan maintains certain unhedged U.S. dollar-denominated securities, which serve as an economic currency hedge of a portion of the Company's investment in Aflac Japan, while utilizing foreign currency options to mitigate against significant movements in the yen/U.S. dollar exchange rate (see Aflac Japan’s U.S. Dollar-Denominated Hedge Program below).

•The Parent Company designates yen-denominated liabilities (notes payable and loans) as non-derivative hedging instruments and designates certain foreign currency forwards and options as derivative hedges of the Company’s net investment in Aflac Japan (see Enterprise Corporate Hedging Program below).

•The Parent Company enters into forward and option contracts to accomplish a dual objective of hedging foreign currency exchange rate risk related to dividend payments by its subsidiary, ALIJ, and reducing enterprise-wide hedge costs (see Enterprise Corporate Hedging Program below).

The following table presents metrics related to Aflac Japan's U.S. dollar-denominated hedge program and the Parent Company's enterprise corporate hedging program, including associated amortized hedge costs/income, for the periods ended March 31. See the Results of Operations section of this MD&A for the Company's definition of amortized hedge costs/income.

	Three Months
	2025	2024
Aflac Japan:
FX Forwards
FX forward (sell USD, buy yen) notional at end of period (in billions) (1)	$0.2	$0.0
Amortized hedge income (cost) for period (in millions)	$0	$2
FX Options
FX option notional at the end of period (in billions) (1)	$24.2	$24.7
Amortized hedge income (cost) for period (in millions)	$(7)	$(8)
Corporate and other (Parent Company):
FX Forwards
FX forward (buy USD, sell yen) notional at end of period (in billions) (1)	$2.7	$2.3
Amortized hedge income (cost) for period (in millions)	$30	$28
FX Options
FX option notional at the end of period (in billions) (1)	$0.0	$0.0
Amortized hedge income (cost) for period (in millions)	$0	$0

(1) Notional is reported net of any offsetting positions within Aflac Japan or the Parent Company, respectively.

Amortized hedge costs/income can fluctuate based upon many factors, including the derivative notional amount, the length of time of the derivative contract, changes in both U.S. and Japan interest rates, and supply and demand for dollar funding. Amortized hedge costs/income have fluctuated in recent periods due to changes in the previously mentioned factors.

Aflac Japan’s U.S. Dollar-Denominated Hedge Program (U.S. Dollar Program)

Aflac Japan buys U.S. dollar-denominated investments, typically corporate bonds, and hedges them back to yen with foreign currency forwards and options to hedge foreign currency exchange rate risk. This economically creates yen assets that match yen liabilities during the life of the derivative and provides favorable capital treatment under the Japan solvency margin ratio (SMR) calculations. The currency risk being hedged is generally based on fair value of hedged investments. The following table summarizes the U.S. dollar-denominated investments held by Aflac Japan.

97

	March 31, 2025				December 31, 2024
(In millions)	Amortized Cost (1)		Fair Value		Amortized Cost (1)		Fair Value
Available-for-sale securities:
Fixed maturity securities	$	11,605	$	13,409	$	9,835	$	12,183
Equity securities	22		22		22		22
Commercial mortgage and other loans:
Transitional real estate loans (floating rate)	3,441		3,443		3,648		3,656
Commercial mortgage loans	906		825		915		811
Middle market loans (floating rate)	3,896		3,824		3,847		3,794
Other loans	151		151		174		173
Other investments	3,871		3,871		2,862		2,862
Total U.S. Dollar Program	23,892		25,545		21,303		23,501
Available-for-sale securities:
Fixed maturity securities - economically converted to yen	1,769		2,465		1,645		2,406
Total U.S. dollar-denominated investments in Aflac Japan	$	25,661	$	28,010	$	22,948	$	25,907

(1) Net of allowance for credit losses

The U.S. Dollar Program includes all U.S. dollar-denominated investments in Aflac Japan other than the investments in certain consolidated VIEs where the instrument is economically converted to yen as a result of a derivative in the consolidated VIE. The Company uses foreign currency forwards to hedge foreign exchange risk on certain U.S. dollar-denominated investments in Aflac Japan's portfolio, and one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also maintains a collar program on a portion of its U.S. Dollar Program to mitigate against more extreme moves in foreign exchange and therefore support SMR. As of March 31, 2025, none of the Company's foreign currency options hedging Aflac Japan's U.S. dollar-denominated assets were in-the-money.

Foreign exchange derivatives used for hedging are periodically settled, which results in cash receipt or payment at maturity or early termination. The following table presents the settlements associated with the Company's currency derivatives used for hedging Aflac Japan’s U.S. dollar-denominated investments.

	Three Months Ended March 31,
(In millions)	2025			2024
Net cash inflows (outflows)		$	(7)		$	(411)

Enterprise Corporate Hedging Program

The Company has designated certain yen-denominated liabilities and foreign currency forwards and options of the Parent Company as accounting hedges of its net investment in Aflac Japan. The Company's consolidated yen-denominated net asset position was partially hedged at $7.0 billion as of March 31, 2025, with hedging instruments comprised of $4.3 billion of yen-denominated debt and $2.7 billion of foreign currency forwards, compared with $5.9 billion as of December 31, 2024, with hedging instruments comprised of $4.1 billion of yen-denominated debt and $1.8 billion of foreign currency forwards.

The Company makes its accounting designation of net investment hedge at the beginning of each quarter. If the total of the designated Parent Company non-derivative and derivative notional is equal to or less than the Company's net investment in Aflac Japan, the hedge is deemed to be effective, and the currency exchange effect on the yen-denominated liabilities and the change in estimated fair value of the derivatives are reported in the unrealized foreign currency component of other comprehensive income. The Company's net investment hedge was effective during the three-month periods ended March 31, 2025 and 2024, respectively. For additional information on the Company's net investment hedging strategy, see Note 4 of the Notes to the Consolidated Financial Statements.

In order to economically mitigate risks associated with the enterprise-wide exposure to the yen and the level and volatility of hedge costs, the Parent Company enters into foreign currency forward and option contracts. By buying U.S. dollars and

98

selling yen, the Parent Company is effectively lowering its overall economic exposure to the yen. In addition to reducing yen exposure from dividend payments by Aflac Japan to the Parent Company, this strategy also reduces enterprise-wide hedge costs. This activity is reported in Corporate and other. The Company continually evaluates the program’s efficacy.

As part of the Company’s internal reinsurance platform, Aflac Re enters into foreign currency forwards with the Parent Company, and may enter into such forwards with third parties, to economically manage the currency mismatch between Aflac Re's assets, which are mostly denominated in U.S. dollars, and liabilities, which are mostly denominated in yen, in order to support and optimize Bermuda Monetary Authority (BMA) capital requirements. For additional information on the Company's internal reinsurance platform, see Note 8 of the Notes to the Consolidated Financial Statements and the Liquidity and Capital Resources section of this MD&A and Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

Interest Rate Risk Hedge Program

Aflac Japan and Aflac U.S. use interest rate swaps from time to time to mitigate the risk of investment income volatility for certain variable-rate investments. Additionally, to manage interest rate risk associated with its U.S. dollar-denominated investments held by Aflac Japan, from time to time the Company utilizes interest rate swaptions.

For additional discussion of the risks associated with the foreign currency exposure refer to the Currency Risk section in Item 7A., Quantitative and Qualitative Disclosures about Market Risk, and Item 1A, specifically to the Risk Factors titled “The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate" and “Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity" in the 2024 Annual Report.

See Note 4 of the Notes to the Consolidated Financial Statements for additional information on the Company's hedging activities.

DEFERRED POLICY ACQUISITION COSTS

The following table presents deferred policy acquisition costs (DAC) by segment.

(In millions)	March 31, 2025			December 31, 2024			% Change
Aflac Japan		$	5,416		$	5,102		6.2	%	(1)
Aflac U.S.		3,667			3,656			.3
Total		$	9,083		$	8,758		3.7	%

(1) Aflac Japan’s deferred policy acquisition costs increased .4% in yen during the three months ended March 31, 2025.

See Note 6 of the Notes to the Consolidated Financial Statements for additional information on the Company's deferred policy acquisition costs.

POLICY LIABILITIES

The following table presents policy liabilities by segment.

(In millions)	March 31, 2025			December 31, 2024			% Change
Aflac Japan		$	68,792		$	67,549		1.8	%	(1)
Aflac U.S.		11,194			11,063			1.2
Corporate and other		4,879			4,839			.8
Intercompany eliminations (2)		(6,037)			(5,943)			(1.6)
Total		$	78,828		$	77,508		1.7	%

(1) Aflac Japan’s policy liabilities decreased 3.7% in yen during the three months ended March 31, 2025.

(2) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture of a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

See Note 7 of the Notes to the Consolidated Financial Statements for additional information on the Company's policy liabilities.

99

BENEFIT PLANS

Aflac Japan and Aflac U.S. have various benefit plans. For additional information on the Company's Japanese and U.S. plans, see Note 12 of the Notes to the Consolidated Financial Statements and Note 14 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

POLICYHOLDER PROTECTION

Policyholder Protection Corporation

The Japanese insurance industry has a policyholder protection system that provides funds for the policyholders of insolvent insurers. Legislation enacted regarding the framework of the Life Insurance Policyholder Protection Corporation (LIPPC) included government fiscal measures supporting the LIPPC. In March 2022, Japan's Diet passed legislation that extended the government's fiscal support of the LIPPC through March 2027. In March 2022, the LIPPC reached the required balance for the total life industry of ¥400 billion as specified by its Articles of Incorporation. As a result, additional contributions are not expected to be required unless the balance is reduced due to payments made by the LIPPC to the policyholders of insolvent insurers. Accordingly, Aflac Japan did not recognize an expense for LIPPC assessments for the three-month periods ended March 31, 2025 and March 31, 2024.

Guaranty Fund Assessments

Under U.S. state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business. The amount of the guaranty fund assessment that an insurer is assessed is based on its proportionate share of premiums in that state. Guaranty fund assessments for the three-month periods ended March 31, 2025 and 2024 were immaterial.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity refers to the ability to generate sufficient cash resources to meet the payment obligations of the Company. Capital refers to the long-term financial resources available to support the operations of the businesses, fund business growth and provide for an ability to withstand adverse circumstances. Financial leverage (leverage) refers to a strategy of utilizing debt in managing the Company's capital structure and cost of capital. The Company targets and actively manages liquidity, capital and leverage in the context of a number of considerations, including:

•business investment and growth needs

•strategic growth objectives

•financial flexibility and obligations

•capital support for hedging activity

•a constantly evolving business and economic environment

•a balanced approach to capital allocation and shareholder deployment.

The governance framework supporting liquidity, capital, and leverage includes global senior management and board committees that review and approve all significant capital related decisions.

The Company's cash and cash equivalents include unrestricted cash on hand, money market instruments, and other debt instruments with a maturity of 90 days or less when purchased, all of which have minimal market, settlement or other risk exposure. The target minimum amount for the Parent Company’s cash and cash equivalents is approximately $1.8 billion to provide a capital buffer and liquidity support at the holding company. The Company remains committed to prudent liquidity and capital management. At March 31, 2025, the Company held $5.2 billion in cash and cash equivalents for stress conditions, which includes the Parent Company's target minimum amount of $1.8 billion.

Aflac Japan and Aflac U.S. generate cash flows from their operations and provide the primary sources of liquidity to the Parent Company through management fees and dividends, with Aflac Japan being the largest contributor. The primary uses of cash by the Parent Company are shareholder dividends, the repurchase of its common stock, interest on its outstanding indebtedness and operating expenses.

100

The following table presents the amounts provided to the Parent Company for the three-month periods ended March 31.

Liquidity Provided by Subsidiaries to Parent Company

(In millions)	2025		2024
Management fees paid by subsidiaries	$	40	$	41
Dividends declared or paid by subsidiaries	1,154		658

The following table details Aflac Japan remittances, which are included in the totals above, for the three-month periods ended March 31.

Aflac Japan Remittances 

(In millions of dollars and billions of yen)	2025		2024
Aflac Japan management fees paid to Parent Company	$	17	$	17
Aflac Japan dividends declared or paid to Parent Company (in dollars)	759		433
Aflac Japan dividends declared or paid to Parent Company (in yen)	¥	113.3	¥	63.9

The Company intends to maintain higher than historical levels of liquidity and capital at the Parent Company for stress conditions and with the goals of addressing the Company’s hedge costs and related potential need for collateral and mitigating against long-term weakening of the Japanese yen. Further, the Company plans to continue to maintain a population of unhedged U.S. dollar-denominated investments at Aflac Japan and to consider whether the amount of such investments should be increased or decreased relative to the Company’s view of economic equity surplus in Aflac Japan in light of potentially rising hedge costs and other factors. See the Hedging Activities subsection of this MD&A for additional information.

The Company believes that its balance of cash and cash equivalents and cash generated by operations will be sufficient to satisfy both its short-term and long-term cash requirements and plans for cash, including material cash requirements from known contractual obligations and returning capital to shareholders through share repurchases and dividends. For additional information, see the Liquidity and Capital Resources section of Item 7. MD&A in the 2024 Annual Report.

In addition to cash and cash equivalents, the Company also maintains credit facilities, both intercompany and with external partners, and a number of other available tools to support liquidity needs on a global basis. In September 2024, the Parent Company filed a shelf registration statement with the SEC that allows the Company to issue an indefinite amount of debt securities, in one or more series, from time to time until September 2027. The Company believes outside sources for additional debt and equity capital, if needed, will continue to be available. The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, 2025. For additional information, see Note 9 of the Notes to the Consolidated Financial Statements.

As part of enterprise-wide capital management and optimization, the Company also utilizes the intercompany reinsurance platform to execute internal reinsurance transactions with Aflac Re. For additional information, see Note 8 of the Notes to the Consolidated Financial Statements.

The Company's consolidated financial statements convey its financing arrangements during the periods presented. The Company has not engaged in material intra-period short-term financings during the periods presented that are not otherwise reported in its balance sheet or disclosed therein. As of March 31, 2025, the Company had no material letters of credit, standby letters of credit, guarantees or standby repurchase obligations. The Company has not entered into transactions involving the transfer of financial assets with an obligation to repurchase financial assets that have been accounted for as a sale under applicable accounting standards, including securities lending transactions. See Notes 3 and 4 of the Notes to the Consolidated Financial Statements and Notes 1, 3, and 4 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report for additional information on the Company's securities lending and derivative activities. See Note 15 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report for information on material unconditional purchase obligations that are not recorded on the Company's balance sheet. With the exception of disclosed activities in those referenced footnotes and the Risk Factors in the 2024 Annual Report entitled, "The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate" and "Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity," the Company is not aware of any trend, demand, commitment, event or uncertainty that would reasonably result in its liquidity increasing or decreasing by a material amount.

101

Consolidated Cash Flows

The Company consistently generates positive cash flows from operations, and has the ability to adjust cash flow management from other sources of liquidity including reinvestment cash flows and selling investments in order to meet short-term cash needs.

The Company translates cash flows for Aflac Japan’s yen-denominated items into U.S. dollars using weighted-average exchange rates. In periods when the yen weakens, translating yen into dollars causes fewer dollars to be reported. When the yen strengthens, translating yen into dollars causes more dollars to be reported.

The following table summarizes consolidated cash flows by activity for the three-month periods ended March 31.

(In millions)	2025		2024
Operating activities	$	589	$	849
Investing activities	(359)		227
Financing activities	(1,261)		(256)
Exchange effect on cash and cash equivalents	33		(28)
Net change in cash and cash equivalents	$	(998)	$	792

Operating Activities

The principal cash inflows for the Company's insurance activities come from insurance premiums and investment income. The principal cash outflows are the result of policy claims, operating expenses, income tax, as well as interest expense. As a result of policyholder aging, claims payments are expected to gradually increase over the life of a policy. Therefore, future policy benefit reserves are accumulated in the early years of a policy and are designed to help fund future claims payments.

The Company expects its future cash flows from premiums and investment portfolios to be sufficient to meet its cash needs for benefits and expenses.

Investing Activities

The Company's investment objectives provide for liquidity primarily through the purchase of publicly traded investment-grade debt securities. Prudent portfolio management dictates that the Company attempts to match the duration of its assets with the duration of its liabilities. Currently, when the Company's fixed maturity securities mature, the proceeds may be reinvested at a yield below that required for the accretion of policy benefit liabilities on policies issued in earlier years. However, the long-term nature of the Company's business and its strong cash flows provide the Company with the ability to minimize the effect of mismatched durations and/or yields identified by various asset adequacy analyses. From time to time or when market opportunities arise, the Company disposes of selected fixed maturity securities that are available-for-sale to improve the duration matching of assets and liabilities, improve future investment yields, and/or rebalance its portfolio. As a result, dispositions before maturity can vary significantly from year to year.

As part of its overall corporate strategy, the Company has committed up to $400 million to Aflac Ventures, LLC (Aflac Ventures), as opportunities emerge. As of March 31, 2025, of the $400 million committed, approximately $290 million has been deployed. Aflac Ventures is a subsidiary of Aflac Global Ventures, LLC (Aflac Global Ventures) which is reported in Corporate and other. The central mission of Aflac Global Ventures is to support the organic growth and business development needs of Aflac Japan and Aflac U.S. with an emphasis on digital applications designed to improve the customer experience, gain efficiencies, and develop new markets in an effort to enhance and defend long-term shareholder value. Investments are included in equity securities or the other investments line in the consolidated balance sheets.

As part of an arrangement with Federal Home Loan Bank of Atlanta (FHLB), Aflac U.S. obtains low-cost investment funding from FHLB supported by acceptable forms of collateral pledged by Aflac U.S. In the first three months of 2025, Aflac U.S. borrowed and repaid $165 million under this program. As of March 31, 2025, Aflac U.S. had outstanding borrowings of $531 million reported in its balance sheet.

See Note 3 of the Notes to the Consolidated Financial Statements for details on certain investment commitments.

102

Financing Activities

Cash flows from financing activities consist primarily of share repurchases, dividends to shareholders and, from time to time, debt issuances and redemptions.

Cash returned to shareholders through treasury stock purchases and dividends was $1.2 billion during the three-month period ended March 31, 2025, compared with $1.0 billion during the three-month period ended March 31, 2024.

The following tables present a summary of treasury stock activity during the three-month periods ended March 31.

Treasury Stock Purchased

(In millions of dollars and thousands of shares)	2025		2024
Treasury stock purchases	$	900	$	750
Number of shares purchased:
Share repurchase program	8,497		9,276
Other	398		457
Total shares purchased	8,895		9,733

Treasury Stock Issued

(In millions of dollars and thousands of shares)	2025		2024
Stock issued from treasury:
Cash financing	$	4	$	6
Noncash financing	23		20
Total stock issued from treasury	$	27	$	26
Number of shares issued	435		450

As of March 31, 2025, a remaining balance of 38.8 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

Cash dividends paid to shareholders were $.58 per share in the first quarter of 2025, compared with $.50 per share in the first quarter of 2024. The following table presents the dividend activity for the three-month periods ended March 31.

(In millions)	2025		2024
Dividends paid in cash	$	306	$	278
Dividends through issuance of treasury shares	11		10
Total dividends to shareholders	$	317	$	288

In April 2025, the board of directors declared the second quarter cash dividend of $.58 per share, an increase of 16.0% compared with the same period in 2024. The dividend is payable on June 2, 2025 to shareholders of record at the close of business on May 21, 2025.

103

Regulatory Restrictions

Aflac Japan

Aflac Japan is required to meet certain financial criteria as governed by the Companies Act of Japan in order to provide dividends to the Parent Company. Under these criteria, dividend capacity at Aflac Japan is defined as total equity excluding common stock and capital reserves (representing statutorily required amounts in Japan) but reduced for net after-tax unrealized losses on available-for-sale securities. These dividend capacity requirements are generally aligned with the SMR. Japan's Financial Services Agency (FSA) maintains its own solvency standard which is quantified through the SMR. Aflac Japan's SMR is sensitive to interest rate, credit spread, and foreign exchange rate changes; therefore, the Company continues to evaluate alternatives for reducing this sensitivity, including the reduction of subsidiary dividends paid to the Parent Company and Parent Company capital contributions. In the event of a rapid change in market risk conditions causing SMR to decline, the Company has a senior unsecured revolving credit facility in the amount of ¥100 billion as a capital contingency plan. Additionally, subject to market conditions, the Company expects that it could take action to enter into derivatives on unhedged U.S. dollar-denominated investments with foreign currency options or forwards or execute additional reinsurance transactions. See Notes 8 and 9 of the Notes to the Consolidated Financial Statements for additional information.

The Company has already undertaken various measures to mitigate the sensitivity of Aflac Japan's SMR. For example, the Company employs policy reserve matching (PRM) investment strategies, which is a Japan-specific accounting treatment that reduces SMR interest rate sensitivity since PRM-designated investments are carried at amortized cost consistent with corresponding liabilities. In order for a PRM-designated asset to be held at amortized cost, there are certain criteria that must be maintained. The primary criterion relates to maintaining the duration of designated assets and liabilities within a specified tolerance range. If the duration difference is not maintained within the specified range without rebalancing, then a certain portion of the assets must be reclassified as available-for-sale and held at fair value with any associated unrealized gain or loss recorded in surplus. To rebalance, assets may need to be sold in order to maintain the duration with the specified range, resulting in realizing a gain or loss from the sale. For U.S. GAAP, PRM investments are categorized as available-for-sale. The Company also uses foreign currency derivatives to hedge a portion of its U.S. dollar-denominated investments. See Notes 3, 4 and 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report for additional information on the Company's investment strategies, hedging activities, and reinsurance, respectively.

As of March 31, 2025, Aflac Japan's SMR remains high and reflects a strong capital and surplus position. The Company is committed to maintaining strong capital levels, consistent with maintaining current insurance financial strength and credit ratings.

The FSA will introduce an economic value-based solvency regime based on the Insurance Capital Standards (ICS) for insurance companies in Japan. The initial report on the Economic Solvency Ratio (ESR) will be issued as of March 31, 2026, which is Aflac Japan's 2025 fiscal year-end.

Aflac U.S.

A life insurance company’s statutory capital and surplus is determined according to rules prescribed by the National Association of Insurance Commissioners (NAIC), as modified by the insurance department in the insurance company’s state of domicile. Statutory accounting rules are different from U.S. GAAP and are intended to emphasize policyholder protection and company solvency. The continued long-term growth of the Company's business may require increases in the statutory capital and surplus of its insurance operations. The Company's insurance operations may secure additional statutory capital through various sources, such as internally generated statutory earnings, reduced dividends paid to the Parent Company, capital contributions by the Parent Company from funds generated through debt or equity offerings, or reinsurance transactions. The NAIC’s Risk-based capital (RBC) formula is used by insurance regulators to help identify inadequately capitalized insurance companies. The RBC formula quantifies insurance risk, business risk, asset risk and interest rate risk by weighing the types and mixtures of risks inherent in the insurer’s operations. As of March 31, 2025, Aflac U.S.'s combined RBC ratio remains high and reflects a strong capital and surplus position.

Aflac, CAIC and TOIC are domiciled in Nebraska and are subject to its regulations. The maximum amount of dividends that can be paid to the Parent Company by Aflac, CAIC and TOIC without prior approval of Nebraska's director of insurance is the greater of the net income from operations, which excludes net investment gains, for the previous year determined under statutory accounting principles, or 10% of statutory capital and surplus as of the previous year-end. Dividends declared by Aflac during 2025 in excess of $912 million would be considered extraordinary and require such approval. Similar laws apply in New York, the domiciliary jurisdiction of Aflac New York.

104

Corporate and Other

Aflac Re is licensed by the BMA as a long-term insurer and is subject to the Bermuda Insurance Act of 1978 (Bermuda Insurance Act). Aflac Re is required to file an annual return for its Bermuda Solvency Capital Requirement (BSCR) which utilizes an Economic Balance Sheet (EBS) framework to determine Aflac Re’s Enhanced Capital Requirement (ECR). Aflac Re is also subject to a Minimum Margin of Solvency (MMS) related to its statutory financial statements. The MMS is equal to the greater of $500,000, 1.5% of the total statutory assets, or 25% of ECR.

Under the Bermuda Insurance Act, Aflac Re is prohibited from paying dividends in an amount that exceeds 25% of the prior year's statutory capital and surplus without an affidavit stating that Aflac Re will continue to meet its solvency margin. Further, Aflac Re may not reduce its total statutory capital by 15% or more without prior regulatory approval. Additionally, Aflac Re is not permitted to pay any dividends that would cause Aflac Re to fail to meet its minimum capital requirements.

Other

For information regarding commitments and contingent liabilities, see Note 13 of the Notes to the Consolidated Financial Statements.

Additional Information

Investors should note that the Company announces material financial information in its SEC filings, press releases and public conference calls. In accordance with SEC guidance, the Company may also use the Investor Relations section of the Company's website (http://investors.aflac.com) to communicate with investors about the Company. It is possible that the financial and other information the Company posts there could be deemed to be material information. The information on the Company's website is not part of this document. Further, the Company's references to website URLs are intended to be inactive textual references only.

CRITICAL ACCOUNTING ESTIMATES

The Company prepares its financial statements in accordance with U.S. GAAP. These principles are established primarily by the Financial Accounting Standards Board (FASB). In this MD&A, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards Codification™ (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The estimates that the Company deems to be most critical to an understanding of its results of operations and financial condition are those related to the valuation of investments and derivatives, DAC, liabilities for future policy benefits, and income taxes. The preparation and evaluation of these critical accounting estimates involve the use of various assumptions developed from management’s analyses and judgments. Calculations of DAC and the liability for future policy benefits require the use of estimates based on actuarial valuation techniques. The application of these critical accounting estimates determines the values at which 93% of the Company's assets and 77% of its liabilities are reported as of March 31, 2025, and thus has a direct effect on net earnings and shareholders’ equity. Subsequent experience or use of other assumptions could produce significantly different results.

There have been no changes in the items the Company has identified as critical accounting estimates during the three-month period ended March 31, 2025. For additional information, see the Critical Accounting Estimates section of Item 7. MD&A included in the 2024 Annual Report.

New Accounting Pronouncements

For information on new accounting pronouncements and the impact, if any, on the Company's financial position or results of operations, see Note 1 of the Notes to the Consolidated Financial Statements.

105

Item 3.Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed primarily to the following types of market risks: currency risk, interest rate risk, credit risk and equity risk. The Company regularly monitors its market risks and uses a variety of strategies to manage its exposure to these market risks. A description of the Company's market risk exposures may be found under “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A, of the 2024 Annual Report. There have been no material changes to the Company's market risk exposures from the market risk exposures previously disclosed in the 2024 Annual Report.

Item 4.Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this quarterly report (the Evaluation Date). Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the first fiscal quarter of 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

106

PART II. OTHER INFORMATION

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

During the first three months of 2025, the Parent Company repurchased shares of its common stock as follows:

Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 - January 31	2,698,784		$	104.83	2,698,784	44,618,770
February 1 - February 28	3,230,149		104.37		2,835,980	41,782,790
March 1 - March 31	2,965,821		108.23		2,961,981	38,820,809
Total	8,894,754	(1)	$	105.80	8,496,745	38,820,809	(2)

(1) During the first three months of 2025, 398,009 shares were purchased in connection with income tax withholding obligations related to the vesting of restricted-share-based awards during the period.

(2) The total remaining shares available for purchase at March 31, 2025, are related to a 100,000,000 share repurchase authorization by the board of directors announced in November 2022.

Item 5.    Other Information

Insider Trading Arrangements

During the first quarter of 2025, no directors or executive officers adopted or terminated a contract, instruction or written plan for the purchase or sale of the Parent Company's securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or a non-Rule 10b5-1 trading arrangement as defined in Regulation S-K Item 408(c).

107

Item 6.    Exhibits

(a)	EXHIBIT INDEX
	3.0	-	Articles of Incorporation, as amended – incorporated by reference from Form 10-Q for June 30, 2008, Exhibit 3.0.
	3.1	-	Bylaws of Aflac Incorporated, as amended and restated – incorporated by reference from Form 8-K dated November 17, 2023, Exhibit 3.1.
	31.1	-	Certification of CEO dated May 7, 2025, required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.
	31.2	-	Certification of CFO dated May 7, 2025, required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.
	32	-	Certification of CEO and CFO dated May 7, 2025, pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	101.INS	-	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
	101.SCH	-	Inline XBRL Taxonomy Extension Schema.
	101.CAL	-	Inline XBRL Taxonomy Extension Calculation Linkbase.
	101.DEF	-	Inline XBRL Taxonomy Extension Definition Linkbase.
	101.LAB	-	Inline XBRL Taxonomy Extension Label Linkbase.
	101.PRE	-	Inline XBRL Taxonomy Extension Presentation Linkbase.
	104	-	Cover Page Interactive Data File - formatted as Inline XBRL and contained in Exhibit 101.

108

Glossary of Selected Terms

Throughout this Quarterly Report on Form 10-Q, the Company may use certain performance metrics and other terms which are defined below.

Adjusted Net Investment Income – Net Investment Income adjusted for i) amortized hedge cost/income related to foreign currency exposure management strategies and certain derivative activity and ii) net interest income/expense from foreign currency and interest rate derivatives associated with certain investment strategies, which are reclassified from net investment gains (losses) to net investment income. The Company considers adjusted net investment income important because it provides a more comprehensive understanding of the costs and income associated with the Company's investments and related hedging strategies. The metric is used in segment reporting as a component of segment profitability.

Affiliated Corporate Agency – Agency in Japan directly affiliated with a specific corporation that sells insurance policies primarily to its employees.

Annualized Premiums in Force – The amount of gross premium that a policyholder must pay over a full year in order to keep coverage. The growth of net earned premiums (defined below) is directly affected by the change in premiums in force and by the change in weighted-average yen/dollar exchange rates.

Average Weekly Producer – The total number of writing agents, including brokers, who have produced greater than $0.00 during the production week - excluding any manual adjustments - divided by the number of weeks in the time period. The Company believes this metric allows sales management to monitor progress and needs, as well as serve as a leading indicator of future production capacity.

Capital Buffer – Established dollar amount of liquidity at the Parent Company reserved for injecting capital into the insurance entities or general liquidity support for general expenses at the Parent Company.

Earnings Per Basic Share – Net earnings divided by weighted-average number of shares outstanding for the period.

Earnings Per Diluted Share – Net earnings divided by the weighted-average number of shares outstanding for the period plus the weighted-average shares for the dilutive effect of share-based awards outstanding.

Economic Solvency Ratio (ESR) – An economic value-based soundness indicator that demonstrates whether the insurance company has sufficient capital to cover future risks. Assets and liabilities are evaluated at economic value, the risk amount incurred in a stressed

environment is measured, and the capital sufficiency for this risk is assessed. The ESR level, which is the basis for supervisory intervention by the authorities, is set at 100%.

Group Insurance – Insurance issued to a group, such as an employer or trade association, that covers employees or association members and their dependents through certificates of coverage.

Individual Insurance – Insurance issued to an individual with the policy designed to cover that person and his or her dependents.

In force Policies – A count of policies that are active contracts at the end of a period.

Liquidity Support – Internally defined and established dollar amount of liquidity reserved for supporting potential collateral and settlements of derivatives at the Parent Company and short-term funding needs.

Net Investment Income – The income derived from interest and dividends on invested assets, after deducting investment expenses.

Net Earned Premiums – is a financial measure that appears on the Company's consolidated statements of earnings and in its segment reporting. This measure reflects collected or due premiums that have been earned ratably on policies in force during the reporting period, reduced by premiums that have been ceded to third parties and increased by premiums assumed through reinsurance.

New Annualized Premium Sales – (sometimes referred to as new sales or sales) An operating measure that is not reflected on the Company's financial statements. New annualized premium sales generally represent annual premiums on policies and riders the Company sold and incremental increases from policy conversions that would be collected over a 12-month period assuming the policies remain in force for that entire period. For Aflac Japan, new annualized premium sales are determined by applications submitted during the reporting period. For Aflac U.S., new annualized premium sales are determined by applications that are issued during the reporting period. Policy conversions are defined as the positive difference in the annualized premium when a policy upgrades in the current reporting period. The Company believes that this metric is a key

indicator of the Company's future source of earnings.

New Money Yield – Gross yields earned on purchases of fixed maturities, loan receivables, and equities. Purchases exclude capitalized interest, securities lending/repurchase agreements, short-term/cash activity, and alternatives. New money yield for equities is based on the assumed dividend yield at the time of purchase. The new money yield for Aflac Japan excludes the

109

impact of any derivatives and associated amortized hedge costs associated with USD-denominated investments. Management uses this metric as a leading indicator of future investment earning potential.

Operating Ratios – Used to evaluate the Company's financial condition and profitability. Examples include: (1) Ratios to total adjusted revenues, which present expenses as a percentage of total revenues and (2) Ratios to total premium, including benefit ratio.

Premium Persistency – Percentage of premiums remaining in force at the end of a period, usually one year, and presented on a trailing 12-month basis. For example, 95% persistency would mean that 95% of the premiums in force at the beginning of the period were still in force at the end of the period. The Company believes that this metric is a key driver of in force levels, which is a key measure of the size of the Company's business and future sources of earnings.

Pretax Adjusted Earnings – Earnings as adjusted earnings before the application of income taxes. This measure is used in the Company's segment reporting.

Pretax Adjusted Profit Margin – Adjusted earnings divided by adjusted revenues, before taxes are applied. This measure is used in the Company's segment reporting.

Return on Average Invested Assets – Net investment income as a percentage of average invested assets during the period. Management uses this metric to demonstrate how the Company's actual net investment income results represent an overall return on the portfolio to provide a more comparative metric as the size of the Company's investment portfolio changes over time.

Risk-based Capital (RBC) Ratio – Statutory adjusted capital divided by statutory required capital. This insurance ratio is based on rules prescribed by the National Association of Insurance Commissioners (NAIC) and provides an indication of the amount of statutory capital the insurance company maintains, relative to the inherent risks in the insurer’s operations.

Solvency Margin Ratio (SMR) – Solvency margin total divided by one half of the risk total. This insurance ratio is prescribed by the Japan Financial Services Agency (FSA) and is used for all life insurance companies in Japan to measure the adequacy of the company’s ability to pay policyholder claims in the event actual risks exceed expected levels.

Statutory Earnings – Earnings determined according to accounting rules prescribed by the National Association of Insurance Commissioners (NAIC), as modified by the insurance department in the insurance company’s state of domicile. These statutory accounting rules are

different from U.S. GAAP and are intended to emphasize policyholder protection and company solvency.

Weighted-Average Foreign Currency Exchange Rate – Japan segment operating earnings for the period (excluding hedge costs) in yen divided by Japan segment operating earnings for the period (excluding hedge costs) in dollars. Management uses this metric to evaluate and determine consolidated results on foreign currency effective basis.

110

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Aflac Incorporated
May 7, 2025	/s/ Max K. Brodén
	(Max K. Brodén)
	Senior Executive Vice President; Chief Financial Officer
May 7, 2025	/s/ Robin L. Blackmon
	(Robin L. Blackmon)
	Senior Vice President, Financial Services; Chief Accounting Officer

111

EX-31.1

Aflac Incorporated 1st Quarter 2025 Form 10-Q

EXHIBIT 31.1

Certification of Chief Executive Officer

I, Daniel P. Amos, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Aflac Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 7, 2025	/s/ Daniel P. Amos
		Daniel P. Amos
		Chairman and Chief Executive Officer

EX-31.2

Aflac Incorporated 1st Quarter 2025 Form 10-Q

EXHIBIT 31.2

Certification of Chief Financial Officer

I, Max K. Brodén, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Aflac Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 7, 2025	/s/ Max K. Brodén
		Max K. Brodén
		Senior Executive Vice President, Chief Financial Officer

EX-32

Aflac Incorporated 1st Quarter 2025 Form 10-Q

EXHIBIT 32

Certification of CEO and CFO Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Aflac Incorporated (the “Company”) for the quarterly period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Daniel P. Amos, as Chief Executive Officer of the Company, and Max K. Brodén, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Daniel P. Amos
Name:	Daniel P. Amos
Title:	Chief Executive Officer
Date:	May 7, 2025

/s/ Max K. Brodén
Name:	Max K. Brodén
Title:	Chief Financial Officer
Date:	May 7, 2025

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2025	Apr. 29, 2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2025
Document Transition Report	false
Entity File Number	001-07434
Entity Registrant Name	Aflac Incorporated
Entity Incorporation, State or Country Code	GA
Entity Tax Identification Number	58-1167100
Entity Address, Address Line One	1932 Wynnton Road
Entity Address, City or Town	Columbus,
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	31999
City Area Code	706.
Local Phone Number	323.3431
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		540,645,028
Amendment Flag	false
Entity Central Index Key	0000004977
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
NEW YORK STOCK EXCHANGE, INC.
Title of 12(b) Security	Common Stock, $.10 par value per share
Trading Symbol	AFL
Security Exchange Name	NYSE

XML

Consolidated Statements of Earnings - USD ($) shares in Thousands, $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Revenues:
Net earned premiums, principally supplemental health insurance	[1]	$ 3,381	$ 3,456
Net investment income		955	1,000
Net investment gains (losses)		(963)	951
Other income (loss)		25	29
Total revenues		3,398	5,436
Benefits and expenses:
Benefits and claims, excluding reserve remeasurement		1,986	2,066
Reserve remeasurement (gains) losses		(41)	(56)
Total benefits and claims, net		1,945	2,010
Acquisition and operating expenses:
Amortization of deferred policy acquisition costs		216	215
Insurance commissions		240	255
Insurance and other expenses		802	739
Interest expense		50	47
Total acquisition and operating expenses		1,308	1,256
Total benefits and expenses		3,253	3,266
Earnings before income taxes		145	2,170
Income taxes		116	291
Net earnings		$ 29	$ 1,879
Net earnings per share:
Basic (in dollars per share)		$ 0.05	$ 3.27
Diluted (in dollars per share)		$ 0.05	$ 3.25
Weighted-average outstanding common shares used in computing earnings per share (In thousands):
Basic (in shares)		544,707	574,886
Diluted (in shares)		546,878	577,482
Cash dividends per share		$ 0.58	$ 0.50

[1] Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

XML

Consolidated Statements of Earnings (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Remeasurement gain (loss), deferred profit liability for limited-payment contracts	$ 0	$ (3)

XML

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Comprehensive Income [Abstract]
Net earnings	$ 29	$ 1,879
Other comprehensive income (loss) before income taxes:
Unrealized foreign currency translation gains (losses) during period	352	(501)
Unrealized gains (losses) on fixed maturity securities:
Unrealized holding gains (losses) on fixed maturity securities during period	(1,541)	103
Reclassification adjustment for (gains) losses on fixed maturity securities included in net earnings	(40)	(168)
Unrealized gains (losses) on derivatives during period	2	(5)
Effect of changes in discount rate assumptions during period	2,396	1,348
Pension liability adjustment during period	41	2
Total other comprehensive income (loss) before income taxes	1,210	779
Income tax expense (benefit) related to items of other comprehensive income (loss)	91	361
Other comprehensive income (loss), net of income taxes	1,119	418
Total comprehensive income (loss)	$ 1,148	$ 2,297

XML

Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2025		Dec. 31, 2024
Investments and cash:
Fixed maturity securities, available-for-sale		$ 67,144		$ 65,269
Fixed maturity securities, held-to-maturity		16,888	[1]	15,966
Equity securities		764		796
Commercial mortgage and other loans		10,656		10,869
Other investments		6,763		5,958
Cash and cash equivalents		5,231		6,229
Total investments and cash		107,446		105,087
Receivables		894		779
Accrued investment income		682		710
Deferred policy acquisition costs		9,083		8,758
Property and equipment, at cost less accumulated depreciation		391		387
Other		1,762		1,845
Total assets		120,258		117,566
Policy liabilities:
Future policy benefits		71,197		70,381
Unpaid policy claims		411		381
Unearned premiums		1,357		1,286
Other policyholders’ funds		5,863		5,460
Total policy liabilities		78,828		77,508
Income taxes		815		573
Payables for return of cash collateral on loaned securities		3,142		2,037
Notes payable and lease obligations		7,751		7,498
Other		3,384		3,852
Total liabilities		93,920		91,468
Commitments and contingent liabilities (Note 13)
Shareholders’ equity:
Common stock of $.10 par value. In thousands: authorized 1,900,000 shares in 2025 and 2024; issued 1,357,752 shares in 2025 and 1,356,763 shares in 2024		136		136
Additional paid-in capital		2,919		2,894
Retained earnings		52,308		52,277
Accumulated other comprehensive income (loss):
Unrealized foreign currency translation gains (losses)		(4,549)		(4,998)
Unrealized gains (losses) on fixed maturity securities		(1,233)		24
Unrealized gains (losses) on derivatives		(18)		(20)
Effect of changes in discount rate assumptions		3,899		2,006
Pension liability adjustment		42		10
Treasury stock, at average cost		(27,166)		(26,231)
Total shareholders’ equity		26,338		26,098
Total liabilities and shareholders’ equity		120,258		117,566
Consolidated Entity Excluding Variable Interest Entities (VIE)
Investments and cash:
Fixed maturity securities, available-for-sale		63,547		61,841
Variable Interest Entity, Consolidated
Investments and cash:
Fixed maturity securities, available-for-sale		3,597		3,428
Commercial mortgage and other loans		8,540		8,693
Other investments	[2]	2,151		2,176
Total assets		14,337		14,350
Policy liabilities:
Total liabilities		$ 642		$ 604

[1] Net of allowance for credit losses

[2] Consists entirely of alternative investments in limited partnerships, which represent VIEs where the Company is not the primary beneficiary and, therefore, are not consolidated

XML

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions		Mar. 31, 2025	Dec. 31, 2024
Fixed maturity securities, available-for-sale, allowance for credit losses		$ 0	$ 0
Fixed maturity securities, available-for-sale, amortized cost		67,545	64,089
Fixed maturity securities, held-to-maturity, allowance for credit losses		5	5
Fixed maturity securities, held-to-maturity, fair value		17,135	16,772
Commercial mortgage and other loans, allowance for credit losses		368	355
Commercial mortgage and other loans		10,656	10,869
Other investments		$ 6,763	$ 5,958
Common stock, par value (in dollars per share)		$ 0.10	$ 0.10
Common stock, shares authorized (in shares)		1,900,000	1,900,000
Common stock, shares issued (in shares)		1,357,752	1,356,763
Consolidated Entity Excluding Variable Interest Entities (VIE)
Fixed maturity securities, available-for-sale, allowance for credit losses		$ 0	$ 0
Fixed maturity securities, available-for-sale, amortized cost		64,638	61,455
Variable Interest Entity, Consolidated
Fixed maturity securities, available-for-sale, amortized cost		2,907	2,634
Commercial mortgage and other loans		8,540	8,693
Other investments	[1]	$ 2,151	$ 2,176

[1] Consists entirely of alternative investments in limited partnerships, which represent VIEs where the Company is not the primary beneficiary and, therefore, are not consolidated

XML

Consolidated Statements of Shareholders' Equity - USD ($) $ in Millions		Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock
Balance, beginning of period at Dec. 31, 2023		$ 21,985	$ 136	$ 2,771	$ 47,993	$ (5,520)	$ (23,395)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings		1,879	0	0	1,879	0	0
Unrealized foreign currency translation gains (losses) during period, net of income taxes		(597)	0	0	0	(597)	0
Unrealized gains (losses) on fixed maturity securities during period, net of income taxes and reclassification adjustments		(47)	0	0	0	(47)	0
Unrealized gains (losses) on derivatives during period, net of income taxes		(4)	0	0	0	(4)	0
Effect of changes in discount rate assumptions during period, net of income taxes		1,065	0	0	0	1,065	0
Pension liability adjustment during period, net of income taxes		1	0	0	0	1	0
Dividends to shareholders	[1]	0	0	0	0	0	0
Exercise of stock options		4	0	4	0	0	0
Share-based compensation		18	0	18	0	0	0
Purchases of treasury stock		(793)	0	0	0	0	(793)
Treasury stock reissued		26	0	13	0	0	13
Balance, end of period at Mar. 31, 2024		23,537	136	2,806	49,872	(5,102)	(24,175)
Balance, beginning of period at Dec. 31, 2024		26,098	136	2,894	52,277	(2,978)	(26,231)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings		29	0	0	29	0	0
Unrealized foreign currency translation gains (losses) during period, net of income taxes		449	0	0	0	449	0
Unrealized gains (losses) on fixed maturity securities during period, net of income taxes and reclassification adjustments		(1,257)	0	0	0	(1,257)	0
Unrealized gains (losses) on derivatives during period, net of income taxes		2	0	0	0	2	0
Effect of changes in discount rate assumptions during period, net of income taxes		1,893	0	0	0	1,893	0
Pension liability adjustment during period, net of income taxes		32	0	0	0	32	0
Dividends to shareholders	[1]	2	0	0	2	0	0
Exercise of stock options		4	0	4	0	0	0
Share-based compensation		8	0	8	0	0	0
Purchases of treasury stock		(949)	0	0	0	0	(949)
Treasury stock reissued		27	0	13	0	0	14
Balance, end of period at Mar. 31, 2025		$ 26,338	$ 136	$ 2,919	$ 52,308	$ (1,859)	$ (27,166)

[1] Dividends to shareholders are recorded in the period in which they are declared.

XML

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]
Dividends to shareholders (in dollars per share)	$ 0.00	$ 0.00

XML

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net earnings	$ 29	$ 1,879
Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Change in receivables and advance premiums	(37)	32
Capitalization of deferred policy acquisition costs	(246)	(254)
Amortization of deferred policy acquisition costs	216	215	$ 851
Increase in policy liabilities	(136)	(41)
Change in income tax liabilities	117	291
Net investment (gains) losses	963	(951)
Other, net	(317)	(322)
Net cash provided (used) by operating activities	589	849
Proceeds from investments sold or matured:
Available-for-sale fixed maturity securities	5,935	2,286
Equity securities	96	267
Commercial mortgage and other loans	500	379
Costs of investments acquired:
Available-for-sale fixed maturity securities	(6,624)	(2,127)
Equity securities	(101)	(73)
Commercial mortgage and other loans	(392)	(251)
Other investments, net	(697)	(2,119)
Settlement of derivatives, net	18	(256)
Cash received (pledged or returned) as collateral, net	984	1,973
Other, net	(78)	148
Net cash provided (used) by investing activities	(359)	227
Cash flows from financing activities:
Purchases of treasury stock	(900)	(750)
Proceeds from borrowings	0	823
Dividends paid to shareholders	(306)	(278)
Change in investment-type contracts, net	(58)	(50)
Treasury stock reissued	4	6
Other, net	(1)	(7)
Net cash provided (used) by financing activities	(1,261)	(256)
Effect of exchange rate changes on cash and cash equivalents	33	(28)
Net change in cash and cash equivalents	(998)	792
Cash and cash equivalents, beginning of period	6,229	4,306	4,306
Cash and cash equivalents, end of period	5,231	5,098	$ 6,229
Supplemental disclosures of cash flow information:
Income taxes paid	(1)	0
Interest paid	40	34
Noncash interest	10	13
Noncash real estate acquired in satisfaction of debt	71	35
Noncash financing activities:
Lease obligations	10	5
Associate stock bonus
Treasury stock issued for:
Treasury stock issued	5	4
Shareholder dividend reinvestment
Treasury stock issued for:
Treasury stock issued	11	10
Share-based compensation grants
Treasury stock issued for:
Treasury stock issued	$ 7	$ 6

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in Japan and the United States (U.S.). The Company's insurance business is marketed and administered through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan and through American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS) in the U.S. The Company’s operations consist of two reportable business segments: Aflac Japan, which includes ALIJ, and Aflac U.S., which includes Aflac, Aflac New York, CAIC, TOIC, and ABS. Aflac New York is a wholly owned subsidiary of Aflac. Most of the Aflac U.S. policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ABS, and certain group life insurance products, Aflac U.S. markets and administers group products through CAIC, branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through TOIC. The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd.(Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits and income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in the consolidated financial statements. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, 2025 and December 31, 2024, and the consolidated statements of earnings, comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, 2025 and 2024. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Accounting Standards Update (ASU) 2023-07 Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued amendments that add certain segment disclosures related to significant segment expenses and require that a public entity disclose the title and position of the Chief Operating Decision Maker (CODM) and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

The Company adopted this guidance for the annual period beginning January 1, 2024, and interim periods beginning January 1, 2025. The adoption of this guidance did not have an impact on the Company’s financial position or results of operations. See Note 2 for expanded disclosures required as a result of the amended guidance.

Accounting Pronouncements Pending Adoption

ASU 2024-03 Income Statement (Topic 220) - Disaggregation of Income Statement Expenses

In November 2024, the FASB issued amendments that require disaggregated disclosure, in the notes to the financial statements, of specified information about certain costs and expenses including (1) the amounts of employee compensation, depreciation, and intangible asset amortization; (2) certain expense, gain, or loss amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and (4) the total amount of selling expenses and, in annual reporting periods, the Company’s definition of selling expenses.

The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

ASU 2023-09 Income Taxes (Topic 740) - Improvements to Income Tax Disclosures

In December 2023, the FASB issued amendments that require enhanced income tax disclosures including (1) disclosure of specific categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures.

The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business.

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

The Company consists of two reportable insurance business segments: Aflac Japan and Aflac U.S., both of which sell supplemental health and life insurance. In addition, the Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re, and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other. The Company does not allocate corporate overhead expenses to business segments.

The Company’s reportable segments are regularly reviewed by the Company's CODM, Senior Executive Vice President and Chief Financial Officer, in deciding how to allocate resources and in assessing performance. The Company's CODM reviews and approves the annual budget and operating forecast, which allocates resources to segments and serves as a key benchmark for tracking performance and accountability of each segment's operating results. The Company’s CODM evaluates the performance of the segments using, in comparison to the annual budget, operating forecast and historical results, a financial performance measure called pretax adjusted earnings and believes this financial performance measure to be vitally important for understanding the underlying profitability drivers and trends of the Company’s insurance business.

•Pretax adjusted earnings are adjusted revenues less benefits and adjusted expenses. The adjustments to both revenues and expenses account for certain items that are outside management’s control because they tend to be driven by general economic conditions and events or are related to infrequent activities not directly associated with insurance operations. The Company excludes income taxes related to operations to arrive at pretax adjusted earnings.

◦Adjusted revenues are U.S. GAAP total revenues excluding net investment gains and losses, except for amortized hedge costs/income related to foreign currency exposure management strategies and net interest income/expense from derivatives associated with certain investment strategies, which are reclassified from net investment gains (losses) and included in adjusted earnings as a component of adjusted net investment income when analyzing operations. 

◦Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest from derivatives associated with notes payable but excluding any non-recurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company’s underlying business performance.

Aflac Japan's adjusted revenues as a percentage of the Company's total adjusted revenues were 53% and 56% in the three-month periods ended March 31, 2025 and 2024, respectively. The percentage of the Company's total assets attributable to Aflac Japan was 78% at March 31, 2025, compared with 77% at December 31, 2024.

Information regarding operations by reportable segment and Corporate and other is presented in the following tables.

	Three Months Ended March 31,
(In millions)	2025		2024
Revenues:
Aflac Japan:
Net earned premiums (1)	$	1,681	$	1,816
Adjusted net investment income	586		648
Other income	5		9
Total adjusted revenue Aflac Japan	2,272		2,473
Aflac U.S.:
Net earned premiums	1,502		1,475
Adjusted net investment income	202		206
Other income	17		18
Total adjusted revenue Aflac U.S.	1,721		1,699
Corporate and other (2)	326		247
Total adjusted revenues	4,319		4,419
Net investment gains (losses)	(963)		951
Reconciling items:
Amortized hedge costs	7		6
Amortized hedge income	(30)		(28)
Net interest (income) expense from derivatives   associated with certain investment strategies	65		88
Total revenues	$	3,398	$	5,436

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025 and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025 and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

	Three Months Ended March 31,
(In millions)	2025		2024
Adjusted revenues:
Aflac Japan (1)	$	2,272	$	2,473
Aflac U.S.	1,721		1,699
Corporate and other (2)	326		247
Total adjusted revenues	4,319		4,419
Benefits and adjusted expenses:
Aflac Japan:
Benefits and claims, excluding reserve remeasurement	1,130		1,243
Reserve remeasurement (gains) losses	(25)		(26)
Total benefits and claims, net	1,105		1,217
Adjusted expenses:
Amortization of deferred policy acquisition costs	79		83
Insurance commissions	105		114
Insurance and other expenses	261		249
Total benefits and adjusted expenses Aflac Japan	1,550		1,663
Aflac U.S.:
Benefits and claims, excluding reserve remeasurement	731		715
Reserve remeasurement (gains) losses	(15)		(29)
Total benefits and claims, net	716		686
Adjusted expenses:
Amortization of deferred policy acquisition costs	137		132
Insurance commissions	135		141
Insurance and other expenses	375		384
Total benefits and adjusted expenses Aflac U.S.	1,363		1,343
Corporate and other	283		250
Total adjusted expenses	$	3,196	$	3,256
Pretax earnings:
Aflac Japan (1)	$	722	$	810
Aflac U.S.	358		356
Corporate and other (2)	43		(3)
Pretax adjusted earnings	1,123		1,163
Other income (loss)	(53)		(2)
Net investment gains (losses)	(963)		951
Reconciling items:
Amortized hedge costs	7		6
Amortized hedge income	(30)		(28)
Net interest (income) expense from derivatives   associated with certain investment strategies	65		88
Impact of interest from derivatives associated   with notes payable	(4)		(8)
Total earnings before income taxes	$	145	$	2,170
Income taxes applicable to pretax adjusted earnings	$	217	$	202
Effect of foreign currency translation on after-tax   adjusted earnings	(8)		(44)

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025, and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025, and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Internal Reinsurance: Aflac Re is a Bermuda domiciled insurer that reinsures certain policies issued by Aflac Japan and is reported as a part of Corporate and other. Under these internal reinsurance transactions, Aflac Japan's net earned premiums are reduced by the amount of premiums ceded to Aflac Re. Aflac Re recorded net earned premiums of $178 million and $136 million for the three-month periods ended March 31, 2025 and 2024, respectively, related to these reinsurance transactions with Aflac Japan. These internal reinsurance transactions have no financial statement impact on a consolidated basis, except for the effect of foreign currency accounting. For additional information on these internal reinsurance transactions, see the accompanying Note 8 and Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

Total Assets: The Company's total assets were as follows:

(In millions)	March 31, 2025			December 31, 2024
Assets:
Aflac Japan		$	93,430		$	90,210
Aflac U.S.		21,881			21,930
Corporate and other		4,947			5,426
Total assets		$	120,258		$	117,566

XML

INVESTMENTS

3 Months Ended

Mar. 31, 2025

Investments [Abstract]

INVESTMENTS

INVESTMENTS

Investment Holdings

The amortized cost and allowance for credit losses for the Company's investments in fixed maturity securities and the fair values of these investments as well as the fair value of the Company's investments in equity securities are shown in the following tables.

	March 31, 2025
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	20,005	$	0	$	145	$	2,608	$	17,542
Municipalities	919		0		50		105		864
Mortgage- and asset-backed securities	342		0		2		29		315
Public utilities	2,771		0		155		155		2,771
Sovereign and supranational	349		0		9		10		348
Banks/financial institutions	5,553		0		225		448		5,330
Other corporate	5,655		0		475		413		5,717
Total yen-denominated	35,594		0		1,061		3,768		32,887
U.S. dollar-denominated:
U.S. government and agencies	275		0		2		2		275
Municipalities	1,190		0		69		68		1,191
Mortgage- and asset-backed securities	3,574		0		205		46		3,733
Public utilities	4,162		0		376		142		4,396
Sovereign and supranational	58		0		20		0		78
Banks/financial institutions	3,673		0		388		30		4,031
Other corporate	18,938		0		2,224		689		20,473
Total U.S. dollar-denominated	31,870		0		3,284		977		34,177
Other currencies:
Public utilities	55		0		0		1		54
Other corporate	26		0		0		0		26
Total other currencies	81		0		0		1		80
Total securities available-for-sale	$	67,545	$	0	$	4,345	$	4,746	$	67,144

	December 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	19,409	$	0	$	465	$	2,234	$	17,640
Municipalities	869		0		65		79		855
Mortgage- and asset-backed securities	327		0		4		23		308
Public utilities	2,746		0		202		108		2,840
Sovereign and supranational	330		0		16		8		338
Banks/financial institutions	5,376		0		267		342		5,301
Other corporate	5,329		0		568		305		5,592
Total yen-denominated	34,386		0		1,587		3,099		32,874
U.S. dollar-denominated:
U.S. government and agencies	208		0		1		3		206
Municipalities	1,167		0		65		53		1,179
Mortgage- and asset-backed securities	2,987		0		302		34		3,255
Public utilities	3,938		0		418		151		4,205
Sovereign and supranational	57		0		21		0		78
Banks/financial institutions	3,271		0		420		36		3,655
Other corporate	18,050		0		2,493		752		19,791
Total U.S. dollar-denominated	29,678		0		3,720		1,029		32,369
Other currencies:
Other corporate	25		0		1		0		26
Total other currencies	25		0		1		0		26
Total securities available-for-sale	$	64,089	$	0	$	5,308	$	4,128	$	65,269

	March 31, 2025
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	16,195	$	2	$	16,193	$	368	$	155	$	16,406
Municipalities	249		0		249		11		0		260
Public utilities	33		0		33		0		0		33
Sovereign and supranational	399		3		396		22		0		418
Other corporate	17		0		17		1		0		18
Total yen-denominated	16,893		5		16,888		402		155		17,135
Total securities held-to-maturity	$	16,893	$	5	$	16,888	$	402	$	155	$	17,135

	December 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	15,311	$	2	$	15,309	$	759	$	9	$	16,059
Municipalities	235		0		235		22		0		257
Public utilities	32		0		32		1		0		33
Sovereign and supranational	377		3		374		31		0		405
Other corporate	16		0		16		2		0		18
Total yen-denominated	15,971		5		15,966		815		9		16,772
Total securities held-to-maturity	$	15,971	$	5	$	15,966	$	815	$	9	$	16,772

	March 31, 2025			December 31, 2024
(In millions)	Fair Value			Fair Value
Equity securities, carried at fair value through net earnings:
Equity securities:
Yen-denominated		$	491		$	484
U.S. dollar-denominated		273			312
Total equity securities		$	764		$	796

The methods of determining the fair values of the Company's investments in fixed maturity securities and equity securities are described in Note 5.

During the first three months of 2025 and 2024, respectively, the Company did not reclassify any investments from the held-to-maturity category to the available-for-sale category.

Contractual and Economic Maturities

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, 2025, were as follows:

(In millions)	Amortized Cost (1)			Fair Value
Available-for-sale:
Due in one year or less		$	1,572		$	1,728
Due after one year through five years		8,158			8,943
Due after five years through 10 years		15,563			16,267
Due after 10 years		38,336			36,158
Mortgage- and asset-backed securities		3,916			4,048
Total fixed maturity securities available-for-sale		$	67,545		$	67,144
Held-to-maturity:
Due in one year or less		$	33		$	35
Due after one year through five years		2			2
Due after five years through 10 years		9,008			9,346
Due after 10 years		7,845			7,752
Total fixed maturity securities held-to-maturity		$	16,888		$	17,135

(1) Net of allowance for credit losses

Economic maturities are used for certain debt instruments with no stated maturity where the expected maturity date is based on the combination of features in the financial instrument such as the right to call or prepay obligations or changes in coupon rates.

Investment Concentrations

The Company's process for investing in credit-related investments begins with an independent approach to underwriting each issuer's fundamental credit quality. The Company evaluates independently those factors that it believes could influence an issuer's ability to make payments under the contractual terms of the Company's instruments. This includes a thorough analysis of a variety of items including the issuer's country of domicile (including political, legal, and financial considerations); the industry in which the issuer competes (with an analysis of industry structure, end-market dynamics, and regulation); company specific issues (such as management, assets, earnings, cash generation, and capital needs); and contractual provisions of the instrument (such as financial covenants and position in the capital structure). The Company further evaluates the investment considering broad business and portfolio management objectives, including asset/liability needs, portfolio diversification, and expected income.

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

	March 31, 2025			December 31, 2024
(In millions)	Credit Rating	Amortized Cost	Fair Value	Credit Rating	Amortized Cost	Fair Value
Japan National Government(1)	A+	$35,251	$33,082	A+	$33,822	$32,844

(1) Japan Government Bonds (JGBs) or JGB-backed securities

Net Investment Gains and Losses

Information regarding pretax net gains and losses from investments is as follows:

	Three Months Ended March 31,
(In millions)	2025		2024
Net investment gains (losses):
Sales and redemptions:
Fixed maturity securities available-for-sale:
Gross gains from sales	$	114	$	34
Gross losses from sales	(235)		(282)
Foreign currency gains (losses)	161		416
Other investments:
Gross gains (losses) from sales and redemptions	1		5
Total sales and redemptions	41		173
Equity securities	(61)		76
Credit losses:
Fixed maturity securities held-to-maturity	0		0
Commercial mortgage and other loans	(53)		(7)
Impairment losses	0		0
Loan commitments	(2)		1
Reinsurance recoverables and other	0		5
Total credit losses	(55)		(1)
Derivatives and other:
Derivative gains (losses)	(45)		(215)
Foreign currency gains (losses)	(843)		918
Total derivatives and other	(888)		703
Total net investment gains (losses)	$	(963)	$	951

The unrealized holding gains, net of losses, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2025 that relate to equity securities held at the March 31, 2025 reporting date were $55 million. The unrealized holding gains, net of losses, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2024 that relate to equity securities held at the March 31, 2024 reporting date were $71 million.

Unrealized Investment Gains and Losses

Effect on Shareholders’ Equity

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:

(In millions)	March 31, 2025			December 31, 2024
Unrealized gains (losses) on securities available-for-sale		$	(401)		$	1,180
Deferred income taxes		(832)			(1,156)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	(1,233)		$	24

Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, 2025 and December 31, 2024, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

	March 31, 2025
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and     agencies:
U.S. dollar-denominated		$	68		$	2		$	33		$	0		$	35		$	2
Japan government and     agencies:
Yen-denominated		11,951			2,608			6,090			179			5,861			2,429
Municipalities:
U.S. dollar-denominated		656			68			72			3			584			65
Yen-denominated		339			105			96			8			243			97
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		1,091			46			697			20			394			26
Yen-denominated		208			29			22			0			186			29
Public utilities:
U.S. dollar-denominated		1,689			142			816			17			873			125
Yen-denominated		1,037			155			258			23			779			132
Other currencies		53			1			53			1			0			0
Sovereign and supranational:
U.S. dollar-denominated		0			0			0			0			0			0
Yen-denominated		49			10			0			0			49			10
Banks/financial institutions:
U.S. dollar-denominated		749			30			544			7			205			23
Yen-denominated		3,576			448			472			14			3,104			434
Other corporate:
U.S. dollar-denominated		6,596			689			2,690			58			3,906			631
Yen-denominated		2,302			413			810			53			1,492			360
Total		$	30,364		$	4,746		$	12,653		$	383		$	17,711		$	4,363

	December 31, 2024
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and     agencies:
U.S. dollar-denominated		$	106		$	3		$	59		$	1		$	47		$	2
Japan government and     agencies:
Yen-denominated		8,136			2,234			2,070			57			6,066			2,177
Municipalities:
U.S. dollar-denominated		666			53			67			3			599			50
Yen-denominated		341			79			96			2			245			77
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		567			34			173			2			394			32
Yen-denominated		196			23			12			0			184			23
Public utilities:
U.S. dollar-denominated		1,570			151			699			19			871			132
Yen-denominated		1,020			108			368			11			652			97
Sovereign and supranational:
Yen-denominated		47			8			0			0			47			8
Banks/financial institutions:
U.S. dollar-denominated		625			36			376			7			249			29
Yen-denominated		3,197			342			471			22			2,726			320
Other corporate:
U.S. dollar-denominated		6,097			752			2,036			59			4,061			693
Yen-denominated		1,733			305			289			14			1,444			291
Total		$	24,301		$	4,128		$	6,716		$	197		$	17,585		$	3,931

Analysis of Securities in Unrealized Loss Positions

The unrealized losses on the Company's available-for-sale securities have been primarily related to general market factors such as changes in interest rates, foreign exchange rates, and/or the levels of credit spreads rather than specific concerns with the issuer's ability to pay interest and repay principal.

For available-for-sale securities in an unrealized loss position, the Company performs detailed analyses to identify whether the drivers of the decline in fair value are due to general market factors, such as the recent rise in interest rates, or due to credit-related factors. Identifying the drivers of the declines in fair value helps to align and allocate the Company‘s resources to the review and monitoring of securities with real credit-related concerns that could impact ultimate collection of principal and interest. For any significant declines in fair value determined to be non-interest rate or market-related, the Company performs a more focused review of the related issuers' specific credit profile.

For corporate issuers, the Company evaluates their assets and business profile, including industry dynamics and competitive positioning, financial statements and other available financial data. For non-corporate issuers, the Company analyzes all sources of credit support, including issuer-specific factors. The Company utilizes information available in the public domain and, for certain private placement issuers, from consultations with the issuers directly. The Company also considers ratings from Nationally Recognized Statistical Rating Organizations (NRSROs), as well as the specific characteristics of the security it owns including seniority in the issuer's capital structure, covenant protections, or other relevant features. From these reviews, the Company evaluates the issuers' continued ability to service the Company's investment through payment of interest and principal.

Assuming no credit-related factors develop, unrealized gains and losses on available-for-sale securities are expected to diminish as investments near maturity. Based on its credit analysis, the Company believes that the issuers of its available-for-sale investments in the sectors shown in the table above have the ability to service their obligations to the Company. Further, the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

However, if the Company identifies certain available-for-sale securities where the amortized cost basis exceeds the present value of the cash flows expected to be collected due to credit-related factors, an allowance for credit losses is recognized. Based on an evaluation of its securities currently in an unrealized loss position, the Company has determined that those securities should not have an allowance for credit losses as of March 31, 2025. Refer to the Allowance for Credit Losses section below for additional information.

As of March 31, 2025 and December 31, 2024, the Company had an immaterial amount of fixed maturity securities on nonaccrual status.

Commercial Mortgage and Other Loans

The Company classifies its transitional real estate loans (TREs), commercial mortgage loans (CMLs), middle market loans (MMLs), and other loans as held-for-investment and includes them in the commercial mortgage and other loans line on the consolidated balance sheets. The Company carries them on the balance sheet at amortized cost less an estimated allowance for credit losses.

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.

	March 31, 2025				December 31, 2024
(In millions)	Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:
Transitional real estate loans:
Office	$	1,238	11.2	%	$	1,361	12.1	%
Retail	350		3.2		349		3.1
Apartments/Multi-Family	2,158		19.6		2,201		19.6
Industrial	100		.9		117		1.1
Hospitality	526		4.8		556		5.0
Other	306		2.8		318		2.8
Total transitional real estate loans	4,678		42.5		4,902		43.7
Commercial mortgage loans:
Office	298		2.7		300		2.7
Retail	212		1.9		214		1.9
Apartments/Multi-Family	569		5.1		572		5.1
Industrial	433		3.9		436		3.9
Other	14		.1		15		.1
Total commercial mortgage loans	1,526		13.7		1,537		13.7
Middle market loans	4,451		40.4		4,423		39.4
Other loans	369		3.4		362		3.2
Total commercial mortgage and other loans	$	11,024	100.0	%	$	11,224	100.0	%
Allowance for credit losses	(368)				(355)
Total net commercial mortgage and other loans	$	10,656			$	10,869

CMLs and TREs are secured by properties entirely within the U.S. (with the largest concentrations in California (21%), Texas (14%) and Florida (10%)). MMLs are issued only to companies domiciled within the U.S. and Canada.

Transitional Real Estate Loans

TREs are relatively short-term floating rate commercial mortgage loans that are secured by a first lien on the property. These loans provide funding for properties undergoing a change in their physical characteristics and/or economic profile and do not typically require any principal repayment prior to the maturity date.

As of March 31, 2025, the Company had $245 million in outstanding commitments to fund TREs. These commitments are contingent on the final underwriting and due diligence to be performed.

Commercial Mortgage Loans

CMLs are typically fixed rate loans on commercial real estate with partial repayment of principal over the life of the loan with the remaining outstanding principal being repaid upon maturity. This loan portfolio is generally considered higher quality investment grade loans.

Middle Market Loans

MMLs are typically first lien senior secured cash flow loans to small to mid-size companies for working capital, refinancing, acquisition, and recapitalization. These loans are generally considered to be below investment grade.

As of March 31, 2025, the Company had commitments of approximately $664 million to fund future MMLs. These commitments are contingent upon the availability of MMLs that meet the Company's underwriting criteria.

Other Loans

Other loans are primarily infrastructure loans. Infrastructure loans are typically senior secured, financing operating portfolios of renewable and conventional energy generation assets characterized by predictable, often contractual cash flows for loan repayment. The infrastructure loan portfolio weighted average rating is investment grade.

As of March 31, 2025, the Company had commitments of approximately $1 million to fund future other loans. These commitments are contingent upon the availability of other loans that meet the Company's underwriting criteria.

Credit Quality Indicators

For TREs, the Company’s key credit quality indicators include performance of the loan and loan-to-value (LTV), which is calculated by dividing the current outstanding loan balance by the estimated property value, primarily using values at origination. Given that TREs involve properties undergoing a repositioning of their commercial profile, LTV provides the most insight into the credit risk of the loan. The Company monitors the performance of the loans periodically, but not less frequently than quarterly. The monitoring process also focuses on higher risk loans, which include those that are delinquent or for which foreclosure or deed in lieu of foreclosure is anticipated.

For CMLs, the Company’s key credit quality indicators include LTV and debt service coverage ratios (DSCR). DSCR is the most recently available net operating income of the underlying property compared to the required debt service of the loan.

For MMLs and held-to-maturity fixed maturity securities, the Company’s key credit quality indicator is credit ratings. The Company’s held-to-maturity portfolio is composed of investment grade securities that are senior unsecured instruments, while its MMLs generally have below-investment-grade ratings but are typically senior secured instruments. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

For other loans, the Company’s key credit quality indicator is credit ratings. The Company monitors these credit ratings periodically, but not less frequently than quarterly.

The following tables present as of March 31, 2025 the amortized cost basis of TREs, CMLs, MMLs, and other loans by year of origination and credit quality indicator.

Transitional Real Estate Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Total
Loan-to-Value Ratio:
0%-59.99%	$	0	$	0	$	0	$	371	$	390	$	47	$	808
60%-69.99%	0		0		77		431		442		396		1,346
70%-79.99%	14		0		14		823		625		64		1,540
80% or greater	0		0		0		335		353		296		984
Total	$	14	$	0	$	91	$	1,960	$	1,810	$	803	$	4,678
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	24	$	24

Commercial Mortgage Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:
0%-59.99%	$	0	$	0	$	32	$	0	$	265	$	1,009	$	1,306	2.72
60%-69.99%	0		0		0		0		25		47		72		2.11
70%-79.99%	0		0		0		0		0		55		55		1.69
80% or greater	0		13		0		0		0		80		93		0.57
Total	$	0	$	13	$	32	$	0	$	290	$	1,191	$	1,526	2.52
Weighted Average DSCR	0.00		1.13		2.62		0.00		3.16		2.38
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Middle Market Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Revolving Loans		Total
Credit Ratings:
BBB	$	0	$	30	$	29	$	0	$	78	$	108	$	12	$	257
BB	61		425		43		426		374		607		76		2,012
B	34		226		53		234		480		662		46		1,735
CCC	0		5		0		14		61		223		19		322
CC	0		0		0		13		0		16		5		34
C and lower	0		0		0		0		0		87		4		91
Total	$	95	$	686	$	125	$	687	$	993	$	1,703	$	162	$	4,451
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	11	$	3	$	0	$	14

Other Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Revolving Loans		Total
Credit Ratings:
A	$	0	$	0	$	0	$	79	$	0	$	0	$	0	$	79
AA	0		0		0		8		3		0		0		11
BBB	0		184		68		27		0		0		0		279
BB	0		0		0		0		0		0		0		0
Total	$	0	$	184	$	68	$	114	$	3	$	0	$	0	$	369
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Past Due and Nonaccrual Loans

The following tables present an aging of past due and nonaccrual loans at amortized cost, before allowance for credit losses, as of the periods presented.

	March 31, 2025
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	4,193	$	18	$	467	$	485	$	4,678	$	467
Commercial mortgage loans	1,526		0		0		0		1,526		0
Middle market loans	4,301		70		80		150		4,451		128
Other loans	369		0		0		0		369		0
Total	$	10,389	$	88	$	547	$	635	$	11,024	$	595

(1) As of March 31, 2025, there were no loans that were 90 days or more past due that continued to accrue interest.

	December 31, 2024
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	4,364	$	195	$	343	$	538	$	4,902	$	378
Commercial mortgage loans	1,537		0		0		0		1,537		0
Middle market loans	4,295		63		65		128		4,423		108
Other loans	362		0		0		0		362		0
Total	$	10,558	$	258	$	408	$	666	$	11,224	$	486

(1) As of December 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

For the three-month period ended March 31, 2025, the Company recognized $1 million of interest income for TREs, CMLs, MMLs, or other loans on nonaccrual status. For the three-month period ended March 31, 2024, the Company recognized no interest income for TREs, CMLs, MMLs, or other loans on nonaccrual status. Of these loans, TREs with an amortized cost of $146 million and $140 million had no credit loss allowance as of March 31, 2025 and December 31, 2024, respectively, because these loans are collateral dependent assets for which the estimated fair values of the collateral were in excess of amortized cost. As of March 31, 2025 and December 31, 2024, MMLs with an amortized cost of $20 million and $5 million, respectively, were on nonaccrual status without an allowance for credit losses.

Loan Modifications to Borrowers Experiencing Financial Difficulties

The Company granted certain loan modifications to borrowers experiencing financial difficulty during the first three months of 2025 and 2024. The types of modifications granted may include interest rate reductions, principal forgiveness, other-than-insignificant payment delays, term extensions or a combination of these types of modifications. The amount, timing, and extent of modifications granted are considered in determining any credit loss allowance recorded.

Loans that have both been modified and are paid or written off during the period, resulting in an amortized cost balance of zero at the end of the period, are not included in the disclosures below.

The following tables present the amortized cost basis of modified loans to borrowers experiencing financial difficulty and the financial effect of the modifications, disaggregated by loan classification and type of modification.

Three Months Ended March 31, 2025
(In millions)	Amortized Cost (1)		% of Total		Financial Effect
Middle Market Loans:
Principal forgiveness	$	1	0.0	%	Reduction in the amortized cost basis of $3 million
Term extension	33		1.0		Term extension of six months on average
Other-than-insignificant   payment delays	47		1.0		Delay in principal and interest payments of 23 months on average

(1) Net of allowance for credit losses

Three Months Ended March 31, 2024
(In millions)	Amortized Cost (1)		% of Total		Financial Effect
Transitional Real Estate Loans:
Other-than-insignificant payment   delays and interest rate   reduction	$	210	3.0	%	Delay in payments of 51 months on average and reduction in the weighted-average contractual interest rate from 8.3% to 6.9%

(1) Net of allowance for credit losses

The following table presents an aging of loans that received modifications in the 12 months preceding the period presented, at amortized cost.

	March 31, 2025
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More Past Due		Nonaccrual Status
Transitional real estate loans	$	347	$	0	$	0	$	0
Middle market loans	96		0		0		20
Total	$	443	$	0	$	0	$	20

The Company closely monitors the performance of the loans that are modified to borrowers experiencing financial difficulty to understand the effectiveness of its modification efforts. Loans that were granted a modification in the past 12 months, as of March 31, 2025 and 2024, and subsequently defaulted in the three-month periods ended March 31, 2025 and 2024, were immaterial.

As of March 31, 2025, the Company had $5 million of outstanding commitments to lend additional funds to borrowers experiencing financial difficulty that were granted a loan modification, compared with $14 million as of December 31, 2024.

Allowance for Credit Losses

The Company calculates its allowance for credit losses for held-to-maturity securities, loan receivables and loan commitments by grouping assets with similar risk characteristics when there is not a specific expectation of a loss for an individual asset. For held-to-maturity securities, MMLs, and MML commitments, the Company groups assets by credit ratings, industry, and country.

The Company groups CMLs and TREs and respective loan commitments by property type, property location and the property’s LTV and DSCR. On a quarterly basis, CMLs and TREs within a portfolio segment that share similar risk characteristics are pooled for calculation of credit loss allowance. On an ongoing basis, TREs, CMLs and other loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is probable), are evaluated individually for credit loss. For example, the credit loss allowance for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of the collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the credit loss allowance as a component of net investment gains (losses) in the consolidated statements of earnings.

The credit allowance for held-to-maturity securities and loan receivables is estimated using a probability-of-default (PD) / loss-given-default (LGD) method, discounted for the time value of money. For held-to-maturity securities, available-for-sale securities and loan receivables, the Company includes the change in present value due to the passage of time in the change in the allowance for credit losses. The Company’s methodology for estimating credit losses utilizes the contractual maturity date of the financial asset, adjusted when necessary to reflect the expected timing of repayment (such as prepayment options, renewal options, call options, or extension options). The Company applies reasonable and supportable forecasts of macroeconomic variables that impact the determination of PD / LGD over a two-year period for held-to-maturity securities and MMLs. The Company reverts to historical loss information over one year, following the two-year forecast period. For the CML and TRE portfolio, the Company applies reasonable and supportable forecasts of macroeconomic variables as well as national and local real-estate market factors to estimate future credit losses where the market factors revert back to historical levels over time with the period being dependent on current market conditions, projected market conditions and difference in the current and historical market levels for each factor. The Company continuously monitors the estimation methodology, due to changes in portfolio composition, changes in underwriting practices and significant events or conditions and makes adjustments as necessary.

The Company’s held-to-maturity portfolio includes Japan Government and Agency securities of $16.1 billion amortized cost as of March 31, 2025 that meet the requirements for zero-credit-loss expectation and therefore these asset classes have been excluded from the current expected credit loss measurement.

An investment in an available-for-sale security may be impaired if the fair value falls below amortized cost. The Company regularly reviews its available-for-sale portfolio for declines in fair value. The Company's available-for-sale impairment model focuses on the ultimate collection of the cash flows from its investments and whether the Company has the intent to sell or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. The determination of the amount of impairments under this model is based upon the Company's periodic evaluation and assessment of known and inherent risks associated with the respective securities. Such evaluations and assessments are revised as conditions change and new information becomes available.

When determining the Company's intention to sell a security prior to recovery of its amortized cost basis, the Company evaluates facts and circumstances such as, but not limited to, future cash flow needs, decisions to reposition its security portfolio, and risk profile of individual investment holdings. The Company performs ongoing analyses of its liquidity needs, which includes cash flow testing of its policy liabilities, debt maturities, projected dividend payments, and other cash flow and liquidity needs.

The Company’s methodology for estimating credit losses for available-for-sale securities utilizes the discounted cash flow model, based on past events, current market conditions and future economic conditions, as well as industry analysis and credit ratings of the securities. In addition, the Company evaluates the specific issuer’s probability of default and expected recovery of its position in the event of default based on the underlying financial condition and assets of the borrower as well as seniority and/or security of other debt holders in the issuer when developing management’s best estimate of expected cash flows.

The following table presents the roll forward of the allowance for credit losses by portfolio segment for loans and by accounting classification for securities.

(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Other Loans and Loan Commitments		Held-to- Maturity Securities		Available- for-Sale Securities		Total
Three Months Ended March 31, 2025:
Balance at December 31, 2024	$	(199)	$	(14)	$	(140)	$	(17)	$	(5)	$	0	$	(375)
(Addition to) release of allowance    for credit losses	(28)		(1)		(24)		(2)		0		0		(55)
Writeoffs, net of recoveries	24		0		14		0		0		0		38
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2025	$	(203)	$	(15)	$	(150)	$	(19)	$	(5)	$	0	$	(392)
Three Months Ended March 31, 2024:
Balance at December 31, 2023	$	(112)	$	(16)	$	(146)	$	(16)	$	(5)	$	0	$	(295)
(Addition to) release of allowance    for credit losses	(2)		(3)		(3)		1		0		0		(7)
Writeoffs, net of recoveries	0		0		50		0		0		0		50
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2024	$	(114)	$	(19)	$	(99)	$	(15)	$	(5)	$	0	$	(252)

As of March 31, 2025, the Company identified TREs with an amortized cost of $311 million in anticipation of potential foreclosure or deed in lieu of foreclosure transactions. As of March 31, 2025, the Company established a credit allowance of $25 million related to these loans.

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.

(In millions)	March 31, 2025			December 31, 2024
Other investments:
Policy loans		$	211		$	203
Short-term investments (1)		2,259			1,599
Limited partnerships (2)		3,482			3,435
Real estate owned		774			682
Other		37			39
Total other investments		$	6,763		$	5,958

(1) Includes securities lending collateral

(2) Includes tax credit investments and asset classes such as private equity and real estate funds

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheets. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statements of earnings.

Real estate owned (REO) consists of office buildings or other commercial properties obtained through foreclosure or deed in lieu of foreclosure of certain of the Company’s TREs. As of March 31, 2025 and December 31, 2024, all REO was classified as held-and-used for the production of income, which is carried at cost less accumulated depreciation. Depreciation expense was $6 million and $1 million for the three-month periods ended March 31, 2025 and 2024, respectively. Additionally, as of March 31, 2025 and December 31, 2024, accumulated depreciation was $20 million and $14 million, respectively.

The Company had $2.6 billion and $2.8 billion in outstanding commitments to fund investments in limited partnerships, which includes $2.0 billion and $2.1 billion of unfunded commitments related to VIEs that are non-consolidated as of March 31, 2025 and December 31, 2024, respectively.

Variable Interest Entities (VIEs)

In the normal course of its activities, the Company invests in legal entities that are VIEs. The Company's variable interests in VIEs are limited to the debt and equity instruments issued by them. With the exception of commitments to limited partnerships and to certain loan investments made in the normal course of business, the Company has not provided any direct or contingent obligations to fund the limited activities of these VIEs, or support related to the limited activities of these VIEs and does not have any intention to do so in the future, nor has it provided any direct or indirect financial guarantees.

The Company's risk of loss related to its interests in any of its VIEs is limited to the carrying value of the related investments, and in certain cases, to any unfunded commitments held in the VIE.

For those VIEs other than certain unit trust structures, the Company's involvement is passive in nature.

VIEs - Consolidated

If the Company determines that it is the VIE’s primary beneficiary, it consolidates the VIE. Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company except to the extent of the unfunded commitments referenced above, as the Company’s obligation to each VIE is limited to the amount of its committed investment.

The following table presents the carrying value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities

(In millions)	March 31, 2025			December 31, 2024
Assets:
Fixed maturity securities, available-for-sale		$	3,597		$	3,428
Commercial mortgage and other loans		8,540			8,693
Other investments (1)		2,151			2,176
Other assets (2)		49			53
Total assets of consolidated VIEs		$	14,337		$	14,350
Liabilities:
Other liabilities (2)		$	642		$	604
Total liabilities of consolidated VIEs		$	642		$	604

(1) Consists entirely of alternative investments in limited partnerships, which represent VIEs where the Company is not the primary beneficiary and, therefore, are not consolidated

(2) Consists entirely of derivatives

The Company is the sole investor in the consolidated VIEs listed in the table above. The Company invests in fixed maturity securities issued by VIEs that in turn hold U.S. dollar-denominated fixed maturity securities coupled with foreign currency swap agreements. The weighted-average lives of the Company's investments in these VIEs are very similar to the underlying collateral held by these VIEs. The activities of these VIEs are limited to holding invested assets and foreign currency swaps and utilizing the cash flows from these securities to service the VIEs' debt. Neither the Company nor any of its creditors are able to obtain the underlying collateral of these VIEs unless there is an event of default or other specified event. The Company is not a direct counterparty to the foreign currency swap contracts and has no control over them. The Company's loss exposure to these VIEs is limited to its original investment. These consolidated VIEs do not rely on outside or ongoing sources of funding to support their activities beyond the underlying collateral and foreign currency swap contracts, if applicable. The underlying collateral assets and funding of these consolidated VIEs are generally static in nature.

Investments in Unit Trust Structures

The Company also utilizes unit trust structures in its Aflac Japan segment to invest in various asset classes, which include CMLs, MMLs, TREs, other loans and limited partnerships. As the sole investor of these VIEs, the Company is required to consolidate these trusts under U.S. GAAP. The limited partnership investments are comprised of private equity and real estate funds. The Company's loss exposure to these VIEs is limited to its original investments, together with any unfunded portion of the Company's commitments made in the normal course of business to fund certain loan investments and limited partnership investments, as described in the Commercial Mortgage and Other Loans and Other Investments sections of this note. Excluding these commitments, the Company does not provide financial or other support to consolidated VIEs.

VIEs - Not Consolidated

The table below reflects the carrying value and balance sheet caption in which the Company's investments in VIEs that are not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated

(In millions)	March 31, 2025			December 31, 2024
Assets:
Fixed maturity securities, available-for-sale		$	6,624		$	6,243
Other investments (1)		1,194			1,124
Total investments in VIEs not consolidated		$	7,818		$	7,367

(1) Consists entirely of alternative investments in limited partnerships

Certain investments in VIEs that the Company is not required to consolidate are investments that are in the form of debt obligations issued by the VIEs. These fixed maturity securities include structured securities, primarily asset-backed securities. The Company's involvement in the related VIEs is limited to that of a passive investor in asset-backed securities issued by the VIEs. The Company also invests in fixed maturity debt securities issued by VIEs that are the primary financing vehicles used by their corporate sponsors to raise financing in the capital markets. The variable interests created by these VIEs are principally or solely a result of the debt instruments issued by them. The Company does not have the power to direct the activities that most significantly impact the entity's economic performance, nor does it have the obligation to absorb losses of the VIE entity or the right to receive benefits from the entity that could be significant to the entity. As such, the Company is not the primary beneficiary of these VIEs and therefore is not required to consolidate them.

The Company also holds equity investments in limited partnerships that have been determined to be VIEs. These partnerships primarily invest in private equity and real estate funds. The Company’s maximum exposure to loss on these investments is limited to the amount of its investment and any unfunded commitments. As described in the Other Investments section of this note, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to unconsolidated VIEs. The Company is not the primary beneficiary of these VIEs and is therefore not required to consolidate them. The Company classifies these investments as other investments in the consolidated balance sheets.

Securities Lending and Pledged Securities

The Company lends fixed maturity securities and, from time to time, public equity securities to financial institutions in short-term securities lending transactions. These short-term securities lending arrangements increase investment income with minimal risk. The Company receives cash or other securities as collateral for such loans. The Company's securities lending policy requires that the fair value of the securities received as collateral be 102% or more of the fair value of the loaned securities and that unrestricted cash received as collateral be 100% or more of the fair value of the loaned securities. The securities loaned continue to be carried as investment assets on the Company's balance sheet during the terms of the loans and are not reported as sales. For loans involving unrestricted cash or securities as collateral, the collateral is reported as an asset with a corresponding liability for the return of the collateral. For loans where the Company receives as collateral securities that the Company is not permitted to sell or repledge, the collateral is not reflected in the consolidated financial statements.

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:

Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements
	March 31, 2025						December 31, 2024
(In millions)	Overnight and Continuous(1)		Up to 30 days		Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending   transactions:
Fixed maturity securities:
Japan government and agencies	$	0	$	2,303	$	2,303	$	0	$	1,027	$	1,027
Public utilities	39		0		39		34		0		34
Banks/financial institutions	131		0		131		193		0		193
Other corporate	669		0		669		783		0		783
Total borrowings	$	839	$	2,303	$	3,142	$	1,010	$	1,027	$	2,037
Gross amount of recognized liabilities for securities    lending transactions					$	3,142					$	2,037

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

In connection with securities lending, in addition to cash collateral received, the Company received from counterparties securities collateral of $1.3 billion and $3.0 billion at March 31, 2025 and December 31, 2024, respectively, which may not be sold or re-pledged, unless the counterparty is in default. Such securities collateral is not reflected on the consolidated financial statements.

The Company did not have any repurchase agreements or repurchase-to-maturity transactions outstanding as of March 31, 2025, and December 31, 2024, respectively.

Certain fixed maturity securities can be pledged as collateral as part of derivative transactions, or pledged to support state deposit requirements on certain investment programs. For additional information regarding pledged securities related to derivative transactions, see Note 4.

XML

DERIVATIVE INSTRUMENTS

3 Months Ended

Mar. 31, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS

The Company's freestanding derivative financial instruments include:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening yen;

•cross-currency swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated debentures;

•foreign currency swaps that are associated with VIE bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Some of the Company's derivatives are designated as cash flow hedges, fair value hedges or net investment hedges; however, other derivatives do not qualify for hedge accounting or the Company elects not to designate them as accounting hedges.

Derivative Types

Foreign currency forwards and options are executed for the Aflac Japan segment in order to hedge the currency risk on the carrying value of certain U.S. dollar-denominated investments. The average maturity of these forwards and options can change depending on factors such as market conditions and types of investments being held. In situations where the maturity of the forwards and options is shorter than the underlying investment being hedged, the Company may enter into new forwards and options near maturity of the existing derivative in order to continue hedging the underlying investment. In forward transactions, Aflac Japan agrees with another party to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. The Company also uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also executes foreign currency option transactions in a collar strategy, where Aflac Japan agrees with another party to simultaneously purchase put options and sell call options. In the purchased put transactions, Aflac Japan obtains the option to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. In the sold call transactions, Aflac Japan agrees to sell a fixed amount of yen and buy a corresponding amount of U.S. dollars at a specified future date. The combination of purchasing the put option and selling the call option results in no net premium being paid (i.e. a costless or zero-cost collar).

From time to time, the Company may also enter into foreign currency forwards and options to hedge the currency risk associated with the net investment in Aflac Japan. In these forward transactions, the Company agrees with another party to buy a fixed amount of U.S. dollars and sell a corresponding amount of yen at a specified price at a specified future date. In the option transactions, the Company may use a combination of foreign currency options to protect expected future cash flows by simultaneously purchasing yen put options (options that protect against a weakening yen) and selling yen call options (options that limit participation in a strengthening yen). The combination of these two actions create a zero-cost collar. Additionally, the Company enters into purchased options to hedge cash flows from the net investment in Aflac Japan.

The Company enters into foreign currency swaps pursuant to which it exchanges an initial principal amount in one currency for an initial principal amount of another currency, with an agreement to re-exchange the principal amounts at a future date. There may also be periodic exchanges of payments at specified intervals based on the agreed upon rates and notional amounts. Foreign currency swaps are used primarily in the consolidated VIEs in the Company's Aflac Japan portfolio to convert foreign-denominated cash flows to yen, the functional currency of Aflac Japan, in order to minimize cash flow fluctuations. The Company also uses foreign currency swaps to economically convert certain of its U.S. dollar-denominated senior note and subordinated debenture principal and interest obligations into yen-denominated obligations.

In order to reduce investment income volatility from its variable-rate investments, the Company enters into receive–fixed, pay–floating interest rate swaps. These derivatives are cleared and settled through a central clearinghouse.

Swaptions are used to mitigate the adverse impact resulting from significant changes in the fair value of U.S. dollar-denominated available-for-sale securities due to fluctuation in interest rates. In a payer swaption, the Company pays a premium to obtain the right, but not the obligation, to enter into a swap contract where it will pay a fixed rate and receive a floating rate. Interest rate swaption collars are combinations of two swaption positions. In order to maximize the efficiency of the collars while minimizing cost, a collar strategy is used whereby the Company purchases a long payer swaption (the Company purchases an option that allows it to enter into a swap where the Company will pay the fixed rate and receive the floating rate of the swap) and sells a short receiver swaption (the Company sells an option that provides the counterparty with the right to enter into a swap where the Company will receive the fixed rate and pay the floating rate of the swap). The combination of purchasing the long payer swaption and selling the short receiver swaption results in no net premium being paid (i.e. a costless or zero-cost collar).

Bond purchase commitments result from repackaged bond structures that are consolidated VIEs whereby there is a delay in the trade date and settlement date of the bond within the structure to ensure completion of all necessary legal agreements to support the consolidated VIE that issues the repackaged bond. Since the Company has a commitment to purchase the underlying bond at a specified price, the agreement meets the definition of a derivative where the value is derived based on the current market value of the bond compared to the fixed purchase price to be paid on the settlement date.

Derivative Balance Sheet Classification

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in other assets, while derivative liabilities are included in other liabilities within the Company’s consolidated balance sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.

		March 31, 2025									December 31, 2024
(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative   Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:
Foreign currency swaps - VIE		$	18		$	0		$	5		$	18		$	0		$	6
Total cash flow hedges		18			0			5			18			0			6
Net investment hedge:
Foreign currency forwards		2,674			91			38			1,809			185			0
Total net investment hedge		2,674			91			38			1,809			185			0
Non-qualifying strategies:
Foreign currency swaps		0			0			0			450			2			0
Foreign currency swaps - VIE		3,068			49			637			3,042			53			598
Foreign currency forwards		173			1			1			0			0			0
Foreign currency options		24,195			2			0			24,195			0			0
Interest rate swaps		29,280			5			304			17,230			0			329
Total non-qualifying strategies		56,716			57			942			44,917			55			927
Total derivatives		$	59,408		$	148		$	985		$	46,744		$	240		$	933

Cash Flow Hedges

From time to time, for certain variable-rate available-for-sale securities held by Aflac Japan via consolidated VIEs, foreign currency swaps are used to swap the variable rate interest to fixed rate interest as well as interest cash flows between Japanese yen and U.S. dollar. The Company has designated foreign currency swaps as a hedge of the variability in cash flows of a forecasted transaction or of amounts to be received or paid related to a recognized asset (“cash flow” hedge). The remaining maximum length of time for which these cash flows are hedged is approximately two years. The derivatives in the Company's consolidated VIEs that are not designated as accounting hedges are discussed in the Non-qualifying Strategies section of this note.

Fair Value Hedges

The Company designates and accounts for certain foreign currency forwards, options, and interest rate swaptions as fair value hedges when they meet the requirements for hedge accounting. The Company recognizes gains and losses on these derivatives as well as the offsetting gain or loss on the related hedged items in current earnings.

Foreign currency forwards and options hedge the foreign currency exposure of certain U.S. dollar-denominated available-for-sale fixed-maturity investments held in Aflac Japan. The change in the fair value of the foreign currency forwards related to the changes in the difference between the spot rate and the forward price is excluded from the assessment of hedge effectiveness. The change in fair value of the foreign currency option related to the time value of the option is recognized in current earnings and is excluded from the assessment of hedge effectiveness.

Interest rate swaptions hedge the interest rate exposure of certain U.S. dollar-denominated available-for-sale securities held in Aflac Japan. For these hedging relationships, the Company excludes time value from the assessment of hedge effectiveness and recognizes changes in the intrinsic value of the swaptions in current earnings within net investment income. The change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into earnings (net investment income) over its legal term.

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount. The Company had no fair value hedges of interest rate risk as of March 31, 2025 and December 31, 2024; therefore, the amounts presented in the table below are related to previous fair value hedges of interest rate risk that were discontinued.

(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
		March 31, 2025		December 31, 2024		March 31, 2025		December 31, 2024
Fixed maturity securities		$	1,305	$	1,294	$	128	$	137

(1) The balance includes hedging adjustment on discontinued hedging relationships of $128 in 2025 and $137 in 2024.

Net Investment Hedge

The Company's investment in Aflac Japan is affected by changes in the yen/dollar exchange rate. To mitigate this exposure, the Parent Company's yen-denominated liabilities (see Note 9) have been designated as non-derivative hedges and certain foreign currency forwards and options have been designated as derivative hedges of the foreign currency exposure of the Company's net investment in Aflac Japan.

The Company's net investment hedge was effective during the three-month periods ended March 31, 2025 and 2024, respectively.

Non-qualifying Strategies

For the Company's derivative instruments in consolidated VIEs that do not qualify for hedge accounting treatment, all changes in their fair value are reported in current period earnings in net investment gains (losses). The amount of gain or loss recognized in earnings for the Company's VIEs is attributable to the derivatives in those investment structures. While the change in value of the swaps is recorded in current period earnings, the change in value of the available-for-sale fixed maturity securities associated with these swaps is recorded in other comprehensive income.

The Parent Company had cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert interest and principal on the notes from U.S. dollar to Japanese yen. These swaps matured in March 2025. Changes in the values of these swaps were recorded in earnings in the period where they occurred.

The Company uses foreign currency forwards and options to economically mitigate the currency risk of some of its U.S. dollar-denominated loan receivables and U.S. government fixed maturity securities held in the Aflac Japan segment. These arrangements are not designated as accounting hedges, as the foreign currency remeasurement of the loan receivables impacts current period earnings, and substantially offsets gains and losses from foreign currency forwards within net investment gains (losses). The Company also has certain foreign currency forwards on U.S. dollar-denominated available-for-sale securities where hedge accounting is not being applied.

The Company uses interest rate swaps to economically convert the variable rate investment income to a fixed rate on certain variable-rate investments.

Impact of Derivatives and Hedging Instruments

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

	Three Months Ended March 31,
	2025										2024
(In millions)	Net Investment Income			Net Investment Gains (Losses)				Other Comprehensive  Income (Loss)			Net Investment Income			Net Investment Gains (Losses)				Other Comprehensive  Income (Loss)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	2		$	0		$	(1)			$	0
Total cash flow hedges		0			(1)		(1)		2			0			(1)		(1)		0
Net investment hedge:
Non-derivative hedging           instruments					0				(240)						0				236
Foreign currency forwards					36				(144)						44				145
Total net investment hedge					36				(384)						44				381
Non-qualifying strategies:
Foreign currency swaps					0										1
Foreign currency swaps - VIE					(57)										(88)
Foreign currency forwards					0										17
Foreign currency options					(5)										(41)
Interest rate swaps					(18)										(147)
Total non-qualifying strategies					(80)										(258)
Total		$	0		$	(45)			$	(382)		$	0		$	(215)			$	381

(1) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2025, and $1 of losses during the three-month period ended March 31, 2024.

Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedged item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items. Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statements of comprehensive income (loss).

As of March 31, 2025, $3 million of deferred losses on derivative instruments recorded in accumulated other comprehensive income are expected to be reclassified into earnings during the next twelve months.

Credit Risk Assumed through Derivatives

For the foreign currency swaps associated with the Company's VIE investments for which it is the primary beneficiary, the Company bears the risk of loss due to counterparty default even though it is not a direct counterparty to those contracts.

The Company is a direct counterparty to the foreign currency swaps that it has entered into in connection with certain of its senior notes and subordinated debentures; foreign currency forwards; and foreign currency options, and therefore the Company is exposed to credit risk in the event of nonperformance by the counterparties in those contracts. The risk of counterparty default for the Company's foreign currency swaps, certain foreign currency forwards, and foreign currency options is mitigated by collateral posting requirements that counterparties to those transactions must meet.

As of March 31, 2025, all of the Company's derivative agreement counterparties were investment grade.

The Company engages in over-the-counter (OTC) bilateral derivative transactions directly with unaffiliated third parties under International Swaps and Derivatives Association, Inc. (ISDA) agreements and other documentation. Most of the ISDA agreements also include Credit Support Annexes (CSAs) provisions, which generally provide for two-way collateral postings at the first dollar of exposure. The Company mitigates the risk that counterparties to transactions might be unable to fulfill their contractual obligations by monitoring counterparty credit exposure and collateral value while generally requiring that collateral be posted at the outset of the transaction. In addition, a significant portion of the derivative transactions have provisions that give the counterparty the right to terminate the transaction upon a downgrade of the Company's financial strength rating. The actual amount of payments that the Company could be required to make depends on market conditions, the fair value of outstanding affected transactions, and other factors prevailing at and after the time of the downgrade.

The Company also engages in OTC cleared derivative transactions through regulated central clearing counterparties. These positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to these derivatives.

Collateral posted by the Company to third parties for derivative transactions can generally be repledged or resold by the counterparties. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position by counterparty was approximately $883 million and $804 million as of March 31, 2025 and December 31, 2024, respectively. If the credit-risk-related contingent features underlying these agreements had been triggered on March 31, 2025, the Company estimates that it would be required to post a maximum of $584 million of additional collateral to these derivative counterparties. The Company is generally allowed to sell or repledge collateral obtained from its derivative counterparties, although it does not typically exercise such rights. See the Offsetting tables below for collateral posted or received as of the reported balance sheet dates.

Offsetting of Financial Instruments and Derivatives

Most of the Company's derivative instruments are subject to enforceable master netting arrangements that provide for the net settlement of all derivative contracts between the Parent Company or its subsidiaries and the respective counterparty in the event of default or upon the occurrence of certain termination events. Collateral support agreements with the master netting arrangements generally provide that the Company will receive or pledge financial collateral at the first dollar of exposure.

The Company has securities lending agreements with unaffiliated financial institutions that post collateral to the Company in return for the use of its fixed maturity and public equity securities (see Note 3). When the Company has entered into securities lending agreements with the same counterparty, the agreements generally provide for net settlement in the event of default by the counterparty. This right of set-off allows the Company to keep and apply collateral received if the counterparty failed to return the securities borrowed from the Company as contractually agreed.

The tables below summarize the Company's derivatives and securities lending transactions, and as reflected in the tables, in accordance with U.S. GAAP, the Company's policy is to not offset these financial instruments in the consolidated balance sheets.

Offsetting of Financial Assets and Derivative Assets

March 31, 2025
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	94		$	0		$	94		$	(36)	$	(12)		$	(46)		$	0
OTC - cleared		5			0			5			(5)		0			0			0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		99			0			99			(41)		(12)			(46)			0
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		49						49											49
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		49						49											49
Total derivative       assets		148			0			148			(41)		(12)			(46)			49
Securities lending    and similar    arrangements		3,128			0			3,128			0		0			(3,128)			0
Total		$	3,276		$	0		$	3,276		$	(41)	$	(12)		$	(3,174)		$	49

December 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	187		$	0		$	187		$	0	$	(45)		$	(135)		$	7
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		187			0			187			0		(45)			(135)			7
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		53						53											53
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		53						53											53
Total derivative       assets		240			0			240			0		(45)			(135)			60
Securities lending    and similar    arrangements		2,001			0			2,001			0		0			(2,001)			0
Total		$	2,241		$	0		$	2,241		$	0	$	(45)		$	(2,136)		$	60

Offsetting of Financial Liabilities and Derivative Liabilities

March 31, 2025
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	39		$	0		$	39		$	(36)	$	0		$	0		$	3
OTC - cleared		304			0			304			(5)		(17)			(282)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		343			0			343			(41)		(17)			(282)			3
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		642						642											642
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		642						642											642
Total derivative       liabilities		985			0			985			(41)		(17)			(282)			645
Securities lending    and similar    arrangements		3,142			0			3,142			(3,128)		0			0			14
Total		$	4,127		$	0		$	4,127		$	(3,169)	$	(17)		$	(282)		$	659

December 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - cleared		$	329		$	0		$	329		$	0	$	0		$	(329)		$	0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		329			0			329			0		0			(329)			0
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		604						604											604
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		604						604											604
Total derivative       liabilities		933			0			933			0		0			(329)			604
Securities lending    and similar    arrangements		2,037			0			2,037			(2,001)		0			0			36
Total		$	2,970		$	0		$	2,970		$	(2,001)	$	0		$	(329)		$	640

For additional information on the Company's financial instruments, see the accompanying Notes 3 and 5 and Notes 1, 3 and 5 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair Value Hierarchy

U.S. GAAP specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. These two types of inputs create three valuation hierarchy levels, as follows:

•Level 1 valuations reflect quoted market prices for identical assets or liabilities in active markets.

•Level 2 valuations reflect quoted market prices for similar assets or liabilities in an active market, quoted market prices for identical or similar assets or liabilities in non-active markets or model-derived valuations in which all significant valuation inputs are observable in active markets.

•Level 3 valuations reflect valuations in which one or more of the significant inputs are not observable in an active market.

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	16,972		$	845		$	0		$	17,817
Municipalities		0			2,055			0			2,055
Mortgage- and asset-backed securities		0			2,445			1,603			4,048
Public utilities		0			6,465			756			7,221
Sovereign and supranational		0			402			24			426
Banks/financial institutions		0			9,351			10			9,361
Other corporate		0			26,079			137			26,216
Total fixed maturity securities		16,972			47,642			2,530			67,144
Equity securities		604			0			160			764
Other investments		2,259			0			0			2,259
Cash and cash equivalents		5,231			0			0			5,231
Other assets:
Foreign currency swaps		0			49			0			49
Foreign currency forwards		0			92			0			92
Foreign currency options		0			2			0			2
Interest rate swaps		0			5			0			5
Total other assets		0			148			0			148
Total assets		$	25,066		$	47,790		$	2,690		$	75,546
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	642		$	0		$	642
Foreign currency forwards		0			39			0			39
Interest rate swaps		0			304			0			304
Total liabilities		$	0		$	985		$	0		$	985

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	17,088		$	758		$	0		$	17,846
Municipalities		0			2,034			0			2,034
Mortgage- and asset-backed securities		0			2,407			1,156			3,563
Public utilities		0			6,398			647			7,045
Sovereign and supranational		0			393			23			416
Banks/financial institutions		0			8,946			10			8,956
Other corporate		0			25,178			231			25,409
Total fixed maturity securities		17,088			46,114			2,067			65,269
Equity securities		639			0			157			796
Other investments		1,599			0			0			1,599
Cash and cash equivalents		6,229			0			0			6,229
Other assets:
Foreign currency swaps		0			55			0			55
Foreign currency forwards		0			185			0			185
Total other assets		0			240			0			240
Total assets		$	25,555		$	46,354		$	2,224		$	74,133
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	604		$	0		$	604
Interest rate swaps		0			329			0			329
Total liabilities		$	0		$	933		$	0		$	933

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.

	March 31, 2025
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,     carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	16,193		$	16,262		$	144		$	0		$	16,406
Municipalities		249			0			260			0			260
Public utilities		33			0			33			0			33
Sovereign and    supranational		396			0			418			0			418
Other corporate		17			0			18			0			18
Commercial mortgage and     other loans		10,656			0			0			10,451			10,451
Other investments (1)		37			0			37			0			37
Total assets		$	27,581		$	16,262		$	910		$	10,451		$	27,623
Liabilities:
Other policyholders’ funds		$	5,863		$	0		$	0		$	5,789		$	5,789
Notes payable    (excluding leases)		7,653			0			6,533			714			7,247
Total liabilities		$	13,516		$	0		$	6,533		$	6,503		$	13,036

(1) Excludes policy loans of $211, equity method investments of $3,482, and REO of $774, at carrying value

	December 31, 2024
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,    carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	15,309		$	15,916		$	143		$	0		$	16,059
Municipalities		235			0			257			0			257
Public utilities		32			0			33			0			33
Sovereign and    supranational		374			0			405			0			405
Other corporate		16			0			18			0			18
Commercial mortgage and     other loans		10,869			0			0			10,653			10,653
Other investments (1)		39			0			39			0			39
Total assets		$	26,874		$	15,916		$	895		$	10,653		$	27,464
Liabilities:
Other policyholders’ funds		$	5,460		$	0		$	0		$	5,389		$	5,389
Notes payable    (excluding leases)		7,402			0			6,352			675			7,027
Total liabilities		$	12,862		$	0		$	6,352		$	6,064		$	12,416

(1) Excludes policy loans of $203, equity method investments of $3,435, and REO of $682, at carrying value

Fair Value of Financial Instruments

Fixed maturity and equity securities

The fair values of the Company's public fixed maturity securities are generally based on prices provided by third-party pricing vendors. The Company utilizes internally generated valuations or broker quotes for privately issued fixed maturity securities or fixed maturity securities where there is no price available from a third-party pricing vendor.

The fair values of the Company's public equity securities are generally based on price quotes, including quoted market prices readily available from independent public exchange markets or established security dealer associations. The Company determines the fair values of privately issued equity securities using the following approaches or techniques:

•price quotes and valuations from third-party pricing vendors,

•in-house valuations, and

•non-binding price quotes the Company obtains from outside brokers.

The pricing data and market quotes the Company obtains from outside sources, including third-party pricing services, are reviewed internally for reasonableness. If a fair value appears unreasonable, the Company will re-examine the inputs and assess the reasonableness of the pricing data with the provider. Additionally, the Company may compare the inputs to relevant market indices and other performance measurements. Based on management's analysis, the valuation is confirmed or may be revised if there is evidence of a more appropriate estimate of fair value based on available market data. The Company has performed verification of the inputs and calculations in any valuation models, including independent validations and back testing, to confirm that the valuations represent reasonable estimates of fair value. For the periods presented, the Company has not adjusted the quotes or prices it obtains from the pricing services and brokers it uses.

For internally generated valuations, the Company utilizes valuation models developed by a third-party pricing vendor. The models and associated processes and controls are executed by Company personnel.

These models are discounted cash flow (DCF) valuation models but also use information from related markets, specifically public bond markets and the credit default swap (CDS) market, to estimate expected cash flows. The models take into consideration any unique characteristics of the securities and make various adjustments to arrive at an appropriate issuer-specific loss adjusted credit curve using the most appropriate comparable security(ies) of the issuer and issuer-specific CDS spreads. This credit curve is then used with the relevant recovery rates to estimate expected cash flows and modeling of additional features, including illiquidity adjustments, if necessary, to price the security by discounting those loss adjusted cash flows. In cases where a credit curve cannot be developed from market information for the specific issuer, the valuation methodology takes into consideration other market observable inputs, including:

•the most appropriate comparable security(ies) of a guarantor and/or parent

•CDS spreads of a guarantor and/or parent

•bonds of comparable issuers with similar characteristics such as rating, geography, or sector

•CDS spreads of an appropriate index or of comparable issuers with similar characteristics such as rating, geography, or sector

•bond indices that are comparative in rating, industry, maturity, and region.

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	16,972		$	524		$	0		$	17,496
Internal		0			321			0			321
Total government and agencies		16,972			845			0			17,817
Municipalities:
Third-party pricing vendor		0			1,812			0			1,812
Internal		0			243			0			243
Total municipalities		0			2,055			0			2,055
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,258			0			2,258
Internal		0			187			37			224
Broker/other		0			0			1,566			1,566
Total mortgage- and asset-backed securities		0			2,445			1,603			4,048
Public utilities:
Third-party pricing vendor		0			3,644			0			3,644
Internal		0			2,821			0			2,821
Broker/other		0			0			756			756
Total public utilities		0			6,465			756			7,221
Sovereign and supranational:
Third-party pricing vendor		0			78			0			78
Internal		0			324			0			324
Broker/other		0			0			24			24
Total sovereign and supranational		0			402			24			426
Banks/financial institutions:
Third-party pricing vendor		0			5,416			0			5,416
Internal		0			3,935			6			3,941
Broker/other		0			0			4			4
Total banks/financial institutions		0			9,351			10			9,361
Other corporate:
Third-party pricing vendor		0			20,762			0			20,762
Internal		0			5,317			21			5,338
Broker/other		0			0			116			116
Total other corporate		0			26,079			137			26,216
Total securities available-for-sale		$	16,972		$	47,642		$	2,530		$	67,144
Equity securities, carried at fair value:
Third-party pricing vendor		$	604		$	0		$	0		$	604
Internal		0			0			26			26
Broker/other		0			0			134			134
Total equity securities		$	604		$	0		$	160		$	764

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	16,262		$	144		$	0		$	16,406
Total government and agencies		16,262			144			0			16,406
Municipalities:
Third-party pricing vendor		0			260			0			260
Total municipalities		0			260			0			260
Public utilities:
Third-party pricing vendor		0			33			0			33
Total public utilities		0			33			0			33
Sovereign and supranational:
Third-party pricing vendor		0			205			0			205
Internal		0			213			0			213
Total sovereign and supranational		0			418			0			418
Other corporate:
Third-party pricing vendor		0			18			0			18
Total other corporate		0			18			0			18
Total securities held-to-maturity		$	16,262		$	873		$	0		$	17,135

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	17,088		$	446		$	0		$	17,534
Internal		0			312			0			312
Total government and agencies		17,088			758			0			17,846
Municipalities:
Third-party pricing vendor		0			1,791			0			1,791
Internal		0			243			0			243
Total municipalities		0			2,034			0			2,034
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,352			0			2,352
Internal		0			55			37			92
Broker/other		0			0			1,119			1,119
Total mortgage- and asset-backed securities		0			2,407			1,156			3,563
Public utilities:
Third-party pricing vendor		0			3,628			0			3,628
Internal		0			2,770			0			2,770
Broker/other		0			0			647			647
Total public utilities		0			6,398			647			7,045
Sovereign and supranational:
Third-party pricing vendor		0			78			0			78
Internal		0			315			0			315
Broker/other		0			0			23			23
Total sovereign and supranational		0			393			23			416
Banks/financial institutions:
Third-party pricing vendor		0			4,975			0			4,975
Internal		0			3,971			5			3,976
Broker/other		0			0			5			5
Total banks/financial institutions		0			8,946			10			8,956
Other corporate:
Third-party pricing vendor		0			20,051			0			20,051
Internal		0			5,127			116			5,243
Broker/other		0			0			115			115
Total other corporate		0			25,178			231			25,409
Total securities available-for-sale		$	17,088		$	46,114		$	2,067		$	65,269
Equity securities, carried at fair value:
Third-party pricing vendor		$	639		$	0		$	0		$	639
Internal		0			0			26			26
Broker/other		0			0			131			131
Total equity securities		$	639		$	0		$	157		$	796

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	15,916		$	143		$	0		$	16,059
Total government and agencies		15,916			143			0			16,059
Municipalities:
Third-party pricing vendor		0			257			0			257
Total municipalities		0			257			0			257
Public utilities:
Third-party pricing vendor		0			33			0			33
Total public utilities		0			33			0			33
Sovereign and supranational:
Third-party pricing vendor		0			198			0			198
Internal		0			207			0			207
Total sovereign and supranational		0			405			0			405
Other corporate:
Third-party pricing vendor		0			18			0			18
Total other corporate		0			18			0			18
Total securities held-to-maturity		$	15,916		$	856		$	0		$	16,772

The following is a discussion of the determination of fair value of the Company's remaining financial instruments.

Derivatives

The Company uses derivative instruments to manage the risk associated with certain assets. However, the derivative instrument may not be classified in the same fair value hierarchy level as the associated asset. The significant inputs to pricing derivatives are generally observable in the market or can be derived by observable market data. When these inputs are observable, the derivatives are classified as Level 2.

The Company uses present value techniques to value non-option based derivatives. It also uses option pricing models to value option based derivatives. Key inputs are as follows:

Instrument Type	Level 2
Interest rate derivatives	Swap yield curves Basis curves Interest rate volatility (1)
Foreign currency exchange rate derivatives - Non-VIEs (forwards, swaps and options)	Foreign currency forward rates Swap yield curves Basis curves Foreign currency spot rates Foreign cross-currency basis curves Foreign currency volatility (1)
Foreign currency exchange rate derivatives - VIEs (swaps)	Foreign currency spot rates Swap yield curves Credit default swap curves Basis curves Recovery rates Foreign currency forward rates Foreign cross-currency basis curves

(1) Option-based only

The fair values of the foreign currency forwards and options are based on observable market inputs, therefore they are classified as Level 2.

The Parent Company had cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S. dollar to Japanese yen. These swaps matured in March 2025. Their fair values were based on observable market inputs, therefore they were classified as Level 2.

To determine the fair value of its interest rate derivatives, the Company uses inputs that are generally observable in the market or can be derived from observable market data. Interest rate swaps are cleared trades. In a cleared swap contract, the clearinghouse provides benefits to the counterparties similar to contracts listed for investment traded on an exchange since it maintains a daily margin to mitigate counterparties' credit risk. These derivatives are priced using observable inputs, accordingly, they are classified as Level 2.

For derivatives associated with VIEs where the Company is the primary beneficiary, the Company is not the direct counterparty to the swap contracts. Nevertheless, the Company has full transparency into the contracts to properly value the swaps for reporting purposes. For these derivatives, the Company utilizes valuation models developed by independent valuation analytics providers. The models are market standard DCF models and all associated processes and controls are executed by Company personnel. These models take into consideration any unique characteristics of the derivatives in determining the appropriate valuation methodology to estimate expected cash flows. The fair values of these swaps are based on observable market inputs and are classified as Level 2 within the fair value hierarchy.

For forward bond purchase commitments with VIEs, the fair value of the derivative is based on the difference in the fixed purchase price and the current market value of the related bond prior to the settlement date. Since the bond is typically a public bond with readily available pricing, the derivatives associated with the forward purchase commitment are classified as Level 2 within the fair value hierarchy.

Commercial mortgage and other loans

Commercial mortgage and other loans include TREs, CMLs, MMLs and other loans. The Company's loan receivables do not have readily determinable market prices and generally lack market liquidity. Fair values for loan receivables are determined based on the present value of expected future cash flows discounted at the applicable U.S. Treasury or floating-rate benchmark yield plus an appropriate spread that considers other risk factors, such as credit and liquidity risk. The spreads are a significant component of the pricing inputs and are generally considered unobservable. Therefore, these investments are classified as Level 3 within the fair value hierarchy.

Other investments

Other investments includes short-term investments that are measured at fair value where amortized cost approximates fair value.

Other policyholders' funds

The largest component of the other policyholders' funds liability is the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums. For this product, the Company estimates the fair value to be equal to the cash surrender value. This is analogous to the value paid to policyholders on the valuation date if they were to surrender their policy. The Company periodically checks the cash value against discounted cash flow projections for reasonableness. The Company considers its inputs for this valuation to be unobservable and have accordingly classified this valuation as Level 3.

Notes payable

The fair values of the Company's publicly issued notes payable are determined by utilizing available sources of observable inputs from third-party pricing vendors and are classified as Level 2. The Company's private placement notes payable are valued using the same internal models that the Company uses for its yen-denominated and U.S. dollar-denominated private placement investment portfolio. The fair values for these private placements are deemed Level 2 valuations, as they are model-derived valuations that are generated internally with all significant valuation inputs being observed in active markets. The fair values of the Company's yen-denominated loans approximate their carrying values and are classified as Level 3.

Transfers between Hierarchy Levels and Level 3 Rollforward

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

The following tables present the changes in fair value of the Company's investments carried at fair value classified as Level 3.

Three Months Ended March 31, 2025
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	1,156	$	647	$	23	$	10	$	231	$	157	$	2,224
Net investment gains (losses) included   in earnings	0		0		0		0		0		1		1
Unrealized gains (losses) included in   other comprehensive income (loss)	10		6		1		0		2		0		19
Purchases, issuances, sales and   settlements:
Purchases	434		110		0		0		0		3		547
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		(1)		(1)
Settlements	(12)		(7)		0		0		(1)		0		(20)
Transfers into Level 3	15		0		0		0		0		0		15
Transfers out of Level 3	0		0		0		0		(95)		0		(95)
Balance, end of period	$	1,603	$	756	$	24	$	10	$	137	$	160	$	2,690
Changes in unrealized gains (losses)   relating to Level 3 assets and liabilities   still held at the end of the period   included in earnings	$	0	$	0	$	0	$	0	$	0	$	1	$	1

Three Months Ended March 31, 2024
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	772	$	253	$	30	$	78	$	648	$	248	$	2,029
Net investment gains (losses) included   in earnings	1		0		0		0		0		(5)		(4)
Unrealized gains (losses) included in   other comprehensive income (loss)	(4)		(10)		(2)		(4)		1		0		(19)
Purchases, issuances, sales and   settlements:
Purchases	118		60		0		5		37		0		220
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(28)		(22)		0		(5)		(3)		(84)		(142)
Transfers into Level 3	0		226		0		0		0		0		226
Transfers out of Level 3	0		0		0		0		(233)		0		(233)
Balance, end of period	$	859	$	507	$	28	$	74	$	450	$	159	$	2,077
Changes in unrealized gains (losses)   relating to Level 3 assets and liabilities   still held at the end of the period   included in earnings	$	1	$	0	$	0	$	0	$	0	$	(3)	$	(2)

Fair Value Sensitivity

Level 3 Significant Unobservable Input Sensitivity

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

March 31, 2025
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	1,603	Consensus pricing	Offered quotes	86.24	-	106.46	(a)	99.62
Public utilities		756		Discounted cash flow	Credit spreads	100 bps	-	407 bps	(c)	164 bps
Sovereign and supranational		24		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		10		Adjusted cost	Private financials	N/A			(d)	N/A
Other corporate		137		Discounted cash flow	Credit spreads	100 bps	-	294 bps	(c)	198 bps
Equity securities		160		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,690

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

(b) Category represents a single security; range not applicable

(c) Actual or equivalent credit spreads in basis points

(d) Prices do not utilize credit spreads; therefore, range is not applicable

December 31, 2024
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	1,156	Consensus pricing	Offered quotes	84.08	-	104.60	(a)	99.07
Public utilities		647		Discounted cash flow	Credit spreads	100 bps	-	375 bps	(c)	162 bps
Sovereign and supranational		23		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		10		Adjusted cost	Private financials	N/A			(d)	N/A
Other corporate		231		Discounted cash flow	Credit spreads	91 bps	-	294 bps	(c)	173 bps
Equity securities		157		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,224

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

(b) Category represents a single security; range not applicable

(c) Actual or equivalent credit spreads in basis points

(d) Prices do not utilize credit spreads; therefore, range is not applicable

The following is a discussion of the significant unobservable inputs or valuation techniques used in determining the fair value of securities classified as Level 3.

Credit Spreads

The Company holds certain assets that are of a unique, specialized, and/or securitized nature that do not trade on a regular basis in an active market, which makes their fair values difficult to estimate. Most of these assets are managed by external asset managers and the Company utilizes these managers for their expertise when evaluating various inputs used to determine the fair values for these assets, including identifying the appropriate credit or risk spread over risk-free interest rates that incorporates the unique nature or structure of the asset in the valuations. For those assets of a similar nature but not managed by external asset managers, the Company internally estimates the spreads and risk adjustments over risk-free interest rates that reflect the unique nature or structure of the asset as well as the current pricing environment and market conditions for comparable or related investments. Credit or risk spreads are an important input needed to complete the discounted cash flow analyses used to estimate an investment’s fair value. Credit or risk spreads underlying these fair values are a significant, unobservable input whose derivation is based on the Company’s evaluation of a combination of the external manager’s expertise and knowledge, the current pricing environment, and market conditions for the specific asset.

Offered Quotes

In circumstances where the Company's valuation model price is overridden because it implies a value that is not consistent with current market conditions, the Company will solicit bids from a limited number of brokers. The Company also receives unadjusted prices from brokers for certain of its mortgage and asset-backed securities. These quotes are non-binding but are reflective of valuation best estimates at that particular point in time. Offered quotes are an unobservable input in the determination of fair value of mortgage- and asset-backed securities, certain banks/financial institutions, certain other corporate, and equity securities investments.

Private Financials

The Company invests in the debt and equity securities of private companies operating in the cancer, healthtech, insurtech, finance, internet of things, big data and analytics sectors. Due to their private and often small, startup nature, these companies rely on capital provided by institutional and private equity investors for their ongoing operations. They do not have public securities that trade on a regular basis in an active market, which makes their fair values difficult to estimate. The Company values these investments on a cost basis with appropriate adjustments made based on monitoring private financial information provided by these companies. Adjustments to valuations are generally made as new funding tranches are executed or if the financial information provided significantly changes indicating the need for impairment. This private financial information is unobservable and is a significant determinant in the fair value of these corporate venture investments.

For additional information on the Company's investments and financial instruments, see the accompanying Notes 3 and 4 and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

DEFERRED POLICY ACQUISITION COSTS

3 Months Ended

Mar. 31, 2025

Deferred Policy Acquisition Costs Disclosures [Abstract]

DEFERRED POLICY ACQUISITION COSTS

DEFERRED POLICY ACQUISITION COSTS

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.

	March 31, 2025
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2024	$	2,776	$	1,833	$	441	$	52	$	915	$	636	$	1,348	$	452	$	86	$	219	$	0	$	8,758
Capitalization	61		27		9		1		33		31		38		21		3		22		0		246
Amortization expense	(46)		(25)		(8)		0		(36)		(31)		(39)		(19)		(3)		(9)		0		(216)
Foreign currency translation and   other	160		107		27		1		0		0		0		0		0		0		0		295
Balance at March 31, 2025	$	2,951	$	1,942	$	469	$	54	$	912	$	636	$	1,347	$	454	$	86	$	232	$	0	$	9,083

	December 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132
Capitalization	300		103		36		4		141		129		165		89		12		77		0		1,056
Amortization expense	(184)		(100)		(34)		(3)		(143)		(118)		(153)		(73)		(12)		(30)		(1)		(851)
Foreign currency translation and   other	(311)		(211)		(52)		(5)		0		0		0		0		0		0		0		(579)
Balance at December 31, 2024	$	2,776	$	1,833	$	441	$	52	$	915	$	636	$	1,348	$	452	$	86	$	219	$	0	$	8,758

The Company uses the following constant level bases to amortize deferred policy acquisition costs:

Policy Type	Constant-level Basis
Life Products (U.S.)	Face Amount
Health Products (U.S.)	Number of Policies in Force
Health & Life Products (Japan)	Units in Force

Face amount is the stated dollar amount that the policy’s beneficiaries receive upon the death of the insured. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount and insurance in force, respectively. Future DAC amortization is impacted by persistency.

There were no changes to the inputs, judgments, assumptions or methods used to determine amortization amounts during the three-month periods ended March 31, 2025 and 2024. For additional information on deferred policy acquisition costs, see Notes 1 and 6 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

POLICY LIABILITIES

3 Months Ended

Mar. 31, 2025

Insurance Loss Reserves [Abstract]

POLICY LIABILITIES

POLICY LIABILITIES

Future Policy Benefits

The liability for future policy benefits is determined as the present value of expected future policy benefits to be paid to or on the behalf of policyholders and certain related expenses less the present value of expected future net premiums receivable under the Company's insurance contracts. Future net premiums receivable are future gross premiums receivable under the contract multiplied by the net premium ratio (NPR).

The following tables present the changes in the present value of expected future net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type. The present value of expected future net premiums and the present value of expected future policy benefits are presented gross of internal and external ceded reinsurance.

	March 31, 2025
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2024	$	14,184	$	11,817	$	5,156	$	846	$	2,497	$	1,635	$	3,901	$	1,122	$	196	$	909	$	826
Beginning balance at original discount rate	14,008		11,845		5,084		864		2,687		1,726		4,340		1,221		209		976		824
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(6)		(45)		(10)		(2)		(14)		(18)		(9)		(1)		(4)		(9)		3
Adjusted beginning of period balance	14,002		11,800		5,074		862		2,673		1,708		4,331		1,220		205		967		827
Issuances	211		72		120		3		108		118		214		88		17		70		229
Interest accrual	91		72		27		4		27		17		44		12		2		10		11
Net premiums collected (1)	(350)		(268)		(201)		(24)		(119)		(99)		(142)		(61)		(10)		(41)		(22)
Foreign currency translation	812		685		292		50		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		(10)
Ending balance at original discount rate	14,766		12,361		5,312		895		2,689		1,744		4,447		1,259		214		1,006		1,035
Effect of changes in discount rate assumptions	(270)		(415)		(29)		(42)		(160)		(72)		(389)		(86)		(11)		(53)		55
Balance at March 31, 2025	$	14,496	$	11,946	$	5,283	$	853	$	2,529	$	1,672	$	4,058	$	1,173	$	203	$	953	$	1,090
Present value of expected future policy benefits:
Balance at December 31, 2024	$	40,781	$	20,606	$	24,265	$	4,225	$	3,127	$	2,330	$	10,701	$	1,897	$	441	$	1,847	$	1,288
Beginning balance at original discount rate	37,856		21,957		26,330		4,765		3,386		2,466		12,013		2,073		477		2,126		1,293
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(20)		(55)		(7)		(7)		(13)		(24)		(13)		(3)		(4)		(14)		4
Adjusted beginning of period balance	37,836		21,902		26,323		4,758		3,373		2,442		12,000		2,070		473		2,112		1,297
Issuances	215		75		122		4		113		125		226		92		15		77		232
Interest accrual	324		138		141		22		34		24		129		21		5		21		17
Benefit payments	(666)		(246)		(604)		(57)		(144)		(120)		(249)		(84)		(15)		(27)		(41)
Foreign currency translation	2,191		1,270		1,518		276		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		0
Ending balance at original discount rate	39,900		23,139		27,500		5,003		3,376		2,471		12,106		2,099		478		2,183		1,505
Effect of changes in discount rate assumptions	1,538		(2,291)		(3,022)		(736)		(221)		(109)		(1,184)		(154)		(30)		(255)		52
Balance at March 31, 2025	41,438		20,848		24,478		4,267		3,155		2,362		10,922		1,945		448		1,928		1,557
Net liability for future policy benefits	26,942		8,902		19,195		3,414		626		690		6,864		772		245		975		467
Less: reinsurance recoverable	5,156		1,259		0		0		0		0		0		0		0		20		2
Net liability for future policy benefits after   reinsurance recoverable	$	21,786	$	7,643	$	19,195	$	3,414	$	626	$	690	$	6,864	$	772	$	245	$	955	$	465

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

	December 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Beginning balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in cash flow assumptions	(625)		(154)		(190)		(19)		65		(47)		(106)		(21)		(17)		(5)		(8)
Effect of actual variances from expected    experience	(71)		(164)		(97)		(14)		66		12		(100)		21		(12)		(29)		13
Adjusted beginning of period balance	15,756		13,722		5,971		1,036		2,761		1,703		4,210		1,193		188		875		277
Issuances	983		361		478		16		307		364		543		231		52		226		592
Interest accrual	378		302		110		17		106		66		173		46		9		37		25
Net premiums collected (1)	(1,453)		(1,135)		(862)		(101)		(479)		(401)		(578)		(244)		(39)		(157)		(53)
Foreign currency translation	(1,655)		(1,405)		(613)		(104)		0		0		0		0		0		0		0
Other	(1)		0		0		0		(8)		(6)		(8)		(5)		(1)		(5)		(17)
Ending balance at original discount rate	14,008		11,845		5,084		864		2,687		1,726		4,340		1,221		209		976		824
Effect of changes in discount rate assumptions	176		(28)		72		(18)		(190)		(91)		(439)		(99)		(13)		(67)		2
Balance at December 31, 2024	$	14,184	$	11,817	$	5,156	$	846	$	2,497	$	1,635	$	3,901	$	1,122	$	196	$	909	$	826
Present value of expected future policy benefits:
Balance at December 31, 2023	$	50,161	$	25,257	$	29,731	$	5,178	$	3,109	$	2,422	$	11,290	$	1,943	$	478	$	1,764	$	798
Beginning balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in cash flow assumptions	(815)		(228)		(302)		(7)		109		(73)		(112)		(31)		(28)		(3)		(12)
Effect of actual variances from expected    experience	(117)		(193)		(110)		(24)		91		(16)		(144)		21		(16)		(43)		(7)
Adjusted beginning of period balance	42,694		24,602		29,844		5,413		3,502		2,452		11,864		2,066		462		1,925		750
Issuances	1,004		373		488		22		311		381		559		237		55		231		597
Interest accrual	1,356		570		582		93		133		98		515		84		20		78		50
Benefit payments	(2,773)		(1,033)		(1,510)		(208)		(560)		(465)		(925)		(314)		(60)		(108)		(104)
Foreign currency translation	(4,425)		(2,555)		(3,074)		(555)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		0
Ending balance at original discount rate	37,856		21,957		26,330		4,765		3,386		2,466		12,013		2,073		477		2,126		1,293
Effect of changes in discount rate assumptions	2,925		(1,351)		(2,065)		(540)		(259)		(136)		(1,312)		(176)		(36)		(279)		(5)
Balance at December 31, 2024	40,781		20,606		24,265		4,225		3,127		2,330		10,701		1,897		441		1,847		1,288
Net liability for future policy benefits	26,597		8,789		19,109		3,379		630		695		6,800		775		245		938		462
Less: reinsurance recoverable	5,085		1,245		0		0		0		0		0		0		0		18		0
Net liability for future policy benefits after    reinsurance recoverable	$	21,512	$	7,544	$	19,109	$	3,379	$	630	$	695	$	6,800	$	775	$	245	$	920	$	462

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.

	March 31, 2025
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/ Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	4.0 %	4.3 %	4.6 %	4.5 %	4.3 %	3.9 %	5.5 %
Weighted-average interest, current discount rate (1)	2.7 %	3.2 %	2.6 %	3.0 %	5.3 %	5.2 %	5.5 %	5.4 %	5.3 %	5.4 %	5.5 %
Weighted-average liability duration (years)	12.6	23.2	16.2	16.5	7.7	5.6	11.0	9.0	7.6	13.5	8.8

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

	December 31, 2024
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/ Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	4.0 %	4.3 %	4.6 %	4.5 %	4.3 %	3.8 %	5.4 %
Weighted-average interest, current discount rate (1)	2.2 %	2.8 %	2.1 %	2.5 %	5.3 %	5.2 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	12.6	23.5	16.1	16.7	7.7	5.6	11.1	9.0	7.6	13.5	9.1

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the consolidated balance sheets. The deferred profit liability for limited-payment contracts and the deferred reinsurance gain liability are presented together with the liability for future policy benefits in the consolidated balance sheets and have been included as reconciling items in the table below.

(In millions)	March 31, 2025			December 31, 2024
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	26,942		$	26,597
Medical and other health		8,902			8,789
Life insurance		19,195			19,109
Other		3,414			3,379
Aflac U.S.
Accident		626			630
Disability		690			695
Critical care		6,864			6,800
Hospital indemnity		772			775
Dental/vision		245			245
Life insurance		975			938
Other		467			462
Corporate and other		5,116			5,072
Deferred profit liability		1,990			1,844
Deferred reinsurance gain liability		860			806
Intercompany eliminations (1)		(5,861)			(5,760)
Total		$	71,197		$	70,381

(1) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

Discount rates are determined using upper-medium grade (low credit risk) fixed-income instrument yields that reflect the duration characteristics of the liability. Locked-in discount rates are determined separately for each issue-year cohort as a single discount rate, calculated as the weighted-average of monthly upper-medium grade (low credit risk) fixed-income instrument forward curves in the calendar year, where the weights are the annualized premiums issued for each month of the cohort. The single discount rate for each issue-year cohort is determined by solving for a rate that produces an equivalent NPR to the forward curve and will remain unchanged after the calendar year of issue.

Discount rates are updated each reporting period and require estimation techniques (e.g., interpolation, extrapolation) for determination of points on the curve for which there is limited or no observable market data. The Company constructs a current discount rate curve separately for discounting cash flows used to calculate each of the Japan and U.S. liabilities for future policy benefits, reflective of the characteristics of the corresponding insurance liabilities, such as currency and tenor.

In the Aflac Japan segment, all long-duration insurance policies are denominated in yen. A significant portion of policies are characterized by tenors exceeding the availability of liquid market data in Japan for single-A rated (as a proxy for upper-medium grade) corporate yen-denominated debt. The discount rate curve is designed to prioritize the observable inputs where available, while past the last liquid point, the data is derived based on estimation techniques consistent with the fair value guidance in ASC 820. The Aflac Japan segment curve utilizes liquid market indices tracking publicly traded yen-denominated single-A corporate debt for the initial 10-year tenor. For the bonds within these market indices where only local ratings are available, the Company prioritizes the bonds with local ratings that are equivalent to a single-A rating based on international rating standards.

For the discount rates applicable to tenors for which the Japan single-A debt market is not liquid but there is sufficient observable market data and/or the observable market data is available for similar instruments (between 10 and 30 years), the Company estimates tenor-specific single-A credit spreads and applies them to risk-free government rates. Lastly, for the tenors where there is limited or no observable single-A or similar market data or risk-free government rates (beyond 30

years), the discount curve is derived by extrapolation of risk free rates beyond their last liquid point following the Smith-Wilson method and grading of the estimated forward credit spread anchored by the ultimate forward rate. The ultimate forward rate is based on the economic value-based solvency regime, which is consistent with the International Association of Insurance Supervisors (IAIS) Insurance Capital Standards (ICS) (effective for Aflac Japan's 2025 fiscal year-end), and is adjusted for credit and inflation components.

For the Aflac U.S. segment where all long-duration insurance policies are denominated in U.S. dollars and substantially all have cash flow duration within 30 years, for which the U.S. upper-medium grade fixed-income market is liquid and observable, the Company uses data from a liquid fixed-income market index tracking single-A U.S. corporate debt. For the insignificant portion of the policies with cash flow tenors exceeding 30 years, the discount curve beyond that tenor is extrapolated following the Smith-Wilson method from year 30 to the same ultimate forward rate calculated for the Japan discount curve at year 60 and held constant thereafter. The use of the same ultimate rate for U.S. and Japan segments is based on the assumption of long-term global economic convergence.

There were no changes to the methods used to determine the discount rates during the three-month periods ended March 31, 2025 and 2024.

Mortality rate assumptions are based on industry tables and adjusted for the Company's actual or expected experience where credible or appropriate. These assumptions typically vary by age, gender, and other demographic characteristics such as smoking status.

Morbidity assumptions are based on the Company's internal data and consider emerging experience. These assumptions are reflective of the coverage and benefits provided and generally vary by age, gender, duration, and any other material policyholder characteristics. In cases where a calendar-year trend is significant, future cash flow projections may include a trend adjustment.

In Japan, separate lapse assumptions are set based on actual or expected experience. These lapse and total termination rate assumptions vary by line of business and with policyholder characteristics such as duration. In the U.S., the majority of the future cash flows are modeled using total termination rates (which include both lapse and mortality) and are adjusted for actual experience. Policy provisions, such as reaching premium paid-up status, are taken into account when setting assumptions.

For the three-month periods ended March 31, 2025 and 2024 the variance of actual experience from expected experience was primarily due to favorable variances in morbidity assumptions as compared to actual experience. There were no changes to the inputs, judgments, assumptions or methods used in measuring the liability for future policy benefits during the three-month periods ended March 31, 2025 and 2024.

The Company performs an annual review of its assumptions during the third quarter. In 2024, the Company's annual assumption review process resulted in favorable changes largely due to reflecting more favorable Japan morbidity experience.

The following table summarizes the amount of net earned premiums recognized in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2025		2024
Net earned premiums:
Aflac Japan
Cancer	$	839	$	878
Medical and other health	529		605
Life insurance	316		339
Other	32		34
Aflac U.S.
Accident	311		325
Disability	352		333
Critical care	441		444
Hospital indemnity	184		185
Dental/vision	49		59
Life insurance	169		138
Other	49		20
Corporate and other	198		165
Reinsurance ceded	(88)		(69)
Total	$	3,381	$	3,456

The following table summarizes the amount of interest expense related to insurance contracts recognized in benefits and claims, excluding reserve remeasurement in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2025		2024
Interest expense:
Aflac Japan
Cancer	$	233	$	246
Medical and other health	66		65
Life insurance	114		118
Other	18		19
Aflac U.S.
Accident	7		6
Disability	7		8
Critical care	85		85
Hospital indemnity	9		9
Dental/vision	3		3
Life insurance	11		10
Other	6		7
Total	$	559	$	576

The following tables summarize the amount of undiscounted expected future gross premiums and expected future policy benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future policy benefits and expenses by reporting segment and disaggregated by product type. These tables are presented gross of internal and external ceded reinsurance. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business of the Company.

	March 31, 2025						December 31, 2024
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums   and expected future policy benefits and   expenses:
Aflac Japan
Cancer		$	54,446		$	59,903		$	51,712		$	56,881
Medical and other health		34,739			36,751			33,250			34,864
Life insurance		11,492			39,412			10,915			37,520
Other		1,538			6,790			1,477			6,479
Aflac U.S.
Accident		8,843			4,673			8,862			4,687
Disability		5,748			3,110			5,727			3,094
Critical care		19,780			20,463			19,624			20,340
Hospital indemnity		4,937			3,052			4,859			3,017
Dental/vision		1,117			684			1,118			679
Life insurance		3,091			3,686			2,966			3,559
Other		2,764			2,691			2,143			2,273
Total		$	148,495		$	181,215		$	142,653		$	173,393

	March 31, 2025						December 31, 2024
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums   and expected future policy benefits and   expenses:
Aflac Japan
Cancer		$	40,989		$	41,438		$	40,170		$	40,781
Medical and other health		25,461			20,848			25,171			20,606
Life insurance		9,630			24,478			9,367			24,265
Other		1,219			4,267			1,204			4,225
Aflac U.S.
Accident		6,116			3,155			6,057			3,127
Disability		4,456			2,362			4,404			2,330
Critical care		12,152			10,922			11,900			10,701
Hospital indemnity		3,412			1,945			3,312			1,897
Dental/vision		768			448			761			441
Life insurance		2,160			1,928			2,050			1,847
Other		1,668			1,557			1,290			1,288
Total		$	108,031		$	113,348		$	105,686		$	111,508

Loss expense as a result of NPR capping for the three-month periods ended March 31, 2025 and 2024 was immaterial.

Other Policyholders' Funds

As of March 31, 2025 and December 31, 2024, the largest component of the other policyholders' funds liability was the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums.

The following table presents the changes in other policyholders’ funds.

(In millions)	March 31, 2025		December 31, 2024
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	5,221	$	5,939
Premiums received	29		104
Transfers from WAYS conversions	74		249
Surrenders and withdrawals	(18)		(58)
Benefit payments	(128)		(446)
Interest credited	12		49
Foreign currency translation and other	304		(616)
Fixed annuities account balance, end of period	5,494		5,221
Other deposit type reserves	369		239
Total	$	5,863	$	5,460

(1) Aflac Japan fixed annuities

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

	March 31, 2025			December 31, 2024
(In millions)	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value
Fixed annuities (1)	0.5% - 2.2%	$5,494	$5,420	0.5% - 2.2%	$5,221	$5,150

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2025 and December 31, 2024.

Aflac Japan’s fixed annuities have guaranteed fixed crediting rates which results in the policyholders' funds balances being sufficient to cover all guaranteed benefit amounts. The reserves are adequate to fully fund future benefits at any given time.

For additional information on policy liabilities, see Notes 1 and 7 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

REINSURANCE

3 Months Ended

Mar. 31, 2025

Reinsurance Disclosures [Abstract]

REINSURANCE

REINSURANCE

The Company periodically enters into fixed quota-share coinsurance agreements in the normal course of business, primarily to provide additional capacity for future growth, optimize capital, limit losses, and minimize exposure to significant risks. For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. These reinsurance transactions are indemnity reinsurance agreements that do not relieve the Company from its obligations to policyholders. In the event that the reinsurer is unable to meet their obligations, the Company remains liable for the reinsured claims.

The following table reconciles direct earned premiums, direct benefits and claims, excluding reserve remeasurement gains and losses, and reserve remeasurement gains and losses to net amounts after the effect of reinsurance.

	Three Months Ended March 31,
(In millions)	2025			2024
Earned premiums:
Direct		$	3,433		$	3,482
Ceded		(88)			(69)
Assumed		36			43
Net earned premiums		$	3,381		$	3,456
Benefits and claims, excluding reserve remeasurement:
Direct		$	2,031		$	2,082
Ceded		(56)			(33)
Assumed		11			17
Benefits and claims, excluding reserve remeasurement		1,986			2,066
Reserve remeasurement (gains) losses:
Direct		(41)			(57)
Ceded		0			1
Reserve remeasurement (gains) losses		(41)			(56)
Total benefits and claims, net		$	1,945		$	2,010

The Company has recorded a deferred reinsurance gain liability related to reinsurance transactions which represents ceded reserves in excess of consideration paid, or consideration received in excess of assumed reserves. The remaining consolidated deferred reinsurance gain liability of $152 million and $146 million as of March 31, 2025 and December 31, 2024, respectively, is included in future policy benefits in the consolidated balance sheets and is being amortized into income over the expected lives of the policies.

The Company has also recorded a reinsurance recoverable for reinsurance transactions. The reinsurance recoverable, which is included in other assets in the consolidated balance sheets, is reported net of allowance for credit losses and had a remaining balance of $166 million and $163 million as of March 31, 2025 and December 31, 2024, respectively. As of both March 31, 2025 and December 31, 2024, the allowance for credit losses related to the Company's reinsurance recoverable balance was $4 million. The credit allowance for the reinsurance recoverable balance is estimated using a PD / LGD method and the key credit quality indicator is the credit rating of the Company’s reinsurance counterparty. The Company uses external credit ratings focused on the reinsurer’s financial strength and credit worthiness. As of March 31, 2025, the Company's reinsurance counterparties were rated A+. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

Aflac Re is a Bermuda domiciled insurer that reinsures certain policies issued by ALIJ. The inter-segment amounts associated with these internal reinsurance transactions are eliminated in consolidation.

For additional information on reinsurance, see Notes 1 and 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

NOTES PAYABLE AND LEASE OBLIGATIONS

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

NOTES PAYABLE AND LEASE OBLIGATIONS

NOTES PAYABLE AND LEASE OBLIGATIONS

A summary of notes payable and lease obligations follows:

(In millions)	March 31, 2025			December 31, 2024
1.125% senior sustainability notes due March 2026		$	399		$	399
2.875% senior notes due October 2026		299			299
3.60% senior notes due April 2030		994			994
6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040		255			255
4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049		542			542
Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)		83			79
.932% senior notes due January 2027 (principal amount ¥60.0 billion)		400			378
1.048% senior notes due March 2029 (principal amount ¥13.0 billion)		86			81
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		223			211
.500% senior notes due December 2029 (principal amount ¥12.6 billion)		84			79
.550% senior notes due March 2030 (principal amount ¥13.3 billion)		89			84
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		195			184
1.412% senior notes due March 2031 (principal amount ¥27.9 billion)		186			176
.633% senior notes due April 2031 (principal amount ¥30.0 billion)		200			189
.843% senior notes due December 2031 (principal amount ¥9.3 billion)		62			58
.750% senior notes due March 2032 (principal amount ¥20.7 billion)		137			130
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		141			133
.844% senior notes due April 2033 (principal amount ¥12.0 billion)		80			76
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		101			95
1.682% senior notes due March 2034 (principal amount ¥7.7 billion)		51			48
1.600% senior notes due March 2034 (principal amount ¥18.3 billion)		122			115
.934% senior notes due December 2034 (principal amount ¥9.8 billion)		65			62
.830% senior notes due March 2035 (principal amount ¥10.6 billion)		70			66
1.740% senior notes due March 2036 (principal amount ¥15.0 billion)		99			94
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		66			63
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		43			41
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		59			56
1.920% senior notes due March 2039 (principal amount ¥16.5 billion)		109			103
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		42			39
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		66			63
2.160% senior notes due March 2044 (principal amount ¥5.7 billion)		37			35
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		397			375
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		133			125
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		80			75
1.958% subordinated bonds due December 2053 (principal amount ¥30.0 billion)		200			188
2.400% senior notes due March 2054 (principal amount ¥19.5 billion)		129			122
Yen-denominated loans:
Variable interest rate loan due August 2027 (1.07% in 2025 and .84% in 2024,   principal amount ¥11.7 billion)		78			74
Variable interest rate loan due August 2029 (1.17% in 2025 and .94% in 2024,   principal amount ¥25.3 billion)		169			160
Variable interest rate loan due August 2032 (1.32% in 2025 and 1.09% in 2024,   principal amount ¥70.0 billion)		467			441
Finance lease obligations payable through 2030		4			5
Operating lease obligations payable through 2049		94			91
Total notes payable and lease obligations		$	7,751		$	7,498

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

Interest expense related to the Company's notes payable, which is included in interest expense in the consolidated statements of earnings, was $49 million and $46 million for the three-month periods March 31, 2025 and 2024, respectively.

A summary of the Company's lines of credit as of March 31, 2025 follows:

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
Aflac Incorporated and Aflac	uncommitted bilateral	364 days	December 5, 2025	$100 million	$0 million	The rate quoted by the bank and agreed upon at the time of borrowing	Up to 3 months	None	General corporate purposes
Aflac Incorporated	unsecured revolving	5 years	May 9, 2027, or the date commitments are terminated pursuant to an event of default	¥100.0 billion	¥0.0 billion	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period	No later than May 10, 2027	.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	unsecured revolving	5 years	November 15, 2027, or the date commitments are terminated pursuant to an event of default	$1.0 billion	$0.0 billion	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar-denominated borrowings or TIBOR for Japanese yen-denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin	No later than November 15, 2027	.08% to .20%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	uncommitted bilateral	None specified	None specified	$50 million	$0 million	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%	Up to 3 months	None	General corporate purposes
Aflac(1)	uncommitted revolving	364 days	December 1, 2025	$250 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac Incorporated(1) (Tranche 1)	uncommitted revolving	364 days	November 25, 2025	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2025	None	General corporate purposes
Aflac Incorporated(1) (Tranche 2)	uncommitted revolving	364 days	November 25, 2025	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2025	None	General corporate purposes
Aflac New York(1)	uncommitted revolving	364 days	December 1, 2025	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
CAIC(1)	uncommitted revolving	364 days	December 1, 2025	$15 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes

(1) Intercompany credit agreement

(continued)

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
TOIC(1)	uncommitted revolving	364 days	December 1, 2025	$0.3 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac GI Holdings LLC(1)	uncommitted revolving	364 days	December 1, 2025	$30 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac Incorporated(1)	uncommitted revolving	364 days	December 1, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Re(1)	uncommitted revolving	364 days	December 1, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Asset Management LLC(1)	uncommitted revolving	364 days	December 1, 2025	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Global Ventures LLC(1)	uncommitted revolving	364 days	December 1, 2025	$2 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes

(1) Intercompany credit agreement

The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, 2025. No events of default or defaults occurred during the three-month period ended March 31, 2025.

For additional information, see Notes 4 and 9 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

SHAREHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2025

Stockholders' Equity Note [Abstract]

SHAREHOLDERS' EQUITY

SHAREHOLDERS’ EQUITY

Share Data: The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.

(In thousands of shares)	2025	2024
Common stock - issued:
Balance, beginning of period	1,356,763	1,355,398
Exercise of stock options and issuance of restricted shares	989	1,082
Balance, end of period	1,357,752	1,356,480
Treasury stock:
Balance, beginning of period	806,799	776,919
Purchases of treasury stock:
Share repurchase program	8,497	9,276
Other	398	457
Dispositions of treasury stock:
Shares issued to AFL Stock Plan	(173)	(212)
Exercise of stock options	(41)	(55)
Other	(221)	(183)
Balance, end of period	815,259	786,202
Shares outstanding, end of period	542,493	570,278

Share Repurchase Program: During the first three months of 2025, the Company repurchased 8.5 million shares of its common stock for $900 million as part of its share repurchase program. During the first three months of 2024, the Company repurchased 9.3 million shares of its common stock for $750 million as part of its share repurchase program. As of March 31, 2025, a remaining balance of 38.8 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

EPS: Outstanding share-based awards are excluded from the calculation of weighted-average shares used in the computation of basic earnings per share (EPS), but are included in the calculation of weighted-average shares used in the computation of diluted EPS. Anti-dilutive share-based awards are excluded from the computation of diluted EPS.

The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.

	Three Months Ended March 31,
(In thousands)	2025		2024
Anti-dilutive share-based awards		0		69

Reclassifications from Accumulated Other Comprehensive Income

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income

Three Months Ended March 31, 2025
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2024		$	(4,998)		$	24		$	(20)		$	2,006		$	10		$	(2,978)
Other comprehensive    income (loss) before    reclassification		449			(1,225)			1			1,893			33			1,151
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(32)			1			0			(1)			(32)
Net current-period other    comprehensive    income (loss)		449			(1,257)			2			1,893			32			1,119
Balance at March 31, 2025		$	(4,549)		$	(1,233)		$	(18)		$	3,899		$	42		$	(1,859)

All amounts in the table above are net of tax.

Three Months Ended March 31, 2024
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2023		$	(4,069)		$	1,139		$	(22)		$	(2,560)		$	(8)		$	(5,520)
Other comprehensive    income (loss) before    reclassification		(597)			86			(5)			1,065			1			550
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(133)			1			0			0			(132)
Net current-period other    comprehensive    income (loss)		(597)			(47)			(4)			1,065			1			418
Balance at March 31, 2024		$	(4,666)		$	1,092		$	(26)		$	(1,495)		$	(7)		$	(5,102)

All amounts in the table above are net of tax.

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

(In millions)	Three Months Ended March 31, 2025
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	40	Net investment gains (losses)
		(8)		Tax (expense) or benefit(1)
		$	32	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Amortization of defined benefit pension items:
Actuarial gains (losses)		$	1	Acquisition and operating expenses(2)
Prior service (cost) credit		0		Acquisition and operating expenses(2)
		0		Tax (expense) or benefit(1)
		$	1	Net of tax
Total reclassifications for the period		$	32	Net of tax

(1) Based on 21% tax rate

(2) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost (see Note 12 for additional details).

(In millions)	Three Months Ended March 31, 2024
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	168	Net investment gains (losses)
		(35)		Tax (expense) or benefit(1)
		$	133	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	132	Net of tax

(1) Based on 21% tax rate

XML

SHARE-BASED COMPENSATION

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION

As of March 31, 2025, the Company has outstanding share-based awards under the Aflac Incorporated Long-Term Incentive Plan (As Amended and Restated February 14, 2017), as further amended on August 9, 2022 (the Plan). Share-based awards are designed to reward employees for their long-term contributions to the Company and provide incentives for them to remain with the Company. The number and frequency of share-based awards are based on competitive practices, operating results of the Company, government regulations, and other factors.

The Plan allows for a maximum number of shares issuable over its term of 75 million shares including 38 million shares that may be awarded in respect of awards other than options or stock appreciation rights. If any awards granted under the Plan are forfeited or are terminated before being exercised or settled for any reason other than tax forfeiture, then the shares underlying the awards will again be available under the Plan.

The Plan allows awards to Company employees for incentive stock options (ISOs), non-qualifying stock options (NQSOs), stock appreciation rights, restricted stock and restricted stock units. Non-employee directors are eligible for grants of NQSOs, restricted stock, and stock appreciation rights. As of March 31, 2025, approximately 32.6 million shares were available for future grants under this plan.

The ISOs, NQSOs and stock appreciation rights granted under the amended Plan have an exercise price of at least the fair market value of the underlying stock on the grant date and have an expiration date no later than 10 years from the grant date. The share-based awards vest upon time-based conditions or time and performance-based conditions. Time-based vesting generally occurs after three years. Performance-based vesting conditions generally include the attainment of goals related to the Company's financial performance. As of March 31, 2025, the only performance-based awards issued and outstanding were restricted stock awards and units. The Compensation Committee of the Board of Directors has the discretion to determine vesting schedules.

Share-based awards granted to U.S.-based grantees are settled with authorized but unissued Company stock, while those issued to Japan-based grantees are settled with treasury shares.

The following table provides information on stock options outstanding and exercisable at March 31, 2025.

	Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding		459		1.7		$	35		$	34.90
Exercisable		459		1.7		35			34.90

The Company received cash from the exercise of stock options in the amount of $5 million during the first three months of both 2025 and 2024. The tax benefit realized as a result of stock option exercises and restricted stock releases was $29 million in the first three months of 2025, compared with $24 million in the first three months of 2024.

As of March 31, 2025, total compensation cost not yet recognized in the Company's consolidated financial statements related to restricted stock awards and units was $50 million, of which $25 million (1.2 million shares) was related to restricted stock awards and units with a performance-based vesting condition. The Company expects to recognize these amounts over a weighted-average period of approximately 2.0 years. There are no other contractual terms covering restricted stock awards once vested.

The following table summarizes restricted stock activity during the three-month period ended March 31, 2025.

(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2024	2,099		$	73.65
Granted in 2025	1,059		104.43
Canceled in 2025	(14)		76.04
Vested in 2025	(1,238)		68.36
Restricted stock at March 31, 2025	1,906		$	85.21

In February 2025, the Company granted 284 thousand performance-based stock awards and units, which are contingent on the achievement of the Company's financial performance metrics and its market-based conditions. On the date of grant, the Company estimated the fair value of restricted stock awards and units with market-based conditions using a Monte Carlo simulation model. The model discounts the value of the stock at the assumed vesting date based on the risk-free interest rate. Based on estimates of actual performance versus the vesting thresholds, the calculated fair value percentage payout estimate will be updated each quarter.

The Company uses third-party analyses to assist in developing the assumptions used in, as well as calibrating, a Monte Carlo simulation model. The Company is responsible for determining the assumptions used in estimating the fair value of its share-based payment awards.

For additional information on the Company's long-term share-based compensation plans and the types of share-based awards, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2024 Annual Report.

XML

BENEFIT PLANS

3 Months Ended

Mar. 31, 2025

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

BENEFIT PLANS

BENEFIT PLANS

The Company has funded defined benefit plans in Japan and the U.S.; however, future benefits under the U.S. plan were frozen effective January 1, 2024. In January 2025, the Company purchased a nonparticipating single premium group annuity contract from an external insurer to settle its obligations under the U.S. defined pension plan and paid to the insurer the related annuity premium. As a result, the Company recognized a settlement charge of $55 million in the first quarter of 2025. Effective April 1, 2025, the external insurer began making annuity payments to plan participants.

The Company also maintains non-qualified, unfunded supplemental retirement plans that provide defined pension benefits in excess of limits imposed by federal tax law for certain Japanese, U.S. and former employees. However, future benefits under the Company's Supplemental Executive Retirement Plan and Retirement Plan for Senior Officers were frozen effective January 1, 2024, provided that actively employed participants may continue to accrue service toward eligibility for early retirement benefits or delayed early retirement benefits.

The Company provides certain health care benefits for eligible U.S. retired employees, their beneficiaries and covered dependents (other postretirement benefits). The health care plan is contributory and unfunded. For certain employees and former employees, additional coverage is provided for all medical expenses for life.

Pension and other postretirement benefit expenses are included in acquisition and operating expenses in the consolidated statements of earnings, which includes other components of net periodic pension cost and postretirement costs (other than service costs) of $57 million and $2 million for the three-month periods ended March 31, 2025 and 2024, respectively. Total net periodic benefit cost includes the following components:

	Three Months Ended March 31,
	Pension Benefits												Other
	Japan						U.S.						Postretirement Benefits
(In millions)	2025			2024			2025			2024			2025			2024
Components of net periodic   benefit cost:
Service cost		$	3		$	4		$	0		$	0		$	0		$	0
Interest cost		2			2			8			9			0			0
Expected return on plan assets		(2)			(2)			(5)			(7)			0			0
Amortization of net actuarial   (gain) loss		0			0			(1)			0			0			0
Settlement (gain) loss		0			0			55			0			0			0
Net periodic benefit cost (credit)		$	3		$	4		$	57		$	2		$	0		$	0

During the three months ended March 31, 2025, Aflac Japan contributed approximately $6 million (using the weighted-average yen/dollar exchange rate for the three-month period ended March 31, 2025) to the Japanese funded defined benefit plan, and Aflac U.S. did not make a contribution to the U.S. funded defined benefit plan.

For additional information regarding the Company's Japanese and U.S. benefit plans, see Note 14 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

COMMITMENTS AND CONTINGENT LIABILITIES

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

COMMITMENTS AND CONTINGENT LIABILITIES

In February 2025, the Company renewed an outsourcing agreement with an information technology and data services company to provide application maintenance and development services for Aflac Japan. The agreement has a remaining term of three years with an aggregate remaining cost of ¥10.3 billion ($69 million using the March 31, 2025 exchange rate).

The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business. Members of the Company's senior legal and financial management teams review litigation and regulatory inquiries on a quarterly and annual basis. The final results of any litigation or regulatory inquiries cannot be predicted with certainty. Although some of this litigation is pending in states where large punitive damages, bearing little relation to the actual damages sustained by plaintiffs, have been awarded in recent years, the Company believes the outcome of pending litigation will not have a material adverse effect on its financial position, results of operations, or cash flows.

See Note 3 for details on certain investment commitments.

Guaranty Fund Assessments

The U.S. insurance industry has a policyholder protection system that is monitored and regulated by state insurance departments. These life and health insurance guaranty associations are state entities (in all 50 states as well as Puerto Rico and the District of Columbia) created to protect policyholders of an insolvent insurance company. All insurance companies (with limited exceptions) licensed to sell life or health insurance in a state must be members of that state’s guaranty association. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business.

Guaranty fund assessments for the three-month periods ended March 31, 2025 and 2024 were immaterial.

XML

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure
Net earnings	$ 29	$ 1,879

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business and Basis of Presentation

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in Japan and the United States (U.S.). The Company's insurance business is marketed and administered through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan and through American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS) in the U.S. The Company’s operations consist of two reportable business segments: Aflac Japan, which includes ALIJ, and Aflac U.S., which includes Aflac, Aflac New York, CAIC, TOIC, and ABS. Aflac New York is a wholly owned subsidiary of Aflac. Most of the Aflac U.S. policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ABS, and certain group life insurance products, Aflac U.S. markets and administers group products through CAIC, branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through TOIC. The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd.(Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits and income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in the consolidated financial statements. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, 2025 and December 31, 2024, and the consolidated statements of earnings, comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, 2025 and 2024. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).

Reclassifications

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

New Accounting Pronouncements

New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Accounting Standards Update (ASU) 2023-07 Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued amendments that add certain segment disclosures related to significant segment expenses and require that a public entity disclose the title and position of the Chief Operating Decision Maker (CODM) and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

The Company adopted this guidance for the annual period beginning January 1, 2024, and interim periods beginning January 1, 2025. The adoption of this guidance did not have an impact on the Company’s financial position or results of operations. See Note 2 for expanded disclosures required as a result of the amended guidance.

Accounting Pronouncements Pending Adoption

ASU 2024-03 Income Statement (Topic 220) - Disaggregation of Income Statement Expenses

In November 2024, the FASB issued amendments that require disaggregated disclosure, in the notes to the financial statements, of specified information about certain costs and expenses including (1) the amounts of employee compensation, depreciation, and intangible asset amortization; (2) certain expense, gain, or loss amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and (4) the total amount of selling expenses and, in annual reporting periods, the Company’s definition of selling expenses.

The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

ASU 2023-09 Income Taxes (Topic 740) - Improvements to Income Tax Disclosures

In December 2023, the FASB issued amendments that require enhanced income tax disclosures including (1) disclosure of specific categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures.

The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business.

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

XML

BUSINESS SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated

Information regarding operations by reportable segment and Corporate and other is presented in the following tables.

	Three Months Ended March 31,
(In millions)	2025		2024
Revenues:
Aflac Japan:
Net earned premiums (1)	$	1,681	$	1,816
Adjusted net investment income	586		648
Other income	5		9
Total adjusted revenue Aflac Japan	2,272		2,473
Aflac U.S.:
Net earned premiums	1,502		1,475
Adjusted net investment income	202		206
Other income	17		18
Total adjusted revenue Aflac U.S.	1,721		1,699
Corporate and other (2)	326		247
Total adjusted revenues	4,319		4,419
Net investment gains (losses)	(963)		951
Reconciling items:
Amortized hedge costs	7		6
Amortized hedge income	(30)		(28)
Net interest (income) expense from derivatives   associated with certain investment strategies	65		88
Total revenues	$	3,398	$	5,436

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025 and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025 and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Reconciliation of Adjusted Profit (Loss) from Segments to Consolidated

	Three Months Ended March 31,
(In millions)	2025		2024
Adjusted revenues:
Aflac Japan (1)	$	2,272	$	2,473
Aflac U.S.	1,721		1,699
Corporate and other (2)	326		247
Total adjusted revenues	4,319		4,419
Benefits and adjusted expenses:
Aflac Japan:
Benefits and claims, excluding reserve remeasurement	1,130		1,243
Reserve remeasurement (gains) losses	(25)		(26)
Total benefits and claims, net	1,105		1,217
Adjusted expenses:
Amortization of deferred policy acquisition costs	79		83
Insurance commissions	105		114
Insurance and other expenses	261		249
Total benefits and adjusted expenses Aflac Japan	1,550		1,663
Aflac U.S.:
Benefits and claims, excluding reserve remeasurement	731		715
Reserve remeasurement (gains) losses	(15)		(29)
Total benefits and claims, net	716		686
Adjusted expenses:
Amortization of deferred policy acquisition costs	137		132
Insurance commissions	135		141
Insurance and other expenses	375		384
Total benefits and adjusted expenses Aflac U.S.	1,363		1,343
Corporate and other	283		250
Total adjusted expenses	$	3,196	$	3,256
Pretax earnings:
Aflac Japan (1)	$	722	$	810
Aflac U.S.	358		356
Corporate and other (2)	43		(3)
Pretax adjusted earnings	1,123		1,163
Other income (loss)	(53)		(2)
Net investment gains (losses)	(963)		951
Reconciling items:
Amortized hedge costs	7		6
Amortized hedge income	(30)		(28)
Net interest (income) expense from derivatives   associated with certain investment strategies	65		88
Impact of interest from derivatives associated   with notes payable	(4)		(8)
Total earnings before income taxes	$	145	$	2,170
Income taxes applicable to pretax adjusted earnings	$	217	$	202
Effect of foreign currency translation on after-tax   adjusted earnings	(8)		(44)

(1) Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

(2) The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025, and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025, and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Reconciliation of Assets from Segment to Consolidated

Total Assets: The Company's total assets were as follows:

(In millions)	March 31, 2025			December 31, 2024
Assets:
Aflac Japan		$	93,430		$	90,210
Aflac U.S.		21,881			21,930
Corporate and other		4,947			5,426
Total assets		$	120,258		$	117,566

XML

INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2025

Available-for-Sale Debt Securities

The amortized cost and allowance for credit losses for the Company's investments in fixed maturity securities and the fair values of these investments as well as the fair value of the Company's investments in equity securities are shown in the following tables.

	March 31, 2025
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	20,005	$	0	$	145	$	2,608	$	17,542
Municipalities	919		0		50		105		864
Mortgage- and asset-backed securities	342		0		2		29		315
Public utilities	2,771		0		155		155		2,771
Sovereign and supranational	349		0		9		10		348
Banks/financial institutions	5,553		0		225		448		5,330
Other corporate	5,655		0		475		413		5,717
Total yen-denominated	35,594		0		1,061		3,768		32,887
U.S. dollar-denominated:
U.S. government and agencies	275		0		2		2		275
Municipalities	1,190		0		69		68		1,191
Mortgage- and asset-backed securities	3,574		0		205		46		3,733
Public utilities	4,162		0		376		142		4,396
Sovereign and supranational	58		0		20		0		78
Banks/financial institutions	3,673		0		388		30		4,031
Other corporate	18,938		0		2,224		689		20,473
Total U.S. dollar-denominated	31,870		0		3,284		977		34,177
Other currencies:
Public utilities	55		0		0		1		54
Other corporate	26		0		0		0		26
Total other currencies	81		0		0		1		80
Total securities available-for-sale	$	67,545	$	0	$	4,345	$	4,746	$	67,144

	December 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	19,409	$	0	$	465	$	2,234	$	17,640
Municipalities	869		0		65		79		855
Mortgage- and asset-backed securities	327		0		4		23		308
Public utilities	2,746		0		202		108		2,840
Sovereign and supranational	330		0		16		8		338
Banks/financial institutions	5,376		0		267		342		5,301
Other corporate	5,329		0		568		305		5,592
Total yen-denominated	34,386		0		1,587		3,099		32,874
U.S. dollar-denominated:
U.S. government and agencies	208		0		1		3		206
Municipalities	1,167		0		65		53		1,179
Mortgage- and asset-backed securities	2,987		0		302		34		3,255
Public utilities	3,938		0		418		151		4,205
Sovereign and supranational	57		0		21		0		78
Banks/financial institutions	3,271		0		420		36		3,655
Other corporate	18,050		0		2,493		752		19,791
Total U.S. dollar-denominated	29,678		0		3,720		1,029		32,369
Other currencies:
Other corporate	25		0		1		0		26
Total other currencies	25		0		1		0		26
Total securities available-for-sale	$	64,089	$	0	$	5,308	$	4,128	$	65,269

Held-to-maturity Securities

	March 31, 2025
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	16,195	$	2	$	16,193	$	368	$	155	$	16,406
Municipalities	249		0		249		11		0		260
Public utilities	33		0		33		0		0		33
Sovereign and supranational	399		3		396		22		0		418
Other corporate	17		0		17		1		0		18
Total yen-denominated	16,893		5		16,888		402		155		17,135
Total securities held-to-maturity	$	16,893	$	5	$	16,888	$	402	$	155	$	17,135

	December 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	15,311	$	2	$	15,309	$	759	$	9	$	16,059
Municipalities	235		0		235		22		0		257
Public utilities	32		0		32		1		0		33
Sovereign and supranational	377		3		374		31		0		405
Other corporate	16		0		16		2		0		18
Total yen-denominated	15,971		5		15,966		815		9		16,772
Total securities held-to-maturity	$	15,971	$	5	$	15,966	$	815	$	9	$	16,772

Equity securities, FV-NI

	March 31, 2025			December 31, 2024
(In millions)	Fair Value			Fair Value
Equity securities, carried at fair value through net earnings:
Equity securities:
Yen-denominated		$	491		$	484
U.S. dollar-denominated		273			312
Total equity securities		$	764		$	796

Investments Classified by Contractual Maturity Date

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, 2025, were as follows:

(In millions)	Amortized Cost (1)			Fair Value
Available-for-sale:
Due in one year or less		$	1,572		$	1,728
Due after one year through five years		8,158			8,943
Due after five years through 10 years		15,563			16,267
Due after 10 years		38,336			36,158
Mortgage- and asset-backed securities		3,916			4,048
Total fixed maturity securities available-for-sale		$	67,545		$	67,144
Held-to-maturity:
Due in one year or less		$	33		$	35
Due after one year through five years		2			2
Due after five years through 10 years		9,008			9,346
Due after 10 years		7,845			7,752
Total fixed maturity securities held-to-maturity		$	16,888		$	17,135

(1) Net of allowance for credit losses

Investment Exposures Exceeding Ten Percent Shareholders Equity

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

	March 31, 2025			December 31, 2024
(In millions)	Credit Rating	Amortized Cost	Fair Value	Credit Rating	Amortized Cost	Fair Value
Japan National Government(1)	A+	$35,251	$33,082	A+	$33,822	$32,844

(1) Japan Government Bonds (JGBs) or JGB-backed securities

Gain (Loss) on Investments

Information regarding pretax net gains and losses from investments is as follows:

	Three Months Ended March 31,
(In millions)	2025		2024
Net investment gains (losses):
Sales and redemptions:
Fixed maturity securities available-for-sale:
Gross gains from sales	$	114	$	34
Gross losses from sales	(235)		(282)
Foreign currency gains (losses)	161		416
Other investments:
Gross gains (losses) from sales and redemptions	1		5
Total sales and redemptions	41		173
Equity securities	(61)		76
Credit losses:
Fixed maturity securities held-to-maturity	0		0
Commercial mortgage and other loans	(53)		(7)
Impairment losses	0		0
Loan commitments	(2)		1
Reinsurance recoverables and other	0		5
Total credit losses	(55)		(1)
Derivatives and other:
Derivative gains (losses)	(45)		(215)
Foreign currency gains (losses)	(843)		918
Total derivatives and other	(888)		703
Total net investment gains (losses)	$	(963)	$	951

Net Effect on Shareholders' Equity of Unrealized Gains and Losses from Investment Securities

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:

(In millions)	March 31, 2025			December 31, 2024
Unrealized gains (losses) on securities available-for-sale		$	(401)		$	1,180
Deferred income taxes		(832)			(1,156)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	(1,233)		$	24

Investments Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, 2025 and December 31, 2024, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

	March 31, 2025
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and     agencies:
U.S. dollar-denominated		$	68		$	2		$	33		$	0		$	35		$	2
Japan government and     agencies:
Yen-denominated		11,951			2,608			6,090			179			5,861			2,429
Municipalities:
U.S. dollar-denominated		656			68			72			3			584			65
Yen-denominated		339			105			96			8			243			97
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		1,091			46			697			20			394			26
Yen-denominated		208			29			22			0			186			29
Public utilities:
U.S. dollar-denominated		1,689			142			816			17			873			125
Yen-denominated		1,037			155			258			23			779			132
Other currencies		53			1			53			1			0			0
Sovereign and supranational:
U.S. dollar-denominated		0			0			0			0			0			0
Yen-denominated		49			10			0			0			49			10
Banks/financial institutions:
U.S. dollar-denominated		749			30			544			7			205			23
Yen-denominated		3,576			448			472			14			3,104			434
Other corporate:
U.S. dollar-denominated		6,596			689			2,690			58			3,906			631
Yen-denominated		2,302			413			810			53			1,492			360
Total		$	30,364		$	4,746		$	12,653		$	383		$	17,711		$	4,363

	December 31, 2024
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and     agencies:
U.S. dollar-denominated		$	106		$	3		$	59		$	1		$	47		$	2
Japan government and     agencies:
Yen-denominated		8,136			2,234			2,070			57			6,066			2,177
Municipalities:
U.S. dollar-denominated		666			53			67			3			599			50
Yen-denominated		341			79			96			2			245			77
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		567			34			173			2			394			32
Yen-denominated		196			23			12			0			184			23
Public utilities:
U.S. dollar-denominated		1,570			151			699			19			871			132
Yen-denominated		1,020			108			368			11			652			97
Sovereign and supranational:
Yen-denominated		47			8			0			0			47			8
Banks/financial institutions:
U.S. dollar-denominated		625			36			376			7			249			29
Yen-denominated		3,197			342			471			22			2,726			320
Other corporate:
U.S. dollar-denominated		6,097			752			2,036			59			4,061			693
Yen-denominated		1,733			305			289			14			1,444			291
Total		$	24,301		$	4,128		$	6,716		$	197		$	17,585		$	3,931

Composition of the Carrying Value for Commercial Mortgage and Other Loans by Property Type

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.

	March 31, 2025				December 31, 2024
(In millions)	Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:
Transitional real estate loans:
Office	$	1,238	11.2	%	$	1,361	12.1	%
Retail	350		3.2		349		3.1
Apartments/Multi-Family	2,158		19.6		2,201		19.6
Industrial	100		.9		117		1.1
Hospitality	526		4.8		556		5.0
Other	306		2.8		318		2.8
Total transitional real estate loans	4,678		42.5		4,902		43.7
Commercial mortgage loans:
Office	298		2.7		300		2.7
Retail	212		1.9		214		1.9
Apartments/Multi-Family	569		5.1		572		5.1
Industrial	433		3.9		436		3.9
Other	14		.1		15		.1
Total commercial mortgage loans	1,526		13.7		1,537		13.7
Middle market loans	4,451		40.4		4,423		39.4
Other loans	369		3.4		362		3.2
Total commercial mortgage and other loans	$	11,024	100.0	%	$	11,224	100.0	%
Allowance for credit losses	(368)				(355)
Total net commercial mortgage and other loans	$	10,656			$	10,869

Financing Receivable Nonaccrual

The following tables present an aging of past due and nonaccrual loans at amortized cost, before allowance for credit losses, as of the periods presented.

	March 31, 2025
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	4,193	$	18	$	467	$	485	$	4,678	$	467
Commercial mortgage loans	1,526		0		0		0		1,526		0
Middle market loans	4,301		70		80		150		4,451		128
Other loans	369		0		0		0		369		0
Total	$	10,389	$	88	$	547	$	635	$	11,024	$	595

(1) As of March 31, 2025, there were no loans that were 90 days or more past due that continued to accrue interest.

	December 31, 2024
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	4,364	$	195	$	343	$	538	$	4,902	$	378
Commercial mortgage loans	1,537		0		0		0		1,537		0
Middle market loans	4,295		63		65		128		4,423		108
Other loans	362		0		0		0		362		0
Total	$	10,558	$	258	$	408	$	666	$	11,224	$	486

(1) As of December 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

Effect of Loan Modifications

The following tables present the amortized cost basis of modified loans to borrowers experiencing financial difficulty and the financial effect of the modifications, disaggregated by loan classification and type of modification.

Three Months Ended March 31, 2025
(In millions)	Amortized Cost (1)		% of Total		Financial Effect
Middle Market Loans:
Principal forgiveness	$	1	0.0	%	Reduction in the amortized cost basis of $3 million
Term extension	33		1.0		Term extension of six months on average
Other-than-insignificant   payment delays	47		1.0		Delay in principal and interest payments of 23 months on average

(1) Net of allowance for credit losses

Three Months Ended March 31, 2024
(In millions)	Amortized Cost (1)		% of Total		Financial Effect
Transitional Real Estate Loans:
Other-than-insignificant payment   delays and interest rate   reduction	$	210	3.0	%	Delay in payments of 51 months on average and reduction in the weighted-average contractual interest rate from 8.3% to 6.9%

(1) Net of allowance for credit losses

Loan Performance After Modifications

The following table presents an aging of loans that received modifications in the 12 months preceding the period presented, at amortized cost.

	March 31, 2025
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More Past Due		Nonaccrual Status
Transitional real estate loans	$	347	$	0	$	0	$	0
Middle market loans	96		0		0		20
Total	$	443	$	0	$	0	$	20

Allowance for Loan Losses by Portfolio Segment

The following table presents the roll forward of the allowance for credit losses by portfolio segment for loans and by accounting classification for securities.

(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Other Loans and Loan Commitments		Held-to- Maturity Securities		Available- for-Sale Securities		Total
Three Months Ended March 31, 2025:
Balance at December 31, 2024	$	(199)	$	(14)	$	(140)	$	(17)	$	(5)	$	0	$	(375)
(Addition to) release of allowance    for credit losses	(28)		(1)		(24)		(2)		0		0		(55)
Writeoffs, net of recoveries	24		0		14		0		0		0		38
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2025	$	(203)	$	(15)	$	(150)	$	(19)	$	(5)	$	0	$	(392)
Three Months Ended March 31, 2024:
Balance at December 31, 2023	$	(112)	$	(16)	$	(146)	$	(16)	$	(5)	$	0	$	(295)
(Addition to) release of allowance    for credit losses	(2)		(3)		(3)		1		0		0		(7)
Writeoffs, net of recoveries	0		0		50		0		0		0		50
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2024	$	(114)	$	(19)	$	(99)	$	(15)	$	(5)	$	0	$	(252)

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.

(In millions)	March 31, 2025			December 31, 2024
Other investments:
Policy loans		$	211		$	203
Short-term investments (1)		2,259			1,599
Limited partnerships (2)		3,482			3,435
Real estate owned		774			682
Other		37			39
Total other investments		$	6,763		$	5,958

(1) Includes securities lending collateral

(2) Includes tax credit investments and asset classes such as private equity and real estate funds

Securities Lending Transactions Accounted for as Secured Borrowings

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:

Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements
	March 31, 2025						December 31, 2024
(In millions)	Overnight and Continuous(1)		Up to 30 days		Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending   transactions:
Fixed maturity securities:
Japan government and agencies	$	0	$	2,303	$	2,303	$	0	$	1,027	$	1,027
Public utilities	39		0		39		34		0		34
Banks/financial institutions	131		0		131		193		0		193
Other corporate	669		0		669		783		0		783
Total borrowings	$	839	$	2,303	$	3,142	$	1,010	$	1,027	$	2,037
Gross amount of recognized liabilities for securities    lending transactions					$	3,142					$	2,037

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

Variable Interest Entity, Consolidated

Investments in Variable Interest Entities

VIEs - Consolidated

If the Company determines that it is the VIE’s primary beneficiary, it consolidates the VIE. Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company except to the extent of the unfunded commitments referenced above, as the Company’s obligation to each VIE is limited to the amount of its committed investment.

The following table presents the carrying value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities

(In millions)	March 31, 2025			December 31, 2024
Assets:
Fixed maturity securities, available-for-sale		$	3,597		$	3,428
Commercial mortgage and other loans		8,540			8,693
Other investments (1)		2,151			2,176
Other assets (2)		49			53
Total assets of consolidated VIEs		$	14,337		$	14,350
Liabilities:
Other liabilities (2)		$	642		$	604
Total liabilities of consolidated VIEs		$	642		$	604

(1) Consists entirely of alternative investments in limited partnerships, which represent VIEs where the Company is not the primary beneficiary and, therefore, are not consolidated

(2) Consists entirely of derivatives

Variable Interest Entity, Not Consolidated

Investments in Variable Interest Entities

VIEs - Not Consolidated

The table below reflects the carrying value and balance sheet caption in which the Company's investments in VIEs that are not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated

(In millions)	March 31, 2025			December 31, 2024
Assets:
Fixed maturity securities, available-for-sale		$	6,624		$	6,243
Other investments (1)		1,194			1,124
Total investments in VIEs not consolidated		$	7,818		$	7,367

(1) Consists entirely of alternative investments in limited partnerships

Transitional real estate loans

Financing Receivable Credit Quality Indicators

The following tables present as of March 31, 2025 the amortized cost basis of TREs, CMLs, MMLs, and other loans by year of origination and credit quality indicator.

Transitional Real Estate Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Total
Loan-to-Value Ratio:
0%-59.99%	$	0	$	0	$	0	$	371	$	390	$	47	$	808
60%-69.99%	0		0		77		431		442		396		1,346
70%-79.99%	14		0		14		823		625		64		1,540
80% or greater	0		0		0		335		353		296		984
Total	$	14	$	0	$	91	$	1,960	$	1,810	$	803	$	4,678
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	24	$	24

Commercial mortgage loans

Financing Receivable Credit Quality Indicators

Commercial Mortgage Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:
0%-59.99%	$	0	$	0	$	32	$	0	$	265	$	1,009	$	1,306	2.72
60%-69.99%	0		0		0		0		25		47		72		2.11
70%-79.99%	0		0		0		0		0		55		55		1.69
80% or greater	0		13		0		0		0		80		93		0.57
Total	$	0	$	13	$	32	$	0	$	290	$	1,191	$	1,526	2.52
Weighted Average DSCR	0.00		1.13		2.62		0.00		3.16		2.38
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Middle market loans

Financing Receivable Credit Quality Indicators

Middle Market Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Revolving Loans		Total
Credit Ratings:
BBB	$	0	$	30	$	29	$	0	$	78	$	108	$	12	$	257
BB	61		425		43		426		374		607		76		2,012
B	34		226		53		234		480		662		46		1,735
CCC	0		5		0		14		61		223		19		322
CC	0		0		0		13		0		16		5		34
C and lower	0		0		0		0		0		87		4		91
Total	$	95	$	686	$	125	$	687	$	993	$	1,703	$	162	$	4,451
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	11	$	3	$	0	$	14

Other loans

Financing Receivable Credit Quality Indicators

Other Loans
(In millions)	2025		2024		2023		2022		2021		Prior		Revolving Loans		Total
Credit Ratings:
A	$	0	$	0	$	0	$	79	$	0	$	0	$	0	$	79
AA	0		0		0		8		3		0		0		11
BBB	0		184		68		27		0		0		0		279
BB	0		0		0		0		0		0		0		0
Total	$	0	$	184	$	68	$	114	$	3	$	0	$	0	$	369
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0

XML

DERIVATIVE INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in other assets, while derivative liabilities are included in other liabilities within the Company’s consolidated balance sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.

		March 31, 2025									December 31, 2024
(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative   Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:
Foreign currency swaps - VIE		$	18		$	0		$	5		$	18		$	0		$	6
Total cash flow hedges		18			0			5			18			0			6
Net investment hedge:
Foreign currency forwards		2,674			91			38			1,809			185			0
Total net investment hedge		2,674			91			38			1,809			185			0
Non-qualifying strategies:
Foreign currency swaps		0			0			0			450			2			0
Foreign currency swaps - VIE		3,068			49			637			3,042			53			598
Foreign currency forwards		173			1			1			0			0			0
Foreign currency options		24,195			2			0			24,195			0			0
Interest rate swaps		29,280			5			304			17,230			0			329
Total non-qualifying strategies		56,716			57			942			44,917			55			927
Total derivatives		$	59,408		$	148		$	985		$	46,744		$	240		$	933

Schedule of Interest Rate Fair Value Hedges Hedged Items

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount. The Company had no fair value hedges of interest rate risk as of March 31, 2025 and December 31, 2024; therefore, the amounts presented in the table below are related to previous fair value hedges of interest rate risk that were discontinued.

(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
		March 31, 2025		December 31, 2024		March 31, 2025		December 31, 2024
Fixed maturity securities		$	1,305	$	1,294	$	128	$	137

(1) The balance includes hedging adjustment on discontinued hedging relationships of $128 in 2025 and $137 in 2024.

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

	Three Months Ended March 31,
	2025										2024
(In millions)	Net Investment Income			Net Investment Gains (Losses)				Other Comprehensive  Income (Loss)			Net Investment Income			Net Investment Gains (Losses)				Other Comprehensive  Income (Loss)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	2		$	0		$	(1)			$	0
Total cash flow hedges		0			(1)		(1)		2			0			(1)		(1)		0
Net investment hedge:
Non-derivative hedging           instruments					0				(240)						0				236
Foreign currency forwards					36				(144)						44				145
Total net investment hedge					36				(384)						44				381
Non-qualifying strategies:
Foreign currency swaps					0										1
Foreign currency swaps - VIE					(57)										(88)
Foreign currency forwards					0										17
Foreign currency options					(5)										(41)
Interest rate swaps					(18)										(147)
Total non-qualifying strategies					(80)										(258)
Total		$	0		$	(45)			$	(382)		$	0		$	(215)			$	381

(1) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2025, and $1 of losses during the three-month period ended March 31, 2024.

Offsetting Assets

Offsetting of Financial Assets and Derivative Assets

March 31, 2025
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	94		$	0		$	94		$	(36)	$	(12)		$	(46)		$	0
OTC - cleared		5			0			5			(5)		0			0			0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		99			0			99			(41)		(12)			(46)			0
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		49						49											49
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		49						49											49
Total derivative       assets		148			0			148			(41)		(12)			(46)			49
Securities lending    and similar    arrangements		3,128			0			3,128			0		0			(3,128)			0
Total		$	3,276		$	0		$	3,276		$	(41)	$	(12)		$	(3,174)		$	49

December 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	187		$	0		$	187		$	0	$	(45)		$	(135)		$	7
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		187			0			187			0		(45)			(135)			7
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		53						53											53
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		53						53											53
Total derivative       assets		240			0			240			0		(45)			(135)			60
Securities lending    and similar    arrangements		2,001			0			2,001			0		0			(2,001)			0
Total		$	2,241		$	0		$	2,241		$	0	$	(45)		$	(2,136)		$	60

Offsetting Liabilities

Offsetting of Financial Liabilities and Derivative Liabilities

March 31, 2025
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	39		$	0		$	39		$	(36)	$	0		$	0		$	3
OTC - cleared		304			0			304			(5)		(17)			(282)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		343			0			343			(41)		(17)			(282)			3
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		642						642											642
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		642						642											642
Total derivative       liabilities		985			0			985			(41)		(17)			(282)			645
Securities lending    and similar    arrangements		3,142			0			3,142			(3,128)		0			0			14
Total		$	4,127		$	0		$	4,127		$	(3,169)	$	(17)		$	(282)		$	659

December 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - cleared		$	329		$	0		$	329		$	0	$	0		$	(329)		$	0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		329			0			329			0		0			(329)			0
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		604						604											604
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		604						604											604
Total derivative       liabilities		933			0			933			0		0			(329)			604
Securities lending    and similar    arrangements		2,037			0			2,037			(2,001)		0			0			36
Total		$	2,970		$	0		$	2,970		$	(2,001)	$	0		$	(329)		$	640

XML

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

Fair Value Hierarchy, Assets and Liabilities Measured on Recurring Basis

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	16,972		$	845		$	0		$	17,817
Municipalities		0			2,055			0			2,055
Mortgage- and asset-backed securities		0			2,445			1,603			4,048
Public utilities		0			6,465			756			7,221
Sovereign and supranational		0			402			24			426
Banks/financial institutions		0			9,351			10			9,361
Other corporate		0			26,079			137			26,216
Total fixed maturity securities		16,972			47,642			2,530			67,144
Equity securities		604			0			160			764
Other investments		2,259			0			0			2,259
Cash and cash equivalents		5,231			0			0			5,231
Other assets:
Foreign currency swaps		0			49			0			49
Foreign currency forwards		0			92			0			92
Foreign currency options		0			2			0			2
Interest rate swaps		0			5			0			5
Total other assets		0			148			0			148
Total assets		$	25,066		$	47,790		$	2,690		$	75,546
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	642		$	0		$	642
Foreign currency forwards		0			39			0			39
Interest rate swaps		0			304			0			304
Total liabilities		$	0		$	985		$	0		$	985

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	17,088		$	758		$	0		$	17,846
Municipalities		0			2,034			0			2,034
Mortgage- and asset-backed securities		0			2,407			1,156			3,563
Public utilities		0			6,398			647			7,045
Sovereign and supranational		0			393			23			416
Banks/financial institutions		0			8,946			10			8,956
Other corporate		0			25,178			231			25,409
Total fixed maturity securities		17,088			46,114			2,067			65,269
Equity securities		639			0			157			796
Other investments		1,599			0			0			1,599
Cash and cash equivalents		6,229			0			0			6,229
Other assets:
Foreign currency swaps		0			55			0			55
Foreign currency forwards		0			185			0			185
Total other assets		0			240			0			240
Total assets		$	25,555		$	46,354		$	2,224		$	74,133
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	604		$	0		$	604
Interest rate swaps		0			329			0			329
Total liabilities		$	0		$	933		$	0		$	933

Fair Value Hierarchy Levels of Assets and Liabilities Carried at Cost or Amortized Cost

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.

	March 31, 2025
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,     carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	16,193		$	16,262		$	144		$	0		$	16,406
Municipalities		249			0			260			0			260
Public utilities		33			0			33			0			33
Sovereign and    supranational		396			0			418			0			418
Other corporate		17			0			18			0			18
Commercial mortgage and     other loans		10,656			0			0			10,451			10,451
Other investments (1)		37			0			37			0			37
Total assets		$	27,581		$	16,262		$	910		$	10,451		$	27,623
Liabilities:
Other policyholders’ funds		$	5,863		$	0		$	0		$	5,789		$	5,789
Notes payable    (excluding leases)		7,653			0			6,533			714			7,247
Total liabilities		$	13,516		$	0		$	6,533		$	6,503		$	13,036

(1) Excludes policy loans of $211, equity method investments of $3,482, and REO of $774, at carrying value

	December 31, 2024
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,    carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	15,309		$	15,916		$	143		$	0		$	16,059
Municipalities		235			0			257			0			257
Public utilities		32			0			33			0			33
Sovereign and    supranational		374			0			405			0			405
Other corporate		16			0			18			0			18
Commercial mortgage and     other loans		10,869			0			0			10,653			10,653
Other investments (1)		39			0			39			0			39
Total assets		$	26,874		$	15,916		$	895		$	10,653		$	27,464
Liabilities:
Other policyholders’ funds		$	5,460		$	0		$	0		$	5,389		$	5,389
Notes payable    (excluding leases)		7,402			0			6,352			675			7,027
Total liabilities		$	12,862		$	0		$	6,352		$	6,064		$	12,416

(1) Excludes policy loans of $203, equity method investments of $3,435, and REO of $682, at carrying value

Fair Value Assets Securities Carried At Fair Value Primary Pricing Sources

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	16,972		$	524		$	0		$	17,496
Internal		0			321			0			321
Total government and agencies		16,972			845			0			17,817
Municipalities:
Third-party pricing vendor		0			1,812			0			1,812
Internal		0			243			0			243
Total municipalities		0			2,055			0			2,055
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,258			0			2,258
Internal		0			187			37			224
Broker/other		0			0			1,566			1,566
Total mortgage- and asset-backed securities		0			2,445			1,603			4,048
Public utilities:
Third-party pricing vendor		0			3,644			0			3,644
Internal		0			2,821			0			2,821
Broker/other		0			0			756			756
Total public utilities		0			6,465			756			7,221
Sovereign and supranational:
Third-party pricing vendor		0			78			0			78
Internal		0			324			0			324
Broker/other		0			0			24			24
Total sovereign and supranational		0			402			24			426
Banks/financial institutions:
Third-party pricing vendor		0			5,416			0			5,416
Internal		0			3,935			6			3,941
Broker/other		0			0			4			4
Total banks/financial institutions		0			9,351			10			9,361
Other corporate:
Third-party pricing vendor		0			20,762			0			20,762
Internal		0			5,317			21			5,338
Broker/other		0			0			116			116
Total other corporate		0			26,079			137			26,216
Total securities available-for-sale		$	16,972		$	47,642		$	2,530		$	67,144
Equity securities, carried at fair value:
Third-party pricing vendor		$	604		$	0		$	0		$	604
Internal		0			0			26			26
Broker/other		0			0			134			134
Total equity securities		$	604		$	0		$	160		$	764

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	17,088		$	446		$	0		$	17,534
Internal		0			312			0			312
Total government and agencies		17,088			758			0			17,846
Municipalities:
Third-party pricing vendor		0			1,791			0			1,791
Internal		0			243			0			243
Total municipalities		0			2,034			0			2,034
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,352			0			2,352
Internal		0			55			37			92
Broker/other		0			0			1,119			1,119
Total mortgage- and asset-backed securities		0			2,407			1,156			3,563
Public utilities:
Third-party pricing vendor		0			3,628			0			3,628
Internal		0			2,770			0			2,770
Broker/other		0			0			647			647
Total public utilities		0			6,398			647			7,045
Sovereign and supranational:
Third-party pricing vendor		0			78			0			78
Internal		0			315			0			315
Broker/other		0			0			23			23
Total sovereign and supranational		0			393			23			416
Banks/financial institutions:
Third-party pricing vendor		0			4,975			0			4,975
Internal		0			3,971			5			3,976
Broker/other		0			0			5			5
Total banks/financial institutions		0			8,946			10			8,956
Other corporate:
Third-party pricing vendor		0			20,051			0			20,051
Internal		0			5,127			116			5,243
Broker/other		0			0			115			115
Total other corporate		0			25,178			231			25,409
Total securities available-for-sale		$	17,088		$	46,114		$	2,067		$	65,269
Equity securities, carried at fair value:
Third-party pricing vendor		$	639		$	0		$	0		$	639
Internal		0			0			26			26
Broker/other		0			0			131			131
Total equity securities		$	639		$	0		$	157		$	796

Fair Value Assets Held-To-Maturity Securities Primary Pricing Sources

	March 31, 2025
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	16,262		$	144		$	0		$	16,406
Total government and agencies		16,262			144			0			16,406
Municipalities:
Third-party pricing vendor		0			260			0			260
Total municipalities		0			260			0			260
Public utilities:
Third-party pricing vendor		0			33			0			33
Total public utilities		0			33			0			33
Sovereign and supranational:
Third-party pricing vendor		0			205			0			205
Internal		0			213			0			213
Total sovereign and supranational		0			418			0			418
Other corporate:
Third-party pricing vendor		0			18			0			18
Total other corporate		0			18			0			18
Total securities held-to-maturity		$	16,262		$	873		$	0		$	17,135

	December 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	15,916		$	143		$	0		$	16,059
Total government and agencies		15,916			143			0			16,059
Municipalities:
Third-party pricing vendor		0			257			0			257
Total municipalities		0			257			0			257
Public utilities:
Third-party pricing vendor		0			33			0			33
Total public utilities		0			33			0			33
Sovereign and supranational:
Third-party pricing vendor		0			198			0			198
Internal		0			207			0			207
Total sovereign and supranational		0			405			0			405
Other corporate:
Third-party pricing vendor		0			18			0			18
Total other corporate		0			18			0			18
Total securities held-to-maturity		$	15,916		$	856		$	0		$	16,772

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The following tables present the changes in fair value of the Company's investments carried at fair value classified as Level 3.

Three Months Ended March 31, 2025
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	1,156	$	647	$	23	$	10	$	231	$	157	$	2,224
Net investment gains (losses) included   in earnings	0		0		0		0		0		1		1
Unrealized gains (losses) included in   other comprehensive income (loss)	10		6		1		0		2		0		19
Purchases, issuances, sales and   settlements:
Purchases	434		110		0		0		0		3		547
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		(1)		(1)
Settlements	(12)		(7)		0		0		(1)		0		(20)
Transfers into Level 3	15		0		0		0		0		0		15
Transfers out of Level 3	0		0		0		0		(95)		0		(95)
Balance, end of period	$	1,603	$	756	$	24	$	10	$	137	$	160	$	2,690
Changes in unrealized gains (losses)   relating to Level 3 assets and liabilities   still held at the end of the period   included in earnings	$	0	$	0	$	0	$	0	$	0	$	1	$	1

Three Months Ended March 31, 2024
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	772	$	253	$	30	$	78	$	648	$	248	$	2,029
Net investment gains (losses) included   in earnings	1		0		0		0		0		(5)		(4)
Unrealized gains (losses) included in   other comprehensive income (loss)	(4)		(10)		(2)		(4)		1		0		(19)
Purchases, issuances, sales and   settlements:
Purchases	118		60		0		5		37		0		220
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(28)		(22)		0		(5)		(3)		(84)		(142)
Transfers into Level 3	0		226		0		0		0		0		226
Transfers out of Level 3	0		0		0		0		(233)		0		(233)
Balance, end of period	$	859	$	507	$	28	$	74	$	450	$	159	$	2,077
Changes in unrealized gains (losses)   relating to Level 3 assets and liabilities   still held at the end of the period   included in earnings	$	1	$	0	$	0	$	0	$	0	$	(3)	$	(2)

Fair Value Measurement Inputs and Valuation Techniques

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

March 31, 2025
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	1,603	Consensus pricing	Offered quotes	86.24	-	106.46	(a)	99.62
Public utilities		756		Discounted cash flow	Credit spreads	100 bps	-	407 bps	(c)	164 bps
Sovereign and supranational		24		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		10		Adjusted cost	Private financials	N/A			(d)	N/A
Other corporate		137		Discounted cash flow	Credit spreads	100 bps	-	294 bps	(c)	198 bps
Equity securities		160		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,690

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

(b) Category represents a single security; range not applicable

(c) Actual or equivalent credit spreads in basis points

(d) Prices do not utilize credit spreads; therefore, range is not applicable

December 31, 2024
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	1,156	Consensus pricing	Offered quotes	84.08	-	104.60	(a)	99.07
Public utilities		647		Discounted cash flow	Credit spreads	100 bps	-	375 bps	(c)	162 bps
Sovereign and supranational		23		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		10		Adjusted cost	Private financials	N/A			(d)	N/A
Other corporate		231		Discounted cash flow	Credit spreads	91 bps	-	294 bps	(c)	173 bps
Equity securities		157		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,224

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

(b) Category represents a single security; range not applicable

(c) Actual or equivalent credit spreads in basis points

(d) Prices do not utilize credit spreads; therefore, range is not applicable

XML

DEFERRED POLICY ACQUISITION COSTS (Tables)

3 Months Ended

Mar. 31, 2025

Deferred Policy Acquisition Costs Disclosures [Abstract]

Schedule Of Deferred Policy Acquisition Costs

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.

	March 31, 2025
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2024	$	2,776	$	1,833	$	441	$	52	$	915	$	636	$	1,348	$	452	$	86	$	219	$	0	$	8,758
Capitalization	61		27		9		1		33		31		38		21		3		22		0		246
Amortization expense	(46)		(25)		(8)		0		(36)		(31)		(39)		(19)		(3)		(9)		0		(216)
Foreign currency translation and   other	160		107		27		1		0		0		0		0		0		0		0		295
Balance at March 31, 2025	$	2,951	$	1,942	$	469	$	54	$	912	$	636	$	1,347	$	454	$	86	$	232	$	0	$	9,083

	December 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132
Capitalization	300		103		36		4		141		129		165		89		12		77		0		1,056
Amortization expense	(184)		(100)		(34)		(3)		(143)		(118)		(153)		(73)		(12)		(30)		(1)		(851)
Foreign currency translation and   other	(311)		(211)		(52)		(5)		0		0		0		0		0		0		0		(579)
Balance at December 31, 2024	$	2,776	$	1,833	$	441	$	52	$	915	$	636	$	1,348	$	452	$	86	$	219	$	0	$	8,758

XML

POLICY LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2025

Insurance Loss Reserves [Abstract]

Schedule of Changes in Present Value of Expected Net Premiums and Expected Future Policy Benefits

The following tables present the changes in the present value of expected future net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type. The present value of expected future net premiums and the present value of expected future policy benefits are presented gross of internal and external ceded reinsurance.

	March 31, 2025
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2024	$	14,184	$	11,817	$	5,156	$	846	$	2,497	$	1,635	$	3,901	$	1,122	$	196	$	909	$	826
Beginning balance at original discount rate	14,008		11,845		5,084		864		2,687		1,726		4,340		1,221		209		976		824
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(6)		(45)		(10)		(2)		(14)		(18)		(9)		(1)		(4)		(9)		3
Adjusted beginning of period balance	14,002		11,800		5,074		862		2,673		1,708		4,331		1,220		205		967		827
Issuances	211		72		120		3		108		118		214		88		17		70		229
Interest accrual	91		72		27		4		27		17		44		12		2		10		11
Net premiums collected (1)	(350)		(268)		(201)		(24)		(119)		(99)		(142)		(61)		(10)		(41)		(22)
Foreign currency translation	812		685		292		50		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		(10)
Ending balance at original discount rate	14,766		12,361		5,312		895		2,689		1,744		4,447		1,259		214		1,006		1,035
Effect of changes in discount rate assumptions	(270)		(415)		(29)		(42)		(160)		(72)		(389)		(86)		(11)		(53)		55
Balance at March 31, 2025	$	14,496	$	11,946	$	5,283	$	853	$	2,529	$	1,672	$	4,058	$	1,173	$	203	$	953	$	1,090
Present value of expected future policy benefits:
Balance at December 31, 2024	$	40,781	$	20,606	$	24,265	$	4,225	$	3,127	$	2,330	$	10,701	$	1,897	$	441	$	1,847	$	1,288
Beginning balance at original discount rate	37,856		21,957		26,330		4,765		3,386		2,466		12,013		2,073		477		2,126		1,293
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(20)		(55)		(7)		(7)		(13)		(24)		(13)		(3)		(4)		(14)		4
Adjusted beginning of period balance	37,836		21,902		26,323		4,758		3,373		2,442		12,000		2,070		473		2,112		1,297
Issuances	215		75		122		4		113		125		226		92		15		77		232
Interest accrual	324		138		141		22		34		24		129		21		5		21		17
Benefit payments	(666)		(246)		(604)		(57)		(144)		(120)		(249)		(84)		(15)		(27)		(41)
Foreign currency translation	2,191		1,270		1,518		276		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		0
Ending balance at original discount rate	39,900		23,139		27,500		5,003		3,376		2,471		12,106		2,099		478		2,183		1,505
Effect of changes in discount rate assumptions	1,538		(2,291)		(3,022)		(736)		(221)		(109)		(1,184)		(154)		(30)		(255)		52
Balance at March 31, 2025	41,438		20,848		24,478		4,267		3,155		2,362		10,922		1,945		448		1,928		1,557
Net liability for future policy benefits	26,942		8,902		19,195		3,414		626		690		6,864		772		245		975		467
Less: reinsurance recoverable	5,156		1,259		0		0		0		0		0		0		0		20		2
Net liability for future policy benefits after   reinsurance recoverable	$	21,786	$	7,643	$	19,195	$	3,414	$	626	$	690	$	6,864	$	772	$	245	$	955	$	465

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

	December 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/ Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Beginning balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in cash flow assumptions	(625)		(154)		(190)		(19)		65		(47)		(106)		(21)		(17)		(5)		(8)
Effect of actual variances from expected    experience	(71)		(164)		(97)		(14)		66		12		(100)		21		(12)		(29)		13
Adjusted beginning of period balance	15,756		13,722		5,971		1,036		2,761		1,703		4,210		1,193		188		875		277
Issuances	983		361		478		16		307		364		543		231		52		226		592
Interest accrual	378		302		110		17		106		66		173		46		9		37		25
Net premiums collected (1)	(1,453)		(1,135)		(862)		(101)		(479)		(401)		(578)		(244)		(39)		(157)		(53)
Foreign currency translation	(1,655)		(1,405)		(613)		(104)		0		0		0		0		0		0		0
Other	(1)		0		0		0		(8)		(6)		(8)		(5)		(1)		(5)		(17)
Ending balance at original discount rate	14,008		11,845		5,084		864		2,687		1,726		4,340		1,221		209		976		824
Effect of changes in discount rate assumptions	176		(28)		72		(18)		(190)		(91)		(439)		(99)		(13)		(67)		2
Balance at December 31, 2024	$	14,184	$	11,817	$	5,156	$	846	$	2,497	$	1,635	$	3,901	$	1,122	$	196	$	909	$	826
Present value of expected future policy benefits:
Balance at December 31, 2023	$	50,161	$	25,257	$	29,731	$	5,178	$	3,109	$	2,422	$	11,290	$	1,943	$	478	$	1,764	$	798
Beginning balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in cash flow assumptions	(815)		(228)		(302)		(7)		109		(73)		(112)		(31)		(28)		(3)		(12)
Effect of actual variances from expected    experience	(117)		(193)		(110)		(24)		91		(16)		(144)		21		(16)		(43)		(7)
Adjusted beginning of period balance	42,694		24,602		29,844		5,413		3,502		2,452		11,864		2,066		462		1,925		750
Issuances	1,004		373		488		22		311		381		559		237		55		231		597
Interest accrual	1,356		570		582		93		133		98		515		84		20		78		50
Benefit payments	(2,773)		(1,033)		(1,510)		(208)		(560)		(465)		(925)		(314)		(60)		(108)		(104)
Foreign currency translation	(4,425)		(2,555)		(3,074)		(555)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		0		0		0
Ending balance at original discount rate	37,856		21,957		26,330		4,765		3,386		2,466		12,013		2,073		477		2,126		1,293
Effect of changes in discount rate assumptions	2,925		(1,351)		(2,065)		(540)		(259)		(136)		(1,312)		(176)		(36)		(279)		(5)
Balance at December 31, 2024	40,781		20,606		24,265		4,225		3,127		2,330		10,701		1,897		441		1,847		1,288
Net liability for future policy benefits	26,597		8,789		19,109		3,379		630		695		6,800		775		245		938		462
Less: reinsurance recoverable	5,085		1,245		0		0		0		0		0		0		0		18		0
Net liability for future policy benefits after    reinsurance recoverable	$	21,512	$	7,544	$	19,109	$	3,379	$	630	$	695	$	6,800	$	775	$	245	$	920	$	462

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

Schedule of Weighted-Average Interest Rate and Liability for Future Policy Benefit

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.

	March 31, 2025
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/ Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	4.0 %	4.3 %	4.6 %	4.5 %	4.3 %	3.9 %	5.5 %
Weighted-average interest, current discount rate (1)	2.7 %	3.2 %	2.6 %	3.0 %	5.3 %	5.2 %	5.5 %	5.4 %	5.3 %	5.4 %	5.5 %
Weighted-average liability duration (years)	12.6	23.2	16.2	16.5	7.7	5.6	11.0	9.0	7.6	13.5	8.8

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

	December 31, 2024
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/ Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	4.0 %	4.3 %	4.6 %	4.5 %	4.3 %	3.8 %	5.4 %
Weighted-average interest, current discount rate (1)	2.2 %	2.8 %	2.1 %	2.5 %	5.3 %	5.2 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	12.6	23.5	16.1	16.7	7.7	5.6	11.1	9.0	7.6	13.5	9.1

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

Reconciliation of Future Policy Benefits

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the consolidated balance sheets. The deferred profit liability for limited-payment contracts and the deferred reinsurance gain liability are presented together with the liability for future policy benefits in the consolidated balance sheets and have been included as reconciling items in the table below.

(In millions)	March 31, 2025			December 31, 2024
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	26,942		$	26,597
Medical and other health		8,902			8,789
Life insurance		19,195			19,109
Other		3,414			3,379
Aflac U.S.
Accident		626			630
Disability		690			695
Critical care		6,864			6,800
Hospital indemnity		772			775
Dental/vision		245			245
Life insurance		975			938
Other		467			462
Corporate and other		5,116			5,072
Deferred profit liability		1,990			1,844
Deferred reinsurance gain liability		860			806
Intercompany eliminations (1)		(5,861)			(5,760)
Total		$	71,197		$	70,381

(1) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 of the Notes to the Consolidated Financial Statements in the 2024 Annual Report.

Summary of Net Earned Premiums Recognized

The following table summarizes the amount of net earned premiums recognized in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2025		2024
Net earned premiums:
Aflac Japan
Cancer	$	839	$	878
Medical and other health	529		605
Life insurance	316		339
Other	32		34
Aflac U.S.
Accident	311		325
Disability	352		333
Critical care	441		444
Hospital indemnity	184		185
Dental/vision	49		59
Life insurance	169		138
Other	49		20
Corporate and other	198		165
Reinsurance ceded	(88)		(69)
Total	$	3,381	$	3,456

Summary of Interest Expense Related to Insurance Contracts Recognized

The following table summarizes the amount of interest expense related to insurance contracts recognized in benefits and claims, excluding reserve remeasurement in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2025		2024
Interest expense:
Aflac Japan
Cancer	$	233	$	246
Medical and other health	66		65
Life insurance	114		118
Other	18		19
Aflac U.S.
Accident	7		6
Disability	7		8
Critical care	85		85
Hospital indemnity	9		9
Dental/vision	3		3
Life insurance	11		10
Other	6		7
Total	$	559	$	576

Summary of Undiscounted and Discounted Expected Future Gross Premiums and Future Benefits and Expenses

The following tables summarize the amount of undiscounted expected future gross premiums and expected future policy benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future policy benefits and expenses by reporting segment and disaggregated by product type. These tables are presented gross of internal and external ceded reinsurance. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business of the Company.

	March 31, 2025						December 31, 2024
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums   and expected future policy benefits and   expenses:
Aflac Japan
Cancer		$	54,446		$	59,903		$	51,712		$	56,881
Medical and other health		34,739			36,751			33,250			34,864
Life insurance		11,492			39,412			10,915			37,520
Other		1,538			6,790			1,477			6,479
Aflac U.S.
Accident		8,843			4,673			8,862			4,687
Disability		5,748			3,110			5,727			3,094
Critical care		19,780			20,463			19,624			20,340
Hospital indemnity		4,937			3,052			4,859			3,017
Dental/vision		1,117			684			1,118			679
Life insurance		3,091			3,686			2,966			3,559
Other		2,764			2,691			2,143			2,273
Total		$	148,495		$	181,215		$	142,653		$	173,393

	March 31, 2025						December 31, 2024
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums   and expected future policy benefits and   expenses:
Aflac Japan
Cancer		$	40,989		$	41,438		$	40,170		$	40,781
Medical and other health		25,461			20,848			25,171			20,606
Life insurance		9,630			24,478			9,367			24,265
Other		1,219			4,267			1,204			4,225
Aflac U.S.
Accident		6,116			3,155			6,057			3,127
Disability		4,456			2,362			4,404			2,330
Critical care		12,152			10,922			11,900			10,701
Hospital indemnity		3,412			1,945			3,312			1,897
Dental/vision		768			448			761			441
Life insurance		2,160			1,928			2,050			1,847
Other		1,668			1,557			1,290			1,288
Total		$	108,031		$	113,348		$	105,686		$	111,508

Schedule of Changes in Other Policyholders' Funds

The following table presents the changes in other policyholders’ funds.

(In millions)	March 31, 2025		December 31, 2024
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	5,221	$	5,939
Premiums received	29		104
Transfers from WAYS conversions	74		249
Surrenders and withdrawals	(18)		(58)
Benefit payments	(128)		(446)
Interest credited	12		49
Foreign currency translation and other	304		(616)
Fixed annuities account balance, end of period	5,494		5,221
Other deposit type reserves	369		239
Total	$	5,863	$	5,460

(1) Aflac Japan fixed annuities

Schedule of Other Policyholders' Funds by Guaranteed Crediting Rates

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

	March 31, 2025			December 31, 2024
(In millions)	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value
Fixed annuities (1)	0.5% - 2.2%	$5,494	$5,420	0.5% - 2.2%	$5,221	$5,150

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2025 and December 31, 2024.

XML

REINSURANCE (Tables)

3 Months Ended

Mar. 31, 2025

Reinsurance Disclosures [Abstract]

Effects of Reinsurance

The following table reconciles direct earned premiums, direct benefits and claims, excluding reserve remeasurement gains and losses, and reserve remeasurement gains and losses to net amounts after the effect of reinsurance.

	Three Months Ended March 31,
(In millions)	2025			2024
Earned premiums:
Direct		$	3,433		$	3,482
Ceded		(88)			(69)
Assumed		36			43
Net earned premiums		$	3,381		$	3,456
Benefits and claims, excluding reserve remeasurement:
Direct		$	2,031		$	2,082
Ceded		(56)			(33)
Assumed		11			17
Benefits and claims, excluding reserve remeasurement		1,986			2,066
Reserve remeasurement (gains) losses:
Direct		(41)			(57)
Ceded		0			1
Reserve remeasurement (gains) losses		(41)			(56)
Total benefits and claims, net		$	1,945		$	2,010

XML

NOTES PAYABLE AND LEASE OBLIGATIONS (Tables)

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

A summary of notes payable and lease obligations follows:

(In millions)	March 31, 2025			December 31, 2024
1.125% senior sustainability notes due March 2026		$	399		$	399
2.875% senior notes due October 2026		299			299
3.60% senior notes due April 2030		994			994
6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040		255			255
4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049		542			542
Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)		83			79
.932% senior notes due January 2027 (principal amount ¥60.0 billion)		400			378
1.048% senior notes due March 2029 (principal amount ¥13.0 billion)		86			81
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		223			211
.500% senior notes due December 2029 (principal amount ¥12.6 billion)		84			79
.550% senior notes due March 2030 (principal amount ¥13.3 billion)		89			84
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		195			184
1.412% senior notes due March 2031 (principal amount ¥27.9 billion)		186			176
.633% senior notes due April 2031 (principal amount ¥30.0 billion)		200			189
.843% senior notes due December 2031 (principal amount ¥9.3 billion)		62			58
.750% senior notes due March 2032 (principal amount ¥20.7 billion)		137			130
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		141			133
.844% senior notes due April 2033 (principal amount ¥12.0 billion)		80			76
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		101			95
1.682% senior notes due March 2034 (principal amount ¥7.7 billion)		51			48
1.600% senior notes due March 2034 (principal amount ¥18.3 billion)		122			115
.934% senior notes due December 2034 (principal amount ¥9.8 billion)		65			62
.830% senior notes due March 2035 (principal amount ¥10.6 billion)		70			66
1.740% senior notes due March 2036 (principal amount ¥15.0 billion)		99			94
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		66			63
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		43			41
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		59			56
1.920% senior notes due March 2039 (principal amount ¥16.5 billion)		109			103
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		42			39
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		66			63
2.160% senior notes due March 2044 (principal amount ¥5.7 billion)		37			35
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		397			375
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		133			125
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		80			75
1.958% subordinated bonds due December 2053 (principal amount ¥30.0 billion)		200			188
2.400% senior notes due March 2054 (principal amount ¥19.5 billion)		129			122
Yen-denominated loans:
Variable interest rate loan due August 2027 (1.07% in 2025 and .84% in 2024,   principal amount ¥11.7 billion)		78			74
Variable interest rate loan due August 2029 (1.17% in 2025 and .94% in 2024,   principal amount ¥25.3 billion)		169			160
Variable interest rate loan due August 2032 (1.32% in 2025 and 1.09% in 2024,   principal amount ¥70.0 billion)		467			441
Finance lease obligations payable through 2030		4			5
Operating lease obligations payable through 2049		94			91
Total notes payable and lease obligations		$	7,751		$	7,498

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

Schedule of Line of Credit Facilities

A summary of the Company's lines of credit as of March 31, 2025 follows:

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
Aflac Incorporated and Aflac	uncommitted bilateral	364 days	December 5, 2025	$100 million	$0 million	The rate quoted by the bank and agreed upon at the time of borrowing	Up to 3 months	None	General corporate purposes
Aflac Incorporated	unsecured revolving	5 years	May 9, 2027, or the date commitments are terminated pursuant to an event of default	¥100.0 billion	¥0.0 billion	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period	No later than May 10, 2027	.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	unsecured revolving	5 years	November 15, 2027, or the date commitments are terminated pursuant to an event of default	$1.0 billion	$0.0 billion	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar-denominated borrowings or TIBOR for Japanese yen-denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin	No later than November 15, 2027	.08% to .20%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	uncommitted bilateral	None specified	None specified	$50 million	$0 million	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%	Up to 3 months	None	General corporate purposes
Aflac(1)	uncommitted revolving	364 days	December 1, 2025	$250 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac Incorporated(1) (Tranche 1)	uncommitted revolving	364 days	November 25, 2025	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2025	None	General corporate purposes
Aflac Incorporated(1) (Tranche 2)	uncommitted revolving	364 days	November 25, 2025	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2025	None	General corporate purposes
Aflac New York(1)	uncommitted revolving	364 days	December 1, 2025	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
CAIC(1)	uncommitted revolving	364 days	December 1, 2025	$15 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes

(1) Intercompany credit agreement

(continued)

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
TOIC(1)	uncommitted revolving	364 days	December 1, 2025	$0.3 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac GI Holdings LLC(1)	uncommitted revolving	364 days	December 1, 2025	$30 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 2, 2025	None	General corporate purposes
Aflac Incorporated(1)	uncommitted revolving	364 days	December 1, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Re(1)	uncommitted revolving	364 days	December 1, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Asset Management LLC(1)	uncommitted revolving	364 days	December 1, 2025	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes
Aflac Global Ventures LLC(1)	uncommitted revolving	364 days	December 1, 2025	$2 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than December 2, 2025	None	General corporate purposes

(1) Intercompany credit agreement

XML

SHAREHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2025

Stockholders' Equity Note [Abstract]

Schedule of Common Stock Outstanding Roll Forward

The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.

(In thousands of shares)	2025	2024
Common stock - issued:
Balance, beginning of period	1,356,763	1,355,398
Exercise of stock options and issuance of restricted shares	989	1,082
Balance, end of period	1,357,752	1,356,480
Treasury stock:
Balance, beginning of period	806,799	776,919
Purchases of treasury stock:
Share repurchase program	8,497	9,276
Other	398	457
Dispositions of treasury stock:
Shares issued to AFL Stock Plan	(173)	(212)
Exercise of stock options	(41)	(55)
Other	(221)	(183)
Balance, end of period	815,259	786,202
Shares outstanding, end of period	542,493	570,278

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.

	Three Months Ended March 31,
(In thousands)	2025		2024
Anti-dilutive share-based awards		0		69

Changes in Accumulated Other Comprehensive Income (Loss)

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income

Three Months Ended March 31, 2025
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2024		$	(4,998)		$	24		$	(20)		$	2,006		$	10		$	(2,978)
Other comprehensive    income (loss) before    reclassification		449			(1,225)			1			1,893			33			1,151
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(32)			1			0			(1)			(32)
Net current-period other    comprehensive    income (loss)		449			(1,257)			2			1,893			32			1,119
Balance at March 31, 2025		$	(4,549)		$	(1,233)		$	(18)		$	3,899		$	42		$	(1,859)

All amounts in the table above are net of tax.

Three Months Ended March 31, 2024
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2023		$	(4,069)		$	1,139		$	(22)		$	(2,560)		$	(8)		$	(5,520)
Other comprehensive    income (loss) before    reclassification		(597)			86			(5)			1,065			1			550
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(133)			1			0			0			(132)
Net current-period other    comprehensive    income (loss)		(597)			(47)			(4)			1,065			1			418
Balance at March 31, 2024		$	(4,666)		$	1,092		$	(26)		$	(1,495)		$	(7)		$	(5,102)

All amounts in the table above are net of tax.

Reclassification Out Of Accumulated Other Comprehensive Income

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

(In millions)	Three Months Ended March 31, 2025
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	40	Net investment gains (losses)
		(8)		Tax (expense) or benefit(1)
		$	32	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Amortization of defined benefit pension items:
Actuarial gains (losses)		$	1	Acquisition and operating expenses(2)
Prior service (cost) credit		0		Acquisition and operating expenses(2)
		0		Tax (expense) or benefit(1)
		$	1	Net of tax
Total reclassifications for the period		$	32	Net of tax

(1) Based on 21% tax rate

(2) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost (see Note 12 for additional details).

(In millions)	Three Months Ended March 31, 2024
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	168	Net investment gains (losses)
		(35)		Tax (expense) or benefit(1)
		$	133	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	132	Net of tax

(1) Based on 21% tax rate

XML

SHARE-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Stock Options Outstanding and Exercisable

The following table provides information on stock options outstanding and exercisable at March 31, 2025.

	Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding		459		1.7		$	35		$	34.90
Exercisable		459		1.7		35			34.90

Schedule of Nonvested Restricted Stock Units Activity

The following table summarizes restricted stock activity during the three-month period ended March 31, 2025.

(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2024	2,099		$	73.65
Granted in 2025	1,059		104.43
Canceled in 2025	(14)		76.04
Vested in 2025	(1,238)		68.36
Restricted stock at March 31, 2025	1,906		$	85.21

XML

BENEFIT PLANS (Tables)

3 Months Ended

Mar. 31, 2025

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Schedule of Net Benefit Costs

Total net periodic benefit cost includes the following components:

	Three Months Ended March 31,
	Pension Benefits												Other
	Japan						U.S.						Postretirement Benefits
(In millions)	2025			2024			2025			2024			2025			2024
Components of net periodic   benefit cost:
Service cost		$	3		$	4		$	0		$	0		$	0		$	0
Interest cost		2			2			8			9			0			0
Expected return on plan assets		(2)			(2)			(5)			(7)			0			0
Amortization of net actuarial   (gain) loss		0			0			(1)			0			0			0
Settlement (gain) loss		0			0			55			0			0			0
Net periodic benefit cost (credit)		$	3		$	4		$	57		$	2		$	0		$	0

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2025 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable insurance business segments	2

XML

BUSINESS SEGMENT INFORMATION - Operations by Segment - Revenues (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Segment Reporting, Revenue Reconciling Item [Line Items]
Net earned premiums	[1]	$ 3,381	$ 3,456
Net investment income		955	1,000
Other income		25	29
Total revenues		3,398	5,436
Net investment gains (losses)		(963)	951
Remeasurement gain (loss), deferred profit liability for limited-payment contracts		0	(3)
Change in value of federal historic rehabilitation and solar tax credit investments		(8)	(32)
Federal historic rehabilitation and solar tax credits, amount		7	33
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues		4,319	4,419
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
Segment Reporting, Revenue Reconciling Item [Line Items]
Net investment gains (losses)		(963)	951
Amortized hedge costs		7	6
Amortized hedge income		(30)	(28)
Net interest (income) expense from derivatives associated with certain investment strategies		65	88
Aflac Japan | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Net earned premiums	[1]	1,681	1,816
Net investment income		586	648
Other income		5	9
Total revenues	[1]	2,272	2,473
Aflac U.S. | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Net earned premiums		1,502	1,475
Net investment income		202	206
Other income		17	18
Total revenues		1,721	1,699
Corporate and other | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues	[2]	$ 326	$ 247

[1] Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

[2] The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025 and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025 and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

XML

BUSINESS SEGMENT INFORMATION - Operations by Segment - Pretax Earnings (Details) - USD ($) $ in Millions		3 Months Ended		12 Months Ended
		Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Total revenues		$ 3,398	$ 5,436
Benefits and claims, excluding reserve remeasurement		1,986	2,066
Reserve remeasurement (gains) losses		(41)	(56)
Total benefits and claims, net		1,945	2,010
Amortization of deferred policy acquisition costs		216	215	$ 851
Insurance commissions		240	255
Insurance and other expenses		802	739
Total benefits and expenses		3,253	3,266
Net investment gains (losses)		(963)	951
Earnings before income taxes		145	2,170
Income taxes applicable to pretax adjusted earnings		217	202
Effect of foreign currency translation on after-tax adjusted earnings		(8)	(44)
Remeasurement gain (loss), deferred profit liability for limited-payment contracts		0	(3)
Change in value of federal historic rehabilitation and solar tax credit investments		(8)	(32)
Federal historic rehabilitation and solar tax credits, amount		7	33
Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Total revenues		4,319	4,419
Total benefits and expenses		3,196	3,256
Pretax adjusted earnings		1,123	1,163
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Other income (loss)		(53)	(2)
Net investment gains (losses)		(963)	951
Amortized hedge costs		7	6
Amortized hedge income		(30)	(28)
Net interest (income) expense from derivatives associated with certain investment strategies		65	88
Impact of interest from derivatives associated with notes payable		(4)	(8)
Aflac Japan | Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Total revenues	[1]	2,272	2,473
Benefits and claims, excluding reserve remeasurement		1,130	1,243
Reserve remeasurement (gains) losses		(25)	(26)
Total benefits and claims, net		1,105	1,217
Amortization of deferred policy acquisition costs		79	83
Insurance commissions		105	114
Insurance and other expenses		261	249
Total benefits and expenses		1,550	1,663
Pretax adjusted earnings	[1]	722	810
Aflac U.S. | Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Total revenues		1,721	1,699
Benefits and claims, excluding reserve remeasurement		731	715
Reserve remeasurement (gains) losses		(15)	(29)
Total benefits and claims, net		716	686
Amortization of deferred policy acquisition costs		137	132
Insurance commissions		135	141
Insurance and other expenses		375	384
Total benefits and expenses		1,363	1,343
Pretax adjusted earnings		358	356
Corporate and other | Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Total revenues	[2]	326	247
Total benefits and expenses		283	250
Pretax adjusted earnings	[2]	$ 43	$ (3)

[1] Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

[2] The change in value of federal historic rehabilitation and solar investments in partnerships of $8 and $32 for the three-month periods ended March 31, 2025 and 2024, respectively, is included as a reduction to net investment income. Tax credits on these investments of $7 and $33 for the three-month periods ended March 31, 2025 and 2024, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

XML

BUSINESS SEGMENT INFORMATION - Operations by Segment - Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 120,258	$ 117,566
Aflac Japan
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	93,430	90,210
Aflac U.S.
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	21,881	21,930
Corporate and other
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 4,947	$ 5,426

XML

BUSINESS SEGMENT INFORMATION - Additional Information (Details) $ in Millions		3 Months Ended
		Mar. 31, 2025 USD ($) segment	Mar. 31, 2024 USD ($)	Dec. 31, 2024
Segment Reporting Information [Line Items]
Number of reportable insurance business segments | segment		2
Net earned premiums	[1]	$ 3,381	$ 3,456
Aflac Re Bermuda
Segment Reporting Information [Line Items]
Net earned premiums		$ 178	$ 136
Aflac Japan
Segment Reporting Information [Line Items]
Percentage of the Company's total revenues		53.00%	56.00%
Percentage of the Company's total assets		78.00%		77.00%

[1] Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

XML

INVESTMENTS - Available-for-sale Debt Securities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 67,545	$ 64,089
Allowance for Credit Losses	0	0	$ 0	$ 0
Gross Unrealized Gains	4,345	5,308
Gross Unrealized Losses	4,746	4,128
Fair Value	67,144	65,269
Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	35,594	34,386
Allowance for Credit Losses	0	0
Gross Unrealized Gains	1,061	1,587
Gross Unrealized Losses	3,768	3,099
Fair Value	32,887	32,874
Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	31,870	29,678
Allowance for Credit Losses	0	0
Gross Unrealized Gains	3,284	3,720
Gross Unrealized Losses	977	1,029
Fair Value	34,177	32,369
Other currencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	81	25
Allowance for Credit Losses	0	0
Gross Unrealized Gains	0	1
Gross Unrealized Losses	1	0
Fair Value	80	26
Japan government and agencies | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	20,005	19,409
Allowance for Credit Losses	0	0
Gross Unrealized Gains	145	465
Gross Unrealized Losses	2,608	2,234
Fair Value	17,542	17,640
Municipalities
Debt Securities, Available-for-sale [Line Items]
Fair Value	2,055	2,034
Municipalities | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	919	869
Allowance for Credit Losses	0	0
Gross Unrealized Gains	50	65
Gross Unrealized Losses	105	79
Fair Value	864	855
Municipalities | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,190	1,167
Allowance for Credit Losses	0	0
Gross Unrealized Gains	69	65
Gross Unrealized Losses	68	53
Fair Value	1,191	1,179
Mortgage- and asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	4,048	3,563
Mortgage- and asset-backed securities | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	342	327
Allowance for Credit Losses	0	0
Gross Unrealized Gains	2	4
Gross Unrealized Losses	29	23
Fair Value	315	308
Mortgage- and asset-backed securities | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3,574	2,987
Allowance for Credit Losses	0	0
Gross Unrealized Gains	205	302
Gross Unrealized Losses	46	34
Fair Value	3,733	3,255
Public utilities
Debt Securities, Available-for-sale [Line Items]
Fair Value	7,221	7,045
Public utilities | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,771	2,746
Allowance for Credit Losses	0	0
Gross Unrealized Gains	155	202
Gross Unrealized Losses	155	108
Fair Value	2,771	2,840
Public utilities | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	4,162	3,938
Allowance for Credit Losses	0	0
Gross Unrealized Gains	376	418
Gross Unrealized Losses	142	151
Fair Value	4,396	4,205
Public utilities | Other currencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	55
Allowance for Credit Losses	0
Gross Unrealized Gains	0
Gross Unrealized Losses	1
Fair Value	54
Sovereign and supranational
Debt Securities, Available-for-sale [Line Items]
Fair Value	426	416
Sovereign and supranational | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	349	330
Allowance for Credit Losses	0	0
Gross Unrealized Gains	9	16
Gross Unrealized Losses	10	8
Fair Value	348	338
Sovereign and supranational | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	58	57
Allowance for Credit Losses	0	0
Gross Unrealized Gains	20	21
Gross Unrealized Losses	0	0
Fair Value	78	78
Banks/financial institutions
Debt Securities, Available-for-sale [Line Items]
Fair Value	9,361	8,956
Banks/financial institutions | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5,553	5,376
Allowance for Credit Losses	0	0
Gross Unrealized Gains	225	267
Gross Unrealized Losses	448	342
Fair Value	5,330	5,301
Banks/financial institutions | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3,673	3,271
Allowance for Credit Losses	0	0
Gross Unrealized Gains	388	420
Gross Unrealized Losses	30	36
Fair Value	4,031	3,655
Other corporate
Debt Securities, Available-for-sale [Line Items]
Fair Value	26,216	25,409
Other corporate | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5,655	5,329
Allowance for Credit Losses	0	0
Gross Unrealized Gains	475	568
Gross Unrealized Losses	413	305
Fair Value	5,717	5,592
Other corporate | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	18,938	18,050
Allowance for Credit Losses	0	0
Gross Unrealized Gains	2,224	2,493
Gross Unrealized Losses	689	752
Fair Value	20,473	19,791
Other corporate | Other currencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	26	25
Allowance for Credit Losses	0	0
Gross Unrealized Gains	0	1
Gross Unrealized Losses	0	0
Fair Value	26	26
U.S. government and agencies | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	275	208
Allowance for Credit Losses	0	0
Gross Unrealized Gains	2	1
Gross Unrealized Losses	2	3
Fair Value	$ 275	$ 206

XML

INVESTMENTS - Held-to-Maturity Debt Securities (Details) - USD ($) $ in Millions	Mar. 31, 2025		Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$ 16,893		$ 15,971
Allowance for Credit Loss	5		5	$ 5	$ 5
Total fixed maturity securities, held-to- maturity, amortized cost	16,888	[1]	15,966
Gross Unrealized Gains	402		815
Gross Unrealized Losses	155		9
Fair Value	17,135		16,772
Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	16,893		15,971
Allowance for Credit Loss	5		5
Total fixed maturity securities, held-to- maturity, amortized cost	16,888		15,966
Gross Unrealized Gains	402		815
Gross Unrealized Losses	155		9
Fair Value	17,135		16,772
Japan government and agencies | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	16,195		15,311
Allowance for Credit Loss	2		2
Total fixed maturity securities, held-to- maturity, amortized cost	16,193		15,309
Gross Unrealized Gains	368		759
Gross Unrealized Losses	155		9
Fair Value	16,406		16,059
Municipalities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	249		235
Fair Value	260		257
Municipalities | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	249		235
Allowance for Credit Loss	0		0
Total fixed maturity securities, held-to- maturity, amortized cost	249		235
Gross Unrealized Gains	11		22
Gross Unrealized Losses	0		0
Fair Value	260		257
Public utilities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	33		32
Fair Value	33		33
Public utilities | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	33		32
Allowance for Credit Loss	0		0
Total fixed maturity securities, held-to- maturity, amortized cost	33		32
Gross Unrealized Gains	0		1
Gross Unrealized Losses	0		0
Fair Value	33		33
Sovereign and supranational
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	396		374
Fair Value	418		405
Sovereign and supranational | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	399		377
Allowance for Credit Loss	3		3
Total fixed maturity securities, held-to- maturity, amortized cost	396		374
Gross Unrealized Gains	22		31
Gross Unrealized Losses	0		0
Fair Value	418		405
Other corporate
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	17		16
Fair Value	18		18
Other corporate | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	17		16
Allowance for Credit Loss	0		0
Total fixed maturity securities, held-to- maturity, amortized cost	17		16
Gross Unrealized Gains	1		2
Gross Unrealized Losses	0		0
Fair Value	$ 18		$ 18

[1] Net of allowance for credit losses

XML

INVESTMENTS - Equity Securities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Equity Securities, FV-NI [Line Items]
Total equity securities	$ 764	$ 796
Yen-denominated
Equity Securities, FV-NI [Line Items]
Total equity securities	491	484
Dollar-denominated
Equity Securities, FV-NI [Line Items]
Total equity securities	$ 273	$ 312

XML

INVESTMENTS - Contractual and Economic Maturities of Investments in Fixed Maturities (Detail) - USD ($) $ in Millions		Mar. 31, 2025		Dec. 31, 2024
Available for sale:
Due in one year or less	[1]	$ 1,572
Due after one year through five years	[1]	8,158
Due after five years through 10 years	[1]	15,563
Due after 10 years	[1]	38,336
Mortgage- and asset-backed securities	[1]	3,916
Total fixed maturity securities, available-for-sale, amortized cost	[1]	67,545
Held to maturity:
Due in one year or less	[1]	33
Due after one year through five years	[1]	2
Due after five years through 10 years	[1]	9,008
Due after 10 years	[1]	7,845
Total fixed maturity securities, held-to- maturity, amortized cost		16,888	[1]	$ 15,966
Available for sale:
Due in one year or less		1,728
Due after one year through five years		8,943
Due after five years through 10 years		16,267
Due after 10 years		36,158
Mortgage- and asset-backed securities		4,048
Fair Value		67,144		65,269
Held to maturity:
Due in one year or less		35
Due after one year through five years		2
Due after five years through 10 years		9,346
Due after 10 years		7,752
Fair Value		$ 17,135		$ 16,772

[1] Net of allowance for credit losses

XML

INVESTMENTS - Investment Exposures Individually Exceeded 10% of Shareholders' Equity (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2025	Dec. 31, 2024
Summary of Investment Holdings [Line Items]
Credit Rating	[1]	A+	A+
Amortized Cost	[1]	$ 35,251	$ 33,822
Fair Value	[1]	$ 33,082	$ 32,844
Investment, Type [Extensible Enumeration]		Japan National Government	Japan National Government

[1] Japan Government Bonds (JGBs) or JGB-backed securities

XML

INVESTMENTS - Information Regarding Pretax Net Gains and Losses From Investments (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Gain (Loss) on Securities [Line Items]
Gross gains (losses) from sales and redemptions	$ 1	$ 5
Net investment gains (losses)	(963)	951
Credit losses:
Fixed maturity securities held-to-maturity	0	0
Commercial mortgage and other loans	(53)	(7)
Impairment losses	0	0
Loan commitments	(2)	1
Reinsurance recoverables and other	0	5
Total credit losses	(55)	(1)
Derivatives and other:
Derivative gains (losses)	(45)	(215)
Foreign currency gains (losses)	(843)	918
Fixed maturity securities
Gain (Loss) on Securities [Line Items]
Gross gains from sales	114	34
Gross losses from sales	(235)	(282)
Foreign currency gains (losses)	161	416
Debt securities and other investments
Gain (Loss) on Securities [Line Items]
Net investment gains (losses)	41	173
Equity securities
Gain (Loss) on Securities [Line Items]
Net investment gains (losses)	(61)	76
Derivatives and other
Gain (Loss) on Securities [Line Items]
Net investment gains (losses)	$ (888)	$ 703

XML

INVESTMENTS - Net Effect on Shareholders' Equity of Unrealized Gains and Losses from Investment Securities (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Investments [Abstract]
Unrealized gains (losses) on securities available-for-sale	$ (401)	$ 1,180
Deferred income taxes	(832)	(1,156)
Unrealized gains (losses) on fixed maturity securities	$ (1,233)	$ 24

XML

INVESTMENTS - Fair Value and Gross Unrealized Losses for Securities That Have Been in Continuous Unrealized Loss Position (Detail) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	$ 30,364	$ 24,301
Total Unrealized Losses	4,746	4,128
Less than 12 months Fair Value	12,653	6,716
Less than 12 months Unrealized Losses	383	197
12 months or Longer Fair Value	17,711	17,585
12 months or Longer Unrealized Losses	4,363	3,931
U.S. government and agencies | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	68	106
Total Unrealized Losses	2	3
Less than 12 months Fair Value	33	59
Less than 12 months Unrealized Losses	0	1
12 months or Longer Fair Value	35	47
12 months or Longer Unrealized Losses	2	2
Japan government and agencies | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	11,951	8,136
Total Unrealized Losses	2,608	2,234
Less than 12 months Fair Value	6,090	2,070
Less than 12 months Unrealized Losses	179	57
12 months or Longer Fair Value	5,861	6,066
12 months or Longer Unrealized Losses	2,429	2,177
Municipalities | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	656	666
Total Unrealized Losses	68	53
Less than 12 months Fair Value	72	67
Less than 12 months Unrealized Losses	3	3
12 months or Longer Fair Value	584	599
12 months or Longer Unrealized Losses	65	50
Municipalities | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	339	341
Total Unrealized Losses	105	79
Less than 12 months Fair Value	96	96
Less than 12 months Unrealized Losses	8	2
12 months or Longer Fair Value	243	245
12 months or Longer Unrealized Losses	97	77
Mortgage- and asset-backed securities | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	1,091	567
Total Unrealized Losses	46	34
Less than 12 months Fair Value	697	173
Less than 12 months Unrealized Losses	20	2
12 months or Longer Fair Value	394	394
12 months or Longer Unrealized Losses	26	32
Mortgage- and asset-backed securities | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	208	196
Total Unrealized Losses	29	23
Less than 12 months Fair Value	22	12
Less than 12 months Unrealized Losses	0	0
12 months or Longer Fair Value	186	184
12 months or Longer Unrealized Losses	29	23
Public utilities | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	1,689	1,570
Total Unrealized Losses	142	151
Less than 12 months Fair Value	816	699
Less than 12 months Unrealized Losses	17	19
12 months or Longer Fair Value	873	871
12 months or Longer Unrealized Losses	125	132
Public utilities | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	1,037	1,020
Total Unrealized Losses	155	108
Less than 12 months Fair Value	258	368
Less than 12 months Unrealized Losses	23	11
12 months or Longer Fair Value	779	652
12 months or Longer Unrealized Losses	132	97
Public utilities | Other currencies
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	53
Total Unrealized Losses	1
Less than 12 months Fair Value	53
Less than 12 months Unrealized Losses	1
12 months or Longer Fair Value	0
12 months or Longer Unrealized Losses	0
Sovereign and supranational | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	0
Total Unrealized Losses	0
Less than 12 months Fair Value	0
Less than 12 months Unrealized Losses	0
12 months or Longer Fair Value	0
12 months or Longer Unrealized Losses	0
Sovereign and supranational | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	49	47
Total Unrealized Losses	10	8
Less than 12 months Fair Value	0	0
Less than 12 months Unrealized Losses	0	0
12 months or Longer Fair Value	49	47
12 months or Longer Unrealized Losses	10	8
Banks/financial institutions | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	749	625
Total Unrealized Losses	30	36
Less than 12 months Fair Value	544	376
Less than 12 months Unrealized Losses	7	7
12 months or Longer Fair Value	205	249
12 months or Longer Unrealized Losses	23	29
Banks/financial institutions | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	3,576	3,197
Total Unrealized Losses	448	342
Less than 12 months Fair Value	472	471
Less than 12 months Unrealized Losses	14	22
12 months or Longer Fair Value	3,104	2,726
12 months or Longer Unrealized Losses	434	320
Other corporate | Dollar-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	6,596	6,097
Total Unrealized Losses	689	752
Less than 12 months Fair Value	2,690	2,036
Less than 12 months Unrealized Losses	58	59
12 months or Longer Fair Value	3,906	4,061
12 months or Longer Unrealized Losses	631	693
Other corporate | Yen-denominated
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	2,302	1,733
Total Unrealized Losses	413	305
Less than 12 months Fair Value	810	289
Less than 12 months Unrealized Losses	53	14
12 months or Longer Fair Value	1,492	1,444
12 months or Longer Unrealized Losses	$ 360	$ 291

XML

INVESTMENTS - Commercial Mortgage and Other Loans by Portfolio Segment (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 11,024	$ 11,224
Percent of total commercial mortgage and other loans	100.00%	100.00%
Allowance for credit losses	$ (368)	$ (355)
Total net commercial mortgage and other loans	10,656	10,869
Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 4,678	$ 4,902
Percent of total commercial mortgage and other loans	42.50%	43.70%
Allowance for credit losses	$ (203)	$ (199)	$ (114)	$ (112)
Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 1,526	$ 1,537
Percent of total commercial mortgage and other loans	13.70%	13.70%
Allowance for credit losses	$ (15)	$ (14)	(19)	(16)
Middle market loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 4,451	$ 4,423
Percent of total commercial mortgage and other loans	40.40%	39.40%
Allowance for credit losses	$ (150)	$ (140)	$ (99)	$ (146)
Other loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 369	$ 362
Percent of total commercial mortgage and other loans	3.40%	3.20%
Office | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 1,238	$ 1,361
Percent of total commercial mortgage and other loans	11.20%	12.10%
Office | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 298	$ 300
Percent of total commercial mortgage and other loans	2.70%	2.70%
Retail | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 350	$ 349
Percent of total commercial mortgage and other loans	3.20%	3.10%
Retail | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 212	$ 214
Percent of total commercial mortgage and other loans	1.90%	1.90%
Apartment/Multi-Family | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 2,158	$ 2,201
Percent of total commercial mortgage and other loans	19.60%	19.60%
Apartment/Multi-Family | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 569	$ 572
Percent of total commercial mortgage and other loans	5.10%	5.10%
Industrial | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 100	$ 117
Percent of total commercial mortgage and other loans	0.90%	1.10%
Industrial | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 433	$ 436
Percent of total commercial mortgage and other loans	3.90%	3.90%
Hospitality | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 526	$ 556
Percent of total commercial mortgage and other loans	4.80%	5.00%
Other | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 306	$ 318
Percent of total commercial mortgage and other loans	2.80%	2.80%
Other | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 14	$ 15
Percent of total commercial mortgage and other loans	0.10%	0.10%

XML

INVESTMENTS - Transitional Real Estate Loans by Key Credit Quality Indicators (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Loan-to-Value Ratio:
Total	$ 11,024	$ 11,224
Transitional real estate loans
Loan-to-Value Ratio:
2025	14
2024	0
2023	91
2022	1,960
2021	1,810
Prior	803
Total	4,678	$ 4,902
Current-period gross writeoffs:
2025	0
2024	0
2023	0
2022	0
2021	0
Prior	24
Total	24
Transitional real estate loans | Loan to Value Ratio, 0.00% to 59.99%
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	371
2021	390
Prior	47
Total	808
Transitional real estate loans | Loan to Value Ratio, 60.00% to 69.99%
Loan-to-Value Ratio:
2025	0
2024	0
2023	77
2022	431
2021	442
Prior	396
Total	1,346
Transitional real estate loans | Loan to Value Ratio, 70.00% to 79.99%
Loan-to-Value Ratio:
2025	14
2024	0
2023	14
2022	823
2021	625
Prior	64
Total	1,540
Transitional real estate loans | Loan-to-Value Ratio, 80.00% or greater
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	335
2021	353
Prior	296
Total	$ 984

XML

INVESTMENTS - Commercial Mortgage Loans by Key Credit Quality Indicator (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Loan-to-Value Ratio:
Total	$ 11,024	$ 11,224
Commercial mortgage loans
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.52
Loan-to-Value Ratio:
2025	$ 0
2024	13
2023	32
2022	0
2021	290
Prior	1,191
Total	1,526	$ 1,537
Current-period gross writeoffs:
2025	0
2024	0
2023	0
2022	0
2021	0
Prior	0
Total	$ 0
Commercial mortgage loans | 2025
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	0.00
Commercial mortgage loans | 2024
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	1.13
Commercial mortgage loans | 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.62
Commercial mortgage loans | 2022
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	0.00
Commercial mortgage loans | 2021
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	3.16
Commercial mortgage loans | Prior
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.38
Commercial mortgage loans | Loan to Value Ratio, 0.00% to 59.99%
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.72
Loan-to-Value Ratio:
2025	$ 0
2024	0
2023	32
2022	0
2021	265
Prior	1,009
Total	$ 1,306
Commercial mortgage loans | Loan to Value Ratio, 60.00% to 69.99%
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.11
Loan-to-Value Ratio:
2025	$ 0
2024	0
2023	0
2022	0
2021	25
Prior	47
Total	$ 72
Commercial mortgage loans | Loan to Value Ratio, 70.00% to 79.99%
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	1.69
Loan-to-Value Ratio:
2025	$ 0
2024	0
2023	0
2022	0
2021	0
Prior	55
Total	$ 55
Commercial mortgage loans | Loan-to-Value Ratio, 80.00% or greater
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	0.57
Loan-to-Value Ratio:
2025	$ 0
2024	13
2023	0
2022	0
2021	0
Prior	80
Total	$ 93

XML

INVESTMENTS - Middle Market Loans by Key Credit Quality Indicators (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Loan-to-Value Ratio:
Total	$ 11,024	$ 11,224
Middle market loans
Loan-to-Value Ratio:
2025	95
2024	686
2023	125
2022	687
2021	993
Prior	1,703
Revolving Loans	162
Total	4,451	$ 4,423
Current-period gross writeoffs:
2025	0
2024	0
2023	0
2022	0
2021	11
Prior	3
Revolving Loans	0
Total	14
Middle market loans | BBB Credit Rating
Loan-to-Value Ratio:
2025	0
2024	30
2023	29
2022	0
2021	78
Prior	108
Revolving Loans	12
Total	257
Middle market loans | BB Credit Rating
Loan-to-Value Ratio:
2025	61
2024	425
2023	43
2022	426
2021	374
Prior	607
Revolving Loans	76
Total	2,012
Middle market loans | B Credit Rating
Loan-to-Value Ratio:
2025	34
2024	226
2023	53
2022	234
2021	480
Prior	662
Revolving Loans	46
Total	1,735
Middle market loans | CCC Credit Rating
Loan-to-Value Ratio:
2025	0
2024	5
2023	0
2022	14
2021	61
Prior	223
Revolving Loans	19
Total	322
Middle market loans | CC Credit Rating
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	13
2021	0
Prior	16
Revolving Loans	5
Total	34
Middle market loans | C and Lower Credit Rating
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	0
2021	0
Prior	87
Revolving Loans	4
Total	$ 91

XML

INVESTMENTS - Other Loans by Key Credit Quality Indicators (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Loan-to-Value Ratio:
Total	$ 11,024	$ 11,224
Other loans
Loan-to-Value Ratio:
2025	0
2024	184
2023	68
2022	114
2021	3
Prior	0
Revolving Loans	0
Total	369	$ 362
Current-period gross writeoffs:
2025	0
2024	0
2023	0
2022	0
2021	0
Prior	0
Revolving Loans	0
Total	0
Other loans | A Credit Rating
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	79
2021	0
Prior	0
Revolving Loans	0
Total	79
Other loans | AA Credit Rating
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	8
2021	3
Prior	0
Revolving Loans	0
Total	11
Other loans | BBB Credit Rating
Loan-to-Value Ratio:
2025	0
2024	184
2023	68
2022	27
2021	0
Prior	0
Revolving Loans	0
Total	279
Other loans | BB Credit Rating
Loan-to-Value Ratio:
2025	0
2024	0
2023	0
2022	0
2021	0
Prior	0
Revolving Loans	0
Total	$ 0

XML

INVESTMENTS - Nonaccrual Loans (Details) - USD ($) $ in Millions	Mar. 31, 2025		Dec. 31, 2024
Financing Receivable, Past Due [Line Items]
Total	$ 11,024		$ 11,224
Total, nonaccrual status	595		486
Total, 90 days or more past due and still accruing	0		0
Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	4,678		4,902
Total, nonaccrual status	467		378
Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	1,526		1,537
Total, nonaccrual status	0		0
Middle market loans
Financing Receivable, Past Due [Line Items]
Total	4,451		4,423
Total, nonaccrual status	128		108
Other loans
Financing Receivable, Past Due [Line Items]
Total	369		362
Total, nonaccrual status	0		0
Current
Financing Receivable, Past Due [Line Items]
Total	10,389		10,558
Current | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	4,193		4,364
Current | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	1,526		1,537
Current | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	4,301		4,295
Current | Other loans
Financing Receivable, Past Due [Line Items]
Total	369		362
Less Than 90 Days Past Due
Financing Receivable, Past Due [Line Items]
Total	88		258
Less Than 90 Days Past Due | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	18		195
Less Than 90 Days Past Due | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	0		0
Less Than 90 Days Past Due | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	70		63
Less Than 90 Days Past Due | Other loans
Financing Receivable, Past Due [Line Items]
Total	0		0
90 Days or More Past Due
Financing Receivable, Past Due [Line Items]
Total	547	[1]	408	[2]
90 Days or More Past Due | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	467	[1]	343	[2]
90 Days or More Past Due | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	0	[1]	0	[2]
90 Days or More Past Due | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	80	[1]	65	[2]
90 Days or More Past Due | Other loans
Financing Receivable, Past Due [Line Items]
Total	0	[1]	0	[2]
Total Past Due
Financing Receivable, Past Due [Line Items]
Total	635		666
Total Past Due | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	485		538
Total Past Due | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	0		0
Total Past Due | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	150		128
Total Past Due | Other loans
Financing Receivable, Past Due [Line Items]
Total	$ 0		$ 0

[1] As of March 31, 2025, there were no loans that were 90 days or more past due that continued to accrue interest.

[2] As of December 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

XML

INVESTMENTS - Effect of Loan Modifications (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Middle market loans | Principal forgiveness
Financing Receivable, Modified [Line Items]
Loan modification, amortized cost	[1]	$ 1
Loan modification, percent of total amortized cost		0.00%
Loan modification, principal forgiven		$ 3
Middle market loans | Term extension
Financing Receivable, Modified [Line Items]
Loan modification, amortized cost	[1]	$ 33
Loan modification, percent of total amortized cost		1.00%
Loan modification, term extension		6 months
Middle market loans | Other-than-insignificant payment delays
Financing Receivable, Modified [Line Items]
Loan modification, amortized cost	[1]	$ 47
Loan modification, percent of total amortized cost		1.00%
Loan modification, deferral period		23 months
Transitional real estate loans | Other-than-insignificant payment delays and interest rate reduction
Financing Receivable, Modified [Line Items]
Loan modification, amortized cost	[1]		$ 210
Loan modification, percent of total amortized cost			3.00%
Loan modification, deferral period			51 months
Weighted-average interest rate before modification			8.30%
Weighted-average interest rate after modification			6.90%

[1] Net of allowance for credit losses

XML

INVESTMENTS - Loan Performance After Modifications (Details) $ in Millions	Mar. 31, 2025 USD ($)
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months, nonaccrual	$ 20
Current
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	443
Less Than 90 Days Past Due
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	0
90 Days or More Past Due
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	0
Transitional real estate loans
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months, nonaccrual	0
Transitional real estate loans | Current
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	347
Transitional real estate loans | Less Than 90 Days Past Due
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	0
Transitional real estate loans | 90 Days or More Past Due
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	0
Middle market loans
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months, nonaccrual	20
Middle market loans | Current
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	96
Middle market loans | Less Than 90 Days Past Due
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	0
Middle market loans | 90 Days or More Past Due
Financing Receivable, Modified, Past Due [Line Items]
Loan modification, after 12 months	$ 0

XML

INVESTMENTS - Allowance for Loan Losses by Portfolio Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	$ (355)
Balance, end of period	(368)
Balance, beginning of period	(5)	$ (5)
(Addition to) release of allowance for credit losses	0	0
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	(5)	(5)
Balance, beginning of period	0	0
(Addition to) release of allowance for credit losses	0	0
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	0	0
Balance, beginning of period	(375)	(295)
(Addition to) release of allowance for credit losses	(55)	(7)
Write-offs, net of recoveries	38	50
Change in foreign exchange	0	0
Balance, end of period	(392)	(252)
Other Loans and Loan Commitments
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(17)	(16)
(Addition to) release of allowance for credit losses	(2)	1
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	(19)	(15)
Transitional real estate loans
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(199)	(112)
(Addition to) release of allowance for credit losses	(28)	(2)
Write-offs, net of recoveries	24	0
Change in foreign exchange	0	0
Balance, end of period	(203)	(114)
Commercial mortgage loans
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(14)	(16)
(Addition to) release of allowance for credit losses	(1)	(3)
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	(15)	(19)
Middle market loans
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(140)	(146)
(Addition to) release of allowance for credit losses	(24)	(3)
Write-offs, net of recoveries	14	50
Change in foreign exchange	0	0
Balance, end of period	$ (150)	$ (99)

XML

INVESTMENTS - Other Investments (Details) - USD ($) $ in Millions		Mar. 31, 2025	Dec. 31, 2024
Investment Holdings [Line Items]
Other investments		$ 6,763	$ 5,958
Policy loans
Investment Holdings [Line Items]
Other investments		211	203
Short-term investments
Investment Holdings [Line Items]
Other investments	[1]	2,259	1,599
Limited partnerships
Investment Holdings [Line Items]
Other investments	[2]	3,482	3,435
Real estate owned
Investment Holdings [Line Items]
Other investments		774	682
Other
Investment Holdings [Line Items]
Other investments		$ 37	$ 39

[1] Includes securities lending collateral

[2] Includes tax credit investments and asset classes such as private equity and real estate funds

XML

INVESTMENTS - Investments in Consolidated Variable Interest Entities (Detail) - USD ($) $ in Millions		Mar. 31, 2025	Dec. 31, 2024
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		$ 67,144	$ 65,269
Commercial mortgage and other loans		10,656	10,869
Other investments		6,763	5,958
Asset derivatives		148	240
Assets		120,258	117,566
Liability derivatives		985	933
Liabilities		93,920	91,468
Variable Interest Entity, Consolidated
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		3,597	3,428
Commercial mortgage and other loans		8,540	8,693
Other investments	[1]	2,151	2,176
Asset derivatives	[2]	49	53
Assets		14,337	14,350
Liability derivatives	[2]	642	604
Liabilities		$ 642	$ 604

[1] Consists entirely of alternative investments in limited partnerships, which represent VIEs where the Company is not the primary beneficiary and, therefore, are not consolidated

[2] Consists entirely of derivatives

XML

INVESTMENTS - Investments in Variable Interest Entities Not Consolidated (Details) - USD ($) $ in Millions		Mar. 31, 2025	Dec. 31, 2024
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		$ 67,144	$ 65,269
Other investments		6,763	5,958
Assets		120,258	117,566
Variable Interest Entity, Not Consolidated
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		6,624	6,243
Other investments	[1]	1,194	1,124
Assets		$ 7,818	$ 7,367

[1] Consists entirely of alternative investments in limited partnerships

XML

INVESTMENTS - Securities Lending Transactions Accounted for as Secured Borrowings (Details) - USD ($) $ in Millions		Mar. 31, 2025	Dec. 31, 2024
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		$ 3,142	$ 2,037
Gross amount of recognized liabilities for securities lending		3,142	2,037
Japan government and agencies
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		2,303	1,027
Public utilities
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		39	34
Banks/financial institutions
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		131	193
Other corporate
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		669	783
Maturity Overnight and Continuous
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		839	1,010	[1]
Maturity Overnight and Continuous | Japan government and agencies
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	0	0
Maturity Overnight and Continuous | Public utilities
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	39	34
Maturity Overnight and Continuous | Banks/financial institutions
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	131	193
Maturity Overnight and Continuous | Other corporate
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	669	783
Maturity up to 30 Days
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		2,303	1,027
Maturity up to 30 Days | Japan government and agencies
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		2,303	1,027
Maturity up to 30 Days | Public utilities
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		0	0
Maturity up to 30 Days | Banks/financial institutions
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		0	0
Maturity up to 30 Days | Other corporate
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		$ 0	$ 0

[1] The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

XML

INVESTMENTS - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($) investment	Mar. 31, 2024 USD ($) investment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Schedule of Investments [Line Items]
Held to maturity securities transferred to available for sale securities, number of investments | investment	0	0
Equity securities, FV-NI, unrealized gain (loss)	$ 55	$ 71
Transitional real estate loan commitments	245
Middle market loan commitments	664
Other Loans Commitments	1
Nonaccrual loans, interest income	1
Financing Receivable, Modified, Commitment to Lend	5		$ 14
Amortized Cost	16,893		15,971
Credit allowance	368		355
REO, accumulated depreciation	20		14
Limited partnerships investment commitments	$ 2,600		2,800
Percentage that the lending policy requires that the fair value of the securities received as collateral be of the fair value of the loaned securities	102.00%
Percentage that the lending policy requires that the fair value of the unrestricted cash received as collateral be of the fair value of the loaned securities	100.00%
Securities Lending, Securities Received as Collateral	$ 1,300		3,000
Repurchase Agreements and Repurchase-to-Maturity Transactions Outstanding	0		0
Financing receivable, before allowance for credit loss	11,024		11,224
Variable Interest Entity, Not Consolidated
Schedule of Investments [Line Items]
Limited partnerships investment commitments	2,000		2,100
Real estate owned
Schedule of Investments [Line Items]
Depreciation	6	1
Transitional real estate loans
Schedule of Investments [Line Items]
Nonaccrual loans, no allowance	146		140
Credit allowance	203	114	199	$ 112
Financing receivable, before allowance for credit loss	4,678		4,902
Transitional real estate loans | Potential Foreclosure or Deed-in-lieu Foreclosure
Schedule of Investments [Line Items]
Mortgage Loans in Process of Foreclosure, Amount	311
Credit allowance	25
Middle market loans
Schedule of Investments [Line Items]
Nonaccrual loans, no allowance	20		5
Credit allowance	150	$ 99	140	$ 146
Financing receivable, before allowance for credit loss	4,451		$ 4,423
Zero-credit-loss expectation | Japan government and agencies
Schedule of Investments [Line Items]
Amortized Cost	$ 16,100
CALIFORNIA | Geographic Concentration Risk | Mortgages
Schedule of Investments [Line Items]
Concentration Risk, Percentage	21.00%
TEXAS | Geographic Concentration Risk | Mortgages
Schedule of Investments [Line Items]
Concentration Risk, Percentage	14.00%
FLORIDA | Geographic Concentration Risk | Mortgages
Schedule of Investments [Line Items]
Concentration Risk, Percentage	10.00%

XML

DERIVATIVE INSTRUMENTS - Summary of Balance Sheet Classification of Derivative Fair Value Amounts, as well as Gross Asset and Liability Fair Value Amounts (Detail) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Derivatives, Fair Value [Line Items]
Notional Amount	$ 59,408	$ 46,744
Derivative Asset, Fair Value	148	240
Derivative Liability, Fair Value	$ 985	$ 933
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other	Other
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other	Other
Cash flow hedges
Derivatives, Fair Value [Line Items]
Notional Amount	$ 18	$ 18
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	5	6
Cash flow hedges | Foreign currency swaps | Variable Interest Entity, Consolidated
Derivatives, Fair Value [Line Items]
Notional Amount	18	18
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	5	6
Net investment hedge
Derivatives, Fair Value [Line Items]
Notional Amount	2,674	1,809
Derivative Asset, Fair Value	91	185
Derivative Liability, Fair Value	38	0
Net investment hedge | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Notional Amount	2,674	1,809
Derivative Asset, Fair Value	91	185
Derivative Liability, Fair Value	38	0
Non-qualifying strategies
Derivatives, Fair Value [Line Items]
Notional Amount	56,716	44,917
Derivative Asset, Fair Value	57	55
Derivative Liability, Fair Value	942	927
Non-qualifying strategies | Foreign currency swaps | Variable Interest Entity, Consolidated
Derivatives, Fair Value [Line Items]
Notional Amount	3,068	3,042
Derivative Asset, Fair Value	49	53
Derivative Liability, Fair Value	637	598
Non-qualifying strategies | Foreign currency swaps | Consolidated Entity Excluding Variable Interest Entities (VIE)
Derivatives, Fair Value [Line Items]
Notional Amount	0	450
Derivative Asset, Fair Value	0	2
Derivative Liability, Fair Value	0	0
Non-qualifying strategies | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Notional Amount	173	0
Derivative Asset, Fair Value	1	0
Derivative Liability, Fair Value	1	0
Non-qualifying strategies | Foreign currency options
Derivatives, Fair Value [Line Items]
Notional Amount	24,195	24,195
Derivative Asset, Fair Value	2	0
Derivative Liability, Fair Value	0	0
Non-qualifying strategies | Interest rate swaps
Derivatives, Fair Value [Line Items]
Notional Amount	29,280	17,230
Derivative Asset, Fair Value	5	0
Derivative Liability, Fair Value	$ 304	$ 329

XML

DERIVATIVE INSTRUMENTS - Schedule of Interest Rate Fair Value Hedges Hedged Items (Details) - Fixed maturity securities - USD ($) $ in Millions		Mar. 31, 2025	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Carrying Amount of Hedged Assets/ (Liabilities)	[1]	$ 1,305	$ 1,294
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)		$ 128	$ 137

[1] The balance includes hedging adjustment on discontinued hedging relationships of $128 in 2025 and $137 in 2024.

XML

DERIVATIVE INSTRUMENTS - Derivatives and Hedging Instruments Gain (Loss) Summary (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other comprehensive income on derivative		$ 2	$ (5)
Unrealized foreign currency translation gains (losses) during period		352	(501)
Derivative and non-derivative hedging instruments, gain (loss) recognized in other comprehensive income, before tax		(382)	381
Net investment income
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		$ 0	$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Net investment income	Net investment income
Net investment gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		$ (45)	$ (215)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Net investment gains (losses)	Net investment gains (losses)
Reclassification Out Of Accumulated Other Comprehensive Income
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments, cash flow hedges, gains (losses) reclassified from accumulated other comprehensive income into earnings		$ (1)	$ (1)
Cash flow hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other comprehensive income on derivative		2	0
Cash flow hedges | Net investment income
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	0
Cash flow hedges | Net investment gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative	[1]	(1)	(1)
Cash flow hedges | Foreign currency swaps | Variable Interest Entity
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other comprehensive income on derivative		2	0
Cash flow hedges | Foreign currency swaps | Variable Interest Entity | Net investment income
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	0
Cash flow hedges | Foreign currency swaps | Variable Interest Entity | Net investment gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(1)	(1)
Net investment hedge
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		36	44
Unrealized foreign currency translation gains (losses) during period		(384)	381
Net investment hedge | Non-derivative hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	0
Unrealized foreign currency translation gains (losses) during period		(240)	236
Net investment hedge | Foreign currency forwards
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		36	44
Unrealized foreign currency translation gains (losses) during period		(144)	145
Non-qualifying strategies
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(80)	(258)
Non-qualifying strategies | Foreign currency swaps | Variable Interest Entity
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(57)	(88)
Non-qualifying strategies | Foreign currency swaps | Consolidated Entity Excluding Variable Interest Entities (VIE)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	1
Non-qualifying strategies | Foreign currency forwards
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	17
Non-qualifying strategies | Foreign currency options
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(5)	(41)
Non-qualifying strategies | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		$ (18)	$ (147)

[1] Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2025, and $1 of losses during the three-month period ended March 31, 2024.

XML

DERIVATIVE INSTRUMENTS - Offsetting of Financial Assets and Derivative Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Offsetting Assets [Line Items]
Gross amount of recognized derivative assets	$ 99	$ 187
Gross amount of liabilities offset in balance sheet	0	0
Net amount of derivative assets presented in balance sheet	99	187
Financial instruments, amount not offset	(41)	0
Derivative, collateral, obligation to return securities	(12)	(45)
Derivative, collateral, obligation to return cash	(46)	(135)
Derivative asset, fair value, amount offset against collateral, subject to master netting agreement	0	7
Derivative asset, not subject to master netting arrangement	49	53
Derivative asset, fair value, gross asset including not subject to master netting arrangement	148	240
Net amount of derivative assets presented in balance sheet	148	240
Derivative asset, fair value, amount offset against collateral	49	60
Securities lending, gross amounts of recognized financial instruments	3,128	2,001
Securities lending, gross amounts offset in balance sheet	0	0
Securities lending, net amounts of assets presented in balance sheet	3,128	2,001
Securities lending, carrying value of financial instruments not offset in balance sheet	0	0
Securities lending, securities collateral, not offset in balance sheet	0	0
Securities lending, cash collateral, not offset in balance sheet	(3,128)	(2,001)
Securities lending, financial instruments, amount of assets offset against collateral	0	0
Gross amount of recognized assets	3,276	2,241
Gross amounts offset in balance sheet	0	0
Net amounts of assets presented in balance sheet	3,276	2,241
Carrying value of financial instruments not offset in balance sheet	(41)	0
Securities collateral, not offset in balance sheet	(12)	(45)
Cash collateral, not offset in balance sheet	(3,174)	(2,136)
Financial instruments, amount of assets offset against collateral	49	60
OTC - Bilateral
Offsetting Assets [Line Items]
Gross amount of recognized derivative assets	94	187
Gross amount of liabilities offset in balance sheet	0	0
Net amount of derivative assets presented in balance sheet	94	187
Financial instruments, amount not offset	(36)	0
Derivative, collateral, obligation to return securities	(12)	(45)
Derivative, collateral, obligation to return cash	(46)	(135)
Derivative asset, fair value, amount offset against collateral, subject to master netting agreement	0	7
Derivative asset, not subject to master netting arrangement	49	$ 53
OTC- Cleared
Offsetting Assets [Line Items]
Gross amount of recognized derivative assets	5
Gross amount of liabilities offset in balance sheet	0
Net amount of derivative assets presented in balance sheet	5
Financial instruments, amount not offset	(5)
Derivative, collateral, obligation to return securities	0
Derivative, collateral, obligation to return cash	0
Derivative asset, fair value, amount offset against collateral, subject to master netting agreement	$ 0

XML

DERIVATIVE INSTRUMENTS - Offsetting of Financial Liabilities and Derivative Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Offsetting Liabilities [Line Items]
Gross amount of recognized derivative liabilities	$ 343	$ 329
Gross amount of assets offset in balance sheet	0	0
Derivative liability, fair value, amount not offset against collateral	343	329
Financial instruments, amount not offset	(41)	0
Derivative, collateral, right to reclaim securities	(17)	0
Derivative, collateral, right to reclaim cash	(282)	(329)
Derivative liability, fair value, amount offset against collateral, subject to master netting agreement	3	0
Derivative liability, not subject to master netting arrangement	642	604
Derivative liability, fair value, gross liability including not subject to master netting arrangement	985	933
Net amount of derivative liabilities presented in balance sheet	985	933
Derivative liability, fair value, amount offset against collateral	645	604
Securities lending, gross amounts of recognized financial instruments, offsetting liabilities	3,142	2,037
Securities lending, gross amounts offset in statement of financial position, offsetting liabilities	0	0
Securities lending, net amounts of financial instruments presented in balance sheet, offsetting liabilities	3,142	2,037
Securities lending, carrying value of financial instruments, liabilities not offset in balance sheet	(3,128)	(2,001)
Securities lending, securities collateral, liabilities not offset in balance sheet	0	0
Securities lending, cash collateral, liabilities not offset in balance sheet	0	0
Securities lending, financial instruments, amount of liabilities offset against collateral	14	36
Gross amounts of recognized financial instruments, offsetting liabilities	4,127	2,970
Gross amounts offset in statement of financial position, offsetting liabilities	0	0
Net amounts of financial instruments presented in balance sheet, offsetting liabilities	4,127	2,970
Carrying value of financial instruments, liabilities not offset in balance sheet	(3,169)	(2,001)
Securities collateral, liabilities not offset in balance sheet	(17)	0
Cash collateral, liabilities not offset in balance sheet	(282)	(329)
Financial instruments, amount of liabilities offset against collateral	659	640
OTC - Bilateral
Offsetting Liabilities [Line Items]
Gross amount of recognized derivative liabilities	39
Gross amount of assets offset in balance sheet	0
Derivative liability, fair value, amount not offset against collateral	39
Financial instruments, amount not offset	(36)
Derivative, collateral, right to reclaim securities	0
Derivative, collateral, right to reclaim cash	0
Derivative liability, fair value, amount offset against collateral, subject to master netting agreement	3
Derivative liability, not subject to master netting arrangement	642	604
OTC- Cleared
Offsetting Liabilities [Line Items]
Gross amount of recognized derivative liabilities	304	329
Gross amount of assets offset in balance sheet	0	0
Derivative liability, fair value, amount not offset against collateral	304	329
Financial instruments, amount not offset	(5)	0
Derivative, collateral, right to reclaim securities	(17)	0
Derivative, collateral, right to reclaim cash	(282)	(329)
Derivative liability, fair value, amount offset against collateral, subject to master netting agreement	$ 0	$ 0

XML

DERIVATIVE INSTRUMENTS - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Maximum Length of Time Hedged in Cash Flow Hedge	2 years
Fair value hedges of interest rate risk	$ 0	$ 0
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(3)
Derivative, net liability position, aggregate fair value	883	$ 804
Additional Collateral, Aggregate Fair Value	$ 584

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Assets:
Fixed maturity securities, available-for-sale	$ 67,144	$ 65,269
Equity securities	764	796
Other investments	2,259	1,599
Cash and cash equivalents	5,231	6,229
Asset derivatives	148	240
Total assets	75,546	74,133
Liabilities:
Liability derivatives	985	933
Total liabilities	985	933
Foreign currency swaps
Assets:
Asset derivatives	49	55
Liabilities:
Liability derivatives	642	604
Foreign currency forwards
Assets:
Asset derivatives	92	185
Liabilities:
Liability derivatives	39
Foreign currency options
Assets:
Asset derivatives	2
Interest rate swaps
Assets:
Asset derivatives	5
Liabilities:
Liability derivatives	304	329
Government and agencies
Assets:
Fixed maturity securities, available-for-sale	17,817	17,846
Municipalities
Assets:
Fixed maturity securities, available-for-sale	2,055	2,034
Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	4,048	3,563
Public utilities
Assets:
Fixed maturity securities, available-for-sale	7,221	7,045
Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	426	416
Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	9,361	8,956
Other corporate
Assets:
Fixed maturity securities, available-for-sale	26,216	25,409
Level 1
Assets:
Fixed maturity securities, available-for-sale	16,972	17,088
Equity securities	604	639
Other investments	2,259	1,599
Cash and cash equivalents	5,231	6,229
Asset derivatives	0	0
Total assets	25,066	25,555
Liabilities:
Total liabilities	0	0
Level 1 | Foreign currency swaps
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0	0
Level 1 | Foreign currency forwards
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0
Level 1 | Foreign currency options
Assets:
Asset derivatives	0
Level 1 | Interest rate swaps
Assets:
Asset derivatives	0
Liabilities:
Liability derivatives	0	0
Level 1 | Government and agencies
Assets:
Fixed maturity securities, available-for-sale	16,972	17,088
Level 1 | Municipalities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Public utilities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Other corporate
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 2
Assets:
Fixed maturity securities, available-for-sale	47,642	46,114
Equity securities	0	0
Other investments	0	0
Cash and cash equivalents	0	0
Asset derivatives	148	240
Total assets	47,790	46,354
Liabilities:
Total liabilities	985	933
Level 2 | Foreign currency swaps
Assets:
Asset derivatives	49	55
Liabilities:
Liability derivatives	642	604
Level 2 | Foreign currency forwards
Assets:
Asset derivatives	92	185
Liabilities:
Liability derivatives	39
Level 2 | Foreign currency options
Assets:
Asset derivatives	2
Level 2 | Interest rate swaps
Assets:
Asset derivatives	5
Liabilities:
Liability derivatives	304	329
Level 2 | Government and agencies
Assets:
Fixed maturity securities, available-for-sale	845	758
Level 2 | Municipalities
Assets:
Fixed maturity securities, available-for-sale	2,055	2,034
Level 2 | Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	2,445	2,407
Level 2 | Public utilities
Assets:
Fixed maturity securities, available-for-sale	6,465	6,398
Level 2 | Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	402	393
Level 2 | Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	9,351	8,946
Level 2 | Other corporate
Assets:
Fixed maturity securities, available-for-sale	26,079	25,178
Level 3
Assets:
Fixed maturity securities, available-for-sale	2,530	2,067
Equity securities	160	157
Other investments	0	0
Cash and cash equivalents	0	0
Asset derivatives	0	0
Total assets	2,690	2,224
Liabilities:
Total liabilities	0	0
Level 3 | Foreign currency swaps
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0	0
Level 3 | Foreign currency forwards
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0
Level 3 | Foreign currency options
Assets:
Asset derivatives	0
Level 3 | Interest rate swaps
Assets:
Asset derivatives	0
Liabilities:
Liability derivatives	0	0
Level 3 | Government and agencies
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 3 | Municipalities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 3 | Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	1,603	1,156
Level 3 | Public utilities
Assets:
Fixed maturity securities, available-for-sale	756	647
Level 3 | Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	24	23
Level 3 | Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	10	10
Level 3 | Other corporate
Assets:
Fixed maturity securities, available-for-sale	$ 137	$ 231

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets and Liabilities Carried at Cost or Amortized Cost (Details) - USD ($) $ in Millions	Mar. 31, 2025		Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 6,763		$ 5,958
Assets:
Amortized Cost	16,893		15,971
Fixed maturity securities, held-to-maturity, fair value	17,135		16,772
Commercial mortgage and other loans	10,656		10,869
Commercial mortgage and other loans, fair value	10,451		10,653
Other investments carried at amortized cost	37	[1]	39	[2]
Other investments carried at amortized cost, fair value	37	[1]	39	[2]
Total financial instruments assets not carried at fair value	27,581		26,874
Assets fair value disclosure financial instruments carried at cost	27,623		27,464
Liabilities:
Other policyholders’ funds	5,863		5,460
Other policyholders' funds fair value disclosure	5,789		5,389
Notes payable	7,653		7,402
Notes payable, fair value disclosure	7,247		7,027
Total financial instrument liabilities not carried at fair value	13,516		12,862
Liabilities fair value disclosure financial instruments carried at cost	13,036		12,416
Government and agencies
Assets:
Amortized Cost	16,193		15,309
Fixed maturity securities, held-to-maturity, fair value	16,406		16,059
Municipalities
Assets:
Amortized Cost	249		235
Fixed maturity securities, held-to-maturity, fair value	260		257
Public utilities
Assets:
Amortized Cost	33		32
Fixed maturity securities, held-to-maturity, fair value	33		33
Sovereign and supranational
Assets:
Amortized Cost	396		374
Fixed maturity securities, held-to-maturity, fair value	418		405
Other corporate
Assets:
Amortized Cost	17		16
Fixed maturity securities, held-to-maturity, fair value	18		18
Policy loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	211		203
Equity method investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	3,482		3,435
Real estate owned
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	774		682
Level 1
Assets:
Fixed maturity securities, held-to-maturity, fair value	16,262		15,916
Commercial mortgage and other loans, fair value	0		0
Other investments carried at amortized cost, fair value	0	[1]	0	[2]
Assets fair value disclosure financial instruments carried at cost	16,262		15,916
Liabilities:
Other policyholders' funds fair value disclosure	0		0
Notes payable, fair value disclosure	0		0
Liabilities fair value disclosure financial instruments carried at cost	0		0
Level 1 | Government and agencies
Assets:
Fixed maturity securities, held-to-maturity, fair value	16,262		15,916
Level 1 | Municipalities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 1 | Public utilities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 1 | Sovereign and supranational
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 1 | Other corporate
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 2
Assets:
Fixed maturity securities, held-to-maturity, fair value	873		856
Commercial mortgage and other loans, fair value	0		0
Other investments carried at amortized cost, fair value	37	[1]	39	[2]
Assets fair value disclosure financial instruments carried at cost	910		895
Liabilities:
Other policyholders' funds fair value disclosure	0		0
Notes payable, fair value disclosure	6,533		6,352
Liabilities fair value disclosure financial instruments carried at cost	6,533		6,352
Level 2 | Government and agencies
Assets:
Fixed maturity securities, held-to-maturity, fair value	144		143
Level 2 | Municipalities
Assets:
Fixed maturity securities, held-to-maturity, fair value	260		257
Level 2 | Public utilities
Assets:
Fixed maturity securities, held-to-maturity, fair value	33		33
Level 2 | Sovereign and supranational
Assets:
Fixed maturity securities, held-to-maturity, fair value	418		405
Level 2 | Other corporate
Assets:
Fixed maturity securities, held-to-maturity, fair value	18		18
Level 3
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Commercial mortgage and other loans, fair value	10,451		10,653
Other investments carried at amortized cost, fair value	0	[1]	0	[2]
Assets fair value disclosure financial instruments carried at cost	10,451		10,653
Liabilities:
Other policyholders' funds fair value disclosure	5,789		5,389
Notes payable, fair value disclosure	714		675
Liabilities fair value disclosure financial instruments carried at cost	6,503		6,064
Level 3 | Government and agencies
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Municipalities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Public utilities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Sovereign and supranational
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Other corporate
Assets:
Fixed maturity securities, held-to-maturity, fair value	$ 0		$ 0

[1] Excludes policy loans of $211, equity method investments of $3,482, and REO of $774, at carrying value

[2] Excludes policy loans of $203, equity method investments of $3,435, and REO of $682, at carrying value

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets by Pricing Source, Securities Carried at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	$ 67,144	$ 65,269
Equity securities	764	796
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	16,972	17,088
Equity securities	604	639
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	47,642	46,114
Equity securities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,530	2,067
Equity securities	160	157
Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	604	639
Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	604	639
Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	26	26
Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	26	26
Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	134	131
Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	134	131
Government and agencies
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	17,817	17,846
Government and agencies | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	16,972	17,088
Government and agencies | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	845	758
Government and agencies | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	17,496	17,534
Government and agencies | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	16,972	17,088
Government and agencies | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	524	446
Government and agencies | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	321	312
Government and agencies | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	321	312
Government and agencies | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,055	2,034
Municipalities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,055	2,034
Municipalities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,812	1,791
Municipalities | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,812	1,791
Municipalities | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	243	243
Municipalities | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	243	243
Municipalities | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4,048	3,563
Mortgage- and asset-backed securities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,445	2,407
Mortgage- and asset-backed securities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,603	1,156
Mortgage- and asset-backed securities | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,258	2,352
Mortgage- and asset-backed securities | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,258	2,352
Mortgage- and asset-backed securities | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	224	92
Mortgage- and asset-backed securities | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	187	55
Mortgage- and asset-backed securities | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	37	37
Mortgage- and asset-backed securities | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,566	1,119
Mortgage- and asset-backed securities | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,566	1,119
Public utilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	7,221	7,045
Public utilities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	6,465	6,398
Public utilities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	756	647
Public utilities | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,644	3,628
Public utilities | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,644	3,628
Public utilities | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,821	2,770
Public utilities | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,821	2,770
Public utilities | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	756	647
Public utilities | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	756	647
Sovereign and supranational
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	426	416
Sovereign and supranational | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	402	393
Sovereign and supranational | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	24	23
Sovereign and supranational | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	78	78
Sovereign and supranational | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	78	78
Sovereign and supranational | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	324	315
Sovereign and supranational | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	324	315
Sovereign and supranational | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	24	23
Sovereign and supranational | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	24	23
Banks/financial institutions
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	9,361	8,956
Banks/financial institutions | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	9,351	8,946
Banks/financial institutions | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	10	10
Banks/financial institutions | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	5,416	4,975
Banks/financial institutions | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	5,416	4,975
Banks/financial institutions | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,941	3,976
Banks/financial institutions | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,935	3,971
Banks/financial institutions | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	6	5
Banks/financial institutions | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4	5
Banks/financial institutions | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4	5
Other corporate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	26,216	25,409
Other corporate | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	26,079	25,178
Other corporate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	137	231
Other corporate | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	20,762	20,051
Other corporate | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	20,762	20,051
Other corporate | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	5,338	5,243
Other corporate | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	5,317	5,127
Other corporate | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	21	116
Other corporate | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	116	115
Other corporate | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	$ 116	$ 115

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets by Pricing Source, Securities Carried at Amortized Cost (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	$ 17,135	$ 16,772
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	16,262	15,916
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	873	856
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Government and agencies
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	16,406	16,059
Government and agencies | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	16,262	15,916
Government and agencies | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	144	143
Government and agencies | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Government and agencies | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	16,406	16,059
Government and agencies | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	16,262	15,916
Government and agencies | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	144	143
Government and agencies | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	260	257
Municipalities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	260	257
Municipalities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	260	257
Municipalities | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	260	257
Municipalities | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	33	33
Public utilities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	33	33
Public utilities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	33	33
Public utilities | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	33	33
Public utilities | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	418	405
Sovereign and supranational | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	418	405
Sovereign and supranational | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	205	198
Sovereign and supranational | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	205	198
Sovereign and supranational | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Internal valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	213	207
Sovereign and supranational | Internal valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Internal valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	213	207
Sovereign and supranational | Internal valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	18	18
Other corporate | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	18	18
Other corporate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate | Third party pricing vendor valuation technique
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	18	18
Other corporate | Third party pricing vendor valuation technique | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate | Third party pricing vendor valuation technique | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	18	18
Other corporate | Third party pricing vendor valuation technique | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	$ 0	$ 0

XML

FAIR VALUE MEASUREMENTS - Changes in Investments and Derivatives Carried at Fair Value Classified as Level 3 (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 2,224	$ 2,029
Net investment gains (losses) included in earnings	1	(4)
Unrealized gains (losses) included in other comprehensive income (loss)	19	(19)
Purchases	547	220
Issuances	0	0
Sales	(1)	0
Settlements	(20)	(142)
Transfers into Level 3	15	226
Transfers out of Level 3	(95)	(233)
Balance, end of period	2,690	2,077
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$ 1	$ (2)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net investment gains (losses)	Net investment gains (losses)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), before Tax	Other Comprehensive Income (Loss), before Tax
Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net investment gains (losses), Other Comprehensive Income (Loss), before Tax	Net investment gains (losses), Other Comprehensive Income (Loss), before Tax
Fixed maturity securities | Mortgage- and asset-backed securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 1,156	$ 772
Net investment gains (losses) included in earnings	0	1
Unrealized gains (losses) included in other comprehensive income (loss)	10	(4)
Purchases	434	118
Issuances	0	0
Sales	0	0
Settlements	(12)	(28)
Transfers into Level 3	15	0
Transfers out of Level 3	0	0
Balance, end of period	1,603	859
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	1
Fixed maturity securities | Public utilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	647	253
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	6	(10)
Purchases	110	60
Issuances	0	0
Sales	0	0
Settlements	(7)	(22)
Transfers into Level 3	0	226
Transfers out of Level 3	0	0
Balance, end of period	756	507
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Fixed maturity securities | Sovereign and supranational
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	23	30
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	1	(2)
Purchases	0	0
Issuances	0	0
Sales	0	0
Settlements	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	24	28
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Fixed maturity securities | Banks/financial institutions
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	10	78
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	0	(4)
Purchases	0	5
Issuances	0	0
Sales	0	0
Settlements	0	(5)
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	10	74
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Fixed maturity securities | Other corporate
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	231	648
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	2	1
Purchases	0	37
Issuances	0	0
Sales	0	0
Settlements	(1)	(3)
Transfers into Level 3	0	0
Transfers out of Level 3	(95)	(233)
Balance, end of period	137	450
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Equity securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	157	248
Net investment gains (losses) included in earnings	1	(5)
Unrealized gains (losses) included in other comprehensive income (loss)	0	0
Purchases	3	0
Issuances	0	0
Sales	(1)	0
Settlements	0	(84)
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	160	159
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$ 1	$ (3)

XML

FAIR VALUE MEASUREMENTS - Fair Value Measurement Inputs and Valuation Techniques (Details) $ in Millions		Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 67,144	$ 65,269
Equity securities		764	796
Total assets		75,546	74,133
Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		2,530	2,067
Equity securities		160	157
Total assets		2,690	2,224
Adjusted cost valuation technique | Level 3 | Private Financials
Fair Value Measurement Inputs and Valuation Techniques
Equity securities		160	157
Municipalities
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		2,055	2,034
Municipalities | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		0	0
Mortgage- and asset-backed securities
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		4,048	3,563
Mortgage- and asset-backed securities | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		1,603	1,156
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 1,603	$ 1,156
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Lower Limit | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]	86.24	84.08
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Upper Limit | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]	106.46	104.60
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Weighted Average | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]	99.62	99.07
Public utilities
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 7,221	$ 7,045
Public utilities | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		756	647
Public utilities | Discounted cash flow technique | Level 3 | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 756	$ 647
Public utilities | Discounted cash flow technique | Level 3 | Lower Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0100	0.0100
Public utilities | Discounted cash flow technique | Level 3 | Upper Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0407	0.0375
Public utilities | Discounted cash flow technique | Level 3 | Weighted Average | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0164	0.0162
Sovereign and supranational
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 426	$ 416
Sovereign and supranational | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		24	23
Sovereign and supranational | Consensus pricing valuation technique | Level 3 | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		24	23
Banks/financial institutions
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		9,361	8,956
Banks/financial institutions | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		10	10
Banks/financial institutions | Adjusted cost valuation technique | Level 3 | Private Financials
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		10	10
Other corporate
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		26,216	25,409
Other corporate | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		137	231
Other corporate | Discounted cash flow technique | Level 3 | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 137	$ 231
Other corporate | Discounted cash flow technique | Level 3 | Lower Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0100	0.0091
Other corporate | Discounted cash flow technique | Level 3 | Upper Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0294	0.0294
Other corporate | Discounted cash flow technique | Level 3 | Weighted Average | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0198	0.0173

[1] Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques

[2] Actual or equivalent credit spreads in basis points

XML

DEFERRED POLICY ACQUISITION COSTS - Schedule Of Deferred Policy Acquisition Costs (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	$ 8,758	$ 9,132	$ 9,132
Capitalization	246		1,056
Amortization expense	(216)	(215)	(851)
Foreign currency translation and other	295		(579)
Ending balance	9,083		8,758
Aflac Japan | Cancer
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	2,776	2,971	2,971
Capitalization	61		300
Amortization expense	(46)		(184)
Foreign currency translation and other	160		(311)
Ending balance	2,951		2,776
Aflac Japan | Medical and other health
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	1,833	2,041	2,041
Capitalization	27		103
Amortization expense	(25)		(100)
Foreign currency translation and other	107		(211)
Ending balance	1,942		1,833
Aflac Japan | Life insurance
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	441	491	491
Capitalization	9		36
Amortization expense	(8)		(34)
Foreign currency translation and other	27		(52)
Ending balance	469		441
Aflac Japan | Other
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	52	56	56
Capitalization	1		4
Amortization expense	0		(3)
Foreign currency translation and other	1		(5)
Ending balance	54		52
Aflac U.S. | Life insurance
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	219	172	172
Capitalization	22		77
Amortization expense	(9)		(30)
Foreign currency translation and other	0		0
Ending balance	232		219
Aflac U.S. | Accident
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	915	917	917
Capitalization	33		141
Amortization expense	(36)		(143)
Foreign currency translation and other	0		0
Ending balance	912		915
Aflac U.S. | Disability
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	636	625	625
Capitalization	31		129
Amortization expense	(31)		(118)
Foreign currency translation and other	0		0
Ending balance	636		636
Aflac U.S. | Critical Care
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	1,348	1,336	1,336
Capitalization	38		165
Amortization expense	(39)		(153)
Foreign currency translation and other	0		0
Ending balance	1,347		1,348
Aflac U.S. | Hospital Indemnity
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	452	436	436
Capitalization	21		89
Amortization expense	(19)		(73)
Foreign currency translation and other	0		0
Ending balance	454		452
Aflac U.S. | Dental/Vision
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	86	86	86
Capitalization	3		12
Amortization expense	(3)		(12)
Foreign currency translation and other	0		0
Ending balance	86		86
Aflac U.S. | Other
Deferred Policy Acquisition Cost [Line Items]
Beginning balance	0	$ 1	1
Capitalization	0		0
Amortization expense	0		(1)
Foreign currency translation and other	0		0
Ending balance	$ 0		$ 0

XML

POLICY LIABILITIES - Schedule of Changes in Present Value of Expected Net Premiums and Expected Future Policy Benefits (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Present value of expected future policy benefits:
Beginning balance		$ 111,508
Ending balance		113,348	$ 111,508
Net liability for future policy benefits		71,197	70,381
Aflac Japan | Cancer
Present value of expected premiums:
Beginning balance		14,184	17,509
Beginning balance at original discount rate		14,008	16,452
Effect of changes in cash flow assumptions			0	$ (625)
Effect of actual variances from expected experience			(6)	(71)
Adjusted beginning of period balance			14,002
Issuances		211	983
Interest accrual		91	378
Net premiums collected	[1]	(350)	(1,453)
Foreign currency translation		812	(1,655)
Other		0	(1)
Ending balance at original discount rate		14,766	14,008
Effect of changes in discount rate assumptions		(270)	176
Ending balance		14,496	14,184
Present value of expected future policy benefits:
Beginning balance		40,781	50,161
Beginning balance at original discount rate		37,856	43,626
Effect of changes in cash flow assumptions			0	(815)
Effect of actual variances from expected experience			(20)	(117)
Adjusted beginning of period balance			37,836	42,694
Issuances		215	1,004
Interest accrual		324	1,356
Benefit payments		(666)	(2,773)
Foreign currency translation		2,191	(4,425)
Other		0	0
Ending balance at original discount rate		39,900	37,856
Effect of changes in discount rate assumptions		1,538	2,925
Ending balance		41,438	40,781
Net liability for future policy benefits		26,942	26,597
Less: reinsurance recoverable		5,156	5,085
Net liability for future policy benefits after reinsurance recoverable		21,786	21,512	15,756
Aflac Japan | Medical and other health
Present value of expected premiums:
Beginning balance		11,817	14,697
Beginning balance at original discount rate		11,845	14,040
Effect of changes in cash flow assumptions			0	(154)
Effect of actual variances from expected experience			(45)	(164)
Adjusted beginning of period balance			11,800
Issuances		72	361
Interest accrual		72	302
Net premiums collected	[1]	(268)	(1,135)
Foreign currency translation		685	(1,405)
Other		0	0
Ending balance at original discount rate		12,361	11,845
Effect of changes in discount rate assumptions		(415)	(28)
Ending balance		11,946	11,817
Present value of expected future policy benefits:
Beginning balance		20,606	25,257
Beginning balance at original discount rate		21,957	25,023
Effect of changes in cash flow assumptions			0	(228)
Effect of actual variances from expected experience			(55)	(193)
Adjusted beginning of period balance			21,902	24,602
Issuances		75	373
Interest accrual		138	570
Benefit payments		(246)	(1,033)
Foreign currency translation		1,270	(2,555)
Other		0	0
Ending balance at original discount rate		23,139	21,957
Effect of changes in discount rate assumptions		(2,291)	(1,351)
Ending balance		20,848	20,606
Net liability for future policy benefits		8,902	8,789
Less: reinsurance recoverable		1,259	1,245
Net liability for future policy benefits after reinsurance recoverable		7,643	7,544	13,722
Aflac Japan | Life insurance
Present value of expected premiums:
Beginning balance		5,156	6,488
Beginning balance at original discount rate		5,084	6,258
Effect of changes in cash flow assumptions			0	(190)
Effect of actual variances from expected experience			(10)	(97)
Adjusted beginning of period balance			5,074
Issuances		120	478
Interest accrual		27	110
Net premiums collected	[1]	(201)	(862)
Foreign currency translation		292	(613)
Other		0	0
Ending balance at original discount rate		5,312	5,084
Effect of changes in discount rate assumptions		(29)	72
Ending balance		5,283	5,156
Present value of expected future policy benefits:
Beginning balance		24,265	29,731
Beginning balance at original discount rate		26,330	30,256
Effect of changes in cash flow assumptions			0	(302)
Effect of actual variances from expected experience			(7)	(110)
Adjusted beginning of period balance			26,323	29,844
Issuances		122	488
Interest accrual		141	582
Benefit payments		(604)	(1,510)
Foreign currency translation		1,518	(3,074)
Other		0	0
Ending balance at original discount rate		27,500	26,330
Effect of changes in discount rate assumptions		(3,022)	(2,065)
Ending balance		24,478	24,265
Net liability for future policy benefits		19,195	19,109
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		19,195	19,109	5,971
Aflac Japan | Other
Present value of expected premiums:
Beginning balance		846	1,088
Beginning balance at original discount rate		864	1,069
Effect of changes in cash flow assumptions			0	(19)
Effect of actual variances from expected experience			(2)	(14)
Adjusted beginning of period balance			862
Issuances		3	16
Interest accrual		4	17
Net premiums collected	[1]	(24)	(101)
Foreign currency translation		50	(104)
Other		0	0
Ending balance at original discount rate		895	864
Effect of changes in discount rate assumptions		(42)	(18)
Ending balance		853	846
Present value of expected future policy benefits:
Beginning balance		4,225	5,178
Beginning balance at original discount rate		4,765	5,444
Effect of changes in cash flow assumptions			0	(7)
Effect of actual variances from expected experience			(7)	(24)
Adjusted beginning of period balance			4,758	5,413
Issuances		4	22
Interest accrual		22	93
Benefit payments		(57)	(208)
Foreign currency translation		276	(555)
Other		0	0
Ending balance at original discount rate		5,003	4,765
Effect of changes in discount rate assumptions		(736)	(540)
Ending balance		4,267	4,225
Net liability for future policy benefits		3,414	3,379
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		3,414	3,379	1,036
Aflac U.S. | Life insurance
Present value of expected premiums:
Beginning balance		909	853
Beginning balance at original discount rate		976	909
Effect of changes in cash flow assumptions			0	(5)
Effect of actual variances from expected experience			(9)	(29)
Adjusted beginning of period balance			967
Issuances		70	226
Interest accrual		10	37
Net premiums collected	[1]	(41)	(157)
Foreign currency translation		0	0
Other		0	(5)
Ending balance at original discount rate		1,006	976
Effect of changes in discount rate assumptions		(53)	(67)
Ending balance		953	909
Present value of expected future policy benefits:
Beginning balance		1,847	1,764
Beginning balance at original discount rate		2,126	1,971
Effect of changes in cash flow assumptions			0	(3)
Effect of actual variances from expected experience			(14)	(43)
Adjusted beginning of period balance			2,112	1,925
Issuances		77	231
Interest accrual		21	78
Benefit payments		(27)	(108)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		2,183	2,126
Effect of changes in discount rate assumptions		(255)	(279)
Ending balance		1,928	1,847
Net liability for future policy benefits		975	938
Less: reinsurance recoverable		20	18
Net liability for future policy benefits after reinsurance recoverable		955	920	875
Aflac U.S. | Accident
Present value of expected premiums:
Beginning balance		2,497	2,488
Beginning balance at original discount rate		2,687	2,630
Effect of changes in cash flow assumptions			0	65
Effect of actual variances from expected experience			(14)	66
Adjusted beginning of period balance			2,673
Issuances		108	307
Interest accrual		27	106
Net premiums collected	[1]	(119)	(479)
Foreign currency translation		0	0
Other		0	(8)
Ending balance at original discount rate		2,689	2,687
Effect of changes in discount rate assumptions		(160)	(190)
Ending balance		2,529	2,497
Present value of expected future policy benefits:
Beginning balance		3,127	3,109
Beginning balance at original discount rate		3,386	3,302
Effect of changes in cash flow assumptions			0	109
Effect of actual variances from expected experience			(13)	91
Adjusted beginning of period balance			3,373	3,502
Issuances		113	311
Interest accrual		34	133
Benefit payments		(144)	(560)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		3,376	3,386
Effect of changes in discount rate assumptions		(221)	(259)
Ending balance		3,155	3,127
Net liability for future policy benefits		626	630
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		626	630	2,761
Aflac U.S. | Disability
Present value of expected premiums:
Beginning balance		1,635	1,652
Beginning balance at original discount rate		1,726	1,738
Effect of changes in cash flow assumptions			0	(47)
Effect of actual variances from expected experience			(18)	12
Adjusted beginning of period balance			1,708
Issuances		118	364
Interest accrual		17	66
Net premiums collected	[1]	(99)	(401)
Foreign currency translation		0	0
Other		0	(6)
Ending balance at original discount rate		1,744	1,726
Effect of changes in discount rate assumptions		(72)	(91)
Ending balance		1,672	1,635
Present value of expected future policy benefits:
Beginning balance		2,330	2,422
Beginning balance at original discount rate		2,466	2,541
Effect of changes in cash flow assumptions			0	(73)
Effect of actual variances from expected experience			(24)	(16)
Adjusted beginning of period balance			2,442	2,452
Issuances		125	381
Interest accrual		24	98
Benefit payments		(120)	(465)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		2,471	2,466
Effect of changes in discount rate assumptions		(109)	(136)
Ending balance		2,362	2,330
Net liability for future policy benefits		690	695
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		690	695	1,703
Aflac U.S. | Critical Care
Present value of expected premiums:
Beginning balance		3,901	4,074
Beginning balance at original discount rate		4,340	4,416
Effect of changes in cash flow assumptions			0	(106)
Effect of actual variances from expected experience			(9)	(100)
Adjusted beginning of period balance			4,331
Issuances		214	543
Interest accrual		44	173
Net premiums collected	[1]	(142)	(578)
Foreign currency translation		0	0
Other		0	(8)
Ending balance at original discount rate		4,447	4,340
Effect of changes in discount rate assumptions		(389)	(439)
Ending balance		4,058	3,901
Present value of expected future policy benefits:
Beginning balance		10,701	11,290
Beginning balance at original discount rate		12,013	12,120
Effect of changes in cash flow assumptions			0	(112)
Effect of actual variances from expected experience			(13)	(144)
Adjusted beginning of period balance			12,000	11,864
Issuances		226	559
Interest accrual		129	515
Benefit payments		(249)	(925)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		12,106	12,013
Effect of changes in discount rate assumptions		(1,184)	(1,312)
Ending balance		10,922	10,701
Net liability for future policy benefits		6,864	6,800
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		6,864	6,800	4,210
Aflac U.S. | Hospital Indemnity
Present value of expected premiums:
Beginning balance		1,122	1,107
Beginning balance at original discount rate		1,221	1,193
Effect of changes in cash flow assumptions			0	(21)
Effect of actual variances from expected experience			(1)	21
Adjusted beginning of period balance			1,220
Issuances		88	231
Interest accrual		12	46
Net premiums collected	[1]	(61)	(244)
Foreign currency translation		0	0
Other		0	(5)
Ending balance at original discount rate		1,259	1,221
Effect of changes in discount rate assumptions		(86)	(99)
Ending balance		1,173	1,122
Present value of expected future policy benefits:
Beginning balance		1,897	1,943
Beginning balance at original discount rate		2,073	2,076
Effect of changes in cash flow assumptions			0	(31)
Effect of actual variances from expected experience			(3)	21
Adjusted beginning of period balance			2,070	2,066
Issuances		92	237
Interest accrual		21	84
Benefit payments		(84)	(314)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		2,099	2,073
Effect of changes in discount rate assumptions		(154)	(176)
Ending balance		1,945	1,897
Net liability for future policy benefits		772	775
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		772	775	1,193
Aflac U.S. | Dental/Vision
Present value of expected premiums:
Beginning balance		196	206
Beginning balance at original discount rate		209	217
Effect of changes in cash flow assumptions			0	(17)
Effect of actual variances from expected experience			(4)	(12)
Adjusted beginning of period balance			205
Issuances		17	52
Interest accrual		2	9
Net premiums collected	[1]	(10)	(39)
Foreign currency translation		0	0
Other		0	(1)
Ending balance at original discount rate		214	209
Effect of changes in discount rate assumptions		(11)	(13)
Ending balance		203	196
Present value of expected future policy benefits:
Beginning balance		441	478
Beginning balance at original discount rate		477	506
Effect of changes in cash flow assumptions			0	(28)
Effect of actual variances from expected experience			(4)	(16)
Adjusted beginning of period balance			473	462
Issuances		15	55
Interest accrual		5	20
Benefit payments		(15)	(60)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		478	477
Effect of changes in discount rate assumptions		(30)	(36)
Ending balance		448	441
Net liability for future policy benefits		245	245
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		245	245	188
Aflac U.S. | Other
Present value of expected premiums:
Beginning balance		826	277
Beginning balance at original discount rate		824	272
Effect of changes in cash flow assumptions			0	(8)
Effect of actual variances from expected experience			3	13
Adjusted beginning of period balance			827
Issuances		229	592
Interest accrual		11	25
Net premiums collected	[1]	(22)	(53)
Foreign currency translation		0	0
Other		(10)	(17)
Ending balance at original discount rate		1,035	824
Effect of changes in discount rate assumptions		55	2
Ending balance		1,090	826
Present value of expected future policy benefits:
Beginning balance		1,288	798
Beginning balance at original discount rate		1,293	769
Effect of changes in cash flow assumptions			0	(12)
Effect of actual variances from expected experience			4	(7)
Adjusted beginning of period balance			1,297	750
Issuances		232	597
Interest accrual		17	50
Benefit payments		(41)	(104)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		1,505	1,293
Effect of changes in discount rate assumptions		52	(5)
Ending balance		1,557	1,288
Net liability for future policy benefits		467	462
Less: reinsurance recoverable		2	0
Net liability for future policy benefits after reinsurance recoverable		$ 465	$ 462	$ 277

[1] Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

XML

POLICY LIABILITIES - Schedule of Weighted-Average Interest Rate and Liability for Future Policy Benefit (Details)		Mar. 31, 2025	Dec. 31, 2024
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	3.90%	3.90%
Weighted-average interest, current discount rate	[1]	2.70%	2.20%
Weighted-average liability duration		12 years 7 months 6 days	12 years 7 months 6 days
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	2.50%	2.50%
Weighted-average interest, current discount rate	[1]	3.20%	2.80%
Weighted-average liability duration		23 years 2 months 12 days	23 years 6 months
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	2.10%	2.10%
Weighted-average interest, current discount rate	[1]	2.60%	2.10%
Weighted-average liability duration		16 years 2 months 12 days	16 years 1 month 6 days
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	3.90%	3.80%
Weighted-average interest, current discount rate	[1]	5.40%	5.30%
Weighted-average liability duration		13 years 6 months	13 years 6 months
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.00%	4.00%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		7 years 8 months 12 days	7 years 8 months 12 days
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.30%	4.30%
Weighted-average interest, current discount rate	[1]	5.20%	5.20%
Weighted-average liability duration		5 years 7 months 6 days	5 years 7 months 6 days
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.60%	4.60%
Weighted-average interest, current discount rate	[1]	5.50%	5.30%
Weighted-average liability duration		11 years	11 years 1 month 6 days
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.50%	4.50%
Weighted-average interest, current discount rate	[1]	5.40%	5.30%
Weighted-average liability duration		9 years	9 years
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.30%	4.30%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		7 years 7 months 6 days	7 years 7 months 6 days
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	1.80%	1.80%
Weighted-average interest, current discount rate	[1]	3.00%	2.50%
Weighted-average liability duration		16 years 6 months	16 years 8 months 12 days
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	5.50%	5.40%
Weighted-average interest, current discount rate	[1]	5.50%	5.30%
Weighted-average liability duration		8 years 9 months 18 days	9 years 1 month 6 days

[1] The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

XML

POLICY LIABILITIES - Reconciliation of Future Policy Benefits (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	$ 71,197	$ 70,381
Deferred reinsurance gain liability	152	146
Intercompany eliminations
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	(5,861)	(5,760)
Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Deferred profit liability	1,990	1,844
Deferred reinsurance gain liability	860	806
Corporate and other
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	5,116	5,072
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	26,942	26,597
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	8,902	8,789
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	19,195	19,109
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	975	938
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	626	630
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	690	695
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	6,864	6,800
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	772	775
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	245	245
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	3,414	3,379
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	$ 467	$ 462

XML

POLICY LIABILITIES - Summary of Net Earned Premiums Recognized (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	$ 3,381	$ 3,456
Reinsurance ceded	(88)	(69)
Corporate and other
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	198	165
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	839	878
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	529	605
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	316	339
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	169	138
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	311	325
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	352	333
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	441	444
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	184	185
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	49	59
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	32	34
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	$ 49	$ 20

XML

POLICY LIABILITIES - Summary of Interest Expense Related to Insurance Contracts Recognized (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	$ 559	$ 576
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	233	246
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	66	65
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	114	118
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	11	10
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	7	6
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	7	8
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	85	85
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	9	9
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	3	3
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	18	19
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	$ 6	$ 7

XML

POLICY LIABILITIES - Summary of Undiscounted Expected Future Gross Premiums and Future Benefits and Expenses (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	$ 148,495	$ 142,653
Benefits and Expenses	181,215	173,393
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	54,446	51,712
Benefits and Expenses	59,903	56,881
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	34,739	33,250
Benefits and Expenses	36,751	34,864
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	11,492	10,915
Benefits and Expenses	39,412	37,520
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	3,091	2,966
Benefits and Expenses	3,686	3,559
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	8,843	8,862
Benefits and Expenses	4,673	4,687
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	5,748	5,727
Benefits and Expenses	3,110	3,094
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	19,780	19,624
Benefits and Expenses	20,463	20,340
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	4,937	4,859
Benefits and Expenses	3,052	3,017
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,117	1,118
Benefits and Expenses	684	679
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,538	1,477
Benefits and Expenses	6,790	6,479
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	2,764	2,143
Benefits and Expenses	$ 2,691	$ 2,273

XML

POLICY LIABILITIES - Summary of Discounted Expected Future Gross Premiums and Future Benefits and Expenses (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	$ 108,031	$ 105,686
Benefits and Expenses	113,348	111,508
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	40,989	40,170
Benefits and Expenses	41,438	40,781	$ 50,161
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	25,461	25,171
Benefits and Expenses	20,848	20,606	25,257
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	9,630	9,367
Benefits and Expenses	24,478	24,265	29,731
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	2,160	2,050
Benefits and Expenses	1,928	1,847	1,764
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	6,116	6,057
Benefits and Expenses	3,155	3,127	3,109
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	4,456	4,404
Benefits and Expenses	2,362	2,330	2,422
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	12,152	11,900
Benefits and Expenses	10,922	10,701	11,290
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	3,412	3,312
Benefits and Expenses	1,945	1,897	1,943
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	768	761
Benefits and Expenses	448	441	478
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,219	1,204
Benefits and Expenses	4,267	4,225	5,178
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,668	1,290
Benefits and Expenses	$ 1,557	$ 1,288	$ 798

XML

POLICY LIABILITIES - Schedule of Changes in Other Policyholders' Funds (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2025	Dec. 31, 2024
Policyholder Account Balance [Line Items]
Other deposit type reserves		$ 369	$ 239
Other policyholders’ funds		5,863	5,460
Aflac Japan | Fixed Annuity
Policyholder Account Balance [Line Items]
Beginning balance	[1]	5,221	5,939
Premiums received	[1]	29	104
Transfers from WAYS conversions	[1]	74	249
Surrenders and withdrawals	[1]	(18)	(58)
Benefit payments	[1]	(128)	(446)
Interest credited	[1]	12	49
Foreign currency translation and other	[1]	304	(616)
Ending balance	[1]	$ 5,494	$ 5,221

[1] Aflac Japan fixed annuities

XML

POLICY LIABILITIES - Schedule of Other Policyholders' Funds by Guaranteed Crediting Rates (Details) - USD ($) $ in Millions		Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder Account Balance, Weighted Average Crediting Rate		1.50%	1.50%
Aflac Japan | Fixed Annuity
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
At Guaranteed Minimum	[1]	$ 5,494	$ 5,221	$ 5,939
Cash Surrender Value	[1]	$ 5,420	$ 5,150
Lower Limit | Aflac Japan | Fixed Annuity
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Guaranteed Minimum Crediting Rates	[1],[2]	0.50%	0.50%
Upper Limit | Aflac Japan | Fixed Annuity
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Guaranteed Minimum Crediting Rates	[1],[2]	2.20%	2.20%

[1] Aflac Japan fixed annuities

[2] Weighted-average crediting rate of 1.5% at March 31, 2025 and December 31, 2024.

XML

REINSURANCE - Effect of Reinsurance on Premiums and Benefits and Claims (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Reinsurance Disclosures [Abstract]
Earned premiums, direct		$ 3,433	$ 3,482
Earned premiums, ceded		(88)	(69)
Earned premiums, assumed		36	43
Net earned premiums	[1]	3,381	3,456
Benefits and claims, excluding reserve remeasurement, direct		2,031	2,082
Benefits and claims, excluding reserve remeasurement, ceded		(56)	(33)
Benefits and claims, excluding reserve remeasurement, assumed		11	17
Benefits and claims, excluding reserve remeasurement		1,986	2,066
Reserve remeasurement (gains) losses, direct		(41)	(57)
Reserve remeasurement (gains) losses, ceded		0	1
Reserve remeasurement (gains) losses		41	56
Total benefits and claims, net		$ 1,945	$ 2,010

[1] Includes a gain (loss) of an immaterial amount and $(3) for the three-month periods ended March 31, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.

XML

REINSURANCE - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Reinsurance Disclosures [Abstract]
Deferred reinsurance gain liability	$ 152	$ 146
Reinsurance recoverable	166	163
Reinsurance Recoverable, Allowance for Credit Loss	$ 4	$ 4

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Summary of Notes Payable (Detail 1) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Notes payable and lease obligations	$ 7,751	$ 7,498
Finance lease obligations	4	5
Operating lease obligations	94	91
1.125% senior sustainability notes due March 2026
Debt Instrument [Line Items]
Notes payable and lease obligations	399	399
2.875% senior notes due October 2026
Debt Instrument [Line Items]
Notes payable and lease obligations	299	299
3.60% senior notes due April 2030
Debt Instrument [Line Items]
Notes payable and lease obligations	994	994
6.90% senior notes due December 2039
Debt Instrument [Line Items]
Notes payable and lease obligations	221	221
6.45% senior notes due August 2040
Debt Instrument [Line Items]
Notes payable and lease obligations	255	255
4.00% senior notes due October 2046
Debt Instrument [Line Items]
Notes payable and lease obligations	394	394
4.750% senior notes due January 2049
Debt Instrument [Line Items]
Notes payable and lease obligations	542	542
.300% senior notes due September 2025
Debt Instrument [Line Items]
Notes payable and lease obligations	83	79
.932% senior notes due January 2027
Debt Instrument [Line Items]
Notes payable and lease obligations	400	378
1.048% senior notes due March 2029
Debt Instrument [Line Items]
Notes payable and lease obligations	86	81
1.075% senior notes due September 2029
Debt Instrument [Line Items]
Notes payable and lease obligations	223	211
.500% senior notes due December 2029
Debt Instrument [Line Items]
Notes payable and lease obligations	84	79
.550% senior notes due March 2030
Debt Instrument [Line Items]
Notes payable and lease obligations	89	84
1.159% senior notes due October 2030
Debt Instrument [Line Items]
Notes payable and lease obligations	195	184
1.412% senior notes due March 2031
Debt Instrument [Line Items]
Notes payable and lease obligations	186	176
.633% senior notes due April 2031
Debt Instrument [Line Items]
Notes payable and lease obligations	200	189
.843% senior notes due December 2031
Debt Instrument [Line Items]
Notes payable and lease obligations	62	58
.750% senior notes due March 2032
Debt Instrument [Line Items]
Notes payable and lease obligations	137	130
1.320% senior notes due December 2032
Debt Instrument [Line Items]
Notes payable and lease obligations	141	133
.844% senior notes due April 2033
Debt Instrument [Line Items]
Notes payable and lease obligations	80	76
1.488% senior notes due October 2033
Debt Instrument [Line Items]
Notes payable and lease obligations	101	95
1.682% senior notes due March 2034
Debt Instrument [Line Items]
Notes payable and lease obligations	51	48
1.600% senior notes due March 2034
Debt Instrument [Line Items]
Notes payable and lease obligations	122	115
.934% senior notes due December 2034
Debt Instrument [Line Items]
Notes payable and lease obligations	65	62
.830% senior notes due March 2035
Debt Instrument [Line Items]
Notes payable and lease obligations	70	66
1.740% senior notes due March 2036
Debt Instrument [Line Items]
Notes payable and lease obligations	99	94
1.039% senior notes due April 2036
Debt Instrument [Line Items]
Notes payable and lease obligations	66	63
1.594% senior notes due September 2037
Debt Instrument [Line Items]
Notes payable and lease obligations	43	41
1.750% senior notes due October 2038
Debt Instrument [Line Items]
Notes payable and lease obligations	59	56
1.920% senior notes due March 2039
Debt Instrument [Line Items]
Notes payable and lease obligations	109	103
1.122% senior notes due December 2039
Debt Instrument [Line Items]
Notes payable and lease obligations	42	39
1.264% senior notes due April 2041
Debt Instrument [Line Items]
Notes payable and lease obligations	66	63
2.160% senior notes due March 2044
Debt Instrument [Line Items]
Notes payable and lease obligations	37	35
2.108% subordinated notes due October 2047
Debt Instrument [Line Items]
Notes payable and lease obligations	397	375
1.560% senior notes due April 2051
Debt Instrument [Line Items]
Notes payable and lease obligations	133	125
2.144% senior notes due September 2052
Debt Instrument [Line Items]
Notes payable and lease obligations	80	75
1.958% subordinated bonds due December 2053
Debt Instrument [Line Items]
Notes payable and lease obligations	200	188
2.400% senior notes due March 2054
Debt Instrument [Line Items]
Notes payable and lease obligations	129	122
Yen-denominated loan variable interest rate due August 2027
Debt Instrument [Line Items]
Notes payable and lease obligations	78	74
Yen-denominated loan variable interest rate due August 2029
Debt Instrument [Line Items]
Notes payable and lease obligations	169	160
Yen-denominated loan variable interest rate due August 2032
Debt Instrument [Line Items]
Notes payable and lease obligations	$ 467	$ 441

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Summary of Notes Payable (Detail 2) - JPY (¥) ¥ in Billions	Mar. 31, 2025	Dec. 31, 2024
1.125% senior sustainability notes due March 2026
Debt Instrument [Line Items]
Debt instrument, interest rate	1.125%	1.125%
2.875% senior notes due October 2026
Debt Instrument [Line Items]
Debt instrument, interest rate	2.875%	2.875%
3.60% senior notes due April 2030
Debt Instrument [Line Items]
Debt instrument, interest rate	3.60%	3.60%
6.90% senior notes due December 2039
Debt Instrument [Line Items]
Debt instrument, interest rate	6.90%	6.90%
6.45% senior notes due August 2040
Debt Instrument [Line Items]
Debt instrument, interest rate	6.45%	6.45%
4.00% senior notes due October 2046
Debt Instrument [Line Items]
Debt instrument, interest rate	4.00%	4.00%
4.750% senior notes due January 2049
Debt Instrument [Line Items]
Debt instrument, interest rate	4.75%	4.75%
.300% senior notes due September 2025
Debt Instrument [Line Items]
Debt instrument, interest rate	0.30%	0.30%
Debt instrument, principal amount	¥ 12.4	¥ 12.4
.932% senior notes due January 2027
Debt Instrument [Line Items]
Debt instrument, interest rate	0.932%	0.932%
Debt instrument, principal amount	¥ 60.0	¥ 60.0
1.048% senior notes due March 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	1.048%	1.048%
Debt instrument, principal amount	¥ 13.0	¥ 13.0
1.075% senior notes due September 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	1.075%	1.075%
Debt instrument, principal amount	¥ 33.4	¥ 33.4
.500% senior notes due December 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	0.50%	0.50%
Debt instrument, principal amount	¥ 12.6	¥ 12.6
.550% senior notes due March 2030
Debt Instrument [Line Items]
Debt instrument, interest rate	0.55%	0.55%
Debt instrument, principal amount	¥ 13.3	¥ 13.3
1.159% senior notes due October 2030
Debt Instrument [Line Items]
Debt instrument, interest rate	1.159%	1.159%
Debt instrument, principal amount	¥ 29.3	¥ 29.3
1.412% senior notes due March 2031
Debt Instrument [Line Items]
Debt instrument, interest rate	1.412%	1.412%
Debt instrument, principal amount	¥ 27.9	¥ 27.9
.633% senior notes due April 2031
Debt Instrument [Line Items]
Debt instrument, interest rate	0.633%	0.633%
Debt instrument, principal amount	¥ 30.0	¥ 30.0
.843% senior notes due December 2031
Debt Instrument [Line Items]
Debt instrument, interest rate	0.843%	0.843%
Debt instrument, principal amount	¥ 9.3	¥ 9.3
.750% senior notes due March 2032
Debt Instrument [Line Items]
Debt instrument, interest rate	0.75%	0.75%
Debt instrument, principal amount	¥ 20.7	¥ 20.7
1.320% senior notes due December 2032
Debt Instrument [Line Items]
Debt instrument, interest rate	1.32%	1.32%
Debt instrument, principal amount	¥ 21.1	¥ 21.1
.844% senior notes due April 2033
Debt Instrument [Line Items]
Debt instrument, interest rate	0.844%	0.844%
Debt instrument, principal amount	¥ 12.0	¥ 12.0
1.488% senior notes due October 2033
Debt Instrument [Line Items]
Debt instrument, interest rate	1.488%	1.488%
Debt instrument, principal amount	¥ 15.2	¥ 15.2
1.682% senior notes due March 2034
Debt Instrument [Line Items]
Debt instrument, interest rate	1.682%	1.682%
Debt instrument, principal amount	¥ 7.7	¥ 7.7
1.600% senior notes due March 2034
Debt Instrument [Line Items]
Debt instrument, interest rate	1.60%	1.60%
Debt instrument, principal amount	¥ 18.3	¥ 18.3
.934% senior notes due December 2034
Debt Instrument [Line Items]
Debt instrument, interest rate	0.934%	0.934%
Debt instrument, principal amount	¥ 9.8	¥ 9.8
.830% senior notes due March 2035
Debt Instrument [Line Items]
Debt instrument, interest rate	0.83%	0.83%
Debt instrument, principal amount	¥ 10.6	¥ 10.6
1.740% senior notes due March 2036
Debt Instrument [Line Items]
Debt instrument, interest rate	1.74%	1.74%
Debt instrument, principal amount	¥ 15.0	¥ 15.0
1.039% senior notes due April 2036
Debt Instrument [Line Items]
Debt instrument, interest rate	1.039%	1.039%
Debt instrument, principal amount	¥ 10.0	¥ 10.0
1.594% senior notes due September 2037
Debt Instrument [Line Items]
Debt instrument, interest rate	1.594%	1.594%
Debt instrument, principal amount	¥ 6.5	¥ 6.5
1.750% senior notes due October 2038
Debt Instrument [Line Items]
Debt instrument, interest rate	1.75%	1.75%
Debt instrument, principal amount	¥ 8.9	¥ 8.9
1.920% senior notes due March 2039
Debt Instrument [Line Items]
Debt instrument, interest rate	1.92%	1.92%
Debt instrument, principal amount	¥ 16.5	¥ 16.5
1.122% senior notes due December 2039
Debt Instrument [Line Items]
Debt instrument, interest rate	1.122%	1.122%
Debt instrument, principal amount	¥ 6.3	¥ 6.3
1.264% senior notes due April 2041
Debt Instrument [Line Items]
Debt instrument, interest rate	1.264%	1.264%
Debt instrument, principal amount	¥ 10.0	¥ 10.0
2.160% senior notes due March 2044
Debt Instrument [Line Items]
Debt instrument, interest rate	2.16%	2.16%
Debt instrument, principal amount	¥ 5.7	¥ 5.7
2.108% subordinated notes due October 2047
Debt Instrument [Line Items]
Debt instrument, interest rate	2.108%	2.108%
Debt instrument, principal amount	¥ 60.0	¥ 60.0
1.560% senior notes due April 2051
Debt Instrument [Line Items]
Debt instrument, interest rate	1.56%	1.56%
Debt instrument, principal amount	¥ 20.0	¥ 20.0
2.144% senior notes due September 2052
Debt Instrument [Line Items]
Debt instrument, interest rate	2.144%	2.144%
Debt instrument, principal amount	¥ 12.0	¥ 12.0
1.958% subordinated bonds due December 2053
Debt Instrument [Line Items]
Debt instrument, interest rate	1.958%	1.958%
Debt instrument, principal amount	¥ 30.0	¥ 30.0
2.400% senior notes due March 2054
Debt Instrument [Line Items]
Debt instrument, interest rate	2.40%	2.40%
Debt instrument, principal amount	¥ 19.5	¥ 19.5
Yen-denominated loan variable interest rate due August 2027
Debt Instrument [Line Items]
Debt instrument, interest rate	1.07%	0.84%
Debt instrument, principal amount	¥ 11.7	¥ 11.7
Yen-denominated loan variable interest rate due August 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	1.17%	0.94%
Debt instrument, principal amount	¥ 25.3	¥ 25.3
Yen-denominated loan variable interest rate due August 2032
Debt Instrument [Line Items]
Debt instrument, interest rate	1.32%	1.09%
Debt instrument, principal amount	¥ 70.0	¥ 70.0

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Summary of Lines of Credit (Details) - 3 months ended Mar. 31, 2025 $ in Millions, ¥ in Billions	USD ($)	JPY (¥)
$100 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 100.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	The rate quoted by the bank and agreed upon at the time of borrowing
100.0 billion yen line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	5 years
Line of credit facility, maximum borrowing capacity | ¥		¥ 100.0
Line of credit facility, amount outstanding | ¥		0.0
Line of credit facility, interest rate description	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period
$1 billion line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	5 years
Line of credit facility, maximum borrowing capacity	$ 1,000.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar-denominated borrowings or TIBOR for Japanese yen-denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin
$50 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 50.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%
$250 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 250.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
50.0 billion yen line of credit (Tranche 1)
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity | ¥		50.0
Line of credit facility, amount outstanding | ¥		0.0
Line of credit facility, interest rate description	Three-month yen TIBOR plus 75 basis points per annum
50.0 billion yen line of credit (Tranche 2)
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity | ¥		50.0
Line of credit facility, amount outstanding | ¥		¥ 0.0
Line of credit facility, interest rate description	Three-month yen TIBOR plus 75 basis points per annum
$25 million line of credit (Aflac New York as borrower)
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 25.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$15 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 15.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$300 thousand line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 0.3
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$30 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 30.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$400 million line of credit (Aflac Incorporated as borrower)
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 400.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings
$400 million line of credit (Aflac Re Bermuda Ltd. as borrower)
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 400.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings
$25 million line of credit (Aflac Asset Management LLC as Borrower)
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 25.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings
$2 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Line of credit facility, maximum borrowing capacity	$ 2.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings
Lower Limit | 100.0 billion yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.28%
Lower Limit | $1 billion line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.08%
Upper Limit | $100 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	3 months
Upper Limit | 100.0 billion yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.45%
Upper Limit | $1 billion line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.20%
Upper Limit | $50 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	3 months

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Debt Instrument [Line Items]
Interest expense on debt	$ 49	$ 46
Lines of credit
Debt Instrument [Line Items]
Debt instrument, debt default, amount	0
Notes payable
Debt Instrument [Line Items]
Debt instrument, debt default, amount	$ 0

XML

SHAREHOLDERS' EQUITY - Reconciliation of Number of Shares of Common Stock (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Common Stock Issued [Roll Forward]
Balance, beginning of period	1,356,763	1,355,398
Exercise of stock options and issuance of restricted shares	989	1,082
Balance, end of period	1,357,752	1,356,480
Treasury Stock [Roll Forward]
Balance, beginning of period	806,799	776,919
Share repurchase program	8,497	9,276
Balance, end of period	815,259	786,202
Shares outstanding, end of period	542,493	570,278
Treasury Stock
Treasury Stock [Roll Forward]
Other purchases	398	457
Shares issued to AFL Stock Plan	(173)	(212)
Exercise of stock options	(41)	(55)
Other dispositions	(221)	(183)

XML

SHAREHOLDERS' EQUITY - Anti-Dilutive Share-Based Awards Excluded from Calculation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Anti-dilutive share-based awards	0	69

XML

SHAREHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	$ 26,098	$ 21,985
Other comprehensive income (loss), net of tax	1,119	418
Balance, end of period	26,338	23,537
Unrealized Foreign Currency Translation Gains (Losses)
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(4,998)	(4,069)
Other comprehensive income (loss) before reclassifications net of tax	449	(597)
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	0	0
Other comprehensive income (loss), net of tax	449	(597)
Balance, end of period	(4,549)	(4,666)
Unrealized Gains (Losses) on Fixed Maturity Securities
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	24	1,139
Other comprehensive income (loss) before reclassifications net of tax	(1,225)	86
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	(32)	(133)
Other comprehensive income (loss), net of tax	(1,257)	(47)
Balance, end of period	(1,233)	1,092
Unrealized Gains (Losses) on Derivatives
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(20)	(22)
Other comprehensive income (loss) before reclassifications net of tax	1	(5)
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	1	1
Other comprehensive income (loss), net of tax	2	(4)
Balance, end of period	(18)	(26)
Effect of Changes in Discount Rate Assumptions
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	2,006	(2,560)
Other comprehensive income (loss) before reclassifications net of tax	1,893	1,065
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	0	0
Other comprehensive income (loss), net of tax	1,893	1,065
Balance, end of period	3,899	(1,495)
Pension Liability Adjustment
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	10	(8)
Other comprehensive income (loss) before reclassifications net of tax	33	1
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	(1)	0
Other comprehensive income (loss), net of tax	32	1
Balance, end of period	42	(7)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(2,978)	(5,520)
Other comprehensive income (loss) before reclassifications net of tax	1,151	550
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	(32)	(132)
Other comprehensive income (loss), net of tax	1,119	418
Balance, end of period	$ (1,859)	$ (5,102)

XML

SHAREHOLDERS' EQUITY - Reclassifications Out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)		$ (963)	$ 951
Net investment income		955	1,000
Acquisition and operating expenses		(1,308)	(1,256)
Income tax (expense) or benefit		(116)	(291)
Net of tax		$ 29	$ 1,879
U.S. federal statutory income tax rate		21.00%	21.00%
Reclassification Out Of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net of tax		$ 32	$ 132
Reclassification Out Of Accumulated Other Comprehensive Income | Unrealized gains (losses) on available-for-sale securities
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)		40	168
Income tax (expense) or benefit	[1]	(8)	(35)
Net of tax		32	133
Reclassification Out Of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)		(1)	(1)
Income tax (expense) or benefit	[1]	0	0
Net of tax		(1)	$ (1)
Reclassification Out Of Accumulated Other Comprehensive Income | Pension liability adjustment, actuarial gains (losses)
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Acquisition and operating expenses	[2]	1
Reclassification Out Of Accumulated Other Comprehensive Income | Pension liability adjustment, prior service (cost) credit
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Acquisition and operating expenses	[2]	0
Reclassification Out Of Accumulated Other Comprehensive Income | Pension Liability Adjustment
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income tax (expense) or benefit	[1]	0
Net of tax		$ 1

[1] Based on 21% tax rate

[2] These accumulated other comprehensive income components are included in the computation of net periodic benefit cost (see Note 12 for additional details).

XML

SHAREHOLDERS' EQUITY - Additional Information (Detail) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Stockholders Equity Note [Line Items]
Stock acquired under share repurchase program, shares	8,497	9,276
Common stock, share repurchase, dollar amount	$ 949	$ 793
Remaining common stock available for purchase under share repurchase authorizations	38,800
Share Repurchase Program
Stockholders Equity Note [Line Items]
Stock acquired under share repurchase program, shares	8,500	9,300
Common stock, share repurchase, dollar amount	$ 900	$ 750

XML

SHARE-BASED COMPENSATION - Stock Options Outstanding and Exercisable (Detail) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Options Outstanding - Stock Option Shares | shares	459
Options Outstanding - Weighted-Average Remaining Term (Yrs)	1 year 8 months 12 days
Options Outstanding - Aggregate Intrinsic Value | $	$ 35
Options Outstanding - Weighted-Average Exercise Price Per Share | $ / shares	$ 34.90
Options Exercisable - Stock Option Shares | shares	459
Options Exercisable - Weighted-Average Remaining Term (Yrs.)	1 year 8 months 12 days
Options Exercisable - Aggregate Intrinsic Value | $	$ 35
Options Exercisable - Weighted-Average Exercise Price Per Share | $ / shares	$ 34.90

XML

SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) - Restricted Stock shares in Thousands	3 Months Ended
	Mar. 31, 2025 $ / shares shares
Shares
Beginning Balance | shares	2,099
Granted | shares	1,059
Canceled | shares	(14)
Vested | shares	(1,238)
Ending Balance | shares	1,906
Weighted-Average Grant-Date Fair Value Per Share
Beginning Balance | $ / shares	$ 73.65
Granted | $ / shares	104.43
Cancelled | $ / shares	76.04
Vested | $ / shares	68.36
Ending Balance | $ / shares	$ 85.21

XML

SHARE-BASED COMPENSATION - Additional Information (Detail) - USD ($) shares in Thousands, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 28, 2025	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from stock options exercised		$ 5	$ 5
Tax benefit from exercise of stock options		$ 29	$ 24
Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, maximum number of shares issuable		75,000
Share-based compensation arrangement by share-based payment award, maximum number of shares issuable other than options and stock appreciation rights		38,000
Shares available for future grants under the long-term incentive plan		32,600
Long-term incentive plan awards, term (in years)		10 years
Long-term incentive plan awards, vesting period		3 years
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost not yet recognized, restricted stock awards		$ 50
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number, shares		1,906		2,099
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition		2 years
Restricted stock awards, grants in period		1,059
Performance Based Vesting Condition | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost not yet recognized, restricted stock awards		$ 25
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number, shares		1,200
Restricted stock awards, grants in period	284

XML

BENEFIT PLANS - Net Periodic (Benefit) Cost Included in Acquisition and Operating Expenses (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Other Postretirement Benefits Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 0	$ 0
Interest cost	0	0
Expected return on plan assets	0	0
Amortization of net actuarial (gain) loss	0	0
Settlement (gain) loss	0	0
Net periodic benefit cost (credit)	0	0
Japan | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	3	4
Interest cost	2	2
Expected return on plan assets	(2)	(2)
Amortization of net actuarial (gain) loss	0	0
Settlement (gain) loss	0	0
Net periodic benefit cost (credit)	3	4
U.S. | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	0	0
Interest cost	8	9
Expected return on plan assets	(5)	(7)
Amortization of net actuarial (gain) loss	(1)	0
Settlement (gain) loss	55	0
Net periodic benefit cost (credit)	$ 57	$ 2

XML

BENEFIT PLANS - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic (benefit) cost, excluding service cost	$ 57	$ 2
Japan | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Settlement (gain) loss	0	0
Employer contributions	6
U.S. | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Settlement (gain) loss	55	$ 0
Employer contributions	$ 0

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Additional Information (Details) - Information Technology and Data Services Company Application Maintenance and Development Services First Agreement $ in Millions, ¥ in Billions	3 Months Ended
	Mar. 31, 2025 JPY (¥)	Mar. 31, 2025 USD ($)
Commitments and Contingencies Disclosure [Line Items]
Outsourcing agreement, remaining term	3 years	3 years
Outsourcing agreement, aggregate remaining cost	¥ 10.3	$ 69